


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2004**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Cumulative Supplement 12

December 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Ribavirin 200mg Oral Capsule	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Change Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. The 25th Edition of the Orange Book will be available in a downloadable PDF format.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

CUMULATIVE SUPPLEMENT 12
December 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT


This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.



The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ALPHARMA INC
(ALPHARMA)
ALPHARMA USPD INC
(ALPHARMA)
AMERSHAM HEALTH
(AMERSHAM)
BERLEX
(BERLEX)

ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
GE HEALTHCARE
(GE HEALTHCARE)
BERLEX INC
(BERLEX INC)

BERLEX LABORATORIES INC (BERLEX LABS)	BERLEX INC (BERLEX INC)
BERLEX LABORATORIES INC SUB SCHERING AG (BERLEX)	BERLEX INC (BERLEX INC)
GENSIA INC (GENSIA)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
GENSIA LABORATORIES LTD (GENSIA)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
GENSIA SICOR PHARMACEUTICALS INC (GENSIA SICOR PHARMS)	SICOR PHARMACEUTICALS INC (SICOR PHARMS)
NOVO NORDISK PHARMACEUTICALS INC (NOVO NORDISK)	NOVO NORDISK INC (NOVO NORDISK INC)
PUREPAC PHARMACEUTICAL COMPANY DIVISION OF PUREPAC INC (PUREPAC PHARM)	PUREPAC INC (PUREPAC PHARM)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187) and Unithrod (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOthyrox	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent

and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website, <http://forms/psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of

administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2004</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	11082	10668	10702	10822
SINGLE SOURCE	2427 (21.9%)	2404 (22.5%)	2385 (22.3%)	2385 (22.0%)
MULTISOURCE	8547 (77.1%)	8156 (76.5%)	8209 (76.7%)	8329 (77.0%)
THERAPEUTICALLY EQUIVALENT	8327 (75.1%)	7885 (73.9%)	7995 (74.7%)	8116 (75.0%)
NOT THERAPEUTICALLY EQUIVALENT	220 (2.0%)	271 (2.5%)	214 (2.0%)	213 (2.0%)
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	9	3	1	1
NUMBER OF APPLICANTS	625	586	602	605

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.


New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.
CFTG Change. A first time generic for the innovator product. A TE Code is added.
CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1 Change. Miscellaneous addition to list.
CMS2 Change. Miscellaneous deletion from list.
CPOT Change. Potency amount/unit.
CRLD Change. Reference Listed Drug.
CTEC Change. Therapeutic Equivalence Code.
CTNA Change. Trade Name.
DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.



PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 12 - December 2004

1-1

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM

+ SMITHKLINE BEECHAM EQ 600MG BASE;300MG N21652 001 Aug 02, 2004 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL

+ FOREST LABS 333MG N21431 001 Jul 29, 2004 Sep CAHN

+ LIPHA 333MG N21431 001 Jul 29, 2004 Jul NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

AB + VALEANT 650MG;50MG N88831 001 Jun 19, 1985 Aug CAHN

TABLET; ORAL

PHRENILIN

AB + VALEANT 325MG;50MG N87811 001 Jun 19, 1985 Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB ANABOLIC LABS 325MG;50MG;40MG;30MG N76560 001 Jun 10, 2004 Jun NEWA

PHRENILIN WITH CAFFEINE AND CODEINE

AB VALEANT 325MG;50MG;40MG;30MG N74911 001 Aug 22, 2001 Aug CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC-A

@ LEITNER PHARMS 356.4MG;30MG;16MG N89166 001 May 14, 1986 Oct CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + AMARIN PHARMS 120MG/5ML;12MG/5ML N86024 001 Apr CRLD

AA + VALEANT 120MG/5ML;12MG/5ML N86024 001 Aug CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ MUTUAL PHARM 300MG;15MG N85795 001 Aug CAHN

@ 300MG;30MG N85794 001 Aug CAHN

@ 300MG;60MG N89673 001 Feb 10, 1988 Aug DISC

ACETAMINOPHEN W/ CODEINE

@ MUTUAL PHARM 300MG;60MG N87653 001 Apr 13, 1982 Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

@ CENT PHARMS 500MG;5MG N88898 001 Mar 27, 1985 Aug DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+ MIKART 300MG;10MG N40556 001 Jun 23, 2004 Jun NEWA

AA MUTUAL PHARM 500MG;5MG N40236 001 Sep 25, 1997 Aug CAHN

AA 650MG;7.5MG N40240 002 Nov 26, 1997 Aug CAHN

TABLET; ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 AA MUTUAL PHARM 650MG;10MG
 AA 750MG;7.5MG

N40240 001 Nov 26, 1997 Aug CAHN
 N40236 002 Sep 25, 1997 Aug CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
 OXYCODONE AND ACETAMINOPHEN
 AA MUTUAL PHARM 500MG;5MG

N40219 001 Jan 22, 1998 Aug CAHN

SOLUTION; ORAL
 ROXICET
 >D> ROXANE 325MG/5ML;5MG/5ML
 >A> + 325MG/5ML;5MG/5ML

N89351 001 Dec 03, 1986 Dec CRLD
 N89351 001 Dec 03, 1986 Dec CRLD

TABLET; ORAL
 OXYCODONE AND ACETAMINOPHEN
 AA MALLINCKRODT 325MG;7.5MG
 AA 325MG;10MG
 AA 500MG;7.5MG
 AA 650MG;10MG

N40545 001 Jun 30, 2004 Jun NEWA
 N40545 002 Jun 30, 2004 Jun NEWA
 N40550 001 Jun 30, 2004 Jun NEWA
 N40550 002 Jun 30, 2004 Jun NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
 WYGESIC
 AA + LEITNER PHARMS 650MG;65MG

N84999 001 Oct CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
 DARVOCET A500
 AAIPHARMA 500MG;100MG
 AB 500MG;100MG
 PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN
 AB ANDRX PHARMS 650MG;100MG
 @ MUTUAL PHARM 325MG;50MG
 @ 650MG;100MG
 AB 650MG;100MG
 AB 650MG;100MG
 AB 650MG;100MG
 AB 650MG;100MG
 VINTAGE PHARMS 325MG;100MG
 AB 500MG;100MG

N76429 001 Sep 10, 2003 May CRLD
 N76429 001 Sep 10, 2003 Jun CFTG
 N76609 001 Nov 16, 2004 Nov NEWA
 N70115 001 Jun 12, 1985 Aug CAHN
 N70116 001 Jun 12, 1985 Aug CAHN
 N70615 001 Mar 21, 1986 Aug CAHN
 N70771 001 Mar 21, 1986 Aug CAHN
 N70775 001 Mar 21, 1986 Aug CAHN
 N76743 001 May 07, 2004 May NEWA
 N76750 001 Jun 28, 2004 Jun NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
 ACETAZOLAMIDE SODIUM
 AP HOSPIRA EQ 500MG BASE/VIAL

N40108 001 Oct 30, 1995 May CAHN

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL
 ACETIC ACID 0.25% IN PLASTIC CONTAINER
 AT HOSPIRA 250MG/100ML

N17656 001 May CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
 ACETADOTE
 + CUMBERLAND PHARMS 6GM /30ML(200MG/ML)

N21539 001 Jan 23, 2004 Jan NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	HOSPIRA	10%	N73664 001	Aug 30, 1994	May	CAHN
AN		20%	N74037 001	Aug 30, 1994	May	CAHN
>D>	AN	ROXANE	10%	N72621 001	Sep 30, 1992	Dec DISC
>A>	@	10%	N72621 001	Sep 30, 1992	Dec	DISC
>D>	AN		20%	N72622 001	Sep 30, 1992	Dec DISC
>A>	@	20%	N72622 001	Sep 30, 1992	Dec	DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

	CONNETICS	10MG	N19821 001	Oct 28, 1996	Mar	CAHN
+		25MG	N19821 002	Oct 28, 1996	Mar	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM.

AP	HOSPIRA	EQ 500MG BASE/VIAL	N74663 001	Apr 22, 1997	May	CAHN
AP		EQ 500MG BASE/VIAL	N74758 001	Apr 22, 1997	May	CAHN
AP		EQ 1GM BASE/VIAL	N74663 002	Apr 22, 1997	May	CAHN
AP		EQ 1GM BASE/VIAL	N74758 002	Apr 22, 1997	May	CAHN
AP	MAYNE PHARMA USA	EQ 50MG BASE/ML	N75065 001	Feb 25, 1999	Apr	CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP	+	FUJISAWA HLTHCARE	3MG/ML	N19937 002	Oct 30, 1989	Jun CFTG
AP		BAXTER HLTHCARE	3MG/ML	N76500 001	Jun 16, 2004	Jun NEWA
AP			3MG/ML	N76501 001	Jun 16, 2004	Jun NEWA
AP		BEDFORD	3MG/ML	N76404 001	Jun 16, 2004	Jun NEWA
AP		SICOR PHARMS	3MG/ML	N76564 001	Jun 16, 2004	Jun NEWA

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

@	PFIZER	EQ 200MG BASE/VIAL	N20760 001	Dec 18, 1997	Jun	DISC
@		EQ 300MG BASE/VIAL	N20760 002	Dec 18, 1997	Jun	DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

	ISO TEX	100UCI/10ML(10UCI/ML)	N17836 003	Jun 08, 2004	Jun	NEWA
		500uCi/0.5ML	N17836 001		Jun	CMFD
+		1,000uCi/ML	N17836 002		Jun	CMFD
	RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125					
@	MALLINCKRODT	10uCi/ML	N17844 001		Jun	DISC

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

BX	+	IVAX RES	EQ 0.09MG BASE/INH	N21457 001	Oct 29, 2004	Oct NEWA
BX	+	IVAX RES	EQ 0.09MG BASE/INH	N21457 001	Oct 29, 2004	Nov CTNA

SOLUTION; INHALATION

ACCUNEB							
AN	+ DEY	EQ 0.042% BASE	N20949	001	Apr 30, 2001	Jun	CFTG
ALBUTEROL SULFATE							
AN	+ BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Jun	CRLD
AN	+	EQ 0.5% BASE	N75050	001	Jun 18, 1998	Jun	CRLD
AN	NEPHRON	EQ 0.042% BASE	N76355	001	Jun 28, 2004	Jun	NEWA
PROVENTIL							
	@ SCHERING	EQ 0.083% BASE	N19243	002	Jan 14, 1987	Jun	DISC
	@	EQ 0.5% BASE	N19243	001	Jan 14, 1987	Jun	DISC
<u>SYRUP; ORAL</u>							
ALBUTEROL SULFATE							
AA	+ TEVA	EQ 2MG BASE/5ML	N73419	001	Mar 30, 1992	Sep	CRLD
<u>TABLET, EXTENDED RELEASE; ORAL</u>							
ALBUTEROL SULFATE							
	+ PLIVA	EQ 4MG BASE	N76130	002	Sep 26, 2002	Jan	CRLD
		EQ 4MG BASE	N76130	002	Sep 26, 2002	Nov	CRLD
	+	EQ 8MG BASE	N76130	003	Sep 26, 2002	Jan	CRLD
VOLMAX							
	@ MURO	EQ 4MG BASE	N19604	002	Dec 23, 1992	Jan	DISC
	@	EQ 8MG BASE	N19604	001	Dec 23, 1992	Jan	DISC

ALCLOMETASONE DIPROPIONATEOINTMENT; TOPICAL

ACLOVATE							
AB	+ GLAXOSMITHKLINE	0.05%	N18702	001	Dec 14, 1982	Jul	CFTG
ALCLOMETASONE DIPROPIONATE							
AB	TARO	0.05%	N76730	001	Jul 29, 2004	Jul	NEWA

ALCOHOL; DEXTROSEINJECTABLE; INJECTION

ALCOHOL 5% IN D5-W							
AP	HOSPIRA	5ML/100ML; 5GM/100ML	N83263	001		May	CAHN

ALFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION

ALFENTANIL							
AP	HOSPIRA	EQ 0.5MG BASE/ML	N75221	001	Oct 28, 1999	May	CAHN

ALLOPURINOLTABLET; ORAL

ALLOPURINOL

@ MUTUAL PHARM

100MG

N70466 001 Dec 24, 1985 Aug CAHN

@

300MG

N70467 001 Dec 24, 1985 Aug CAHN

ALLOPURINOL SODIUMINJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP	BEDFORD LABS	EQ 500MG BASE/VIAL	N76870	001	Aug 26, 2004	Aug	NEWA
ALOPRIM							
	+ NABI	EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Jun	CAHN
AP	+	EQ 500MG BASE/VIAL	N20298	001	May 17, 1996	Aug	CFTG

ALMOTRIPTAN MALATETABLET; ORAL

AXERT

ORTHO MCNEIL PHARM

EQ 6.25MG BASE

N21001 001 May 07, 2001 Jul CAHN

TABLET; ORAL
AXERT

+ ORTHO MCNEIL PHARM EQ 12.5MG BASE N21001 002 May 07, 2001 Jul CAHN

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

@ PFIZER 0.005MG/ML N20755 001 Oct 31, 1997 Nov CAHN
@ 0.01MG/ML N20755 002 Oct 01, 1997 Nov CAHN
@ 0.02MG/ML N20755 003 Oct 01, 1997 Nov CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA SILARX 50MG/5ML N76352 001 Sep 10, 2004 Sep NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

@ BAXTER HLTHCARE EQ 50MG BASE/ML N63274 001 May 18, 1992 Aug CAHN
@ EQ 250MG BASE/ML N63275 001 May 18, 1992 Aug CAHN
AP HOSPIRA EQ 50MG BASE/ML N63263 001 Nov 30, 1994 May CAHN
EQ 62.5MG BASE/ML N63283 001 Oct 31, 1994 May CAHN
AP EQ 250MG BASE/ML N63264 001 Nov 30, 1994 May CAHN
AP EQ 250MG BASE/ML N64098 001 Jun 26, 1995 May CAHN
@ EQ 250MG BASE/ML N64099 001 Jun 20, 1995 May CAHN
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HOSPIRA EQ 500MG BASE/100ML N64146 001 Apr 02, 1997 May CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA 5.2% (5.2GM/100ML) N18901 001 Apr 06, 1984 Aug CAHN
AMINOSYN 10%
HOSPIRA 10% (10GM/100ML) N17673 003 May CAHN
AMINOSYN 10% (PH6)
HOSPIRA 10% (10GM/100ML) N17673 008 Nov 18, 1985 May CAHN
AMINOSYN 3.5%
HOSPIRA 3.5% (3.5GM/100ML) N17789 004 May CAHN
AMINOSYN 5%
HOSPIRA 5% (5GM/100ML) N17673 001 May CAHN
AMINOSYN 7%
@ HOSPIRA 7% (7GM/100ML) N17673 002 May CAHN
AMINOSYN 7% (PH6)
HOSPIRA 7% (7GM/100ML) N17673 006 Nov 18, 1985 May CAHN
AMINOSYN 8.5%
@ HOSPIRA 8.5% (8.5GM/100ML) N17673 004 May CAHN
AMINOSYN 8.5% (PH6)
HOSPIRA 8.5% (8.5GM/100ML) N17673 007 Nov 18, 1985 May CAHN
AMINOSYN II 10%
HOSPIRA 10% (10GM/100ML) N19438 005 Apr 03, 1986 May CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER
HOSPIRA 10% (10GM/100ML) N20015 001 Dec 19, 1991 May CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER
HOSPIRA 15% (15GM/100ML) N20041 001 Dec 19, 1991 May CAHN
AMINOSYN II 3.5%
@ HOSPIRA 3.5% (3.5GM/100ML) N19438 001 Apr 03, 1986 May CAHN

INJECTABLE; INJECTION

AMINOSYN II 5%							
@ HOSPIRA	5% (5GM/100ML)	N19438	002	Apr 03, 1986	May	CAHN	
AMINOSYN II 7%							
HOSPIRA	7% (7GM/100ML)	N19438	003	Apr 03, 1986	May	CAHN	
AMINOSYN II 8.5%							
HOSPIRA	8.5% (8.5GM/100ML)	N19438	004	Apr 03, 1986	May	CAHN	
AMINOSYN-HBC 7%							
HOSPIRA	7% (7GM/100ML)	N19374	001	Jul 12, 1985	May	CAHN	
AMINOSYN-HF 8%							
HOSPIRA	8% (8GM/100ML)	N20345	001	Apr 04, 1996	May	CAHN	
AMINOSYN-PF 10%							
HOSPIRA	10% (10GM/100ML)	N19492	002	Oct 17, 1986	May	CAHN	
AMINOSYN-PF 7%							
HOSPIRA	7% (7GM/100ML)	N19398	001	Sep 06, 1985	May	CAHN	
AMINOSYN-RF 5.2%							
HOSPIRA	5.2% (5.2GM/100ML)	N18429	001		May	CAHN	
NEOPHAM 6.4%							
@ HOSPIRA	6.4% (6.4GM/100ML)	N18792	001	Jan 17, 1984	Aug	CAHN	
NOVAMINE 11.4%							
HOSPIRA	11.4% (11.4GM/100ML)	N17957	003	Aug 09, 1982	Aug	CAHN	
NOVAMINE 15%							
HOSPIRA	15% (15GM/100ML)	N17957	004	Nov 28, 1986	Aug	CAHN	
NOVAMINE 8.5%							
@ HOSPIRA	8.5% (8.5GM/100ML)	N17957	002	Aug 09, 1982	Aug	CAHN	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	001	Nov 07, 1988	May	CAHN	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER							
HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	002	Nov 07, 1988	May	CAHN	
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	003	Nov 07, 1988	May	CAHN	
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683	004	Nov 07, 1988	May	CAHN	

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER							
HOSPIRA	3.5%;25GM/100ML	N19681	001	Nov 01, 1988	May	CAHN	
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER							
HOSPIRA	3.5%;5GM/100ML	N19681	002	Nov 01, 1988	May	CAHN	
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER							
HOSPIRA	4.25%;10GM/100ML	N19681	004	Nov 01, 1988	May	CAHN	
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER							
HOSPIRA	4.25%;20GM/100ML	N19681	005	Nov 01, 1988	May	CAHN	
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER							
HOSPIRA	4.25%;25GM/100ML	N19681	003	Nov 01, 1988	May	CAHN	
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER							
HOSPIRA	5%;25GM/100ML	N19681	006	Nov 01, 1988	May	CAHN	

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100 ML;205MG/100ML	N19682 003	Nov 01, 1988	May	CAHN
-----------	--	------------	--------------	-----	------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML	N19682 001	Nov 01, 1988	May	CAHN
---------	---	------------	--------------	-----	------

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;5GM/100ML;30MG/100ML;97MG/1 00ML;120MG/100ML;49.3MG/100ML	N19682 002	Nov 01, 1988	May	CAHN
---------	--	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/ 100ML;234MG/100ML	N17789 003		May	CAHN
---------	--	------------	--	-----	------

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

@ HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG /100ML	N17789 005		May	CAHN
-----------	---	------------	--	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

@ HOSPIRA	8%;61MG/100ML;211MG/100ML;56MG/10 OML;388MG/100ML	N17957 001		Aug	CAHN
-----------	--	------------	--	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/ 100ML;410MG/100ML	N19437 004	Apr 03, 1986	May	CAHN
---------	--	------------	--------------	-----	------

AMINOSYN II 7% W/ ELECTROLYTES

@ HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/1 00ML;410MG/100ML	N19437 006	Apr 03, 1986	May	CAHN
-----------	---	------------	--------------	-----	------

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG /100ML;410MG/100ML	N19437 005	Apr 03, 1986	May	CAHN
---------	---	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

@ HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/ 100ML;49MG/100ML	N19437 007	Apr 03, 1986	May	CAHN
-----------	---	------------	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/ 100ML	N17789 002		May	CAHN
---------	--	------------	--	-----	------

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML N17673 005

May CAHN

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP HOSPIRA 250MG/ML N70888 001 Jun 16, 1988 May CAHN

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP HOSPIRA 250MG/ML N70010 001 Mar 09, 1987 May CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP HOSPIRA 25MG/ML N87242 001 Oct 26, 1983 May CAHN

AP + HOSPIRA 25MG/ML N87601 001 Jul 23, 1982 May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

+ HOSPIRA 100MG/100ML N88147 002 May 03, 1983 May CAHN

+ HOSPIRA 200MG/100ML N88147 003 May 03, 1983 May CAHN

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ HOSPIRA 100MG/100ML N18924 001 Dec 12, 1984 May CAHN

@ HOSPIRA 200MG/100ML N18924 002 Dec 12, 1984 May CAHN

@ HOSPIRA 400MG/100ML N18924 003 Dec 12, 1984 May CAHN

@ HOSPIRA 500MG/100ML N18924 004 Dec 12, 1984 May CAHN

TABLET; ORAL

AMINOPHYLLINE

>D> AB + ROXANE 100MG N87500 001 Feb 09, 1982 Dec DISC

>A> @ 100MG N87500 001 Feb 09, 1982 Dec DISC

>D> AB + 200MG N87501 001 Feb 09, 1982 Dec DISC

>A> @ 200MG N87501 001 Feb 09, 1982 Dec DISC

>D> AB WEST WARD 100MG N84540 001 Dec CRLD

>A> + 100MG N84540 001 Dec CRLD

>D> AB 200MG N85003 001 Dec CRLD

>A> + 200MG N85003 001 Dec CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP HOSPIRA 50MG/ML N75955 001 Oct 18, 2002 May CAHN

AMIODARONE HYDROCHLORIDE

AP INTL MEDICATION SYS 50MG/ML N21594 001 Feb 04, 2004 Feb NEWA

TABLET; ORAL

AMIODARONE HCL

>D> @ TARO 400MG N76362 001 Nov 29, 2002 Dec CMFD

>A> AB 400MG N76362 001 Nov 29, 2002 Dec CMFD

@ 400MG N76362 001 Nov 29, 2002 Jul DISC

CORDARONE

>D> AB WYETH PHARMS INC 200MG N18972 001 Dec 24, 1985 Dec CRLD

>A> AB + 200MG N18972 001 Dec 24, 1985 Dec CRLD

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

@ ASTRAZENECA 10MG/ML

N12704 001

Sep DISC

TABLET; ORAL

AMITRIPTYLINE HCL

	@ MUTUAL PHARM	10MG	N85744 001	Aug	CAHN
	@	25MG	N85627 001	Aug	CAHN
	@	50MG	N85745 001	Aug	CAHN
	@	75MG	N85743 001	Aug	CAHN
	@	100MG	N85742 002	May 11, 1982	Aug CAHN
	@	150MG	N89423 001	Feb 17, 1987	Aug CAHN
AB	+ SANDOZ	25MG	N85966 001	Oct	CRLD
	ELAVIL				
	@ ASTRAZENECA	10MG	N12703 001	Jul	DISC
	@	25MG	N12703 003	Jul	DISC
	@	50MG	N12703 004	Jul	DISC
	@	75MG	N12703 005	Jul	DISC
	@	100MG	N12703 006	Jul	DISC
	@	150MG	N12703 007	Jul	DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

	@ MUTUAL PHARM	EQ 12.5MG BASE;5MG	N70765 001	Dec 10, 1986	Aug CAHN
	@	EQ 25MG BASE;10MG	N70766 001	Dec 10, 1986	Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

	@ MUTUAL PHARM	10MG;2MG	N71077 001	Nov 12, 1986	Aug CAHN
	@	10MG;4MG	N71078 001	Nov 12, 1986	Aug CAHN
	@	25MG;2MG	N70297 001	Nov 12, 1986	Aug CAHN
	@	25MG;4MG	N71079 001	Nov 12, 1986	Aug CAHN

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

	+ ACCESS PHARMS	2MG	N21727 001	Sep 29, 2004	Sep NEWA
--	-----------------	-----	------------	--------------	----------

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER

		EQ 2.5MG BASE;EQ 10MG BASE	N21540 009	Jul 29, 2004	Aug NEWA
		EQ 2.5MG BASE;EQ 20MG BASE	N21540 010	Jul 29, 2004	Aug NEWA
		EQ 2.5MG BASE;EQ 40MG BASE	N21540 011	Jul 29, 2004	Aug NEWA
		EQ 5MG BASE;EQ 10MG BASE	N21540 001	Jan 30, 2004	Jan NEWA
		EQ 5MG BASE;EQ 20MG BASE	N21540 002	Jan 30, 2004	Jan NEWA
		EQ 5MG BASE;EQ 40MG BASE	N21540 003	Jan 30, 2004	Jan NEWA
		EQ 5MG BASE;EQ 80MG BASE	N21540 004	Jan 30, 2004	Jan NEWA
		EQ 10MG BASE;EQ 10MG BASE	N21540 005	Jan 30, 2004	Jan NEWA
		EQ 10MG BASE;EQ 20MG BASE	N21540 006	Jan 30, 2004	Jan NEWA
		EQ 10MG BASE;EQ 40MG BASE	N21540 007	Jan 30, 2004	Jan NEWA
	+	EQ 10MG BASE;EQ 80MG BASE	N21540 008	Jan 30, 2004	Jan NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

	@ DR REDDYS LABS INC	2.5MG	N21435 001	Oct 31, 2003	Mar DISC
	@	5MG	N21435 002	Oct 31, 2003	Mar DISC

TABLET; ORAL

AMVAZ

@ DR REDDYS LABS INC 10MG

N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA 5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

AB CLAY PARK EQ 12% BASE

N75570 001 Jun 23, 2004 Jun NEWA

AB TARO EQ 12% BASE

N76216 001 May 28, 2004 May NEWA

AMOXICILLIN

TABLET, CHEWABLE; ORAL

AMOXIL

@ GLAXOSMITHKLINE 125MG

N50542 002 Aug DISC

@ 250MG

N50542 001 Aug DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB TEVA 200MG/5ML;EQ 28.5MG BASE/5ML

N65089 001 May 25, 2004 May NEWA

AB 400MG/5ML;EQ 57MG BASE/5ML

N65089 002 May 25, 2004 May NEWA

AB 600MG/5ML;EQ 42.9MG BASE/5ML

N65162 001 Mar 12, 2004 Mar NEWA

AUGMENTIN ES-600

AB + GLAXOSMITHKLINE 600MG/5ML;EQ 42.9MG BASE/5ML

N50755 001 Jun 22, 2001 Mar CFTG

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

+ GLAXOSMITHKLINE 1GM;EQ 62.5MG BASE

N50785 001 Sep 25, 2002 Sep CPOT

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D> AP APOTHECON EQ 1GM BASE/VIAL

N62738 001 Feb 19, 1987 Dec CAHN

>D> AP EQ 2GM BASE/VIAL

N62738 002 Feb 19, 1987 Dec CAHN

AP IBI EQ 2GM BASE/VIAL

N62797 002 Jul 12, 1993 Aug CMFD

AP + SANDOZ EQ 125MG BASE/VIAL

N61395 001 Jun CAHN

AP + EQ 250MG BASE/VIAL

N61395 002 Jun CAHN

AP + EQ 500MG BASE/VIAL

N61395 003 Jun CAHN

AP + EQ 1GM BASE/VIAL

N61395 004 Jun CAHN

>A> AP EQ 1GM BASE/VIAL

N62738 001 Feb 19, 1987 Dec CAHN

AP + EQ 2GM BASE/VIAL

N61395 005 Jun CAHN

>A> AP EQ 2GM BASE/VIAL

N62738 002 Feb 19, 1987 Dec CAHN

AP + EQ 10GM BASE/VIAL

N61395 006 Jun CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP BAXTER HLTHCARE EQ 1GM BASE/VIAL;EQ 500MG
BASE/VIAL

N65074 001 Mar 19, 2002 Aug CAHN

AP EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

N65074 002 Mar 19, 2002 Aug CAHN

AP EQ 10GM BASE/VIAL;EQ 5GM
BASE/VIAL

N65076 001 Mar 19, 2002 Aug CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Apr	NEWA
+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Apr	NEWA
	MYLAN BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Aug	CAHN
+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Aug	CAHN

ARIPIPRAZOLE

>A> SOLUTION; ORAL

>A> ABILIFY

>A>	+	OTSUKA	1MG/ML	N21713 001	Dec 10, 2004	Dec	NEWA
-----	---	--------	--------	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001	Jan 29, 2004	Jan	NEWA
---	------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	MAYNE PHARMA USA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	Sep 21, 2000	Apr	CAHN
---	------------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	10MG/ML;0.006MG/ML;0.05UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	Aug 08, 1985	Apr	CAHN
---	------------------	---	------------	--------------	-----	------

M.V.I.-12 (WITHOUT VITAMIN K)

+	MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.05UGM/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N08809 006	Sep 09, 2004	Sep	NEWA
---	------------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+	AAIPHARMA LLC	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625 001	Jan 30, 2004	Jan	NEWA
+	MAYNE PHARMA USA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N21625 001	Jan 30, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+	AAIPHARMA LLC	200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1MG/5ML;10MG/5ML;0.15MG/5ML	N21643 001	Feb 18, 2004	Feb	NEWA
+	MAYNE PHARMA USA	200MG/5ML;0.06MG/5ML;0.005MG/5ML; 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML; 1MG/5ML;10MG/5ML;0.15MG/5ML	N21643 001	Feb 18, 2004	Apr	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A;
VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

+	MAYNE PHARMA USA	20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M G/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0. 36MG/ML;0.6MG/ML;330 UNITS/ML;1 IU/ML	N08809 005	Apr 22, 2004	May	NEWA
---	------------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC
ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED
@ HOSPIRA

		80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;400 IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG /VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML;7 IU/10ML	N20176 001	Dec 29, 1993	Aug	CAHN
--	--	--	------------	--------------	-----	------

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL
SYNALGOS-DC

+	LEITNER PHARMS	356.4MG;30MG;16MG	N11483 004	Sep 06, 1983	Sep	CAHN
---	----------------	-------------------	------------	--------------	-----	------

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON COMPOUND
@ AAIPHARMA LLC

		389MG;32.4MG;32MG	N10996 006	Mar 08, 1983	Jun	DISC
--	--	-------------------	------------	--------------	-----	------

ASPIRIN; MEPROBAMATE

TABLET; ORAL
EQUAGESIC

+	LEITNER PHARMS	325MG;200MG	N11702 003	Dec 29, 1983	Sep	CAHN
---	----------------	-------------	------------	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA	MUTUAL PHARM	325MG;4.5MG;0.38MG	N40260 001	Jul 17, 1998	Aug	CAHN
AA		325MG;4.5MG;0.38MG	N87794 001	May 26, 1982	Aug	CAHN

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	ABLE	25MG	N76907 001	Jul 30, 2004	Jul	NEWA
AB		50MG	N76907 002	Jul 30, 2004	Jul	NEWA
AB		100MG	N76907 003	Jul 30, 2004	Jul	NEWA
AB	TEVA	25MG	N74056 003	Jul 19, 2004	Jul	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION						
ATRACURIUM BESYLATE						
AP	BAXTER HLTHCARE	10MG/ML	N74824 001	Sep 30, 1997	Aug	CAHN
AP	HOSPIRA	10MG/ML	N74632 001	Dec 23, 1996	May	CAHN
ATRACURIUM BESYLATE PRESERVATIVE FREE						
@ BAXTER HLTHCARE		10MG/ML	N74825 001	Sep 30, 1997	Aug	CAHN
AP	HOSPIRA	10MG/ML	N74633 001	Dec 23, 1996	May	CAHN
AP		10MG/ML	N74639 001	Mar 25, 1997	May	CAHN
TRACRIUM						
AP	+ HOSPIRA	10MG/ML	N18831 002	Jun 20, 1985	May	CAHN
TRACRIUM PRESERVATIVE FREE						
AP	+ HOSPIRA	10MG/ML	N18831 001	Nov 23, 1983	May	CAHN

ATROPINE

INJECTABLE; INJECTION						
ATROPEN						
	+ MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N17106 004	Sep 17, 2004	Sep	NEWA

ATROPINE SULFATE

INJECTABLE; IM-IV-SC						
ATROPINE SULFATE ANSYR PLASTIC SYRINGE						
	HOSPIRA	0.05MG/ML	N21146 002	Jul 09, 2001	May	CAHN
	+	0.1MG/ML	N21146 001	Jul 09, 2001	May	CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL						
MOTOFEN						
	+ VALEANT	0.025MG;1MG	N17744 002		May	CAHN
MOTOFEN HALF-STRENGTH						
	@ VALEANT	0.025MG;0.5MG	N17744 001		May	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL						
DIPHENOXYLATE HCL AND ATROPINE SULFATE						
	@ MUTUAL PHARM	0.025MG;2.5MG	N85506 001		Aug	CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS						
VIDAZA						
	+ PHARMION	100MG/VIAL	N50794 001	May 19, 2004	May	NEWA

AZATADINE MALEATE

TABLET; ORAL						
OPTIMINE						
	@ SCHERING	1MG	N17601 001		May	DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL						
TRINALIN						
	@ SCHERING	1MG;120MG	N18506 001	Mar 23, 1982	May	DISC

AZATHIOPRINE SODIUMINJECTABLE; INJECTION
AZATHIOPRINE SODIUM

+	BEDFORD	EQ 100MG BASE/VIAL	N74419 001	Mar 31, 1995	May	CRLD
	IMURAN					
	@ PROMETHEUS LABS	EQ 100MG BASE/VIAL	N17391 001		May	DISC

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

@ PFIZER

EQ 250MG BASE

N50670 001 Nov 01, 1991 Mar DISC

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

+ BRISTOL MYERS SQUIBB 500MG/VIAL

N50580 001 Dec 31, 1986 Jul CMFD

+ 1GM/VIAL

N50580 002 Dec 31, 1986 Jul CMFD

+ 2GM/VIAL

N50580 003 Dec 31, 1986 Jul CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT	MONARCH PHARMS	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002		Mar	CRLD
----	----------------	--	------------	--	-----	------

AT	+	BAUSCH AND LOMB	400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64068 001	Oct 30, 1995	Mar	CRLD
----	---	-----------------	--	------------	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT	AKORN	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N65088 001	Feb 06, 2004	Feb	NEWA
----	-------	--	------------	--------------	-----	------

AT	+	BAUSCH AND LOMB	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N64064 001	Oct 30, 1995	Mar	CRLD
----	---	-----------------	--	------------	--------------	-----	------

NEOSPORIN

AT	MONARCH PHARMS	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50417 001		Mar	CRLD
----	----------------	--	------------	--	-----	------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+	BAUSCH AND LOMB	500 UNITS/GM; 10,000 UNITS/GM	N64046 001	Jan 26, 1995	Mar	CRLD
----	---	-----------------	-------------------------------	------------	--------------	-----	------

POLYSPORIN

AT	MONARCH PHARMS	500 UNITS/GM; 10,000 UNITS/GM	N61229 001		Mar	CRLD
----	----------------	-------------------------------	------------	--	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+ SCHERING 0.042MG/INH

N17573 001 Jun CTEC

VANCERIL DOUBLE STRENGTH

@ SCHERING 0.084MG/INH

N20486 001 Dec 24, 1996 Jun DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY

N19389 001 Jul 27, 1987 Jun CTEC

SPRAY, METERED; NASAL
 VANCENASE AQ
 @ SCHERING

EQ 0.042MG DIPROP/SPRAY

N19589 001 Dec 23, 1987 Jun DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76267 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76267 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76267 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG	N76402 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76402 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76402 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76402 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG	N76476 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76476 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76476 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76476 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG	N76333 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76333 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76333 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76333 004	Feb 11, 2004	Feb	NEWA
AB	KV PHARM	5MG	N76118 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76118 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76118 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76118 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG	N76430 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76430 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76430 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76430 004	Feb 11, 2004	Feb	NEWA
AB	RANBAXY	5MG	N76344 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344 004	Feb 11, 2004	Feb	NEWA
AB	TEVA	5MG	N76211 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76211 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76211 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76211 004	Feb 11, 2004	Feb	NEWA
	LOTENSIN					
AB	NOVARTIS	5MG	N19851 001	Jun 25, 1991	Feb	CFTG
AB		10MG	N19851 002	Jun 25, 1991	Feb	CFTG
AB		20MG	N19851 003	Jun 25, 1991	Feb	CFTG
AB	+	40MG	N19851 004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG; 6.25MG	N76342 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76342 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76342 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76342 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG; 6.25MG	N76631 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76631 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76631 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76631 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG; 6.25MG	N76612 001	Feb 11, 2004	Feb	NEWA

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	GENPHARM	10MG;12.5MG	N76612 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76612 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76612 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG;6.25MG	N76348 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76348 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76348 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76348 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG;6.25MG	N76688 001	Feb 11, 2004	Feb	NEWA
AB		10MG;12.5MG	N76688 002	Feb 11, 2004	Feb	NEWA
AB		20MG;12.5MG	N76688 003	Feb 11, 2004	Feb	NEWA
AB		20MG;25MG	N76688 004	Feb 11, 2004	Feb	NEWA
LOTENSIN HCT						
AB	NOVARTIS	5MG;6.25MG	N20033 001	May 19, 1992	Feb	CFTG
AB		10MG;12.5MG	N20033 002	May 19, 1992	Feb	CFTG
AB		20MG;12.5MG	N20033 004	May 19, 1992	Feb	CFTG
AB	+	20MG;25MG	N20033 003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	DERMIK LABS	5%;EQ 1% BASE	N50756 001	Dec 21, 2000	Nov	CTEC
DUAC							
BT	+	STIEFEL	5%;EQ 1% BASE	N50741 001	Aug 26, 2002	Nov	CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	DERMIK LABS	5%;3%	N50557 001	Oct 26, 1984	Mar	CFTG
ERYTHROMYCIN AND BENZOYL PEROXIDE							
AB		ATRIX	5%;3%	N65112 001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ATRIX	EQ 0.05% BASE	N76603 001	Jan 23, 2004	Jan	NEWA
----	--	-------	---------------	------------	--------------	-----	------

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	FOUGERA	EQ 0.05% BASE	N70275 001	Aug 12, 1985	Dec	CRLD
>A>	AB	+	EQ 0.05% BASE	N70275 001	Aug 12, 1985	Dec	CRLD
>D>		DIPROSONE		N17781 001		Dec	DISC
>D>	AB	+	SCHERING	EQ 0.05% BASE		Dec	DISC
>A>		@	EQ 0.05% BASE	N17781 001		Dec	DISC

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		TARO	EQ 0.05% BASE	N76753 001	Oct 12, 2004	Oct	NEWA
----	--	------	---------------	------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		TARO	EQ 0.05% BASE;1%	N76493 001	Jul 28, 2004	Jul	NEWA
LOTRISONE							
AB	+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	Dec 08, 2000	Jul	CFTG

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

@ STERIS EQ 3MG BASE/ML N85738 001 Feb DISC

CELESTONE

@ SCHERING EQ 3MG BASE/ML N17561 001 Feb DISC

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

LUXIQ

+ CONNETICS EQ 0.12% BASE N20934 001 Feb 28, 1999 Nov CDFR

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

@ ODYSSEY PHARMS 5MG/ML N06536 001 Jun CAHN

TABLET; ORAL

BETHANECHOL CHLORIDE

AA ABLE 5MG N40492 001 Jul 27, 2004 Jul NEWA

AA 10MG N40483 001 Jul 27, 2004 Jul NEWA

AA 25MG N40485 001 Jul 27, 2004 Jul NEWA

AA 50MG N40509 001 Jul 27, 2004 Jul NEWA

AA AMIDE PHARM 5MG N40552 001 Oct 28, 2004 Oct NEWA

AA 10MG N40553 001 Oct 28, 2004 Oct NEWA

AA 25MG N40554 001 Oct 28, 2004 Oct NEWA

AA 50MG N40551 001 Oct 28, 2004 Oct NEWA

DUVOID

AA WELLSRING PHARM 10MG N86262 001 Jul CMFD

AA 25MG N86263 001 Jul CMFD

URECHOLINE

@ ODYSSEY PHARMS 5MG N06536 003 Jun CAHN

@ 10MG N06536 002 Jun CAHN

@ 25MG N06536 004 Jun CAHN

@ 50MG N06536 005 Jun CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+ BRAINTREE 5MG;210GM;0.74GM;2.86GM;5.6GM N21551 001 May 10, 2004 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

AP + HOSPIRA 50MG/ML N19033 001 Apr 29, 1986 May CAHN

@ 50MG/ML N19033 001 Apr 29, 1986 Jun DISC

AP + INTL MEDICATION 50MG/ML N70119 001 Apr 29, 1986 Jun CRLD

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA 200MG/100ML N19008 002 Apr 29, 1986 May CAHN

AP + 400MG/100ML N19008 003 Apr 29, 1986 May CAHN

@ 800MG/100ML N19008 001 Apr 29, 1986 May CAHN

BRETYLIUM TOSYLATE IN PLASTIC CONTAINER

AP + HOSPIRA 50MG/ML N19030 001 Apr 29, 1986 May CAHN

<u>BRIMONIDINE TARTRATE</u>			
SOLUTION/DROPS; OPHTHALMIC			
BRIMONIDINE TARTRATE			
AT	IVAX PHARMS	0.2%	N76372 001 Sep 10, 2004 Sep NEWA
<u>BROMOCRIPTINE MESYLATE</u>			
TABLET; ORAL			
BROMOCRIPTINE MESYLATE			
AB	MYLAN	EQ 2.5MG BASE	N76962 001 Sep 24, 2004 Sep NEWA
<u>BUMETANIDE</u>			
INJECTABLE; INJECTION			
BUMETANIDE			
AP	HOSPIRA	0.25MG/ML	N74160 001 Oct 30, 1997 May CAHN
AP		0.25MG/ML	N74332 001 Oct 31, 1994 May CAHN
<u>BUPIVACAINE HYDROCHLORIDE</u>			
INJECTABLE; INJECTION			
BUPIVACAINE HCL			
AP	HOSPIRA	0.25%	N18053 002 May CAHN
AP		0.25%	N70583 001 Feb 17, 1987 May CAHN
AP		0.25%	N70586 001 Mar 03, 1987 May CAHN
AP		0.25%	N70590 001 Feb 17, 1987 May CAHN
AP		0.5%	N18053 001 May CAHN
AP		0.5%	N70584 001 Feb 17, 1986 May CAHN
AP		0.5%	N70597 001 Mar 03, 1987 May CAHN
AP		0.5%	N70609 001 Mar 03, 1987 May CAHN
AP		0.75%	N18053 003 May CAHN
AP		0.75%	N70585 001 Mar 03, 1987 May CAHN
AP		0.75%	N70587 001 Mar 03, 1987 May CAHN
BUPIVACAINE HCL KIT			
	@ HOSPIRA	0.075%	
	@	0.114%	N19978 001 Sep 03, 1992 May CAHN
	@	0.23%	N19978 002 Sep 03, 1992 May CAHN
			N19978 003 Sep 03, 1992 May CAHN
MARCAINE HCL			
AP +	HOSPIRA	0.25%	N16964 001 May CAHN
AP +		0.5%	N16964 006 May CAHN
MARCAINE HCL PRESERVATIVE FREE			
AP +	HOSPIRA	0.25%	N16964 012 May CAHN
AP +		0.5%	N16964 005 May CAHN
AP +		0.75%	N16964 009 May CAHN
INJECTABLE; SPINAL			
BUPIVACAINE			
AP	HOSPIRA	0.75%	N71810 001 Dec 11, 1987 May CAHN
MARCAINE			
AP +	HOSPIRA	0.75%	N18692 001 May 04, 1984 May CAHN
<u>BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE</u>			
INJECTABLE; INJECTION			
BUPIVACAINE HCL AND EPINEPHRINE			
+	HOSPIRA	0.25%;0.005MG/ML	N71165 001 Jun 16, 1988 May CAHN
		0.25%;0.005MG/ML	N71166 001 Jun 16, 1988 May CAHN
		0.25%;0.005MG/ML	N71167 001 Jun 16, 1988 May CAHN
+		0.5%;0.005MG/ML	N71168 001 Jun 16, 1988 May CAHN
		0.5%;0.005MG/ML	N71169 001 Jun 16, 1988 May CAHN
		0.5%;0.005MG/ML	N71170 001 Jun 16, 1988 May CAHN

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+ HOSPIRA 0.75%;0.005MG/ML N71171 001 Jun 16, 1988 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP + HOSPIRA 0.25%;0.0091MG/ML N16964 004 May CAHN

AP + 0.5%;0.0091MG/ML N16964 008 May CAHN

MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE

AP + HOSPIRA 0.25%;0.0091MG/ML N16964 013 May CAHN

AP + 0.5%;0.0091MG/ML N16964 007 May CAHN

AP + 0.75%;0.0091MG/ML N16964 010 May CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HCL

AP HOSPIRA EQ 0.3MG BASE/ML N74137 001 Jun 03, 1996 May CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1 EON 100MG N75932 001 Nov 25, 2003 May CFTG
 AB1 150MG N75932 002 Mar 22, 2004 May CTEC
 AB 150MG N75932 002 Mar 22, 2004 Mar NEWA
 AB IMPAX LABS 100MG N75913 001 Jan 28, 2004 Jan NEWA
 AB1 100MG N75913 001 Jan 28, 2004 May CTEC
 AB1 150MG N75913 002 Mar 22, 2004 May CTEC
 AB 150MG N75913 002 Mar 22, 2004 Mar NEWA
 AB2 150MG N75914 001 May 27, 2004 May NEWA
 >A> AB1 200MG N76711 001 Dec 03, 2004 Dec NEWA

WELLBUTRIN SR

AB1 GLAXOSMITHKLINE 100MG N20358 002 Oct 04, 1996 May CTEC
 AB1 + 150MG N20358 003 Oct 04, 1996 Jun CTEC
 AB + 150MG N20358 003 Oct 04, 1996 Mar CFTG
 AB + 150MG N20358 003 Oct 04, 1996 May CTEC
 >D> 200MG N20358 004 Jun 14, 2002 Dec CFTG
 >A> AB1 200MG N20358 004 Jun 14, 2002 Dec CFTG

ZYBAN

AB + GLAXOSMITHKLINE 150MG N20711 003 May 14, 1997 May CFTG
 AB2 + 150MG N20711 003 May 14, 1997 Jun CTEC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB TEVA 30MG N75022 004 Mar 25, 2004 Mar NEWA

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP HOSPIRA 1MG/ML N75559 001 Mar 20, 2000 May CAHN
 AP 2MG/ML N75559 002 Mar 20, 2000 May CAHN

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP HOSPIRA 1MG/ML N74620 001 Jan 22, 1997 May CAHN
 AP 1MG/ML N74626 001 Jan 23, 1997 May CAHN
 AP 2MG/ML N74620 002 Jan 22, 1997 May CAHN
 AP 2MG/ML N74626 002 Jan 23, 1997 May CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+ MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N20793 001 Sep 21, 1999 Sep CPOT

SOLUTION; ORAL

CAFCIT

+ MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N20793 002 Apr 12, 2000 Sep NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

CAFERGOT

AA + SANDOZ 100MG;1MG N84294 001 Nov CTNA

ERCATAB

AB + SANDOZ 100MG;1MG N84294 001 Sep CFTG

AA + 100MG;1MG N84294 001 Oct CTEC

ERGOTAMINE TARTRATE AND CAFFEINE

AA WEST WARD 100MG;1MG N40510 001 Sep 17, 2004 Oct CTEC

AB 100MG;1MG N40510 001 Sep 17, 2004 Sep NEWA

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP MAYNE PHARMA USA 0.001MG/ML N75816 001 Jan 16, 2004 Jan NEWA

AP 0.002MG/ML N75816 002 Jan 16, 2004 Jan NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA 100MG/ML N21117 001 Jan 28, 2000 May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML N18254 001 May CAHN

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

@ B BRAUN 33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML N18256 001 Nov DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;6 00MG/100ML;310MG/100ML N17608 001 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML N19685 005 Oct 17, 1988 May CAHN

@ 20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML N19685 006 Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML N19685 007 Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML N19685 002 Oct 17, 1988 May CAHN

AP 20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML N19685 008 Oct 17, 1988 May CAHN

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 003	Oct 17, 1988	May	CAHN	
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	HOSPIRA	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 004	Oct 17, 1988	May	CAHN	
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	@ HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685 001	Oct 17, 1988	May	CAHN	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121 MG/ML;16.1MG/ML	N18895 001	Jul 20, 1984	May	CAHN	
--	---------	---	------------	--------------	-----	------	--

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML	N18608 001	Feb 26, 1982	May	CAHN	
----	-----------	--	------------	--------------	-----	------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

	@ B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N18721 001	Nov 09, 1982	Nov	DISC	
AP	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N18251 001		May	CAHN	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N17635 001		May	CAHN	
----	---------	-----------------------------------	------------	--	-----	------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N17641 001		May	CAHN	
----	---------	--	------------	--	-----	------	--

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N19416 001	Jan 17, 1986	May	CAHN	
----	---------	--	------------	--------------	-----	------	--

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	DURAMED PHARMS BARR	12.5MG	N74477 001	Feb 13, 1996	May	CAHN	
AB		25MG	N74477 002	Feb 13, 1996	May	CAHN	
AB		50MG	N74477 003	Feb 13, 1996	May	CAHN	
AB		100MG	N74477 004	Feb 13, 1996	May	CAHN	
AB	KALI LABS	12.5MG	N74477 001	Feb 13, 1996	Aug	CAHN	
AB		25MG	N74477 002	Feb 13, 1996	Aug	CAHN	
AB		50MG	N74477 003	Feb 13, 1996	Jul	CAHN	
AB		100MG	N74477 004	Feb 13, 1996	Aug	CAHN	
>D>	AB	PAR PHARM	N74493 001	Feb 13, 1996	Dec	DISC	
>A>	@	12.5MG	N74493 001	Feb 13, 1996	Dec	DISC	
>D>	AB	25MG	N74493 002	Feb 13, 1996	Dec	DISC	
>A>	@	25MG	N74493 002	Feb 13, 1996	Dec	DISC	
>D>	AB	50MG	N74493 003	Feb 13, 1996	Dec	DISC	
>A>	@	50MG	N74493 003	Feb 13, 1996	Dec	DISC	

TABLET; ORAL

CAPTOPRIL

>D>	AB	PAR PHARM	100MG	N74493 004	Feb 13, 1996	Dec	DISC
>A>		@	100MG	N74493 004	Feb 13, 1996	Dec	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

>A>		SHIRE	100MG	N20712 003	Sep 30, 1997	Dec	CAHN
>A>			200MG	N20712 001	Sep 30, 1997	Dec	CAHN
>A>	+		300MG	N20712 002	Sep 30, 1997	Dec	CAHN
>D>		SHIRE PHARM	100MG	N20712 003	Sep 30, 1997	Dec	CAHN
			100MG	N20712 003	Sep 30, 1997	Mar	CRLD
>D>			200MG	N20712 001	Sep 30, 1997	Dec	CAHN
			200MG	N20712 001	Sep 30, 1997	Mar	CRLD
>D>	+		300MG	N20712 002	Sep 30, 1997	Dec	CAHN
>A>		EQUETRO					
>A>		SHIRE	100MG				
>A>			200MG	N21710 001	Dec 10, 2004	Dec	NEWA
>A>	+		300MG	N21710 002	Dec 10, 2004	Dec	NEWA
				N21710 003	Dec 10, 2004	Dec	NEWA

SUSPENSION; ORAL

TERIL

AB		TARO	100MG/5ML	N76729 001	Sep 20, 2004	Sep	NEWA
----	--	------	-----------	------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB		IMPAX LABS	25MG;100MG	N76521 001	May 14, 2004	May	NEWA
AB			50MG;200MG	N76521 002	May 14, 2004	May	NEWA
AB		KV PHARM	50MG;200MG	N76663 001	Jun 24, 2004	Jun	NEWA
AB		TORPHARM	25MG;100MG	N76212 001	Jun 16, 2004	Jun	NEWA
AB			50MG;200MG	N76212 002	Jun 16, 2004	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

		SCHWARZ PHARMA	10MG;100MG	N76699 001	Aug 27, 2004	Aug	NEWA
			25MG;100MG	N76699 002	Aug 27, 2004	Aug	NEWA
	+		25MG;250MG	N76699 003	Aug 27, 2004	Aug	NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP		AM PHARM PARTNERS	50MG/VIAL	N76235 001	Oct 14, 2004	Oct	NEWA
AP			150MG/VIAL	N76235 002	Oct 14, 2004	Oct	NEWA
AP			450MG/VIAL	N76235 003	Oct 14, 2004	Oct	NEWA
AP		BEDFORD	50MG/VIAL	N76099 001	Oct 14, 2004	Oct	NEWA
AP			150MG/VIAL	N76099 002	Oct 14, 2004	Oct	NEWA
AP			450MG/VIAL	N76099 003	Oct 14, 2004	Oct	NEWA
AP		MAYNE PHARMA USA	50MG/VIAL	N76473 001	Oct 27, 2004	Oct	NEWA
AP			150MG/VIAL	N76473 002	Oct 27, 2004	Oct	NEWA
AP			450MG/VIAL	N76473 003	Oct 27, 2004	Oct	NEWA
AP		PHARMACHEMIE	50MG/VIAL	N76162 001	Oct 14, 2004	Oct	NEWA
AP			150MG/VIAL	N76162 002	Oct 14, 2004	Oct	NEWA
AP			450MG/VIAL	N76162 003	Oct 14, 2004	Oct	NEWA
AP		PLIVA	50MG/VIAL	N76602 001	Nov 16, 2004	Nov	NEWA
AP			150MG/VIAL	N76602 002	Nov 16, 2004	Nov	NEWA
AP			450MG/VIAL	N76602 003	Nov 16, 2004	Nov	NEWA

INJECTABLE; INJECTION

PARAPLATIN

AP	+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	Mar 03, 1989	Oct	CFTG
AP	+		150MG/VIAL	N19880 002	Mar 03, 1989	Oct	CFTG
AP	+		450MG/VIAL	N19880 003	Mar 03, 1989	Oct	CFTG

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP		AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77247 003	Oct 21, 2004	Oct	NEWA
AP		BEDFORD LABS	EQ 50MG/5ML (10MG/ML)	N77244 001	Oct 15, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77244 002	Oct 15, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77244 003	Oct 15, 2004	Oct	NEWA
AP		MAYNE PHARMA USA	EQ 50MG/5ML (10MG/ML)	N76517 001	Oct 14, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N76517 002	Oct 14, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N76517 003	Oct 14, 2004	Oct	NEWA
AP			600MG/60ML (10MG/ML)	N77059 001	Nov 23, 2004	Nov	NEWA
AP		PHARMACHEMIE	EQ 50MG/5ML (10MG/ML)	N77269 001	Oct 14, 2004	Oct	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77269 002	Oct 14, 2004	Oct	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77269 003	Oct 14, 2004	Oct	NEWA

PARAPLATIN

AP	+	BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452 001	Jul 14, 2003	Oct	CFTG
AP	+		EQ 150MG /15ML(10MG/ML)	N20452 002	Jul 14, 2003	Oct	CFTG
AP	+		EQ 450MG /45ML(10MG/ML)	N20452 003	Jul 14, 2003	Oct	CFTG
	+		EQ 600MG /60ML(10MG/ML)	N20452 004	Jan 15, 2004	Jan	NEWA
AP	+		EQ 600MG /60ML(10MG/ML)	N20452 004	Jan 15, 2004	Nov	CFTG

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

@ ABBOTT

2.5MG

N19204 001 Dec 28, 1988 Jun DISC

@

5MG

N19204 002 Dec 28, 1988 Jun DISC

CEFACTOR

CAPSULE; ORAL

CEFACTOR

AB		CARLSBAD	EQ 250MG BASE	N65146 001	Jan 22, 2004	Jan	NEWA
AB			EQ 500MG BASE	N65146 002	Jan 22, 2004	Jan	NEWA

FOR SUSPENSION; ORAL

CECLOR

AB		CEPH INTL	EQ 125MG BASE/5ML	N62206 001		May	CAHN
AB			EQ 187MG BASE/5ML	N62206 003	Apr 20, 1988	May	CAHN
AB			EQ 250MG BASE/5ML	N62206 002		May	CAHN
AB	+		EQ 375MG BASE/5ML	N62206 004	Apr 20, 1988	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

@ LILLY

EQ 500MG BASE

N50673 002 Jun 28, 1996 Jun DISC

CEFACTOR

AB	+	IVAX PHARMS	EQ 500MG BASE	N65057 001	Jan 05, 2001	Jun	CRLD
----	---	-------------	---------------	------------	--------------	-----	------

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

@ LILLY

EQ 1GM BASE/VIAL

N50504 002 Jul DISC

@

EQ 2GM BASE/VIAL

N50504 003 Jul DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION					
ANCEF					
	@ GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N50461 002		
	@	EQ 5GM BASE/VIAL	N50461 004	Oct	DISC
	CEFAZOLIN SODIUM			Oct	DISC
AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL			
AP	+	EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998	Nov CRLD
AP	+	EQ 20GM BASE/VIAL	N64169 001	Aug 14, 1998	Oct CRLD
AP	HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	N64170 002	Mar 18, 1998	Nov CRLD
	@ MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N65143 001	Oct 18, 2004	Oct NEWA
	@	EQ 500MG BASE/VIAL	N62988 001	Dec 29, 1989	Jun DISC
	@	EQ 1GM BASE/VIAL	N62988 002	Dec 29, 1989	Jun DISC
	@	EQ 5GM BASE/VIAL	N62988 003	Dec 29, 1989	Jun DISC
	@	EQ 10GM BASE/VIAL	N62989 001	Dec 29, 1989	Jun DISC
	@	EQ 20GM BASE/VIAL	N62989 002	Dec 29, 1989	Jun DISC
	KEFZOL		N62989 003	Dec 29, 1989	Jun DISC
	@ LILLY	EQ 250MG BASE/VIAL	N61773 001		Jun DISC
	@	EQ 500MG BASE/VIAL	N61773 002		Jun DISC
	@	EQ 1GM BASE/VIAL	N61773 003		Jun DISC
	@	EQ 10GM BASE/VIAL	N61773 004		Jun DISC
	@	EQ 20GM BASE/VIAL	N61773 005	Sep 08, 1987	Jun DISC

CEFDINIR

FOR SUSPENSION; ORAL					
OMNICEF					
	ABBOTT	125MG/5ML			
	+	250MG/5ML	N50749 001	Dec 04, 1997	Jul CRLD
			N50749 002	Jul 29, 2004	Jul NEWA

CEFIXIME

SUSPENSION; ORAL					
SUPRAX					
+	LUPIN	100MG/5ML			
TABLET; ORAL					
SUPRAX					
+	LUPIN	400MG	N65129 001	Feb 23, 2004	Feb NEWA
			N65130 001	Feb 12, 2004	Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION					
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER					
+	B BRAUN	EQ 2GM BASE			
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER					
+	B BRAUN	EQ 1GM BASE	N50792 001	Jul 29, 2004	Jul NEWA
			N50792 002	Jul 29, 2004	Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION					
CEFTAZIDIME					
AP	ACS DOBFAR	500MG/VIAL			
AP		1GM/VIAL	N62640 001	Nov 20, 1985	Apr CTNA
AP		2GM/VIAL	N62640 002	Nov 20, 1985	Apr CTNA
	TAZICEF		N62640 003	Nov 20, 1985	Apr CTNA
AP	HOSPIRA	500MG/VIAL	N62662 001	Mar 06, 1986	May CAHN
AP		1GM/VIAL	N62662 002	Mar 06, 1986	May CAHN
AP		1GM/VIAL	N64032 001	Oct 31, 1993	May CAHN
AP		2GM/VIAL	N62662 003	Mar 06, 1986	May CAHN
AP		2GM/VIAL	N64032 002	Oct 31, 1993	May CAHN

INJECTABLE; INJECTION

	TAZICEF							
AP	HOSPIRA	6GM/VIAL		N62662 004	Mar 06, 1986	May	CAHN	
	TAZIDIME							
	@ LILLY	1GM/VIAL		N62655 001	Nov 20, 1985	Apr	DISC	
	@	2GM/VIAL		N62655 002	Nov 20, 1985	Apr	DISC	

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ SHIONOGI

EQ 400MG BASE

N50685 002 Dec 20, 1995 Sep CAHN

FOR SUSPENSION; ORAL

CEDAX

SHIONOGI

EQ 90MG BASE/5ML

N50686 001 Dec 20, 1995 Sep CAHN

+

EQ 180MG BASE/5ML

N50686 002 Dec 20, 1995 Sep CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	SANDOZ	EQ 250MG BASE		N65126 001	Oct 28, 2003	Aug	CAHN	
AB		EQ 500MG BASE		N65126 002	Oct 28, 2003	Aug	CAHN	
AB	TEVA	EQ 250MG BASE		N65190 001	Oct 18, 2004	Oct	NEWA	
AB		EQ 500MG BASE		N65190 002	Oct 18, 2004	Oct	NEWA	

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL		N65048 001	Jan 09, 2004	Jan	NEWA	
	KEFUROX							
	@ LILLY	EQ 750MG BASE/VIAL		N62591 001	Jan 10, 1986	Jun	DISC	

INJECTABLE; INJECTION

CEFUROXIME

AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL		N65048 002	Jan 09, 2004	Jan	NEWA	
AP		EQ 7.5GM BASE/VIAL		N65046 001	Jan 09, 2004	Jan	NEWA	
	KEFUROX							
	@ LILLY	EQ 1.5GM BASE/VIAL		N62591 002	Jan 10, 1986	Jun	DISC	
	@	EQ 1.5GM BASE/VIAL		N62592 002	Jan 10, 1986	Jun	DISC	
	@	EQ 7.5GM BASE/VIAL		N62591 003	Dec 17, 1987	Jun	DISC	

INJECTABLE; INTRAVENOUS

KEFUROX

@ LILLY

EQ 750MG BASE/VIAL

N62592 001 Jan 10, 1986 Jun DISC

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

@ MISSION PHARMA

300GM/BOT

N18757 003 Oct 16, 1984 Sep DISC

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

AB	ADVANCIS PHARM	EQ 250MG BASE		N50405 002		Jun	CAHN	
AB	+	EQ 500MG BASE		N50405 003		Jun	CAHN	

FOR SUSPENSION; ORAL

KEFLEX

@ ADVANCIS PHARM

EQ 100MG BASE/ML

N50406 003 Jun CAHN

@

EQ 125MG BASE/5ML

N50406 001 Jun CAHN

@

EQ 250MG BASE/5ML

N50406 002 Jun CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

+	CELLTECH PHARMS	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369 001	Jun 21, 2004	Jun	NEWA
---	-----------------	--	------------	--------------	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ MUTUAL PHARM

25MG

N87292 001

Aug CAHN

@

50MG

N87293 001

Aug CAHN

CHOLESTYRAMINE

POWDER; ORAL

PREVALITE

>A>	AB	UPSHER SMITH	EQ 4GM RESIN/SCOOPFUL	N73263 002	Oct 30, 1997	Dec	NEWA
-----	----	--------------	-----------------------	------------	--------------	-----	------

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

@ SERONO INC

0.25MG/VIAL

N21149 001 Sep 20, 2000 May DISC

INJECTABLE; SUBCUTANEOUS

OVIDREL

+	SERONO INC	EQ 0.25MG /0.5ML	N21149 002	Oct 06, 2003	Apr	CPOT
---	------------	------------------	------------	--------------	-----	------

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961 001	Jun 26, 1986	May	CAHN
---	---------	------------------------	------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

>A>		CICLOPIROX				
-----	--	------------	--	--	--	--

>A>	AB	ALTANA	0.77%	N76435 001	Dec 29, 2004	Dec	NEWA
-----	----	--------	-------	------------	--------------	-----	------

LOPROX

>D>	+	MEDICIS	0.77%	N18748 001	Dec 30, 1982	Dec	CFTG
-----	---	---------	-------	------------	--------------	-----	------

>A>	AB	+	0.77%	N18748 001	Dec 30, 1982	Dec	CFTG
-----	----	---	-------	------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

	AB	ALTANA	0.77%	N76422 001	Aug 06, 2004	Aug	NEWA
--	----	--------	-------	------------	--------------	-----	------

LOPROX

>D>	AT	+	MEDICIS	0.77%	N19824 001	Dec 30, 1988	Dec	CTEC
-----	----	---	---------	-------	------------	--------------	-----	------

>A>	AB	+	0.77%	N19824 001	Dec 30, 1988	Dec	CTEC
-----	----	---	-------	------------	--------------	-----	------

	AT	+	0.77%	N19824 001	Dec 30, 1988	Aug	CFTG
--	----	---	-------	------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	AB	ALPHAPHARM	50MG	N77019 001	Nov 23, 2004	Nov	NEWA
--	----	------------	------	------------	--------------	-----	------

	AB		100MG	N77019 002	Nov 23, 2004	Nov	NEWA
--	----	--	-------	------------	--------------	-----	------

	AB	AMIDE PHARM	100MG	N77028 002	Nov 26, 2004	Nov	NEWA
--	----	-------------	-------	------------	--------------	-----	------

>A>	AB	APOTEX	50MG	N77030 001	Dec 10, 2004	Dec	NEWA
-----	----	--------	------	------------	--------------	-----	------

>A>	AB		100MG	N77030 002	Dec 10, 2004	Dec	NEWA
-----	----	--	-------	------------	--------------	-----	------

	AB	COREPHARMA	100MG	N77022 001	Nov 23, 2004	Nov	NEWA
--	----	------------	-------	------------	--------------	-----	------

	AB	EON	100MG	N77021 001	Nov 23, 2004	Nov	NEWA
--	----	-----	-------	------------	--------------	-----	------

	AB	TEVA	50MG	N77027 001	Nov 24, 2004	Nov	NEWA
--	----	------	------	------------	--------------	-----	------

TABLET; ORAL
CILOSTAZOL

AB	TEVA	100MG	N77027 002	Nov 24, 2004	Nov	NEWA
AB	+ PLETAL					
AB	+ OTSUKA	50MG	N20863 001	Jan 15, 1999	Nov	CFTG
AB	+	100MG	N20863 002	Jan 15, 1999	Nov	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	HOSPIRA	EQ 300MG BASE/2ML	N74296 001	Mar 28, 1997	May	CAHN
AP		EQ 300MG BASE/2ML	N74344 001	Jan 31, 1995	May	CAHN
AP		EQ 300MG BASE/2ML	N74345 001	Jan 31, 1995	May	CAHN
AP		EQ 300MG BASE/2ML	N74412 001	Mar 28, 1997	May	CAHN
AP		EQ 300MG BASE/2ML	N74422 001	Jan 31, 1995	May	CAHN
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HOSPIRA	EQ 6MG BASE/ML	N74269 001	Dec 27, 1994	May	CAHN
	+	EQ 90MG BASE/100ML	N74468 005	Dec 29, 1994	May	CAHN
	+	EQ 120MG BASE/100ML	N74468 006	Dec 29, 1994	May	CAHN
	+	EQ 180MG BASE/100ML	N74468 003	Dec 29, 1994	May	CAHN
	+	EQ 240MG BASE/100ML	N74468 004	Dec 29, 1994	May	CAHN
	+	EQ 360MG BASE/100ML	N74468 001	Dec 29, 1994	May	CAHN
	+	EQ 480MG BASE/100ML	N74468 002	Dec 29, 1994	May	CAHN

SOLUTION; ORAL

CIMETIDINE HCL

>D>	AA	ROXANE	EQ 300MG BASE/5ML	N74541 001	Aug 05, 1997	Dec	DISC
>A>		@	EQ 300MG BASE/5ML	N74541 001	Aug 05, 1997	Dec	DISC

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

		EQ 30MG BASE	N21688 001	Mar 08, 2004	Mar	NEWA
		EQ 60MG BASE	N21688 002	Mar 08, 2004	Mar	NEWA
	+	EQ 90MG BASE	N21688 003	Mar 08, 2004	Mar	NEWA

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

>D>	+	ALCON	EQ 0.3% BASE	N20369 001	Mar 30, 1998	Dec	CAHN
>A>	+		EQ 0.3% BASE	N20369 001	Mar 30, 1998	Dec	CAHN

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

AT	+	ALCON	EQ 0.3% BASE	N19992 001	Dec 31, 1990	Sep	CFTG
CIPROFLOXACIN							
AT		BAUSCH AND LOMB	EQ 0.3% BASE	N76754 001	Jun 09, 2004	Jun	NEWA
AT		NOVEX	EQ 0.3% BASE	N75928 001	Jun 09, 2004	Jun	NEWA

TABLET; ORAL

CIPRO

AB		BAYER PHARMS	EQ 100MG BASE	N19537 001	Apr 08, 1996	Jun	CFTG
AB			EQ 250MG BASE	N19537 002	Oct 22, 1987	Jun	CFTG
AB			EQ 500MG BASE	N19537 003	Oct 22, 1987	Jun	CFTG
AB	+		EQ 750MG BASE	N19537 004	Oct 22, 1987	Jun	CFTG

CIPROFLOXACIN

AB		BARR	EQ 250MG BASE	N74124 001	Jun 09, 2004	Jun	NEWA
AB			EQ 500MG BASE	N74124 002	Jun 09, 2004	Jun	NEWA
AB			EQ 750MG BASE	N74124 003	Jun 09, 2004	Jun	NEWA
>A>	AB	CARLSBAD	EQ 250MG BASE	N76126 002	Jun 09, 2004	Dec	NEWA

TABLET; ORAL
CIPROFLOXACIN

>A>	AB	CARLSBAD	EQ 500MG BASE	N76126 003	Jun 09, 2004	Dec	NEWA
>A>	AB		EQ 750MG BASE	N76126 004	Jun 09, 2004	Dec	NEWA
	AB	COBALT	EQ 250MG BASE	N76794 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76794 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76794 004	Jun 09, 2004	Jun	NEWA
	AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 250MG BASE	N75593 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75593 004	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75593 001	Jun 09, 2004	Jun	NEWA
	AB	EON	EQ 250MG BASE	N76593 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76593 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76593 004	Jun 09, 2004	Jun	NEWA
	AB	GENPHARM	EQ 250MG BASE	N75817 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75817 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75817 004	Jun 09, 2004	Jun	NEWA
	AB	HIKMA	EQ 250MG BASE	N76558 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76558 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76558 004	Jun 09, 2004	Jun	NEWA
	AB	IVAX PHARMS	EQ 250MG BASE	N76089 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76089 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76089 004	Jun 09, 2004	Jun	NEWA
	AB	MARTEC	EQ 250MG BASE	N76138 001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76138 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76138 003	Jun 09, 2004	Jun	NEWA
	AB	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Jun	NEWA
	AB	RANBAXY	EQ 250MG BASE	N75747 001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75747 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75747 003	Jun 09, 2004	Jun	NEWA
	AB	SANDOZ	EQ 250MG BASE	N75939 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N75939 003	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N75939 004	Jun 09, 2004	Jun	NEWA
	AB	TARO	EQ 250MG BASE	N76912 002	Oct 06, 2004	Oct	NEWA
	AB		EQ 500MG BASE	N76912 003	Oct 06, 2004	Oct	NEWA
	AB		EQ 750MG BASE	N76912 004	Oct 06, 2004	Oct	NEWA
	AB	TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jun	NEWA
	AB		EQ 500MG BASE	N76136 002	Jun 09, 2004	Jun	NEWA
	AB		EQ 750MG BASE	N76136 003	Jun 09, 2004	Jun	NEWA
	AB	TORPHARM	EQ 250MG BASE	N76896 001	Nov 04, 2004	Nov	NEWA
	AB		EQ 500MG BASE	N76896 002	Nov 04, 2004	Nov	NEWA
	AB		EQ 750MG BASE	N76896 003	Nov 04, 2004	Nov	NEWA
	AB	UNIQUE PHARM LABS	EQ 250MG BASE	N76639 001	Sep 10, 2004	Sep	NEWA
	AB		EQ 500MG BASE	N76639 002	Sep 10, 2004	Sep	NEWA
	AB		EQ 750MG BASE	N76639 003	Sep 10, 2004	Sep	NEWA

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

>D>	+	ALCON	EQ 0.2% BASE;1%	N20805 001	Feb 10, 1998	Dec	CAHN
>A>	+		EQ 0.2% BASE;1%	N20805 001	Feb 10, 1998	Dec	CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+ BAYER PHARMS 425.2MG;EQ 574.9MG BASE

N21473 002 Aug 28, 2003 Feb CDFR

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CELEXA

>D> + FOREST LABS EQ 10MG BASE/5ML
 >A> AA + EQ 10MG BASE/5ML
 >A> CITALOPRAM HYDROBROMIDE
 >A> AA ROXANE EQ 10MG BASE/5ML

N21046 001 Dec 22, 1999 Dec CFTG
 N21046 001 Dec 22, 1999 Dec CFTG

N77043 001 Dec 13, 2004 Dec NEWA

TABLET; ORAL

CELEXA

AB FOREST LABS EQ 10MG BASE
 AB EQ 20MG BASE
 AB + EQ 40MG BASE

N20822 001 Apr 27, 2000 Oct CFTG
 N20822 002 Jul 17, 1998 Oct CFTG
 N20822 003 Jul 17, 1998 Oct CFTG

CITALOPRAM HYDROBROMIDE

AB ALPHAPHARM EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB APOTEX EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB AUROBINDO EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB CARACO EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB COREPHARMA EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB DR REDDYS LABS LTD EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB EON EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB IVAX PHARMS EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB KALI LABS EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB PUREPAC PHARM EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB ROXANE EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE
 AB WATSON LABS EQ 10MG BASE
 AB EQ 20MG BASE
 AB EQ 40MG BASE

N77037 001 Nov 05, 2004 Nov NEWA
 N77037 002 Nov 05, 2004 Nov NEWA
 N77037 003 Nov 05, 2004 Nov NEWA
 N77046 001 Nov 24, 2004 Nov NEWA
 N77046 002 Nov 24, 2004 Nov NEWA
 N77046 003 Nov 24, 2004 Nov NEWA
 N77031 001 Oct 28, 2004 Oct NEWA
 N77031 002 Oct 28, 2004 Oct NEWA
 N77031 003 Oct 28, 2004 Oct NEWA
 N77032 001 Nov 12, 2004 Nov NEWA
 N77032 002 Nov 12, 2004 Nov NEWA
 N77032 003 Nov 12, 2004 Nov NEWA
 N77036 001 Oct 28, 2004 Oct NEWA
 N77036 002 Oct 28, 2004 Oct NEWA
 N77036 003 Oct 28, 2004 Oct NEWA
 N77038 001 Oct 28, 2004 Oct NEWA
 N77038 002 Oct 28, 2004 Oct NEWA
 N77038 003 Oct 28, 2004 Oct NEWA
 N77035 001 Oct 28, 2004 Oct NEWA
 N77035 002 Oct 28, 2004 Oct NEWA
 N77035 003 Oct 28, 2004 Oct NEWA
 N77048 001 Nov 16, 2004 Nov NEWA
 N77048 002 Nov 16, 2004 Nov NEWA
 N77048 003 Nov 16, 2004 Nov NEWA
 N77042 001 Nov 05, 2004 Nov NEWA
 N77042 002 Nov 05, 2004 Nov NEWA
 N77042 003 Nov 05, 2004 Nov NEWA
 N77033 001 Oct 28, 2004 Oct NEWA
 N77033 002 Oct 28, 2004 Oct NEWA
 N77033 003 Oct 28, 2004 Oct NEWA
 N77041 001 Nov 23, 2004 Nov NEWA
 N77041 002 Nov 23, 2004 Nov NEWA
 N77041 003 Nov 23, 2004 Nov NEWA
 N77044 001 Nov 05, 2004 Nov NEWA
 N77044 002 Nov 05, 2004 Nov NEWA
 N77044 003 Nov 05, 2004 Nov NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

UROLOGIC G IN PLASTIC CONTAINER

AT	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001	May 27, 1983	May	CAHN
----	---------	--------------------------------------	------------	--------------	-----	------

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP	AM PHARM	1MG/ML	N76571 001	Apr 22, 2004	Apr	NEWA
----	----------	--------	------------	--------------	-----	------

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

AB	+ ABBOTT	500MG	N50775 001	Mar 03, 2000	Jun	CFTG
----	----------	-------	------------	--------------	-----	------

CLARITHROMYCIN

AB	ANDRX PHARMS	500MG	N65145 001	Jun 24, 2004	Jun	NEWA
----	--------------	-------	------------	--------------	-----	------

TABLET; ORAL

BIAXIN

AB	+ ABBOTT	250MG	N50662 001	Oct 31, 1991	May	CFTG
----	----------	-------	------------	--------------	-----	------

AB	+ ABBOTT	500MG	N50662 002	Oct 31, 1991	May	CFTG
----	----------	-------	------------	--------------	-----	------

CLARITHROMYCIN

AB	RANBAXY	250MG	N65174 001	Sep 24, 2004	Sep	NEWA
----	---------	-------	------------	--------------	-----	------

AB	RANBAXY	500MG	N65174 002	Sep 24, 2004	Sep	NEWA
----	---------	-------	------------	--------------	-----	------

AB	ROXANE	250MG	N65178 002	May 25, 2004	May	NEWA
----	--------	-------	------------	--------------	-----	------

AB	ROXANE	500MG	N65178 001	May 25, 2004	May	NEWA
----	--------	-------	------------	--------------	-----	------

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

AB	+ TEVA	2.68MG	N73283 001	Jan 31, 1992	Mar	CRLD
----	--------	--------	------------	--------------	-----	------

TAVIST

@ NOVARTIS

N17661 001		Mar	DISC
------------	--	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HCL

AB	COREPHARMA	EQ 150MG BASE	N65194 001	Mar 22, 2004	Mar	NEWA
----	------------	---------------	------------	--------------	-----	------

AB	COREPHARMA	EQ 300MG BASE	N65194 002	Mar 22, 2004	Mar	NEWA
----	------------	---------------	------------	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

+ PHARMACIA AND UPJOHN EQ 75MG BASE/5ML

N62644 001	Apr 07, 1986	May	CRLD
------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

EVOCLIN

+ CONNETICS 1%

N50801 001	Oct 22, 2004	Nov	CDFR
------------	--------------	-----	------

AEROSOL; TOPICAL

EVOCLIN FOAM

+ CONNETICS 1%

N50801 001	Oct 22, 2004	Oct	NEWA
------------	--------------	-----	------

CREAM; VAGINAL

CLEOCIN

>D>	+ PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	Mar 02, 1998	Dec	CFTG
-----	------------------------	------------	------------	--------------	-----	------

>A>	AB + PHARMACIA AND UPJOHN	EQ 2% BASE	N50680 002	Mar 02, 1998	Dec	CFTG
-----	---------------------------	------------	------------	--------------	-----	------

CREAM; VAGINAL								
>A>	CLINDAMYCIN PHOSPHATE							
>A>	AB ALTANA PHARMA	EQ 2% BASE		N65139	001	Dec 27, 2004	Dec	NEWA
	CLINDESSE							
>D>	KV PHARM	EQ 2% BASE		N50793	001	Nov 30, 2004	Dec	CRLD
>A>	+	EQ 2% BASE		N50793	001	Nov 30, 2004	Dec	CRLD
		EQ 2% BASE		N50793	001	Nov 30, 2004	Nov	NEWA
INJECTABLE; INJECTION								
CLINDAMYCIN PHOSPHATE								
	@ BAXTER HLTHCARE	EQ 150MG BASE/ML		N62953	001	Apr 21, 1988	Aug	CAHN
AP	BEDFORD	EQ 150MG BASE/ML		N65206	001	Sep 24, 2004	Sep	NEWA
AP	HOSPIRA	EQ 150MG BASE/ML		N62800	001	Jul 24, 1987	May	CAHN
AP		EQ 150MG BASE/ML		N62801	001	Jul 24, 1987	May	CAHN
	@	EQ 150MG BASE/ML		N62943	001	Sep 29, 1988	May	CAHN
SOLUTION; TOPICAL								
CLINDAMYCIN PHOSPHATE								
AT	TARO PHARM INDS	EQ 1% BASE		N65184	001	Mar 31, 2004	Mar	NEWA
<u>CLOBETASOL PROPIONATE</u>								
AEROSOL, FOAM; TOPICAL								
	OLUX							
	+ CONNETICS	0.05%		N21142	001	May 26, 2000	Nov	CDFR
SHAMPOO; TOPICAL								
	CLOBEX							
	+ GALDERMA LABS	0.05%		N21644	001	Feb 05, 2004	Feb	NEWA
>A>	<u>CLOFARABINE</u>							
>A>	INJECTABLE; IV (INFUSION)							
>A>	CLOLAR							
>A>	+ GENZYME	20MG/20ML (1MG/ML)		N21673	001	Dec 28, 2004	Dec	NEWA
<u>CLONIDINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
	DURACLON							
	AAIPHARMA	0.1MG/ML		N20615	001	Oct 02, 1996	Jun	CRLD
	+	0.5MG/ML		N20615	002	Apr 27, 1999	Jun	NEWA
TABLET; ORAL								
	CLONIDINE HCL							
AB	MUTUAL PHARM	0.1MG		N70925	001	Sep 04, 1987	Aug	CAHN
	@	0.2MG		N70924	001	Sep 04, 1987	Aug	CAHN
	@	0.3MG		N70923	001	Sep 04, 1987	Aug	CAHN
<u>CLORAZEPATE DIPOTASSIUM</u>								
CAPSULE; ORAL								
	CLORAZEPATE DIPOTASSIUM							
	@ SANDOZ	7.5MG		N72220	001	Aug 26, 1988	Aug	DISC
TABLET; ORAL								
	CLORAZEPATE DIPOTASSIUM							
AB	RANBAXY	3.75MG		N76911	001	Sep 29, 2004	Sep	NEWA
AB		7.5MG		N76911	002	Sep 29, 2004	Sep	NEWA
AB		15MG		N76911	003	Sep 29, 2004	Sep	NEWA
<u>CLOTRIMAZOLE</u>								
TROCHE/LOZENGE; ORAL								
	CLOTRIMAZOLE							
AB	ROXANE	10MG		N76387	001	Jul 29, 2004	Jul	NEWA

TROCHE/LOZENGE; ORAL

	MYCELEX						
AB	+	BAYER PHARMS	10MG	N18713 001	Jun 17, 1983	Jul	CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO

		ALAMO PHARMS	25MG	N21590 001	Feb 10, 2004	Feb	NEWA
--	--	--------------	------	------------	--------------	-----	------

+			100MG	N21590 002	Feb 10, 2004	Feb	NEWA
---	--	--	-------	------------	--------------	-----	------

FAZACLO ODT

		ALAMO PHARMS	25MG	N21590 001	Feb 10, 2004	Jul	CTNA
--	--	--------------	------	------------	--------------	-----	------

+			100MG	N21590 002	Feb 10, 2004	Jul	CTNA
---	--	--	-------	------------	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE

AP		PADDOCK	EQ 150MG BASE/VIAL	N65177 001	Mar 19, 2004	Mar	NEWA
----	--	---------	--------------------	------------	--------------	-----	------

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

+		KING PHARMS	0.8MG/INH	N18887 001	Dec 05, 1985	Jan	CAHN
---	--	-------------	-----------	------------	--------------	-----	------

SOLUTION; INHALATION

INTAL

AN	+	KING PHARMS	10MG/ML	N18596 001	May 28, 1982	Jan	CAHN
----	---	-------------	---------	------------	--------------	-----	------

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+		HOSPIRA	EQ 0.4MG COPPER/ML	N18960 001	Jun 26, 1986	May	CAHN
---	--	---------	--------------------	------------	--------------	-----	------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP		BIONICHE ANIM HLTH	1MG/ML	N40451 001	Sep 23, 2003	Apr	CAHN
----	--	--------------------	--------	------------	--------------	-----	------

AP		BIONICHE PHARMA	1MG/ML	N40451 001	Sep 23, 2003	Sep	CAHN
----	--	-----------------	--------	------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB		MUTUAL PHARM	10MG	N73541 001	May 23, 1995	Aug	CAHN
----	--	--------------	------	------------	--------------	-----	------

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

AB1		ABBOTT	100MG/ML	N65025 001	Mar 03, 2000	Sep	CTEC
-----	--	--------	----------	------------	--------------	-----	------

AB2		MORTON GROVE	100MG/ML	N65133 001	Sep 17, 2004	Sep	NEWA
-----	--	--------------	----------	------------	--------------	-----	------

AB1		PLIVA	100MG/ML	N65054 001	Dec 18, 2001	Sep	CTEC
-----	--	-------	----------	------------	--------------	-----	------

NEORAL

AB1	+	NOVARTIS	100MG/ML	N50716 001	Jul 14, 1995	Sep	CTEC
-----	---	----------	----------	------------	--------------	-----	------

SANDIMMUNE

AB2	+	NOVARTIS	100MG/ML	N50574 001	Nov 14, 1983	Sep	CFTG
-----	---	----------	----------	------------	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL

+ ALPHARMA 2MG/5ML

N86833 001

Aug CRLD

PERIACTIN

@ MERCK 2MG/5ML

N13220 002

Aug DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HCL

@ HOSPIRA 7.25%

N19523 001 Oct 22, 1986 Aug CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP AM PHARM 100MG/ML

N76512 001 Jan 15, 2004 Jan NEWA

AP + MAYNE PHARMA USA 100MG/ML

N75383 001 Nov 22, 1999 Jan CFTG

>A> DARIFENACIN HYDROBROMIDE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> ENABLEX

>A> NOVARTIS EQ 7.5MG BASE

N21513 001 Dec 22, 2004 Dec NEWA

>A> + EQ 15MG BASE

N21513 002 Dec 22, 2004 Dec NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

AP BIGMAR BIOREN PHARMS EQ 20MG BASE/VIAL

N65000 001 May 25, 1999 Jul CAHN

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP ABBOTT 500MG/VIAL

N76019 001 Mar 17, 2004 Mar NEWA

AP 2GM/VIAL

N76019 002 Mar 17, 2004 Mar NEWA

AP HOSPIRA 500MG/VIAL

N76019 001 Mar 17, 2004 May CAHN

AP 2GM/VIAL

N76019 002 Mar 17, 2004 May CAHN

DESFERAL

AP + NOVARTIS 500MG/VIAL

N16267 001 Mar CFTG

AP + 2GM/VIAL

N16267 002 May 25, 2000 Mar CFTG

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

AB ESP PHARMA 150MG

N50261 002

Mar CFTG

AB + 300MG

N50261 003

Mar CFTG

DEMECLOCYCLINE HCL

>A> AB BARR 150MG

N65171 001 Dec 13, 2004 Dec NEWA

>A> AB 300MG

N65171 002 Dec 13, 2004 Dec NEWA

AB IMPAX LABS 150MG

N65094 001 Mar 22, 2004 Mar NEWA

AB 300MG

N65094 002 Mar 22, 2004 Mar NEWA

DESERPIDINE; METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

@ ABBOTT 0.25MG; 5MG

N12775 001

Jun DISC

TABLET; ORAL
ENDURONYL FORTE
@ ABBOTT

0.5MG;5MG

N12775 002

Jun DISC

DESFLURANE

LIQUID; INHALATION
SUPRANE

>D> BAXTER HLTHCARE CORP 99.9%
>A> + 99.9%

N20118 001 Sep 18, 1992 Dec CRLD
N20118 001 Sep 18, 1992 Dec CRLD

DESIRUDIN

INJECTABLE; SUBCUTANEOUS
IPRIVASK
+ CANYON

15MG/VIAL

N21271 001 Apr 04, 2003 Apr CAHN

DESLORATADINE

SYRUP; ORAL
CLARINEX
+ SCHERING

0.5MG/ML

N21300 001 Sep 01, 2004 Sep NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP HOSPIRA 0.004MG/ML

N75220 001 Aug 28, 2000 May CAHN

SPRAY, METERED; NASAL
STIMATE

+ ZLB BEHRING 0.15MG/SPRAY

N20355 001 Mar 07, 1994 Sep CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
CYCLESSA

AB + ORGANON USA INC 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG

N21090 001 Dec 20, 2000 Feb CFTG

VELIVET

AB DURAMED PHARMS BARR 0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG

N76455 001 Feb 24, 2004 Feb NEWA

DESOXIMETASONE

CREAM; TOPICAL
TOPICORT

AB + TARO PHARMS NORTH 0.25%

N17856 001

Jun CAHN

TOPICORT LP

AB + TARO PHARMS NORTH 0.05%

N18309 001

Jun CAHN

GEL; TOPICAL

TOPICORT

AB + TARO PHARMS NORTH 0.05%

N18586 001

Mar 29, 1982 Jun CAHN

OINTMENT; TOPICAL

TOPICORT

@ TARO PHARMS NORTH 0.05%

N18594 001

Jan 17, 1985 Jun CAHN

AB + 0.25%

N18763 001

Sep 30, 1983 Jun CAHN

DEXAMETHASONE

TABLET; ORAL
DECADRON

@ MERCK 0.25MG

N11664 004

Oct DISC

@ 1.5MG

N11664 003

Oct DISC

@ 4MG

N11664 005

Oct DISC

TABLET; ORAL

			DECADRON						
			@ MERCK	6MG		N11664	006	Jul 30, 1982	Oct DISC
			DEXAMETHASONE						
			@ MUTUAL PHARM	0.25MG		N84013	001		Aug CAHN
			@	0.25MG		N84764	001		Aug CAHN
			@	0.5MG		N84084	001		Aug CAHN
			@	0.5MG		N84766	001		Aug CAHN
			@	0.75MG		N84081	001		Aug CAHN
			@	0.75MG		N84765	001		Aug CAHN
			@	1.5MG		N84086	001		Aug CAHN
			@	1.5MG		N84763	001		Aug CAHN
>D>	BP	+	PAR PHARM	0.25MG		N88149	001	Apr 28, 1983	Dec CTEC
>A>		+		0.25MG		N88149	001	Apr 28, 1983	Dec CTEC
	BP	+		0.25MG		N88149	001	Apr 28, 1983	Oct CRLD
>D>	AB		ROXANE	1.5MG		N84610	001		Dec CRLD
>A>	BP	+		1.5MG		N84610	001		Dec CRLD
>D>	AB			4MG		N84612	001		Dec CTEC
>A>	BP			4MG		N84612	001		Dec CTEC
	BP	+		6MG		N88316	001	Sep 15, 1983	Oct CRLD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

			DECADRON						
			@ MERCK	EQ 0.1% PHOSPHATE		N11984	001		Sep DISC
			DEXAMETHASONE SODIUM PHOSPHATE						
AT	+		ALCON UNIVERSAL	EQ 0.1% PHOSPHATE		N88771	001	Jan 16, 1985	Sep CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

			@ NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		N62544	001	Oct 29, 1984	Apr DISC
--	--	--	------------	---------------------------------------	--	--------	-----	--------------	----------

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

	+		HOSPIRA	EQ 100UGM BASE/ML		N21038	001	Dec 17, 1999	May CAHN
--	---	--	---------	-------------------	--	--------	-----	--------------	----------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE

AP			BEDFORD	EQ 250MG BASE/VIAL		N76068	001	Sep 28, 2004	Sep NEWA
AP				EQ 500MG BASE/VIAL		N76068	002	Sep 28, 2004	Sep NEWA
			ZINECARD						
AP	+		PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL		N20212	001	May 26, 1995	Sep CFTG
AP	+			EQ 500MG BASE/VIAL		N20212	002	May 26, 1995	Sep CFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

AB			ABLE	5MG		N76814	001	Aug 25, 2004	Aug NEWA
AB				10MG		N76814	002	Aug 25, 2004	Aug NEWA
AB				15MG		N76814	003	Aug 25, 2004	Aug NEWA

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 10% IN PLASTIC CONTAINER							
	@ B BRAUN	10GM/100ML		N18046 001			Nov	DISC
AP	HOSPIRA	10GM/100ML		N18080 001			May	CAHN
	DEXTROSE 2.5% IN PLASTIC CONTAINER							
	@ B BRAUN	2.5GM/100ML		N18358 001			May	DISC
	DEXTROSE 20% IN PLASTIC CONTAINER							
AP	HOSPIRA	20GM/100ML		N18564 001	Mar 23, 1982	May		CAHN
	DEXTROSE 25%							
	HOSPIRA	250MG/ML		N19445 002	Nov 23, 1998	May		CAHN
	DEXTROSE 30% IN PLASTIC CONTAINER							
AP	HOSPIRA	30GM/100ML		N19345 001	Jan 26, 1985	May		CAHN
	DEXTROSE 40% IN PLASTIC CONTAINER							
AP	HOSPIRA	40GM/100ML		N18562 001	Mar 23, 1982	May		CAHN
	DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	50MG/ML		N16367 002		May		CAHN
AP		50MG/ML		N19222 001	Jul 13, 1984	May		CAHN
AP		5GM/100ML		N19466 001	Jul 15, 1985	May		CAHN
AP		5GM/100ML		N19479 001	Sep 17, 1985	May		CAHN
	DEXTROSE 50% IN PLASTIC CONTAINER							
	@ HOSPIRA	500MG/ML		N19445 001	Jun 03, 1986	May		CAHN
AP		50GM/100ML		N18563 001	Mar 23, 1982	May		CAHN
AP		50GM/100ML		N19894 001	Dec 26, 1989	May		CAHN
	DEXTROSE 60% IN PLASTIC CONTAINER							
AP	HOSPIRA	60GM/100ML		N19346 001	Jan 25, 1985	May		CAHN
	DEXTROSE 70% IN PLASTIC CONTAINER							
AP	HOSPIRA	70GM/100ML		N18561 001	Mar 23, 1982	May		CAHN
AP		70GM/100ML		N19893 001	Dec 26, 1989	May		CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML		N17610 001			May	CAHN
--	---------	---	--	------------	--	--	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML		N19025 001	Dec 27, 1984	May		DISC
--	-----------	---	--	------------	--------------	-----	--	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML		N19515 001	May 08, 1986	May		CAHN
--	---------	---	--	------------	--------------	-----	--	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML		N19513 001	May 08, 1986	May		CAHN
--	---------	---	--	------------	--------------	-----	--	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 2 20MG/100ML; 140MG/100ML	N18273 001	May	DISC
-----------	---	------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 3 70MG/100ML; 530MG/100ML; 500MG/100M L	N19843 001	Aug 09, 1993	Nov	CTEC
---------	--	------------	--------------	-----	------

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 3 70MG/100ML; 530MG/100ML; 500MG/100M L	N18274 001		Nov	DISC
-----------	--	------------	--	-----	------

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 2 22MG/100ML; 526MG/100ML; 502MG/100M L	N17609 001		May	CAHN
---------	--	------------	--	-----	------

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 3 68MG/100ML; 526MG/100ML; 502MG/100M L	N17451 001		Nov	CTEC
-----------------	--	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 149MG/100ML	N18371 001		May	CAHN
---------	------------------------	------------	--	-----	------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML; 224MG/100ML	N18371 003		May	CAHN
----	---------	------------------------	------------	--	-----	------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 298MG/100ML	N18371 002		May	CAHN
---------	------------------------	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML ; 146MG/100ML; 207MG/100ML	N19514 001	May 08, 1986	May	CAHN
---------	---	------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML ; 280MG/100ML; 91MG/100ML	N18270 001		May	DISC
-----------	--	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 74.5MG/100ML; 225MG/100M L	N18365 002	Jul 05, 1983	May	CAHN
	5GM/100ML; 149MG/100ML; 225MG/100ML	N18365 006	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100M L	N18876 001	Jan 17, 1986	May	CAHN
	5GM/100ML; 149MG/100ML; 300MG/100ML	N18876 006	Mar 28, 1988	May	CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML; 74.5MG/100ML; 450MG/100M L	N18362 005	Mar 28, 1988	May	CAHN
----	---------	--	------------	--------------	-----	------

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N18362 009	Jul 05, 1983	May	CAHN		
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N19691 002	Mar 24, 1988	May	CAHN		
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N19691 004	Mar 24, 1988	May	CAHN		
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 224MG/100ML; 225MG/100ML	N18365 008	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N18876 007	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 224MG/100ML; 450MG/100ML	N18362 006	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 224MG/100ML; 900MG/100ML	N19691 006	Mar 24, 1988	May	CAHN		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 149MG/100ML; 225MG/100ML	N18365 001		May	CAHN		
		5GM/100ML; 298MG/100ML; 225MG/100ML	N18365 009	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N18876 008	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 149MG/100ML; 450MG/100ML	N18362 010	Jul 05, 1983	May	CAHN		
AP		5GM/100ML; 298MG/100ML; 450MG/100ML	N18362 007	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 149MG/100ML; 900MG/100ML	N19691 005	Mar 24, 1988	May	CAHN		
AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N19691 008	Mar 24, 1988	May	CAHN		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 149MG/100ML; 300MG/100ML	N18876 002	Jan 17, 1986	May	CAHN		
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 224MG/100ML; 225MG/100ML	N18365 003	Jul 05, 1983	May	CAHN		
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N18876 003	Jan 17, 1986	May	CAHN		
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 224MG/100ML; 450MG/100ML	N18362 002		May	CAHN		
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 224MG/100ML; 900MG/100ML	N19691 007	Mar 24, 1988	May	CAHN		
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 298MG/100ML; 225MG/100ML	N18365 004	Jul 05, 1983	May	CAHN		
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N18876 004	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 298MG/100ML; 450MG/100ML	N18362 003		May	CAHN		
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 298MG/100ML; 900MG/100ML	N19691 009	Mar 24, 1988	May	CAHN		
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N18365 005	Mar 28, 1988	May	CAHN		
		5GM/100ML; 149MG/100ML; 225MG/100ML	N18365 007	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N18876 005	Mar 28, 1988	May	CAHN		
		5GM/100ML; 149MG/100ML; 300MG/100ML	N18876 009	Mar 28, 1988	May	CAHN		
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	HOSPIRA	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N18362 008	Mar 28, 1988	May	CAHN		
AP		5GM/100ML; 149MG/100ML; 450MG/100ML	N18362 004	Mar 28, 1988	May	CAHN		

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML; 74.5MG/100ML; 900MG/100ML N19691 001 Mar 24, 1988 May CAHN
 L
 AP 5GM/100ML; 149MG/100ML; 900MG/100ML N19691 003 Mar 24, 1988 May CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 2.5GM/100ML; 450MG/100ML N18096 001 May CAHN
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML; 225MG/100ML N17606 001 May CAHN
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 HOSPIRA 5GM/100ML; 300MG/100ML N17799 001 May CAHN
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML; 450MG/100ML N17607 001 May CAHN
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 AP ABBOTT 5GM/100ML; 900MG/100ML N17585 001 May CAHN
 AP HOSPIRA 5GM/100ML; 900MG/100ML N17585 001 Aug CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAAQUE
 @ GE HEALTHCARE 30% N16403 002 May DISC
 RENO-DIP
 + BRACCO 30% N10040 012 May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAAQUE-76
 AP GE HEALTHCARE 66%; 10% N86505 001 Oct CMFD
 @ 66%; 10% N86505 001 May DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM
 @ BAXTER HLTHCARE 5MG/ML N70311 001 Dec 16, 1985 Aug CAHN
 @ 5MG/ML N70312 001 Dec 16, 1985 Aug CAHN
 @ 5MG/ML N70313 001 Dec 16, 1985 Aug CAHN
 AP + HOSPIRA 5MG/ML N71583 001 Oct 13, 1987 May CAHN
 AP 5MG/ML N71584 001 Oct 13, 1987 May CAHN
 AP 5MG/ML N72079 001 Dec 20, 1988 May CAHN
 AP PARENTA PHARMS 5MG/ML N76815 001 Apr 15, 2004 Apr NEWA
 TABLET; ORAL
 DIAZEPAM
 @ PAR PHARM 10MG N70464 001 Feb 25, 1986 Sep DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM
 AB TORPHARM 50MG N76561 001 Mar 18, 2004 Mar NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ BIOGLAN PHARMS CORP 3% N21005 001 Oct 16, 2000 Aug CAHN

SOLUTION/DROPS; OPHTHALMIC

VOLTAREN
 + NOVARTIS 0.1% N20037 001 Mar 28, 1991 Aug CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM EQ 125MG BASE N61454 002 Mar CAHN
 SANDOZ

AB EQ 250MG BASE N61454 001 Mar CAHN

AB + EQ 500MG BASE N61454 003 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL @ MUTUAL PHARM 10MG N84505 001 Oct 21, 1986 Aug CAHN

TABLET; ORAL

DICYCLOMINE HCL @ MUTUAL PHARM 20MG N84600 001 Jul 29, 1985 Aug CAHN

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

>A> DIDANOSINE N77167 001 Dec 03, 2004 Dec NEWA

>A> AB BARR 200MG N77167 002 Dec 03, 2004 Dec NEWA

>A> AB 250MG N77167 003 Dec 03, 2004 Dec NEWA

>A> AB 400MG

VIDEX EC

>D> + BRISTOL MYERS SQUIBB 125MG N21183 001 Oct 31, 2000 Dec CRLD

>A> 125MG N21183 001 Oct 31, 2000 Dec CRLD

>D> + 200MG N21183 002 Oct 31, 2000 Dec CFTG

>A> AB 200MG N21183 002 Oct 31, 2000 Dec CFTG

>D> + 250MG N21183 003 Oct 31, 2000 Dec CFTG

>A> AB 250MG N21183 003 Oct 31, 2000 Dec CFTG

>D> + 400MG N21183 004 Oct 31, 2000 Dec CFTG

>A> AB + 400MG N21183 004 Oct 31, 2000 Dec CFTG

FOR SOLUTION; ORAL

VIDEX

+ BRISTOL MYERS SQUIBB 10MG/ML N20156 001 Oct 09, 1991 Jun CRLD

@ 100MG/PACKET N20155 003 Oct 09, 1991 Jun DISC

@ 167MG/PACKET N20155 004 Oct 09, 1991 Jun DISC

@ 250MG/PACKET N20155 005 Oct 09, 1991 Jun DISC

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB 25MG N20154 002 Oct 09, 1991 Jul CRLD

+ 200MG N20154 006 Oct 28, 1999 Jul CRLD

DIENESTROL

CREAM; VAGINAL

DIENESTROL

@ ORTHO MCNEIL PHARM 0.01% N06110 005 Jul CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D> AB ROXANE 250MG N73562 001 Nov 27, 1992 Dec DISC

>A> @ 250MG N73562 001 Nov 27, 1992 Dec DISC

>D> AB 500MG N73563 001 Nov 27, 1992 Dec DISC

>A> @ 500MG N73563 001 Nov 27, 1992 Dec DISC

DIGOXIN

ELIXIR; ORAL					
DIGOXIN					
	+ ROXANE	0.05MG/ML			
	INJECTABLE; INJECTION		N21648	001	Aug 26, 2004 Aug NEWA
DIGOXIN					
AP	BAXTER HLTHCARE	0.25MG/ML			
AP	HOSPIRA	0.25MG/ML	N83391	001	Aug CAHN
AP		0.25MG/ML	N40093	001	May 16, 1996 May CAHN
	DIGOXIN PEDIATRIC		N40206	001	Aug 28, 1998 May CAHN
AP	HOSPIRA	0.1MG/ML			
			N40092	001	Apr 25, 1996 May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
CARDIZEM SR					
	@ AVENTIS PHARMS	60MG			
	@	90MG			
	@	120MG			
	@ BIOVAIL	60MG	N19471	001	Jan 23, 1989 Jun DISC
	@	90MG	N19471	002	Jan 23, 1989 Jun DISC
	@	120MG	N19471	003	Jan 23, 1989 Jun DISC
	@	60MG	N19471	001	Jan 23, 1989 Nov CAHN
	@	90MG	N19471	002	Jan 23, 1989 Nov CAHN
	@	120MG	N19471	003	Jan 23, 1989 Nov CAHN
	@	180MG	N19471	004	Jan 23, 1989 Nov CAHN
DILT-CD					
AB3	TORPHARM	120MG			
AB3		180MG	N76151	001	May 20, 2004 May NEWA
AB3		240MG	N76151	002	May 20, 2004 May NEWA
AB3		300MG	N76151	003	May 20, 2004 May NEWA
			N76151	004	May 20, 2004 May NEWA
DILTIAZEM HCL					
	@ BIOVAIL	60MG			
	@	90MG			
	@	120MG			
	+ MYLAN	60MG	N74845	001	Sep 15, 1999 Jun DISC
	+	90MG	N74845	002	Sep 15, 1999 Jun DISC
	+	120MG	N74845	003	Sep 15, 1999 Jun DISC
	@ TEVA	60MG	N74910	001	May 02, 1997 Jun CRLD
	@	90MG	N74910	002	May 02, 1997 Jun CRLD
	@	120MG	N74910	003	May 02, 1997 Jun CRLD
		60MG	N74079	001	Nov 30, 1993 Jun DISC
		90MG	N74079	002	Nov 30, 1993 Jun DISC
		120MG	N74079	003	Nov 30, 1993 Jun DISC
INJECTABLE; INJECTION					
CARDIZEM					
AP	+ BIOVAIL	100MG/VIAL	N20792	001	Sep. 05, 1997 Nov CAHN
DILTIAZEM HCL					
AP	HOSPIRA	5MG/ML			
AP		5MG/ML	N74941	001	Apr 15, 1998 May CAHN
AP		100MG/VIAL	N75004	001	Feb 16, 2000 May CAHN
			N75853	001	Dec 17, 2002 May CAHN
TABLET, EXTENDED RELEASE; ORAL					
CARDIZEM LA					
	BIOVAIL	120MG			
		180MG	N21392	001	Feb 06, 2003 Jan CRLD
		240MG	N21392	002	Feb 06, 2003 Jan CRLD
		300MG	N21392	003	Feb 06, 2003 Jan CRLD
		360MG	N21392	004	Feb 06, 2003 Jan CRLD
			N21392	005	Feb 06, 2003 Jan CRLD
TABLET; ORAL					
CARDIZEM					
AB	BIOVAIL	30MG			
AB		60MG	N18602	001	Nov 05, 1982 Nov CAHN
AB		90MG	N18602	002	Nov 05, 1982 Nov CAHN
			N18602	003	Dec 08, 1986 Nov CAHN

TABLET; ORAL
CARDIZEM

AB + BIOVAIL 120MG N18602 004 Dec 08, 1986 Nov CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

AP AM PHARM 50MG/ML N40519 001 Jun 23, 2004 Jun NEWA
AP + STERIS 50MG/ML N80615 001 Jun CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT

+ IMCOR PH 0.92MG/VIAL;0.092MG/VIAL N21191 001 May 31, 2002 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA MUTUAL PHARM 25MG N84506 001 Aug CAHN

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

>D> AA MK LABS 12.5MG/5ML N83088 002 Dec DISC
>A> @ 12.5MG/5ML N83088 002 Dec DISC
>D> AA PHARM ASSOC 12.5MG/5ML N87513 001 Feb 10, 1982 Dec CRLD
>A> AA + 12.5MG/5ML N87513 001 Feb 10, 1982 Dec CRLD
>D> AA + ROXANE 12.5MG/5ML N80643 001 Dec DISC
>A> @ 12.5MG/5ML N80643 001 Dec DISC

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP HOSPIRA 50MG/ML N40140 001 Nov 20, 1998 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE

AP BAXTER HLTHCARE 5MG/ML N74521 001 Oct 18, 1996 Aug CAHN
AP HOSPIRA 5MG/ML N74601 001 Dec 19, 1997 May CAHN

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL
DYNABAC

@ LILLY RES LABS 250MG N50678 001 Jun 19, 1995 Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

@ MUTUAL PHARM EQ 100MG BASE N70351 001 Dec 17, 1985 Aug CAHN
@ EQ 150MG BASE N70352 001 Dec 17, 1985 Aug CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

@ ODYSSEY PHARMS 250MG N07883 003 Jun CAHN
@ 500MG N07883 002 Jun CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

ABBOTT

EQ 125MG VALPROIC ACID

N18723 003 Oct 26, 1984 Jan CRLD

EQ 250MG VALPROIC ACID

N18723 001 Mar 10, 1983 Jan CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP HOSPIRA

EQ 12.5MG BASE/ML

N74086 001 Nov 29, 1993 May CAHN

AP

EQ 12.5MG BASE/ML

N74292 001 Feb 16, 1995 May CAHN

AP

EQ 1.25GM BASE/100ML

N74634 001 Sep 27, 1996 May CAHN

DOBUTAMINE HCL IN DEXTROSE 5%

AP + HOSPIRA

EQ 50MG BASE/100ML

N20269 001 Oct 19, 1993 May CAHN

AP

+

EQ 100MG BASE/100ML

N20269 002 Oct 19, 1993 May CAHN

AP

+

EQ 200MG BASE/100ML

N20269 003 Oct 19, 1993 May CAHN

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA

EQ 50MG BASE/100ML

N20201 003 Oct 19, 1993 May CAHN

AP

+

EQ 100MG BASE/100ML

N20201 002 Oct 19, 1993 May CAHN

AP

+

EQ 200MG BASE/100ML

N20201 001 Oct 19, 1993 May CAHN

AP

+

EQ 400MG BASE/100ML

N20201 006 Jul 07, 1994 May CAHN

DOBUTREX

@ LILLY

EQ 12.5MG BASE/ML

N17820 002 Jun DISC

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

+ EISAI MEDCL RES

5MG/5ML

N21719 001 Oct 18, 2004 Oct NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

+ EISAI MEDCL RES

5MG

N21720 001 Oct 18, 2004 Oct NEWA

+

10MG

N21720 002 Oct 18, 2004 Oct NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP + HOSPIRA

40MG/ML

N18132 001 May CAHN

AP

40MG/ML

N74403 001 May 23, 1996 May CAHN

AP

+

80MG/100ML

N18132 002 Feb 04, 1982 May CAHN

AP

+

80MG/ML

N18132 004 Jul 09, 1982 May CAHN

AP

+

160MG/100ML

N18132 003 Feb 04, 1982 May CAHN

DOPAMINE HCL IN DEXTROSE 5%

@ HOSPIRA

AP

+

1.6MG/ML

N20542 001 Aug 30, 1995 Jun DISC

1.6MG/ML

N20542 001 Aug 30, 1995 May CAHN

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA

80MG/100ML

N18826 001 Sep 30, 1983 May CAHN

AP

+

160MG/100ML

N18826 002 Sep 30, 1983 May CAHN

AP

+

320MG/100ML

N18826 003 Sep 30, 1983 May CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB CLONMEL HLTHCARE

EQ 1MG BASE

N76161 001 Jun 10, 2004 Jun NEWA

AB

EQ 2MG BASE

N76161 002 Jun 10, 2004 Jun NEWA

AB

EQ 4MG BASE

N76161 003 Jun 10, 2004 Jun NEWA

AB

EQ 8MG BASE

N76161 004 Jun 10, 2004 Jun NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

	@ MUTUAL PHARM	EQ 25MG BASE	N71502 001	Feb 18, 1988	Aug	CAHN
	@	EQ 50MG BASE	N71653 001	Feb 18, 1988	Aug	CAHN
	@	EQ 75MG BASE	N71654 001	Feb 18, 1988	Aug	CAHN
	@	EQ 100MG BASE	N71521 001	Feb 18, 1988	Aug	CAHN
	@ SANDOZ	EQ 25MG BASE	N70827 001	May 15, 1986	Sep	DISC
	@	EQ 50MG BASE	N70828 001	May 15, 1986	Sep	DISC
>D>	AB	EQ 75MG BASE	N70825 001	May 15, 1986	Dec	DISC
>A>	@	EQ 75MG BASE	N70825 001	May 15, 1986	Dec	DISC
	@	EQ 100MG BASE	N71562 001	Mar 02, 1987	Sep	DISC

CONCENTRATE; ORAL

DOXEPIN HCL

AA	PHARM ASSOC	EQ 10MG BASE/ML	N75924 001	Jan 15, 2004	Jan	NEWA
----	-------------	-----------------	------------	--------------	-----	------

CREAM; TOPICAL

ZONALON

+	BIOGLAN PHARMS CORP	5%	N20126 001	Apr 01, 1994	Aug	CAHN
+	BRADLEY PHARMS	5%	N20126 001	Apr 01, 1994	Nov	CAHN

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

	BONE CARE	0.5UGM	N20862 002	Apr 23, 2004	Apr	NEWA
--	-----------	--------	------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

	@ PHARMACIA AND UPJOHN	10MG/VIAL	N50467 001		Jun	DISC
	@	20MG/VIAL	N50467 003	May 20, 1985	Jun	DISC
	@	50MG/VIAL	N50467 002		Jun	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	WATSON LABS	EQ 50MG BASE	N65041 001	Apr 28, 2000	Apr	CAHN
AB		EQ 100MG BASE	N65041 002	Apr 28, 2000	Apr	CAHN

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

	FH FAULDING CO LTD	EQ 75MG BASE	N50582 002	Aug 13, 2001	Jul	CAHN
AB	+	EQ 100MG BASE	N50582 001	Jul 22, 1985	Jul	CAHN

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

	@ MUTUAL PHARM	EQ 50MG BASE	N62418 001	Jan 28, 1983	Aug	CAHN
	@	EQ 100MG BASE	N62418 002	Jan 28, 1983	Aug	CAHN
AB	WATSON LABS	EQ 50MG BASE	N61717 001		Apr	CAHN
AB		EQ 100MG BASE	N61717 002		Apr	CAHN

LIQUID, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

>D>	+	ATRIX	EQ 10% W/W	N50751 001	Sep 03, 1998	Dec	CAHN
>A>	+	QLT USA	EQ 10% W/W	N50751 001	Sep 03, 1998	Dec	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

	@ MUTUAL PHARM	EQ 100MG BASE	N62391 001	Sep 30, 1982	Aug	CAHN
--	----------------	---------------	------------	--------------	-----	------

DROPERIDOL

INJECTABLE; INJECTION
 DROPERIDOL
 AP HOSPIRA 2.5MG/ML N71981 001 Feb 29, 1988 May CAHN
 AP 2.5MG/ML N72272 001 Aug 31, 1995 May CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
 FENTANYL CITRATE AND DROPERIDOL
 + HOSPIRA 2.5MG/ML;EQ 0.05MG BASE/ML N71982 001 May 04, 1988 May CAHN
 @ 2.5MG/ML;EQ 0.05MG BASE/ML N71982 001 May 04, 1988 Sep DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL
 CYMBALTA
 LILLY EQ 20MG BASE N21733 001 Sep 03, 2004 Sep NEWA
 EQ 30MG BASE N21733 002 Sep 03, 2004 Sep NEWA
 + EQ 60MG BASE N21733 004 Sep 03, 2004 Sep NEWA
 CAPSULE; ORAL
 CYMBALTA
 LILLY EQ 20MG BASE N21427 001 Aug 03, 2004 Aug NEWA
 EQ 30MG BASE N21427 002 Aug 03, 2004 Aug NEWA
 + EQ 60MG BASE N21427 004 Aug 03, 2004 Aug NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
 ECONAZOLE NITRATE
 AB CLAY PARK 1% N76479 001 Jun 23, 2004 Jun NEWA
 >A> AB HEALTHPOINT 1% N76574 001 Dec 17, 2004 Dec NEWA

EDETATE DISODIUM

INJECTABLE; INJECTION
 EDETATE DISODIUM
 @ STERIS 150MG/ML N80391 001 Sep DISC
 ENDRATE
 AP + HOSPIRA 150MG/ML N11355 001 May CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
 EDROPHONIUM CHLORIDE
 AP HOSPIRA 10MG/ML N40131 001 Feb 24, 1998 May CAHN

EFAVIRENZ

TABLET; ORAL
 SUSTIVA
 @ BRISTOL MYERS SQUIBB 300MG N21360 001 Feb 01, 2002 Jun DISC

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL
 VANIQA
 + SKINMEDICA 13.9% N21145 001 Jul 27, 2000 Jul CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

	+ GILEAD	200MG;300MG	N21752 001	Aug 02, 2004	Aug	NEWA
--	----------	-------------	------------	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	APOTEX	5MG;12.5MG	N76486 001	Oct 27, 2004	Oct	NEWA
AB		10MG;25MG	N76486 002	Oct 27, 2004	Oct	NEWA

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	HOSPIRA	1.25MG/ML	N75456 001	Aug 22, 2000	May	CAHN
AP		1.25MG/ML	N75458 001	Aug 22, 2000	May	CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

	+ HOLLISTER STIER LABS	EQ 0.15MG /DELIVERY	N20800 002	May 28, 2004	May	NEWA
--	------------------------	---------------------	------------	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	HOSPIRA	0.005MG/ML;0.5%	N89635 001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1%	N89649 001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1.5%	N88571 001	Sep 13, 1985	May	CAHN
AP		0.005MG/ML;1.5%	N89645 001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;1.5%	N89650 001	Jun 21, 1988	May	CAHN
AP		0.005MG/ML;2%	N89651 001	Jun 21, 1988	May	CAHN
AP		0.01MG/ML;1%	N89644 001	Jun 21, 1988	May	CAHN
AP		0.01MG/ML;2%	N89646 001	Jun 21, 1988	May	CAHN

PATCH; IONTOPHORESIS

LIDOSITE TOPICAL SYSTEM KIT

	+ VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504 001	May 06, 2004	May	NEWA
--	-----------	--------------------------	------------	--------------	-----	------

SOLUTION; IONTOPHORESIS

LIDOCAINE HCL AND EPINEPHRINE

	+ EMPI	0.01MG/ML;2%	N21486 001	Oct 26, 2004	Oct	NEWA
--	--------	--------------	------------	--------------	-----	------

EPLERENONE

TABLET; ORAL

INSPIRA

	+ GD SEARLE LLC	50MG	N21437 002	Sep 27, 2002	Nov	CRLD
	@	100MG	N21437 003	Sep 27, 2002	Nov	DISC

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

@	MUTUAL PHARM	1MG	N88891 001	Nov 01, 1985	Aug	CAHN
---	--------------	-----	------------	--------------	-----	------

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

@	MUTUAL PHARM	0.5MG	N87407 001		Aug	CAHN
---	--------------	-------	------------	--	-----	------

@		1MG	N87552 001		Aug	CAHN
---	--	-----	------------	--	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

OSI PHARMS

EQ 25MG BASE

N21743 001 Nov 18, 2004 Nov NEWA

EQ 100MG BASE

N21743 002 Nov 18, 2004 Nov NEWA

+

EQ 150MG BASE

N21743 003 Nov 18, 2004 Nov NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT

250MG

N62338 001

Jan CMFD

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS

2%

N50617 001 Oct 21, 1987 Jul CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FOUGERA

0.5%

N62447 001 Sep 26, 1983 Jul CRLD

ILOTYCIN

@ DISTA

0.5%

N50368 001

Jul DISC

SOLUTION; TOPICAL

C-SOLVE-2

@ BIOGLAN PHARMA

2%

N62468 001 Jul 03, 1985 Jun DISC

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA

EQ 125MG BASE/5ML

N62353 001 Nov 18, 1982 Jan CTEC

+

EQ 250MG BASE/5ML

N62409 001 Dec 16, 1982 Jan CRLD

ILOSONE

@ LILLY

EQ 125MG BASE/5ML

N50010 001

Jan DISC

@

EQ 250MG BASE/5ML

N50010 002

Jan DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP + HOSPIRA

EQ 500MG BASE/VIAL

N50182 002

May CAHN

AP

EQ 500MG BASE/VIAL

N50609 001

Sep 24, 1986 May CAHN

AP

EQ 500MG BASE/VIAL

N62638 001

Oct 31, 1986 May CAHN

AP +

EQ 1GM BASE/VIAL

N50182 003

May CAHN

AP

EQ 1GM BASE/VIAL

N50609 002

Sep 24, 1986 May CAHN

AP

EQ 1GM BASE/VIAL

N62638 002

Oct 31, 1986 May CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

FOREST LABS

5MG

N21323 001 Aug 14, 2002 Apr CMFD

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

AP + BAXTER HLTHCARE CORP

10MG/ML

N19386 006

Feb 25, 2003 Aug CFTG

AP

ESMOLOL HCL

AP

BEDFORD LABS

10MG/ML

N76323 001

Aug 10, 2004 Aug NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

MENOSTAR

+ BERLEX LABS 0.014MG/24HR N21674 001 Jun 08, 2004 Jun NEWA

VIVELLE

ABI + NOVARTIS 0.025MG/24HR N20323 005 Aug 16, 2000 Jul CTEC

@ 0.0375MG/24HR N20323 001 Oct 28, 1994 Jul DISC

@ 0.075MG/24HR N20323 003 Oct 28, 1994 Jul DISC

VIVELLE-DOT

ABI NOVARTIS 0.025MG/24HR N20538 009 May 03, 2002 Jul NEWA

BX 0.0375MG/24HR N20538 005 Jan 08, 1999 Jul CTEC

BX 0.075MG/24HR N20538 007 Jan 08, 1999 Jul CTEC

GEL, METERED; TOPICAL

ESTROGEL

+ SOLVAY 0.06% N21166 002 Feb 09, 2004 Aug CRLD

0.06% N21166 002 Feb 09, 2004 Feb NEWA

GEL; TOPICAL

ESTROGEL

SOLVAY 0.06% N21166 001 Feb 09, 2004 Feb NEWA

+ 0.06% N21166 001 Feb 09, 2004 Mar CRLD

@ 0.06% N21166 001 Feb 09, 2004 Aug DISC

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD EQ 0.05MG BASE/24HR N21367 001 Mar 20, 2003 May CPOT

+ EQ 0.1MG BASE/24HR N21367 002 Mar 20, 2003 May CPOT

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT 0.45MG N21633 001 Aug 20, 2004 Aug NEWA

0.9MG N21633 002 Aug 20, 2004 Aug NEWA

+ 1.8MG N21633 003 Aug 20, 2004 Aug NEWA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ DURAMED 1MG, 1MG; 0.09MG N21040 001 Oct 22, 1999 Nov CAHN

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

@ WYETH PHARMS INC 2.5MG N04782 002 May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED 0.45MG N20992 005 Feb 05, 2004 Feb NEWA

>A> ESTROGENS, CONJUGATED SYNTHETIC B

>A> TABLET; ORAL

>A> ENJUVIA

>A> DURAMED 0.3MG N21609 001 Dec 20, 2004 Dec NEWA

>A> + 0.45MG N21609 002 Dec 20, 2004 Dec NEWA

0.625MG N21443 003 May 10, 2004 May NEWA

@ 0.625MG N21443 003 May 10, 2004 Jul DISC

>A>	TABLET; ORAL						
>A>	ENJUWIA						
	+ DURAMED	1.25MG	N21443	004	May 10, 2004	May	NEWA
	@	1.25MG	N21443	004	May 10, 2004	Jul	DISC
>A>	<u>ESZOPICLONE</u>						
>A>	TABLET; ORAL						
>A>	LUNESTA						
>A>	SEPRACOR	1MG	N21476	001	Dec 15, 2004	Dec	NEWA
>A>		2MG	N21476	002	Dec 15, 2004	Dec	NEWA
>A>	+	3MG	N21476	003	Dec 15, 2004	Dec	NEWA
	<u>ETHAMBUTOL HYDROCHLORIDE</u>						
	TABLET; ORAL						
	MYAMBUTOL						
	@ ELAN PHARMS	100MG	N16320	001		Feb	CAHN
	@	200MG	N16320	002		Feb	CAHN
	@	400MG	N16320	003		Feb	CAHN
	@	500MG	N16320	004		Feb	CAHN
AB	STAT TRADE	100MG	N16320	001		May	CMFD
	@	200MG	N16320	002		May	CAHN
AB		400MG	N16320	003		May	CMFD
	@	500MG	N16320	004		May	CAHN
	<u>ETHINYL ESTRADIOL</u>						
	TABLET; ORAL						
	ESTINYL						
	@ SCHERING	0.02MG	N05292	001		Apr	DISC
	@	0.05MG	N05292	002		Apr	DISC
	@	0.5MG	N05292	003		Apr	DISC
	<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>						
	TABLET; ORAL						
	PREVEN EMERGENCY CONTRACEPTIVE KIT						
	+ DURAMED	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Feb	CAHN
	@	0.05MG;0.25MG	N20946	001	Sep 01, 1998	Jul	DISC
	SEASONALE						
>D>	+ BARR	0.03MG;0.15MG	N21544	001	Sep 05, 2003	Dec	CAHN
>A>	+ DURAMED	0.03MG;0.15MG	N21544	001	Sep 05, 2003	Dec	CAHN
	TABLET; ORAL-21						
	ALESSE						
	@ WYETH PHARMS INC	0.02MG;0.1MG	N20683	001	Mar 27, 1997	Aug	DISC
	AVIANE-21						
	+ DURAMED PHARMS BARR	0.02MG;0.1MG	N75796	002	Apr 30, 2001	Aug	CRLD
	LEVLITE						
AB2	+ BERLEX	0.02MG;0.1MG	N20860	001	Jul 13, 1998	May	CTEC
	NORDETTE-21						
>A>	AB + DURAMED	0.03MG;0.15MG	N18668	001	May 10, 1982	Dec	CAHN
>D>	AB + MONARCH PHARMS	0.03MG;0.15MG	N18668	001	May 10, 1982	Dec	CAHN
	TRIPHASIL-21						
	@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19192	001	Nov 01, 1984	Nov	DISC
	TABLET; ORAL-28						
	ALESSE						
AB1	+ WYETH PHARMS INC	0.02MG;0.1MG	N20683	002	Mar 27, 1997	Jul	CRLD
	LESSINA-28						
AB2	BARR	0.02MG;0.1MG	N75803	002	Mar 20, 2002	May	CTEC

TABLET; ORAL-28

LEVLITE

AB2	+	BERLEX	0.02MG;0.1MG	N20860 002	Jul 13, 1998	Jul	CRLD
AB2			0.02MG;0.1MG	N20860 002	Jul 13, 1998	May	CTEC
LEVONORGESTREL AND ETHINYL ESTRADIOL							
AB1		WATSON LABS	0.02MG;0.1MG	N76625 001	Nov 18, 2004	Nov	NEWA
NORDETTE-28							
>A>	AB	DURAMED	0.03MG;0.15MG	N18782 001	Jul 21, 1982	Dec	CAHN
>D>	AB	MONARCH PHARMS	0.03MG;0.15MG	N18782 001	Jul 21, 1982	Dec	CAHN
TRIPHASIL-28							
@ WYETH PHARMS INC							
			0.03MG,0.04MG,0.03MG;0.05MG,0.075	N19190 001	Nov 01, 1984	Aug	DISC
			MG,0.125MG				
AB	+		0.03MG,0.04MG,0.03MG;0.05MG,0.075	N19190 001	Nov 01, 1984	Nov	CMFD
			MG,0.125MG				

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

AB		BARR	0.035MG;0.4MG	N76198 001	Apr 22, 2004	Apr	NEWA
NORCEPT-E 1/35 21							
@ ORTHO MCNEIL PHARM							
			0.035MG;1MG	N71545 001	Feb 09, 1989	Nov	DISC
OVCON-35							
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N18127 001		Apr	CFTG

TABLET; ORAL-28

ARANELLE

AB		BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG	N76783 001	Sep 29, 2004	Sep	NEWA
			,0.5MG				
BALZIVA-28							
AB		BARR	0.035MG;0.4MG	N76238 001	Apr 22, 2004	Apr	NEWA
NORCEPT-E 1/35 28							
@ ORTHO MCNEIL PHARM							
			0.035MG;1MG	N71546 001	Feb 09, 1989	Nov	DISC
ORTHO-NOVUM 1/35-28							
AB	+	ORTHO MCNEIL PHARM	0.035MG;1MG	N17919 002		Mar	CRLD
ORTHO-NOVUM 10/11-28							
AB		ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 002	Jan 11, 1982	Nov	CTNA
OVCON-35							
AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		Apr	CFTG
TRI-NORINYL 28-DAY							
AB	+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG	N18977 002	Apr 13, 1984	Sep	CFTG
			,0.5MG				

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

+	WARNER CHILCOTT	0.005MG;1MG	N21065 002	Oct 15, 1999	Aug	CAHN
---	-----------------	-------------	------------	--------------	-----	------

TABLET; ORAL-21

ESTROSTEP 21

@ WARNER CHILCOTT							
			0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130 001	Oct 09, 1996	Aug	CAHN
LOESTRIN 21 1.5/30							
AB	+	WARNER CHILCOTT	0.03MG;1.5MG	N17875 001		Aug	CAHN
LOESTRIN 21 1/20							
AB	+	WARNER CHILCOTT	0.02MG;1MG	N17876 001		Aug	CAHN

TABLET; ORAL-28

ESTROSTEP FE

+	WARNER CHILCOTT	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130 002	Oct 09, 1996	Aug	CAHN	
LOESTRIN FE 1.5/30							
AB	+	WARNER CHILCOTT	0.03MG;1.5MG	N17355 001		Aug	CAHN

TABLET; ORAL-28

LOESTRIN FE 1/20

AB	+	WARNER CHILCOTT	0.02MG;1MG	N17354 001		Aug	CAHN
----	---	-----------------	------------	------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

	+	ORTHO MCNEIL PHARM	0.025MG,0.025MG,0.25MG;0.18MG,0.215MG,0.25MG	N21241 001	Aug 22, 2002	Jun	CAHN
--	---	--------------------	--	------------	--------------	-----	------

PREVIFEM

AB		ANDRX PHARMS	0.035MG;0.25MG	N76334 001	Jan 09, 2004	Jan	NEWA
----	--	--------------	----------------	------------	--------------	-----	------

TRI-PREVIFEM

AB		ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Mar	NEWA
----	--	--------------	---	------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

@ WYETH PHARMS INC

0.03MG;0.3MG

N17612 001

Aug DISC

LOW-OGESTREL-21

AB	+	WATSON LABS	0.03MG;0.3MG	N75288 001	Jul 28, 1999	Aug	CRLD
----	---	-------------	--------------	------------	--------------	-----	------

OGESTREL 0.5/50-21

	+	WATSON LABS	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Aug	CRLD
--	---	-------------	--------------	------------	--------------	-----	------

OVRAL

@ WYETH PHARMS INC

0.05MG;0.5MG

N16672 001

Aug DISC

TABLET; ORAL-28

OGESTREL 0.5/50-28

AB	+	WATSON LABS	0.05MG;0.5MG	N75406 002	Dec 15, 1999	Aug	CRLD
----	---	-------------	--------------	------------	--------------	-----	------

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

@ MGI PHARMA INC

50MG/ML

N19545 001 Apr 20, 1987 Jun DISC

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

AB		WYETH PHARMS INC	400MG	N20584 001	Oct 25, 1996	May	CRLD
----	--	------------------	-------	------------	--------------	-----	------

AB	+		500MG	N20584 003	Jan 20, 1998	Jul	CRLD
----	---	--	-------	------------	--------------	-----	------

AB			500MG	N20584 003	Jan 20, 1998	May	CRLD
----	--	--	-------	------------	--------------	-----	------

	@		600MG	N20584 002	Oct 25, 1996	Jul	DISC
--	---	--	-------	------------	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

AP	+	HOSPIRA	2MG/ML	N18227 001	Sep 07, 1982	May	CAHN
----	---	---------	--------	------------	--------------	-----	------

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE

AP		HOSPIRA	20MG/ML	N74320 001	Aug 30, 1995	May	CAHN
----	--	---------	---------	------------	--------------	-----	------

AP			20MG/ML	N74351 001	Aug 30, 1995	May	CAHN
----	--	--	---------	------------	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSP SINGAPORE

10MG;10MG

N21687 001 Jul 23, 2004 Jul NEWA

TABLET; ORAL

VYTORIN

	MSP SINGAPORE	10MG;20MG	N21687 002	Jul 23, 2004	Jul	NEWA
		10MG;40MG	N21687 003	Jul 23, 2004	Jul	NEWA
+		10MG;80MG	N21687 004	Jul 23, 2004	Jul	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	HOSPIRA	10MG/ML	N75870 001	Nov 23, 2001	May	CAHN
AP		10MG/ML	N75905 001	Nov 23, 2001	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	SCHWARZ PHARMA	20MG	N21712 001	Sep 24, 2004	Sep	NEWA
+		40MG	N21712 002	Sep 24, 2004	Sep	NEWA

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	MUTUAL PHARM	2.5MG	N75896 001	Nov 02, 2004	Nov	NEWA
AB		5MG	N75896 002	Nov 02, 2004	Nov	NEWA
AB		10MG	N75896 003	Nov 02, 2004	Nov	NEWA

PLENDIL

AB	ASTRAZENECA	2.5MG	N19834 004	Sep 22, 1994	Nov	CFTG
AB		5MG	N19834 001	Jul 25, 1991	Nov	CFTG
AB	+	10MG	N19834 002	Jul 25, 1991	Nov	CFTG

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

	RELIANT PHARMS INC	43MG	N21695 001	Nov 30, 2004	Nov	NEWA
		87MG	N21695 002	Nov 30, 2004	Nov	NEWA
+		130MG	N21695 003	Nov 30, 2004	Nov	NEWA

TABLET; ORAL

TRICOR

	ABBOTT	48MG	N21656 001	Nov 05, 2004	Nov	NEWA
+		145MG	N21656 002	Nov 05, 2004	Nov	NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP	+	HOSPIRA	EQ 10MG BASE/ML	N19922 001	Sep 23, 1997	May	CAHN
AP		BEDFORD LABS	EQ 10MG BASE/ML	N76582 001	Oct 12, 2004	Oct	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

+	ALZA	0.6MG/24HR	N19813 004	Aug 07, 1990	Jul	CTEC
		1.2MG/24HR	N19813 003	Aug 07, 1990	Jul	CTEC
		1.8MG/24HR	N19813 002	Aug 07, 1990	Jul	CTEC
		2.4MG/24HR	N19813 001	Aug 07, 1990	Jul	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

	FENTANYL CITRATE								
AP	HOSPIRA	EQ 0.05MG BASE/ML	N19115	001	Jan 12, 1985	May	CAHN		
	FENTANYL CITRATE PRESERVATIVE FREE								
AP	HOSPIRA	EQ 0.05MG BASE/ML	N72786	001	Sep 24, 1991	May	CAHN		

TROCHE/LOZENGE; ORAL

ACTIQ

	CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Feb	CAHN		
		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Feb	CAHN		
+		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Sep	CRLD		
		EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Feb	CAHN		
		EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Feb	CAHN		
		EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Feb	CAHN		
+		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Feb	CAHN		
		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Sep	CRLD		

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ALLEGRA D 24 HOUR								
+	AVENTIS PHARMS	180MG;240MG	N21704	001	Oct 19, 2004	Oct	NEWA		
>D>	ALLEGRA-D								
>D>	+ AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Dec	CTNA		
>A>	ALLEGRA-D 12 HOUR								
>A>	+ AVENTIS PHARMS	60MG;120MG	N20786	001	Dec 24, 1997	Dec	CTNA		

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HCL

>A>	AB	PADDOCK	100MG	N76831	001	Dec 16, 2004	Dec	NEWA	
-----	----	---------	-------	--------	-----	--------------	-----	------	--

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

AB	PFIZER	50MG/5ML	N20090	001	Dec 23, 1993	Jul	CFTG		
AB	+	200MG/5ML	N20090	002	Dec 23, 1993	Jul	CFTG		

FLUCONAZOLE

AB	RANBAXY	50MG/5ML	N76332	001	Jul 29, 2004	Jul	NEWA		
AB		200MG/5ML	N76332	002	Jul 29, 2004	Jul	NEWA		
AB	ROXANE	50MG/5ML	N76246	001	Jul 29, 2004	Jul	NEWA		
AB		200MG/5ML	N76246	002	Jul 29, 2004	Jul	NEWA		

INJECTABLE; INJECTION

	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	+ PFIZER	200MG/100ML	N19950	003	Sep 29, 1992	Jul	CFTG		
	DIFLUCAN IN SODIUM CHLORIDE 0.9%								
AP	+ PFIZER	200MG/100ML	N19950	001	Jan 29, 1990	Jul	CFTG		
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	+ PFIZER	200MG/100ML	N19950	002	Jan 29, 1990	Jul	CFTG		
	FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	HOSPIRA	200MG/100ML	N76304	001	Jul 29, 2004	Jul	NEWA		
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%								
AP	AM PHARM PARTNERS	200MG/100ML	N76145	001	Jul 29, 2004	Jul	NEWA		
AP	BEDFORD	200MG/100ML	N76087	001	Jul 29, 2004	Jul	NEWA		
AP	SICOR PHARMS	200MG/100ML	N76653	001	Jul 29, 2004	Jul	NEWA		
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	BAXTER HLTHCARE	200MG/100ML	N76766	001	Jul 29, 2004	Jul	NEWA		

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	200MG/100ML	N76303 001	Jul 29, 2004	Jul	NEWA
AP	+ MAYNE PHARMA USA	200MG/100ML	N76617 001	Jul 29, 2004	Jul	NEWA
AP		200MG/100ML	N76617 001	Jul 29, 2004	Aug	CRLD
>A> AP	SICOR PHARMS	200MG/100ML	N76837 001	Jan 13, 2005	Dec	NEWA

TABLET; ORAL

DIFLUCAN

AB	PFIZER	50MG	N19949 001	Jan 29, 1990	Jul	CFTG
AB		100MG	N19949 002	Jan 29, 1990	Jul	CFTG
AB		150MG	N19949 004	Jun 30, 1994	Jul	CFTG
AB	+	200MG	N19949 003	Jan 29, 1990	Jul	CFTG

FLUCONAZOLE

AB	DR REDDYS LABS INC	50MG	N76658 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76658 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76658 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76658 004	Jul 29, 2004	Jul	NEWA
AB	GEDEON RICHTER USA	50MG	N76432 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76432 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76432 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76432 004	Jul 29, 2004	Jul	NEWA
AB	GENPHARM	50MG	N76042 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76042 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76042 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76042 004	Jul 29, 2004	Jul	NEWA
AB	IVAX PHARMS	50MG	N76077 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76077 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76077 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76077 004	Jul 29, 2004	Jul	NEWA
AB	MYLAN	50MG	N76351 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76351 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76351 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76351 004	Jul 29, 2004	Jul	NEWA
AB	PLIVA	50MG	N76424 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76424 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76424 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76424 004	Jul 29, 2004	Jul	NEWA
AB	RANBAXY	50MG	N76386 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76386 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76386 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76386 004	Jul 29, 2004	Jul	NEWA
AB	ROXANE	50MG	N76213 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76213 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76213 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76213 004	Jul 29, 2004	Jul	NEWA
AB	SANDOZ	50MG	N76086 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76086 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76086 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76086 004	Jul 29, 2004	Jul	NEWA
AB	TARO	50MG	N76507 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76507 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76507 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76507 004	Jul 29, 2004	Jul	NEWA
AB	TEVA	50MG	N74681 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N74681 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N74681 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N74681 004	Jul 29, 2004	Jul	NEWA

TABLET; ORAL
FLUCONAZOLE

AB	TORPHARM	50MG					
AB		100MG	N76665	001	Jul 29, 2004	Jul	NEWA
AB		150MG	N76665	002	Jul 29, 2004	Jul	NEWA
AB		200MG	N76665	003	Jul 29, 2004	Jul	NEWA
			N76665	004	Jul 29, 2004	Jul	NEWA

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON

	ICN	250MG					
+		500MG	N17001	001		Nov	CAHN
			N17001	002		Nov	CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

+	GENSIA SICOR PHARMS	50MG/2ML (25MG/ML)					
			N76661	001	Apr 28, 2004	Apr	NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18
@ DOWNSTATE CLINCL

		4-90mCi/ML					
			N20306	002	Sep 25, 2001	May	DISC

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F 18

+	WEILL MEDCL COLL	10-100mCi/ML					
			N21768	001	Aug 05, 2004	Aug	NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP	AM PHARM	0.5MG/5ML (0.1MG/ML)					
AP		1MG/10ML (0.1MG/ML)	N76955	002	Oct 12, 2004	Oct	NEWA
AP	APOTEX	0.5MG/5ML (0.1MG/ML)	N76955	001	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76755	002	Oct 12, 2004	Oct	NEWA
AP	BAXTER HLTHCARE	0.5MG/5ML (0.1MG/ML)	N76755	001	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76787	002	Oct 12, 2004	Oct	NEWA
AP	BEDFORD LABS	0.5MG/5ML (0.1MG/ML)	N76787	001	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76256	002	Oct 12, 2004	Oct	NEWA
AP	GENSIA SICOR PHARMS	0.5MG/5ML (0.1MG/ML)	N76256	001	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76589	002	Oct 12, 2004	Oct	NEWA
	ROMAZICON		N76589	001	Oct 12, 2004	Oct	NEWA
AP	+ HLR	1MG/10ML (0.1MG/ML)					
AP		0.5MG/5ML (0.1MG/ML)	N20073	001	Dec 20, 1991	Oct	CFTG
			N20073	002	Dec 20, 1991	Oct	CFTG

FLUNISOLIDE

SPRAY, METERED; NASAL
FLUNISOLIDE

+	BAUSCH AND LOMB	0.025MG/SPRAY					
	NASALIDE						
	@ IVAX RES	0.025MG/SPRAY					
			N74805	001	Feb 20, 2002	Jun	CRLD
			N18148	001		Jun	DISC

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE

AB2	ALTANA	0.05%					
			N76586	001	Jun 23, 2004	Jun	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BIGMAR BIOREN PHARMS	50MG/ML	N40291 001	Mar 24, 1999	Jul	CAHN
AP		50MG/ML	N40379 001	Nov 15, 2000	Jul	CAHN

FLUOXETINE

CAPSULE; ORAL

FLUOXETINE

>A>	AB	RANBAXY	40MG	N76990 001	Dec 13, 2004	Dec	NEWA
-----	----	---------	------	------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

	AB	IVAX PHARMS	EQ 40MG BASE	N75245 003	Sep 28, 2004	Sep	NEWA
>A>	AB	PAR PHARM	EQ 10MG BASE	N76922 001	Dec 16, 2004	Dec	NEWA
>A>	AB		EQ 20MG BASE	N76922 002	Dec 16, 2004	Dec	NEWA
>A>	AB		EQ 30MG BASE	N76922 003	Dec 16, 2004	Dec	NEWA

SOLUTION; ORAL

FLUOXETINE HCL

AA	PAR PHARM	EQ 20MG BASE/5ML	N76458 001	May 14, 2004	May	NEWA
----	-----------	------------------	------------	--------------	-----	------

TABLET; ORAL

FLUOXETINE

AB	IVAX PHARMS	EQ 40MG BASE	N75865 003	Aug 30, 2004	Aug	NEWA
AB	IVAX PHARMS	EQ 10MG BASE	N75865 001	Feb 28, 2002	Aug	CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ MAYNE PHARMA USA	25MG/ML	N74966 001	Apr 16, 1998	Apr	CAHN
--------------------	---------	------------	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

PERMITIL

@ SCHERING	5MG/ML	N16008 001		Jun	DISC
------------	--------	------------	--	-----	------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

@ MUTUAL PHARM	15MG	N70454 001	Aug 04, 1986	Aug	CAHN
@	30MG	N70455 001	Aug 04, 1986	Aug	CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

GLAXOSMITHKLINE	0.044MG/INH	N21433 003	May 14, 2004	May	NEWA
	0.11MG/INH	N21433 002	May 14, 2004	May	NEWA
+	0.22MG/INH	N21433 001	May 14, 2004	May	NEWA

CREAM; TOPICAL

CUTIVATE

AB	+	GLAXOSMITHKLINE	0.05%	N19958 001	Dec 18, 1990	May	CFTG
AB		FLUTICASONE PROPIONATE					
AB		ALTANA	0.05%	N76451 001	May 14, 2004	May	NEWA
AB		ATRIX	0.05%	N76633 001	May 14, 2004	May	NEWA

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB CLAY PARK 0.05%
 AB KV PHARM 0.05%

N76793 001 May 14, 2004 May NEWA
 N76865 001 Sep 10, 2004 Sep NEWA

OINTMENT; TOPICAL

CUTIVATE

AB + GLAXOSMITHKLINE 0.005%
 FLUTICASONE PROPIONATE
 AB ALTANA 0.005%
 AB CLAY PARK 0.005%

N19957 001 Dec 14, 1990 May CFTG
 N76300 001 May 14, 2004 May NEWA
 N76668 001 May 14, 2004 May NEWA

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

FOLLISTIM

BX ORGANON USA INC 75 IU/VIAL
 + 75 IU/VIAL
 @ 75 IU/VIAL
 BX 150 IU/VIAL
 + 150 IU/VIAL
 @ 150 IU/VIAL

N20582 001 Sep 29, 1997 Mar CDFR
 N20582 001 Sep 29, 1997 Jun CTEC
 N20582 001 Sep 29, 1997 Aug DISC
 N20582 002 Sep 29, 1997 Mar CDFR
 N20582 002 Sep 29, 1997 Jun CTEC
 N20582 002 Sep 29, 1997 Aug DISC

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC 300 IU/0.525ML
 + 600 IU/0.885ML
 GONAL-F
 @ SERONO INC 37.5 IU/VIAL
 37.5 IU/VIAL
 BX 75 IU/VIAL
 @ 75 IU/VIAL
 75 IU/VIAL
 + 75 IU/VIAL
 @ 150 IU/VIAL
 BX 150 IU/VIAL
 @ 150 IU/VIAL
 + 150 IU/VIAL
 450 IU/VIAL
 + 1,200 IU/VIAL
 + 1,050 IU/VIAL

N21211 001 Mar 23, 2004 Mar NEWA
 N21211 002 Mar 23, 2004 Mar NEWA
 N21765 001 Mar 25, 2004 May DISC
 N21765 001 Mar 25, 2004 Mar NEWA
 N20378 001 Sep 29, 1997 Mar CDFR
 N20378 001 Sep 29, 1997 Jun DISC
 N21765 002 Mar 25, 2004 Mar NEWA
 N21765 002 Mar 25, 2004 Jun CRLD
 N20378 002 Sep 29, 1997 Jun DISC
 N20378 002 Sep 29, 1997 Mar CDFR
 N21765 003 Mar 25, 2004 May DISC
 N21765 003 Mar 25, 2004 Mar NEWA
 N20378 005 Mar 26, 2004 Mar NEWA
 N20378 004 Feb 28, 2001 Mar CAIN
 N20378 004 Feb 28, 2001 Apr CPOT

GONAL-F RFF PEN

SERONO INC

300 IU/0.5ML
 450 IU/0.75ML
 + 900 IU/1.5ML

N21684 001 May 25, 2004 May NEWA
 N21684 002 May 25, 2004 May NEWA
 N21684 003 May 25, 2004 May NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

+ NOVARTIS 6.6MG/ML

N20961 001 Aug 26, 1998 Jan CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

+ FONDA BV 5MG/0.4ML
 + 7.5MG/0.6ML
 + GLAXOSMITHKLINE 2.5MG/0.5ML
 + 5MG/0.4ML
 + 7.5MG/0.6ML
 + 10MG/0.8ML

N21345 002 May 28, 2004 May NEWA
 N21345 003 May 28, 2004 May NEWA
 N21345 001 Dec 07, 2001 Aug CAHN
 N21345 002 May 28, 2004 Aug CAHN
 N21345 003 May 28, 2004 Aug CAHN
 N21345 004 May 28, 2004 Aug CAHN

INJECTABLE; SUBCUTANEOUS

ARIXTRA

+	GLAXOSMITHKLINE	10MG/0.8ML	N21345 004	May 28, 2004	May	NEWA
---	-----------------	------------	------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	ANDRX PHARMS	10MG	N76620 001	Oct 15, 2004	Oct	NEWA	
AB		20MG	N76620 002	Oct 15, 2004	Oct	NEWA	
AB		40MG	N76620 003	Oct 15, 2004	Oct	NEWA	
AB	EON	10MG	N76483 001	Apr 23, 2004	Apr	NEWA	
AB		20MG	N76483 002	Apr 23, 2004	Apr	NEWA	
AB		40MG	N76483 003	Apr 23, 2004	Apr	NEWA	
AB	RANBAXY	10MG	N76580 001	Apr 23, 2004	Apr	NEWA	
AB		20MG	N76580 002	Apr 23, 2004	Apr	NEWA	
AB		40MG	N76580 003	Apr 23, 2004	Apr	NEWA	
AB	SANDOZ	10MG	N76188 001	Oct 08, 2004	Oct	NEWA	
AB		20MG	N76188 002	Oct 08, 2004	Oct	NEWA	
AB		40MG	N76188 003	Oct 08, 2004	Oct	NEWA	
>A>	AB	WATSON LABS	10MG	N76987 001	Dec 23, 2004	Dec	NEWA
>A>	AB		20MG	N76987 002	Dec 23, 2004	Dec	NEWA
>A>	AB		40MG	N76987 003	Dec 23, 2004	Dec	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	10MG;12.5MG	N76608 001	Dec 03, 2004	Nov	NEWA	
AB		20MG;12.5MG	N76608 002	Dec 03, 2004	Nov	NEWA	
>A>	AB	RANBAXY	10MG;12.5MG	N76739 001	Dec 17, 2004	Dec	NEWA
>A>	AB		20MG;12.5MG	N76739 002	Dec 17, 2004	Dec	NEWA
		MONOPRIL-HCT					
AB	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	Nov 30, 1994	Nov	CFTG	
AB	+	20MG;12.5MG	N20286 001	Nov 30, 1994	Nov	CFTG	

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	Aug	CAHN
+	VERNALIS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667 001	May 28, 1982	May	CAHN
AP		10MG/ML	N70578 001	Jul 08, 1987	May	CAHN
AP		10MG/ML	N72080 001	Aug 13, 1991	May	CAHN
AP		10MG/ML	N74337 001	Oct 31, 1994	May	CAHN
AP		10MG/ML	N75241 001	May 28, 1999	May	CAHN

TABLET; ORAL

FUROSEMIDE

	@ MUTUAL PHARM	20MG	N70043 001	Sep 26, 1985	Aug	CAHN
	@	40MG	N18790 001	Nov 29, 1983	Aug	CAHN
	@	80MG	N70100 001	Jan 26, 1988	Aug	CAHN
AB	VINTAGE PHARMS	20MG	N76796 001	Mar 26, 2004	Mar	NEWA
AB		40MG	N76796 002	Mar 26, 2004	Mar	NEWA
AB		80MG	N76796 003	Mar 26, 2004	Mar	NEWA

TABLET; ORAL
FUROSEMIDE
@ WATSON LABS

40MG

N70413 001 Feb 26, 1986 Sep DISC

GABAPENTIN

CAPSULE; ORAL
GABAPETIN

AB TEVA PHARMS 100MG
AB 300MG
AB 400MG

N75435 001 Oct 08, 2004 Oct NEWA
N75435 002 Oct 08, 2004 Oct NEWA
N75435 003 Oct 08, 2004 Oct NEWA

TABLET; ORAL
GABAPENTIN

IVAX PHARMS 100MG
300MG
400MG
AB PUREPAC PHARM 600MG
AB 800MG
>A> AB TEVA 600MG
>A> AB 800MG

N76017 001 Apr 28, 2004 Apr NEWA
N76017 002 Apr 28, 2004 Apr NEWA
N76017 003 Apr 28, 2004 Apr NEWA
N75694 001 Oct 21, 2004 Oct NEWA
N75694 002 Oct 21, 2004 Oct NEWA
N75827 001 Dec 15, 2004 Dec NEWA
N75827 002 Dec 15, 2004 Dec NEWA

NEURONTIN

AB PFIZER PHARMS 600MG
AB + 800MG

N20882 001 Oct 09, 1998 Oct CFTG
N20882 002 Oct 09, 1998 Oct CFTG

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS
MULTIHANCE

+ BRACCO 2.645GM/5ML (529MG/ML)
+ 5.29GM/10ML (529MG/ML)
+ 7.935GM/15ML (529MG/ML)
+ 10.58GM/20ML (529MG/ML)

N21357 001 Nov 23, 2004 Nov NEWA
N21357 002 Nov 23, 2004 Nov NEWA
N21357 003 Nov 23, 2004 Nov NEWA
N21357 004 Nov 23, 2004 Nov NEWA

MULTIHANCE MULTIPACK

+ BRACCO 26.45GM/50ML (529MG/ML)
+ 52.9GM/100ML (529MG/ML)

N21358 001 Nov 23, 2004 Nov NEWA
N21358 002 Nov 23, 2004 Nov NEWA

GALANTAMINE HYDROBROMIDE

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> REMINYL

>A> JOHNSON AND JOHNSON EQ 8MG BASE
>A> EQ 16MG BASE
>A> + EQ 24MG BASE

N21615 001 Dec 22, 2004 Dec NEWA
N21615 002 Dec 22, 2004 Dec NEWA
N21615 003 Dec 22, 2004 Dec NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION
GANIRELIX ACETATE INJECTION

+ ORGANON USA INC EQ 250UGM BASE/0.5ML

N21057 001 Jul 29, 1999 Jun CTNA

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN

>D> + BRISTOL MYERS SQUIBB EQ 10MG /ML(200MG)
>A> @ EQ 10MG /ML(200MG)

N21062 003 Dec 17, 1999 Dec DISC
N21062 003 Dec 17, 1999 Dec DISC

SUSPENSION; ORAL
TEQUIN

+ BRISTOL MYERS SQUIBB 200MG/5ML

N21678 001 Aug 27, 2004 Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

+ OSCIENT EQ 320MG BASE N21158 001 Apr 04, 2003 Apr CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP HOSPIRA EQ 10MG BASE/ML N62420 001 Aug 15, 1983 May CAHN
AP EQ 10MG BASE/ML N62612 004 Feb 20, 1986 May CAHN
AP EQ 40MG BASE/ML N62420 002 Aug 15, 1983 May CAHN

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA EQ 1.2MG BASE/ML N62414 001 Aug 15, 1983 May CAHN
@ EQ 1.2MG BASE/ML N62588 001 Jan 06, 1986 May CAHN
AP EQ 1.4MG BASE/ML N62414 002 Aug 15, 1983 May CAHN
@ EQ 1.4MG BASE/ML N62588 002 Jan 06, 1986 May CAHN
AP EQ 1.6MG BASE/ML N62414 003 Aug 15, 1983 May CAHN
@ EQ 1.6MG BASE/ML N62588 003 Jan 06, 1986 May CAHN
AP EQ 1.8MG BASE/ML N62414 004 Aug 15, 1983 May CAHN
@ EQ 1.8MG BASE/ML N62588 004 Jan 06, 1986 May CAHN
AP EQ 2MG BASE/ML N62414 005 Aug 15, 1983 May CAHN
@ EQ 2MG BASE/ML N62588 005 Jan 06, 1986 May CAHN
AP EQ 60MG BASE/100ML N62414 006 Aug 15, 1983 May CAHN
@ EQ 60MG BASE/100ML N62588 006 Jan 06, 1986 May CAHN
AP EQ 70MG BASE/100ML N62414 007 Aug 15, 1983 May CAHN
@ EQ 70MG BASE/100ML N62588 007 Jan 06, 1986 May CAHN
AP EQ 80MG BASE/100ML N62414 008 Aug 15, 1983 May CAHN
@ EQ 80MG BASE/100ML N62588 008 Jan 06, 1986 May CAHN
AP EQ 90MG BASE/100ML N62414 009 Aug 15, 1983 May CAHN
@ EQ 90MG BASE/100ML N62588 009 Jan 06, 1986 May CAHN
AP EQ 100MG BASE/100ML N62414 010 Aug 15, 1983 May CAHN
@ EQ 100MG BASE/100ML N62588 010 Jan 06, 1986 May CAHN

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT + AKORN EQ 0.3% BASE N64093 001 Aug 31, 1995 Jul CFTG
AT ALTANA EQ 0.3% BASE N65024 001 Jul 30, 2004 Jul NEWA

SOLUTION/DROPS; OPHTHALMIC
GARAMYCIN

AT + SCHERING EQ 0.3% BASE N50039 002 Jan CDFR
AT GENTAMICIN SULFATE
ALTANA EQ 3% BASE N65121 001 Jan 30, 2004 Jan NEWA

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS
COPAXONE

>D> + TEVA 20MG/VIAL N20622 001 Dec 20, 1996 Dec CAHN
>A> + 20MG/VIAL N20622 001 Dec 20, 1996 Dec CAHN

INJECTABLE; SUBCUTANEOUS
COPAXONE

>D> + TEVA 20MG/ML N20622 002 Feb 12, 2002 Dec CAHN
>A> + 20MG/ML N20622 002 Feb 12, 2002 Dec CAHN

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB KALI LABS 5MG N74550 001 Sep 11, 1997 Aug CAHN

TABLET; ORAL
 GLIPIZIDE
 AB KALI LABS 10MG N74550 002 Sep 11, 1997 Aug CAHN

GLUTAMINE

FOR SOLUTION; ORAL
 NUTRESTORE

+ NUTRITIONAL RESTART 5GM/PACKET
 @ 5GM/PACKET

N21667 001 Jun 10, 2004 Jul CMS2
 N21667 001 Jun 10, 2004 Sep DISC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
 GLUCOVANCE

AB BRISTOL MYERS SQUIBB 1.25MG;250MG
 AB 2.5MG;500MG
 AB + 5MG;500MG

N21178 001 Jul 31, 2000 Feb CFTG
 N21178 002 Jul 31, 2000 Feb CFTG
 N21178 003 Jul 31, 2000 Feb CFTG

GLYBURIDE AND METFORMIN HCL

AB COREPHARMA 1.25MG;250MG
 AB 2.5MG;500MG
 AB 5MG;500MG
 AB IVAX PHARMS 1.25MG;250MG
 AB 2.5MG;500MG
 AB 5MG;500MG

N76731 001 Nov 19, 2004 Nov NEWA
 N76731 002 Nov 19, 2004 Nov NEWA
 N76731 003 Nov 19, 2004 Nov NEWA
 N76345 001 Feb 18, 2004 Feb NEWA
 N76345 002 Feb 18, 2004 Feb NEWA
 N76345 003 Feb 18, 2004 Feb NEWA

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT HOSPIRA 1.5GM/100ML
 AT 1.5GM/100ML

N17633 001 May CAHN
 N18315 001 May CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

@ HOSPIRA 0.2MG/ML

N89393 001 Jun 15, 1988 May CAHN

TABLET; ORAL

>A> GLYCOPYRROLATE
 >A> AB COREPHARMA 1MG
 >A> AB 2MG

N40568 001 Dec 22, 2004 Dec NEWA
 N40568 002 Dec 22, 2004 Dec NEWA

ROBINUL

>D> + FIRST HORIZON 1MG
 >A> AB + 1MG

N12827 001 Dec CFTG
 N12827 001 Dec CFTG

ROBINUL FORTE

>D> + FIRST HORIZON 2MG
 >A> AB + 2MG

N12827 002 Dec CFTG
 N12827 002 Dec CFTG

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@ BAXTER HLTHCARE CORP EQ 0.1MG BASE/VIAL

N18123 001 Sep 30, 1982 Jun DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL

+ ROCHE EQ 0.1MG BASE/ML (EQ 0.1MG
 BASE/ML)
 + EQ 1MG BASE/ML (EQ 1MG BASE/ML)
 + EQ 4MG BASE/4ML (EQ 1MG BASE /ML)

N20239 003 Sep 17, 2004 Sep NEWA
 N20239 004 Mar 11, 1994 Sep NEWA
 N20239 002 Mar 11, 1994 Sep CPOT

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

AB	+	SCHERING	250MG	N60569 002	Sep	CRLD
----	---	----------	-------	------------	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ SCHERING

125MG

N61996 001

Jun DISC

@

250MG

N61996 002

Jun DISC

FULVICIN P/G 165

@ SCHERING

165MG

N61996 003 Apr 06, 1982 Jun DISC

FULVICIN P/G 330

@ SCHERING

330MG

N61996 004 Apr 06, 1982 Jun DISC

GRIS-PEG

PEDINOL

125MG

N50475 001

Sep CTEC

+

250MG

N50475 002

Jun CRLD

HALAZEPAM

TABLET; ORAL

PAXIPAM

@ SCHERING

20MG

N17736 003

Apr DISC

@

40MG

N17736 004

Apr DISC

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

>A>						
>A>	AB	AGIS INDS	0.05%	N77123 001	Dec 16, 2004	Dec NEWA
>A>	AB	ALTANA	0.05%	N77001 001	Dec 16, 2004	Dec NEWA

ULTRAVATE

>D>		+	WESTWOOD SQUIBB	0.05%	N19967 001	Dec 27, 1990	Dec CFTG
>A>	AB	+		0.05%	N19967 001	Dec 27, 1990	Dec CFTG

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>A>						
>A>	AB	AGIS INDS	0.05%	N76872 001	Dec 16, 2004	Dec NEWA
>A>	AB	ALTANA	0.05%	N76903 001	Dec 16, 2004	Dec NEWA
>A>	AB	TARO	0.05%	N76994 001	Dec 16, 2004	Dec NEWA

ULTRAVATE

>D>		+	WESTWOOD SQUIBB	0.05%	N19968 001	Dec 17, 1990	Dec CFTG
>A>	AB	+		0.05%	N19968 001	Dec 17, 1990	Dec CFTG

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ MUTUAL PHARM

0.5MG

N71156 001 Jan 02, 1987 Aug CAHN

@

1MG

N71157 001 Jan 02, 1987 Aug CAHN

@

2MG

N71172 001 Jan 02, 1987 Aug CAHN

@

5MG

N71212 001 Jan 07, 1988 Aug CAHN

@

10MG

N71173 001 Jan 07, 1988 Aug CAHN

@

20MG

N71177 001 Jan 07, 1988 Aug CAHN

AB	+	SANDOZ	2MG	N71208 001	Nov 17, 1986	Oct CRLD
			20MG	N71211 001	Mar 11, 1988	Oct CRLD

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
 HALOPERIDOL DECANOATE
 @ MAYNE PHARMA USA
 @

EQ 50MG BASE/ML
 EQ 100MG BASE/ML

N75176 001 Feb 09, 2000 Apr CAHN
 N75176 002 Feb 09, 2000 Apr CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
 HALOPERIDOL

AA + COPLEY PHARM
 @ TEVA

EQ 2MG BASE/ML
 EQ 2MG BASE/ML

N71617 001 Dec 01, 1988 Nov CRLD
 N71015 001 Aug 25, 1987 Nov DISC

INJECTABLE; INJECTION
 HALOPERIDOL

AP APOTEX

EQ 5MG BASE/ML

N76774 001 Aug 25, 2004 Aug NEWA

AP

EQ 5MG BASE/ML

N76791 001 Aug 25, 2004 Aug NEWA

AP

EQ 5MG BASE/ML

N76828 001 Aug 25, 2004 Aug NEWA

AP

SABEX 2002

EQ 5MG BASE/ML

N76464 001 Sep 29, 2004 Sep NEWA

HALOTHANE

LIQUID; INHALATION
 HALOTHANE

AN + HOSPIRA

99.99%

N83254 001

May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
 HEPARIN LOCK FLUSH

AP HOSPIRA

10 UNITS/ML

N05264 001

May CAHN

AP

10 UNITS/ML

N40082 001 Feb 28, 1995 May CAHN

AP

10 UNITS/ML

N88097 001 Apr 28, 1983 May CAHN

AP

@

100 UNITS/ML

N88346 001 May 18, 1983 May CAHN

AP

100 UNITS/ML

N05264 010 May CAHN

AP

100 UNITS/ML

N40082 002 Feb 28, 1995 May CAHN

AP

100 UNITS/ML

N88098 001 Apr 28, 1983 May CAHN

AP

100 UNITS/ML

N88347 001 May 18, 1983 May CAHN

HEPARIN LOCK FLUSH IN PLASTIC CONTAINER

AP HOSPIRA

10 UNITS/ML

N05264 015 May 21, 1985 May CAHN

AP

100 UNITS/ML

N05264 016 May 21, 1985 May CAHN

HEPARIN SODIUM

@ HOSPIRA

2,500 UNITS/ML

N88099 001 Apr 28, 1983 Aug DISC

AP +

2,500 UNITS/ML

N88099 001 Apr 28, 1983 May CAHN

AP

5,000 UNITS/ML

N88100 001 Apr 28, 1983 May CAHN

@

10,000 UNITS/ML

N40095 001 Jul 26, 1996 May CAHN

@ LILLY

10,000 UNITS/ML

N05521 002 Jun DISC

@ MARSAM PHARMS LLC

1,000 UNITS/ML

N40007 001 Jun 07, 1996 Sep DISC

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA

200 UNITS/100ML

N18916 010 Jun 23, 1989 May CAHN

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

@ HOSPIRA

10,000 UNITS/100ML

N18911 006 Jan 30, 1985 May CAHN

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP HOSPIRA

10,000 UNITS/100ML

N19339 003 Mar 27, 1985 May CAHN

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

@ HOSPIRA

10,000 UNITS/100ML

N18911 001 Jan 30, 1985 May CAHN

@

10,000 UNITS/100ML

N18916 005 Jan 31, 1984 May CAHN

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

@ HOSPIRA

10,000 UNITS/100ML

N18911 003 Jan 30, 1985 May CAHN

@

10,000 UNITS/100ML

N18916 002 Jan 31, 1984 May CAHN

INJECTABLE; INJECTION

	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%								
	@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May	CAHN			
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER								
	HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May	CAHN			
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
	HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%								
	@ HOSPIRA	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May	CAHN			
	@	5,000 UNITS/100ML	N18916 003	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	HOSPIRA	200 UNITS/100ML	N18916 011	Jun 23, 1989	May	CAHN			
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	HOSPIRA	4,000 UNITS/100ML	N19805 001	Jan 25, 1989	May	CAHN			
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%								
	@ HOSPIRA	5,000 UNITS/100ML	N18911 009	Jan 30, 1985	May	CAHN			
	@	10,000 UNITS/100ML	N18911 008	Jan 30, 1985	May	CAHN			
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP	HOSPIRA	5,000 UNITS/100ML	N19339 004	Mar 27, 1985	May	CAHN			
AP		5,000 UNITS/100ML	N19805 002	Jan 25, 1989	May	CAHN			
AP		10,000 UNITS/100ML	N19339 002	Mar 27, 1985	May	CAHN			
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER								
	HOSPIRA	5,000 UNITS/100ML	N18916 007	Jan 31, 1984	May	CAHN			
		10,000 UNITS/100ML	N18916 008	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%								
	@ HOSPIRA	5,000 UNITS/100ML	N18911 004	Jan 30, 1985	May	CAHN			
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
	@ HOSPIRA	5,000 UNITS/100ML	N18916 009	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%								
	@ HOSPIRA	100 UNITS/ML	N18911 002	Jan 30, 1985	May	CAHN			
	@	100 UNITS/ML	N18916 004	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%								
	@ HOSPIRA	1,000 UNITS/100ML	N18916 001	Jan 31, 1984	May	CAHN			
	HEPARIN SODIUM PRESERVATIVE FREE								
	+ HOSPIRA	2,000 UNITS/ML	N05264 013	Apr 07, 1986	May	CAHN			
AP	+	2,500 UNITS/ML	N05264 014	Apr 07, 1986	May	CAHN			
AP	+	10,000 UNITS/ML	N89522 001	May 04, 1987	May	CAHN			
	@ MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001	Jun 03, 1986	Sep	DISC			
	PANHEPRIN								
	@ HOSPIRA	1,000 UNITS/ML	N05264 004		May	CAHN			
	@	5,000 UNITS/ML	N05264 006		May	CAHN			
	@	10,000 UNITS/ML	N05264 007		May	CAHN			
	@	20,000 UNITS/ML	N05264 008		May	CAHN			
	@	40,000 UNITS/ML	N05264 009		May	CAHN			

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

VANTAS

	+ VALERA	50MG	N21732 001	Oct 12, 2004	Oct	NEWA			
--	----------	------	------------	--------------	-----	------	--	--	--

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

>A>	ISTA PHARMS	200 UNITS/VIAL	N21640 002	Dec 02, 2004	Dec	NEWA			
	+	6,200 UNITS/VIAL	N21640 001	May 05, 2004	May	NEWA			

INJECTABLE; SUBCUTANEOUS
AMPHADASE

+	AMPHASTAR PHARM	150 UNITS/ML	N21665 001	Oct 26, 2004	Oct	NEWA
---	-----------------	--------------	------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

@	MUTUAL PHARM	10MG	N88728 001	Apr 11, 1985	Aug	CAHN
@		25MG	N84106 002		Aug	CAHN
@		50MG	N84107 002		Aug	CAHN
@		100MG	N88729 001	Apr 11, 1985	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG;15MG;0.1MG	N88570 001	Apr 10, 1984	Aug	CAHN
---	--------------	-----------------	------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	MUTUAL PHARM	25MG	N83972 001		Aug	CAHN
@		50MG	N83972 002		Aug	CAHN
@		100MG	N83972 003		Aug	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG;10MG	N76674 001	Oct 05, 2004	Oct	NEWA
AB		12.5MG;20MG	N76674 002	Oct 05, 2004	Oct	NEWA
AB		25MG;20MG	N76674 003	Oct 05, 2004	Oct	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	NOVARTIS	25MG;50MG	N18303 001	Dec 31, 1984	Aug	CFTG
AB		25MG;100MG	N18303 002	Dec 31, 1984	Aug	CFTG
AB	+	50MG;100MG	N18303 003	Dec 31, 1984	Aug	CFTG

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;50MG	N76792 001	Aug 20, 2004	Aug	NEWA
AB		25MG;100MG	N76792 002	Aug 20, 2004	Aug	NEWA
AB		50MG;100MG	N76792 003	Aug 20, 2004	Aug	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	Dec 28, 1999	Mar	CFTG
AB		12.5MG;EQ 20MG BASE	N20125 002	Dec 28, 1999	Mar	CFTG
AB	+	25MG;EQ 20MG BASE	N20125 003	Dec 28, 1999	Mar	CFTG

QUINARETIC

AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374 001	Mar 31, 2004	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N76374 002	Mar 31, 2004	Mar	NEWA
AB		25MG;EQ 20MG BASE	N76374 003	Mar 31, 2004	Mar	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	MUTUAL PHARM	25MG;25MG	N87267 001		Aug	CAHN
----	--------------	-----------	------------	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

BOEHRINGER INGELHEIM 12.5MG;80MG

N21162 002 Nov 17, 2000 May CRLD

+ 25MG;80MG

N21162 003 Apr 19, 2004 May NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

+ INTERPHARM 5MG;200MG

N76642 002 Mar 18, 2004 Mar NEWA

AB 7.5MG;200MG

N76642 001 Oct 12, 2004 Oct NEWA

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

AT SALIX PHARMS 2.5%

N88250 001 Jun 06, 1984 Nov CAHN

HYDROCORTISONE

AT VINTAGE PHARMS 2.5%

N40503 001 Mar 12, 2004 Mar NEWA

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX BOCA PHARMA 1%;1%

N89440 001 May 17, 1988 Apr CAHN

HYDROCORTISONE BUTYRATE

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE

>A> AB TARO 0.1%

N76842 001 Dec 27, 2004 Dec NEWA

LOCOID

>D> + FERNDAL LABS 0.1%

N18652 001 Oct 29, 1982 Dec CFTG

>A> AB + 0.1%

N18652 001 Oct 29, 1982 Dec CFTG

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT TARO PHARM INDS 0.1%

N76364 001 Jan 14, 2004 Jan NEWA

LOCOID

AT + FERNDAL LABS 0.1%

N19116 001 Feb 25, 1987 Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP HOSPIRA EQ 100MG BASE/VIAL

N85929 001 May CAHN

AP EQ 250MG BASE/VIAL

N85930 001 May CAHN

AP EQ 500MG BASE/VIAL

N85931 001 May CAHN

AP EQ 1GM BASE/VIAL

N85932 001 May CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP 12MG

N21044 001 Sep 24, 2004 Sep NEWA

+ 16MG

N21044 002 Sep 24, 2004 Sep NEWA

CAPSULE, EXTENDED RELEASE; ORAL
PALLADONE

PURDUE PHARMA LP 24MG
32MG

N21044 003 Sep 24, 2004 Sep NEWA
N21044 004 Sep 24, 2004 Sep NEWA

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP HOSPIRA 10MG/ML

N74598 001 Jun 19, 1997 May CAHN

TABLET; ORAL
HYDROMORPHONE HCL

>A> AB MALLINCKRODT 8MG

N76855 001 Dec 23, 2004 Dec NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP HOSPIRA 25MG/ML

N87416 001 May CAHN

@ 50MG/ML

N86821 001 May CAHN

AP 50MG/ML

N87546 001 May CAHN

TABLET; ORAL
HYDROXYZINE HCL

AB ABLE 10MG

N40559 001 Jul 22, 2004 Jul NEWA

AB 25MG

N40562 001 Jul 22, 2004 Jul NEWA

AB 50MG

N40563 001 Jul 22, 2004 Jul NEWA

>A> AB AMIDE PHARM 10MG

N40600 001 Dec 28, 2004 Dec NEWA

>A> AB 25MG

N40602 001 Dec 28, 2004 Dec NEWA

>A> AB 50MG

N40604 001 Dec 28, 2004 Dec NEWA

@ MUTUAL PHARM 10MG

N88409 001 Nov 15, 1983 Aug CAHN

@ 25MG

N87857 001 Apr 18, 1983 Aug CAHN

@ 50MG

N87860 001 Apr 18, 1983 Aug CAHN

@ 100MG

N87862 001 Apr 18, 1983 Aug CAHN

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

AB PERRIGO R AND D 100MG/5ML

N76925 001 Sep 23, 2004 Sep NEWA

TABLET; ORAL

IBUPROFEN
@ MUTUAL PHARM 400MG

N70079 001 Jul 24, 1985 Aug CAHN

@ 600MG

N70080 001 Jul 24, 1985 Aug CAHN

@ 800MG

N71448 001 Feb 18, 1987 Aug CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
COMBUNOX

>D> + FOREST LABS 450MG; 5MG

N21378 001 Nov 26, 2004 Dec CPOT

>A> + 400MG; 5MG

N21378 001 Nov 26, 2004 Dec CPOT

+ 450MG; 5MG

N21378 001 Nov 26, 2004 Nov NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HCL

+ GENSLA SICOR PHARMS 5MG/VIAL

N65037 003 May 01, 2002 Feb CTEC

>A> ILOPROST

>A> SOLUTION; INHALATION

>A> VENTAVIS

>A> + COTHERIX 20UGM/2ML (10UGM/ML)

N21779 001 Dec 29, 2004 Dec NEWA

INAMRINONE LACTATEINJECTABLE; INJECTION
AMRINONE

AP + HOSPIRA EQ 5MG BASE/ML N74616 001 Aug 03, 1998 May CAHN

INDIUM IN 111 CHLORIDEINJECTABLE; INJECTION
INDICLOR

+ AMERSHAM 2mCi/0.2ML N19862 001 Dec 29, 1992 Nov CMS1

INDIUM IN 111 CHLORIDE
+ MALLINCKRODT 5mCi/0.5ML N19841 001 Sep 27, 1994 Nov CMS1INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

@ MUTUAL PHARM 25MG N70067 001 Oct 03, 1986 Aug CAHN

@ 50MG N70068 001 Oct 03, 1986 Aug CAHN

INSULIN ASPART RECOMBINANTINJECTABLE; SUBCUTANEOUS
NOVOLOG

+ NOVO NORDISK 100 UNITS/ML N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANTINJECTABLE; INJECTION
LANTUS

+ AVENTIS PHARMS 100 UNITS/ML N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANTINJECTABLE; SUBCUTANEOUS
APIDRA

@ AVENTIS PHARMS 100 UNITS/ML N21629 001 Apr 16, 2004 Jun DISC

+ 100 UNITS/ML N21629 001 Apr 16, 2004 Apr NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANTINJECTABLE; INJECTION
HUMALOG MIX 50/50

+ LILLY 50 UNITS/ML; 50 UNITS/ML N21018 001 Dec 22, 1999 May CAIN

HUMALOG MIX 75/25
+ LILLY 75 UNITS/ML; 25 UNITS/ML N21017 001 Dec 22, 1999 May CAININSULIN LISPRO RECOMBINANTINJECTABLE; INJECTION
HUMALOG

+ LILLY 100 UNITS/ML N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN
+ LILLY 100 UNITS/ML N20563 002 Aug 06, 1998 May CAINIODIXANOLINJECTABLE; INJECTION
VISIPAQUE 270

GE HEALTHCARE 55% N20808 001 Aug 29, 1997 Jun CMFD

VISIPAQUE 320
GE HEALTHCARE 65.2% N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION					
IOPAMIDOL-200					
AP	HOSPIRA	41%	N74898 001	Dec 30, 1997	May CAHN
IOPAMIDOL-200 IN PLASTIC CONTAINER					
AP	HOSPIRA	41%	N74636 001	Dec 30, 1997	May CAHN
IOPAMIDOL-250					
AP	HOSPIRA	51%	N74898 002	Dec 30, 1997	May CAHN
AP		51%	N75005 001	Feb 24, 1998	May CAHN
IOPAMIDOL-250 IN PLASTIC CONTAINER					
AP	HOSPIRA	51%	N74636 002	Dec 30, 1997	May CAHN
IOPAMIDOL-300					
AP	HOSPIRA	61%	N74898 003	Dec 30, 1997	May CAHN
AP		61%	N75005 002	Feb 24, 1998	May CAHN
IOPAMIDOL-300 IN PLASTIC CONTAINER					
AP	HOSPIRA	61%	N74636 003	Dec 30, 1997	May CAHN
AP		61%	N74637 001	Apr 03, 1997	May CAHN
IOPAMIDOL-370					
AP	HOSPIRA	76%	N74898 004	Dec 30, 1997	May CAHN
AP		76%	N75005 003	Feb 24, 1998	May CAHN
IOPAMIDOL-370 IN PLASTIC CONTAINER					
AP	HOSPIRA	76%	N74636 004	Dec 30, 1997	May CAHN

IOPANOIC ACID

TABLET; ORAL					
TELEPAQUE					
	@ GE HEALTHCARE	500MG	N08032 001		May DISC

IOPROMIDE

INJECTABLE; INJECTION					
ULTRAVIST (PHARMACY BULK)					
+	BERLEX	49.9%	N21425 003	Mar 12, 2004	Mar NEWA
+		62.3%	N21425 001	Sep 20, 2002	Mar CPOT
+		76.9%	N21425 002	Sep 20, 2002	Mar CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION					
VASCORAY					
	@ MALLINCKRODT	52%;26%	N16783 001		Jun DISC

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION					
ATROVENT HFA					
+	BOEHRINGER INGELHEIM	0.021MG/INH	N21527 001	Nov 27, 2004	Nov NEWA
SOLUTION; INHALATION					
IPRATROPIUM BROMIDE					
AN	HOLOPACK INTL	0.02%	N75693 001	Jan 26, 2001	Apr CAHN

IRON DEXTRAN

INJECTABLE; INJECTION					
IRON DEXTRAN					
>A>	@ AVENTIS PHARMS	EQ 50MG IRON/ML	N10787 002		Dec CAHN
>D>	@ FISOXS	EQ 50MG IRON/ML	N10787 002		Dec CAHN

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
BETA-2

>D>	AN	NEPHRON	1%	N86711 001		Dec	CRLD
>A>		+	1%	N86711 001		Dec	CRLD
ISOETHARINE HCL							
>D>	AN	+ ROXANE	1%	N86899 001		Dec	DISC
>A>		@	1%	N86899 001		Dec	DISC

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

AN	HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May	CAHN
----	---------	-------	------------	--------------	-----	------

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

	+	SANDOZ	100MG/ML	N08662 001		Feb	CAHN
--	---	--------	----------	------------	--	-----	------

TABLET; ORAL

ISONIAZID

	@	MUTUAL PHARM	100MG	N80136 001		Aug	CAHN
AA			300MG	N83633 001		Aug	CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

		HOSPIRA	0.02MG/ML	N83283 001		May	CAHN
AP			0.2MG/ML	N83346 001		May	CAHN

ISUPREL

AP	+	HOSPIRA	0.2MG/ML	N10515 001		May	CAHN
----	---	---------	----------	------------	--	-----	------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

	@	MUTUAL PHARM	5MG	N86166 002	Sep 19, 1986	Aug	CAHN
--	---	--------------	-----	------------	--------------	-----	------

	@		10MG	N86169 001	Sep 19, 1986	Aug	CAHN
--	---	--	------	------------	--------------	-----	------

	@		20MG	N86167 001	Sep 19, 1986	Aug	CAHN
--	---	--	------	------------	--------------	-----	------

	@		30MG	N87564 001	Sep 18, 1986	Aug	CAHN
--	---	--	------	------------	--------------	-----	------

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

	@	MUTUAL PHARM	2.5MG	N84204 001	Sep 18, 1986	Aug	CAHN
--	---	--------------	-------	------------	--------------	-----	------

	@		5MG	N86168 001	Sep 18, 1986	Aug	CAHN
--	---	--	-----	------------	--------------	-----	------

	@		10MG	N87545 001	Sep 18, 1986	Aug	CAHN
--	---	--	------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB		SCHERING PLOUGH	30MG	N20225 001	Aug 12, 1993	Apr	CRLD
----	--	-----------------	------	------------	--------------	-----	------

AB			60MG	N20225 002	Aug 12, 1993	Apr	CRLD
----	--	--	------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

>A>	AB	WEST WARD	60MG	N76813 001	Jan 07, 2005	Dec	NEWA
-----	----	-----------	------	------------	--------------	-----	------

ITRACONAZOLE

CAPSULE; ORAL
 ITRACONAZOLE
 AB EON 100MG N76104 001 May 28, 2004 May NEWA
 SPORANOX
 AB + JANSSEN PHARMA 100MG N20083 001 Sep 11, 1992 May CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
 KETAMINE HCL
 AP HOSPIRA EQ 50MG BASE/ML N74549 001 Jun 27, 1996 May CAHN
 AP EQ 100MG BASE/ML N74549 002 Jun 27, 1996 May CAHN

KETOCONAZOLE

CREAM; TOPICAL
 KETOCONAZOLE
 AB ALTANA 2% N76294 001 Apr 28, 2004 Apr NEWA
 AB + TEVA 2% N75581 001 Apr 25, 2000 Apr CRLD
 NIZORAL
 @ JANSSEN PHARMA 2% N19084 001 Dec 31, 1985 Apr DISC
 SHAMPOO; TOPICAL
 KETOCONAZOLE
 AB CLAY PARK 2% N76419 001 Jan 07, 2004 Jan NEWA
 NIZORAL
 AB + MCNEIL CONS SPECLT 2% N19927 001 Aug 31, 1990 Jan CFTG
 SUSPENSION; ORAL
 NIZORAL
 @ JANSSEN PHARMA 100MG/5ML N70767 001 Nov 07, 1986 Jul CAHN
 TABLET; ORAL
 NIZORAL
 AB + JANSSEN PHARMA 200MG N18533 001 Jul CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
 KETOROLAC TROMETHAMINE
 AP AMPHASTAR PHARM 15MG/ML N76209 001 Jul 21, 2004 Jul NEWA
 AP 30MG/ML N76209 002 Jul 21, 2004 Jul NEWA
 AP APOTEX 15MG/ML N76722 001 Jul 27, 2004 Jul NEWA
 AP 30MG/ML N76722 002 Jul 27, 2004 Jul NEWA
 AP BAXTER HLTHCARE 15MG/ML N75772 001 Jul 21, 2004 Jul NEWA
 AP 30MG/ML N75772 002 Jul 21, 2004 Jul NEWA
 AP + BEDFORD 15MG/ML N75222 001 Apr 26, 1999 Jan CRLD
 AP + 30MG/ML N75222 002 Apr 26, 1999 Jan CRLD
 @ HOSPIRA 15MG/ML N74801 001 Jun 05, 1997 May CAHN
 AP 15MG/ML N74802 001 Jun 05, 1997 May CAHN
 AP 15MG/ML N74993 001 Jan 27, 1999 May CAHN
 @ 30MG/ML N74801 002 Jun 05, 1997 May CAHN
 AP 30MG/ML N74802 002 Jun 05, 1997 May CAHN
 AP 30MG/ML N74993 002 Jan 27, 1999 May CAHN
 AP SABEX 2002 15MG/ML N76271 001 Oct 06, 2004 Oct NEWA
 AP 30MG/ML N76271 002 Oct 06, 2004 Oct NEWA
 TORADOL
 @ ROCHE PALO 15MG/ML N19698 001 Nov 30, 1989 Jan DISC
 @ 30MG/ML N19698 002 Nov 30, 1989 Jan DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

	+	NOVARTIS	EQ 0.025% BASE	N21066 001	Jul 02, 1999	Feb	CAHN
--	---	----------	----------------	------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP		HOSPIRA	5MG/ML	N75239 001	Nov 29, 1999	May	CAHN
----	--	---------	--------	------------	--------------	-----	------

AP			5MG/ML	N75240 001	Nov 29, 1999	May	CAHN
----	--	--	--------	------------	--------------	-----	------

NORMODYNE

@ SCHERING

			5MG/ML	N18686 001	Aug 01, 1984	Sep	DISC
--	--	--	--------	------------	--------------	-----	------

TABLET; ORAL

NORMODYNE

@ SCHERING

			100MG	N18687 001	Aug 31, 1987	Sep	DISC
--	--	--	-------	------------	--------------	-----	------

@

			200MG	N18687 002	Aug 01, 1984	Sep	DISC
--	--	--	-------	------------	--------------	-----	------

@

			300MG	N18687 003	Aug 01, 1984	Sep	DISC
--	--	--	-------	------------	--------------	-----	------

TRANDATE

AB	+	PROMETHEUS LABS	300MG	N18716 003	Aug 01, 1984	Sep	CRLD
----	---	-----------------	-------	------------	--------------	-----	------

LAMIVUDINE

TABLET; ORAL

EPIVIR

GLAXOSMITHKLINE

			150MG	N20564 001	Nov 17, 1995	May	CRLD
--	--	--	-------	------------	--------------	-----	------

+

			300MG	N20564 003	Jun 24, 2002	May	CRLD
--	--	--	-------	------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE

			25MG	N20241 005	Dec 27, 1994	Apr	CRLD
--	--	--	------	------------	--------------	-----	------

+

			200MG	N20241 003	Dec 27, 1994	Apr	CRLD
--	--	--	-------	------------	--------------	-----	------

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAP PHARM

			15MG/PACKET	N21281 001	May 03, 2001	Jul	CDFR
--	--	--	-------------	------------	--------------	-----	------

+

			30MG/PACKET	N21281 002	May 03, 2001	Jul	CDFR
--	--	--	-------------	------------	--------------	-----	------

INJECTABLE; INTRAVENOUS

PREVACID IV

TAP PHARM

			30MG/VIAL	N21566 001	May 27, 2004	May	NEWA
--	--	--	-----------	------------	--------------	-----	------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

PREVACID

TAP PHARM

			15MG	N21428 001	Aug 30, 2002	Jul	CDFR
--	--	--	------	------------	--------------	-----	------

+

			30MG	N21428 002	Aug 30, 2002	Jul	CDFR
--	--	--	------	------------	--------------	-----	------

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE PHARM

			250MG	N21468 001	Oct 26, 2004	Oct	NEWA
--	--	--	-------	------------	--------------	-----	------

+

			500MG	N21468 002	Oct 26, 2004	Oct	NEWA
--	--	--	-------	------------	--------------	-----	------

LEFLUNOMIDE

TABLET; ORAL

ARAVA

AVENTIS PHARMS

			100MG	N20905 003	Sep 10, 1998	Jul	CMFD
--	--	--	-------	------------	--------------	-----	------

LEUCOVORIN CALCIUM

	INJECTABLE; INJECTION				
	LEUCOVORIN CALCIUM				
	@ PHARMACHEMIE USA	EQ 100MG BASE/VIAL			
	LEUCOVORIN CALCIUM PRESERVATIVE FREE				
AP	BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL	N89915	001	Apr 17, 1997 Aug DISC
	+	EQ 500MG BASE/VIAL	N40258	001	Feb 26, 1999 Jul CAHN
AP	HOSPIRA	EQ 10MG BASE/ML	N40286	001	Feb 26, 1999 Jul CAHN
			N40147	001	Jun 25, 1997 May CAHN

LEUPROLIDE ACETATE

	INJECTABLE; SUBCUTANEOUS				
	ELIGARD				
>D>	+ ATRIX	7.5MG/VIAL			
>D>	+	30MG/VIAL			
>A>	+ QLT USA	7.5MG/VIAL	N21343	001	Jan 23, 2002 Dec CAHN
>A>	+	30MG/VIAL	N21488	001	Feb 13, 2003 Dec CAHN
>A>	+	45MG/VIAL	N21343	001	Jan 23, 2002 Dec CAHN
			N21488	001	Feb 13, 2003 Dec CAHN
			N21731	001	Dec 14, 2004 Dec NEWA

LEVOBUPIVACAINE HYDROCHLORIDE

	INJECTABLE; INJECTION				
	CHIROCAINE				
	@ PURDUE PHARMA LP	EQ 2.5MG BASE/ML			
	@	EQ 5MG BASE/ML			
	@	EQ 7.5MG BASE/ML	N20997	001	Aug 05, 1999 May DISC
			N20997	002	Aug 05, 1999 May DISC
			N20997	003	Aug 05, 1999 May DISC

LEVOCABASTINE HYDROCHLORIDE

	SUSPENSION/DROPS; OPHTHALMIC				
	LIVOSTIN				
	+ NOVARTIS	EQ 0.05% BASE			
			N20219	001	Nov 10, 1993 Feb CAHN

LEVOCARNITINE

	SOLUTION; ORAL				
	CARNITOR				
AA	+ SIGMA TAU	1GM/10ML			
AA	LEVOCARNITINE				
	LYNE	1GM/10ML	N19257	001	Apr 10, 1986 Aug CFTG
	TABLET; ORAL				
	CARNITOR				
AB	+ SIGMA TAU	330MG	N76851	001	Aug 10, 2004 Aug NEWA
AB	LEVOCARNITINE				
	COREPHARMA	330MG	N18948	001	Dec 27, 1985 Sep CFTG
			N76858	001	Sep 20, 2004 Sep NEWA

LEVOFLOXACIN

	SOLUTION/DROPS; OPHTHALMIC				
	IQUIX				
	+ SANTEN	1.5%			
	SOLUTION; ORAL				
	LEVAQUIN				
	+ ORTHO MCNEIL PHARM	250MG/10ML	N21571	001	Mar 01, 2004 Mar NEWA
	TABLET; ORAL				
	LEVAQUIN				
AB	ORTHO MCNEIL PHARM	250MG	N21721	001	Oct 21, 2004 Oct NEWA
AB		500MG			
	LEVOFLOXACIN				
AB	MYLAN	250MG	N20634	001	Dec 20, 1996 Oct CFTG
AB		500MG	N20634	002	Dec 20, 1996 Oct CFTG
			N76276	001	Oct 15, 2004 Oct NEWA
			N76276	002	Oct 15, 2004 Oct NEWA

LEVONORGESTREL

TABLET; ORAL
PLAN B

+ DURAMED 0.75MG N21045 001 Jul 28, 1999 Feb CAHN

LEVOTHYROXINE SODIUM*

TABLET; ORAL
LEVOLET

BX	VINTAGE	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
BX		0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
BX		0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
BX		0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN
BX		0.1MG	N21137 005	Jun 06, 2003	Jul	CAHN
BX		0.112MG	N21137 006	Jun 06, 2003	Jul	CAHN
BX		0.125MG	N21137 007	Jun 06, 2003	Jul	CAHN
BX		0.137MG	N21137 008	Jun 06, 2003	Jul	CAHN
BX		0.15MG	N21137 009	Jun 06, 2003	Jul	CAHN
BX		0.175MG	N21137 010	Jun 06, 2003	Jul	CAHN
BX		0.2MG	N21137 011	Jun 06, 2003	Jul	CAHN
BX		0.3MG	N21137 012	Jun 06, 2003	Jul	CAHN

LEVO-T

AB2,	ALARA PHARM	0.025MG	N21342 001	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.05MG	N21342 002	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.075MG	N21342 003	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.088MG	N21342 004	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.1MG	N21342 005	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.112MG	N21342 006	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.125MG	N21342 007	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.137MG	N21342 012	Dec 08, 2003	Jun	CTEC
AB3						
AB2,		0.15MG	N21342 008	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.175MG	N21342 009	Mar 01, 2002	Jun	CTEC
AB3						
AB2,		0.2MG	N21342 010	Mar 01, 2002	Jun	CTEC
AB3						
AB2, +		0.3MG	N21342 011	Mar 01, 2002	Jun	CTEC
AB3						

LEVOTHYROXINE SODIUM

AB1,	MYLAN	0.025MG	N76187 001	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						
AB1,		0.05MG	N76187 002	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						
AB1,		0.075MG	N76187 003	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						
AB1,		0.088MG	N76187 004	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						
AB1,		0.1MG	N76187 005	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						
AB1,		0.112MG	N76187 006	Jun 05, 2002	Jun	CTEC
AB2,						
AB3						

* SEE PREFACE 1.4 LEVOTHYROXINE SODIUM

TABLET; ORAL

Product Name	Strength	Approval Number	Start Date	End Date	Category
LEVOTHYROXINE SODIUM					
AB1, AB2, AB3 MYLAN	0.125MG	N76187 007	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.15MG	N76187 008	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.175MG	N76187 009	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.2MG	N76187 010	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.3MG	N76187 011	Jun 05, 2002	Jun	CTEC
LEVOXYL					
AB1, AB3 JONES PHARMA	0.025MG	N21301 001	May 25, 2001	Jun	CTEC
AB1, AB3	0.05MG	N21301 002	May 25, 2001	Jun	CTEC
AB1, AB3	0.075MG	N21301 003	May 25, 2001	Jun	CTEC
AB1, AB3	0.088MG	N21301 004	May 25, 2001	Jun	CTEC
AB1, AB3	0.1MG	N21301 005	May 25, 2001	Jun	CTEC
AB1, AB3	0.112MG	N21301 006	May 25, 2001	Jun	CTEC
AB1, AB3	0.125MG	N21301 007	May 25, 2001	Jun	CTEC
AB1	0.137MG	N21301 008	May 25, 2001	Jun	CTEC
AB1, AB3	0.137MG	N21301 008	May 25, 2001	Jul	CTEC
AB1, AB3	0.15MG	N21301 009	May 25, 2001	Jun	CTEC
AB1, AB3	0.175MG	N21301 010	May 25, 2001	Jun	CTEC
AB1, AB3	0.2MG	N21301 011	May 25, 2001	Jun	CTEC
AB1, + AB3	0.3MG	N21301 012	May 25, 2001	Jun	CTEC
SYNTHROID					
AB2 ABBOTT	0.025MG	N21402 001	Jul 24, 2002	Jun	CFTG
AB2	0.05MG	N21402 002	Jul 24, 2002	Jun	CFTG
AB2	0.075MG	N21402 003	Jul 24, 2002	Jun	CFTG
AB2	0.088MG	N21402 004	Jul 24, 2002	Jun	CFTG
AB2	0.1MG	N21402 005	Jul 24, 2002	Jun	CFTG
AB2	0.112MG	N21402 006	Jul 24, 2002	Jun	CFTG
AB2	0.125MG	N21402 007	Jul 24, 2002	Jun	CFTG
AB2	0.137MG	N21402 008	Jul 24, 2002	Jun	CFTG
AB2	0.15MG	N21402 009	Jul 24, 2002	Jun	CFTG
AB2	0.175MG	N21402 010	Jul 24, 2002	Jun	CFTG
AB2	0.2MG	N21402 011	Jul 24, 2002	Jun	CFTG
AB2 +	0.3MG	N21402 012	Jul 24, 2002	Jun	CFTG
THYRO-TABS					
BX LLOYD	0.137MG	N21116 012	Dec 07, 2004	Nov	NEWA
UNITHROID					
AB1, AB2, AB3 STEVENS J	0.025MG	N21210 001	Aug 21, 2000	Nov	CTEC
AB1, AB3	0.025MG	N21210 001	Aug 21, 2000	Jun	CTEC
AB1, AB3	0.05MG	N21210 002	Aug 21, 2000	Jun	CTEC

TABLET; ORAL
UNITHROID

AB1, AB2, AB3	STEVENS J	0.05MG	N21210 002	Aug 21, 2000	Nov	CTEC
AB1, AB2, AB3		0.075MG	N21210 003	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.075MG	N21210 003	Aug 21, 2000	Jun	CTEC
AB1, AB3		0.088MG	N21210 004	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.088MG	N21210 004	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.1MG	N21210 005	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.1MG	N21210 005	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.112MG	N21210 006	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.112MG	N21210 006	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.125MG	N21210 007	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.125MG	N21210 007	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.15MG	N21210 008	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.15MG	N21210 008	Aug 21, 2000	Nov	CTEC
AB1, AB2, AB3		0.175MG	N21210 009	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.175MG	N21210 009	Aug 21, 2000	Jun	CTEC
AB1, AB2, AB3		0.2MG	N21210 010	Aug 21, 2000	Nov	CTEC
AB1, AB3		0.2MG	N21210 010	Aug 21, 2000	Jun	CTEC
AB1, + AB3		0.3MG	N21210 011	Aug 21, 2000	Jun	CTEC
AB1, + AB2, AB3		0.3MG	N21210 011	Aug 21, 2000	Nov	CTEC

LIDOCAINE

PATCH; TOPICAL

LIDODERM

+ TEIKOKU PHARMA USA

5%

N20612 001 Mar 19, 1999 Sep CDFR

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

@ BAXTER HLTHCARE

@

AP HOSPIRA

AP

AP

AP

AP

AP

@

1%

2%

0.5%

1%

1%

1%

1.5%

2%

N80407 001

N80407 002

N88328 001 May 17, 1984 May CAHN

N40013 001 Jun 23, 1995 May CAHN

N83158 001 May CAHN

N88329 001 May 17, 1984 May CAHN

N88330 001 May 17, 1984 May CAHN

N40078 001 Jun 23, 1995 May CAHN

Aug CAHN

Aug CAHN

INJECTABLE; INJECTION						
LIDOCAINE HCL						
AP	HOSPIRA	2%	N83158 002		May	CAHN
AP		2%	N88294 001	May 17, 1984	May	CAHN
AP		2%	N88331 001	May 17, 1984	May	CAHN
AP		20%	N83158 003		May	CAHN
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN 200MG/100ML						
			N18967 001	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.2% IN DEXTROSE 5% HOSPIRA 200MG/100ML						
AP			N83158 005		May	CAHN
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA 200MG/100ML						
AP			N18388 001		May	CAHN
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN 400MG/100ML						
			N18967 002	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.4% IN DEXTROSE 5% HOSPIRA 400MG/100ML						
AP			N83158 006		May	CAHN
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA 400MG/100ML						
AP			N18388 002		May	CAHN
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN 800MG/100ML						
			N18967 003	Mar 30, 1984	Apr	DISC
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA 800MG/100ML						
AP			N18388 003	Nov 05, 1982	May	CAHN
LIDOCAINE HCL IN PLASTIC CONTAINER HOSPIRA 0.5%						
AP			N88325 001	Jul 31, 1984	May	CAHN
AP		1%	N88299 001	Jul 31, 1984	May	CAHN
AP		1.5%	N88326 001	Jul 31, 1984	May	CAHN
AP		2%	N88327 001	Jul 31, 1984	May	CAHN
AP		10%	N88367 001	Jul 31, 1984	May	CAHN
AP		20%	N88368 001	Jul 31, 1984	May	CAHN
LIDOCAINE HCL PRESERVATIVE FREE HOSPIRA 1%						
AP			N80408 001		May	CAHN
AP		1.5%	N80408 002		May	CAHN
AP		4%	N88295 001	May 17, 1984	May	CAHN
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER HOSPIRA 1%						
AP			N40302 001	Sep 28, 1998	May	CAHN
AP		2%	N40302 002	Sep 28, 1998	May	CAHN
INJECTABLE; SPINAL						
LIDOCAINE HCL 5% AND DEXTROSE 7.5% + HOSPIRA 5%						
			N83914 001		May	CAHN
SOLUTION; TOPICAL						
LTA II KIT						
AT	HOSPIRA	4%	N80409 001		May	CAHN
AT		4%	N88542 001	Jul 31, 1984	May	CAHN
PEDIATRIC LTA KIT						
AT	HOSPIRA	2%	N85995 001		May	CAHN
LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE						
INJECTABLE; INJECTION						
TERRAMYCIN						
+	PFIZER	2%;50MG/ML	N60567 001		Feb	CRLD
+		2%;125MG/ML	N60567 002		Feb	CRLD
LIDOCAINE; PRILOCAINE						
DISC; TOPICAL						
EMLA @ ASTRAZENECA 2.5%;2.5%						
			N20962 001	Feb 04, 1998	Nov	DISC

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ABLE	150MG	N76823 001	Jun 29, 2004	Jun	NEWA
AB		300MG	N76823 002	Jun 29, 2004	Jun	NEWA
AB		600MG	N76823 003	Jun 29, 2004	Jun	NEWA
AB	APOTEX	300MG	N76795 001	Nov 22, 2004	Nov	NEWA
AB	+ ROXANE	600MG	N17812 003	Jan 28, 1987	Jun	CFTG

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	ROXANE	300MG	N76832 001	Oct 28, 2004	Oct	NEWA
AB		450MG	N76691 001	Jan 05, 2004	Jan	NEWA
AB	+ LITHOBID					
AB	+ JDS PHARMS	300MG	N18027 001		Sep	CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM

@ JANSSEN PHARMA

1MG/5ML

N19037 001 Jul 31, 1984 Jul CAHN

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

@ BAXTER HLTHCARE

2MG/ML

N74496 001 Sep 28, 1998 Sep DISC

AP		2MG/ML	N74496 001	Sep 28, 1998	Aug	CAHN
AP		4MG/ML	N74496 002	Sep 28, 1998	Aug	CAHN
	@	4MG/ML	N74496 002	Sep 28, 1998	Sep	DISC
AP	HOSPIRA	2MG/ML	N74243 001	Apr 12, 1994	May	CAHN
AP		2MG/ML	N74280 001	May 27, 1994	May	CAHN
AP		2MG/ML	N74282 001	May 27, 1994	May	CAHN
AP		2MG/ML	N74300 001	Apr 12, 1994	May	CAHN
AP		4MG/ML	N74243 002	Apr 12, 1994	May	CAHN
AP		4MG/ML	N74280 002	May 27, 1994	May	CAHN
AP		4MG/ML	N74282 002	May 27, 1994	May	CAHN
AP		4MG/ML	N74300 003	Mar 19, 1997	May	CAHN
AP	INTL MEDICATION SYS	2MG/ML	N76150 001	Nov 15, 2004	Nov	NEWA

>D> SOLUTION; ORAL

>D> LORAZEPAM

>D> + ROXANE 0.5MG/5ML N74648 001 Mar 18, 1997 Dec DISC

>A> @ 0.5MG/5ML N74648 001 Mar 18, 1997 Dec DISC

TABLET; ORAL

LORAZEPAM

@ MUTUAL PHARM

0.5MG

N70472 001 Dec 10, 1985 Aug CAHN

@

1MG

N70473 001 Dec 10, 1985 Aug CAHN

@

2MG

N70474 001 Dec 10, 1985 Aug CAHN

@ WATSON LABS

1MG

N71087 001 Mar 23, 1987 Nov DISC

@

2MG

N71088 001 Mar 23, 1987 Nov DISC

>A> LOTEPREDNOL ETABONATE; TOBRAMYCIN

>A> SUSPENSION/DROPS; OPHTHALMIC

>A> ZYLET

>A> + BAUSCH AND LOMB 0.5%;0.3% N50804 001 Dec 14, 2004 Dec NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

	ANDRX	10MG	N21316 001	Jun 26, 2002	Jul	CTNA
		20MG	N21316 002	Jun 26, 2002	Jul	CTNA
		40MG	N21316 003	Jun 26, 2002	Jul	CTNA
+		60MG	N21316 004	Jun 26, 2002	Jul	CTNA
	ANDRX LABS LLC	10MG	N21316 001	Jun 26, 2002	Sep	CAHN
		20MG	N21316 002	Jun 26, 2002	Sep	CAHN
		40MG	N21316 003	Jun 26, 2002	Sep	CAHN
+		60MG	N21316 004	Jun 26, 2002	Sep	CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	KOS	20MG;500MG	N21249 001	Dec 17, 2001	Feb	CRLD
	@	20MG;750MG	N21249 002	Dec 17, 2001	Jul	DISC
+		20MG;750MG	N21249 002	Dec 17, 2001	Feb	CRLD

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE

AB	MYLAN	EQ 5MG BASE	N76762 001	Nov 01, 2004	Nov	NEWA
AB		EQ 10MG BASE	N76762 002	Nov 01, 2004	Nov	NEWA
AB		EQ 25MG BASE	N76762 003	Nov 01, 2004	Nov	NEWA
AB		EQ 50MG BASE	N76762 004	Nov 01, 2004	Nov	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

+	SERONO INC	75 IU/VIAL	N21322 001	Oct 08, 2004	Oct	NEWA
---	------------	------------	------------	--------------	-----	------

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

SULFAMYLN

+	MYLAN BERTEK	5%	N19832 003	Jun 05, 1998	Aug	CAHN
---	--------------	----	------------	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

@	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML ;530MG/100ML;500MG/100ML	N18252 001		Nov	DISC
---	---------	---	------------	--	-----	------

NORMOSOL-R IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001		May	CAHN
--	---------	---	------------	--	-----	------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

@	HOSPIRA	14MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 001		May	CAHN
---	---------	---	------------	--	-----	------

		30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17637 002	Jul 08, 1982	May	CAHN
--	--	---	------------	--------------	-----	------

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N18406 002	Jul 08, 1982	May	CAHN
--	---------	---	------------	--------------	-----	------

MAGNESIUM SULFATE

	INJECTABLE; INJECTION						
	MAGNESIUM SULFATE						
AP	HOSPIRA	500MG/ML		N75151 001	Apr 25, 2000	May	CAHN
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
+	HOSPIRA	1GM/100ML		N20488 001	Jul 11, 1995	May	CAHN
+		2GM/100ML		N20488 002	Jul 11, 1995	May	CAHN
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
+	HOSPIRA	80MG/ML		N20309 002	Jun 24, 1994	May	CAHN
+		4GM/100ML		N20309 001	Jun 24, 1994	May	CAHN

MALATHION

LOTION; TOPICAL
OVIDE

+	TARO PHARMS NORTH	0.5%		N18613 001	Aug 02, 1982	Jun	CAHN
---	-------------------	------	--	------------	--------------	-----	------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML		N18962 001	Jun 26, 1986	May	CAHN
--	---------	-----------------------	--	------------	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

@	HOSPIRA	10GM/100ML		N16269 002		May	CAHN
---	---------	------------	--	------------	--	-----	------

MANNITOL 10% IN PLASTIC CONTAINER

AP	HOSPIRA	10GM/100ML		N19603 002	Jan 08, 1987	May	CAHN
----	---------	------------	--	------------	--------------	-----	------

MANNITOL 15%

@	HOSPIRA	15GM/100ML		N16269 003		May	CAHN
---	---------	------------	--	------------	--	-----	------

MANNITOL 15% IN PLASTIC CONTAINER

AP	HOSPIRA	15GM/100ML		N19603 003	Jan 08, 1990	May	CAHN
----	---------	------------	--	------------	--------------	-----	------

MANNITOL 20%

@	HOSPIRA	20GM/100ML		N16269 004		May	CAHN
---	---------	------------	--	------------	--	-----	------

MANNITOL 20% IN PLASTIC CONTAINER

AP	HOSPIRA	20GM/100ML		N19603 004	Jan 08, 1990	May	CAHN
----	---------	------------	--	------------	--------------	-----	------

MANNITOL 25%

@	HOSPIRA	12.5GM/50ML		N16269 005		May	CAHN
---	---------	-------------	--	------------	--	-----	------

AP		12.5GM/50ML		N16269 006	Aug 25, 1994	May	CAHN
----	--	-------------	--	------------	--------------	-----	------

MANNITOL 5%

@	HOSPIRA	5GM/100ML		N16269 001		May	CAHN
---	---------	-----------	--	------------	--	-----	------

MANNITOL 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML		N19603 001	Jan 08, 1987	May	CAHN
----	---------	-----------	--	------------	--------------	-----	------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

@	HOSPIRA	540MG/100ML; 2.7GM/100ML		N80224 001		May	CAHN
---	---------	--------------------------	--	------------	--	-----	------

SORBITOL-MANNITOL IN PLASTIC CONTAINER

AT	HOSPIRA	540MG/100ML; 2.7GM/100ML		N17636 001		May	CAHN
----	---------	--------------------------	--	------------	--	-----	------

AT		540MG/100ML; 2.7GM/100ML		N18316 001		May	CAHN
----	--	--------------------------	--	------------	--	-----	------

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

@	NOVARTIS	25MG		N17543 001		Jun	DISC
---	----------	------	--	------------	--	-----	------

@		50MG		N17543 002		Jun	DISC
---	--	------	--	------------	--	-----	------

TABLET; ORAL						
	LUDIOMIL					
	@ NOVARTIS	75MG		N17543 003	Sep 30, 1982	Jun DISC
	MAPROTIline HCL					
AB	+ MYLAN	50MG		N72285 001	Oct 03, 1988	Jun CRLD
<u>MEDROXYPROGESTERONE ACETATE</u>						
INJECTABLE; INJECTION						
DEPO-PROVERA						
AB	+ PHARMACIA AND UPJOHN	150MG/ML		N20246 001	Oct 29, 1992	Jul CFTG
>A>	DEPO-SUBQ PROVERA 104					
>A>	+ PFIZER	104MG/0.65ML		N21583 001	Dec 17, 2004	Dec NEWA
MEDROXYPROGESTERONE ACETATE						
AB	SICOR PHARMS	150MG/ML		N76552 001	Oct 27, 2004	Oct NEWA
AB		150MG/ML		N76553 001	Jul 28, 2004	Jul NEWA
<u>MEFLOQUINE HYDROCHLORIDE</u>						
TABLET; ORAL						
MEFLOQUINE HCL						
AB	ROXANE	250MG		N76523 001	Oct 01, 2004	Oct NEWA
<u>MEGESTROL ACETATE</u>						
SUSPENSION; ORAL						
MEGESTROL ACETATE						
AB	MORTON GROVE	40MG/ML		N76721 001	Nov 01, 2004	Nov NEWA
<u>MELOXICAM</u>						
SUSPENSION; ORAL						
MOBIC						
	+ BOEHRINGER INGELHEIM	7.5MG/5ML		N21530 001	Jun 01, 2004	Jun NEWA
<u>MENOTROPINS (FSH;LH)</u>						
INJECTABLE; IM-SC						
REPRONEX						
	+ FERRING	75 IU/VIAL;75 IU/VIAL		N21047 001	Aug 27, 1999	Oct CDFR
INJECTABLE; INJECTION						
PERGONAL						
	@ SERONO	75 IU/AMP;75 IU/AMP		N17646 001		May DISC
	REPRONEX					
	+ FERRING	75 IU/VIAL;75 IU/VIAL		N21047 001	Aug 27, 1999	May CTEC
INJECTABLE; SUBCUTANEOUS						
MENOPUR						
	+ FERRING	75 IU/VIAL;75 IU/VIAL		N21663 001	Oct 29, 2004	Oct NEWA
<u>MEPERIDINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
DEMEROL						
AP	+ HOSPIRA	25MG/ML		N21171 001		May CAHN
AP		50MG/ML		N21171 002		May CAHN
AP		75MG/ML		N21171 003		May CAHN
AP		100MG/ML		N21171 004		May CAHN
MEPERIDINE HCL PRESERVATIVE FREE						
AP	+ HOSPIRA	10MG/ML		N88432 001	Aug 16, 1984	May CAHN
TABLET; ORAL						
MEPERIDINE HCL						
AA	MUTUAL PHARM	50MG		N80448 001		Aug CAHN
AA		100MG		N80448 002		Aug CAHN

MEPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
CARBOCAINE

AP	+	HOSPIRA	1%	N12250 001		May	CAHN
AP	+		1.5%	N12250 005		May	CAHN
AP	+		2%	N12250 002		May	CAHN

MEPROBAMATETABLET; ORAL
MEPROBAMATE

	@	MUTUAL PHARM	200MG	N80699 001		Aug	CAHN
	@		400MG	N80699 002		Aug	CAHN

MERCAPTOPYRINETABLET; ORAL
MERCAPTOPYRINE

AB		PROMETHEUS LABS	50MG	N40461 001	Feb 11, 2004	Feb	NEWA
AB		ROXANE	50MG	N40528 001	Feb 13, 2004	Feb	NEWA
AB	+	TEVA	50MG	N09053 002		Feb	CFTG

MESALAMINECAPSULE, EXTENDED RELEASE; ORAL
PENTASA

		SHIRE LABS	250MG	N20049 001	May 10, 1993	Aug	CRLD
	+		500MG	N20049 002	Jul 08, 2004	Aug	NEWA

ENEMA; RECTAL
MESALAMINE

AB		CLAY PARK	4GM/60ML	N76751 001	Sep 17, 2004	Sep	NEWA
AB		TEVA	4GM/60ML	N76841 001	Sep 30, 2004	Sep	NEWA
AB	+	SOLVAY	4GM/60ML	N19618 001	Dec 24, 1987	Sep	CFTG

SUPPOSITORY; RECTAL
CANASA

		AXCAN SCANDIPHARM	500MG	N21252 001	Jan 05, 2001	Nov	CRLD
	+		1GM	N21252 002	Nov 05, 2004	Nov	NEWA

MESNAINJECTABLE; INTRAVENOUS
MESNA

AP		BEDFORD	100MG/ML	N75739 001	Jan 09, 2004	Jan	NEWA
----	--	---------	----------	------------	--------------	-----	------

MESORIDAZINE BESYLATECONCENTRATE; ORAL
SERENTIL

	@	NOVARTIS	EQ 25MG BASE/ML	N16997 001		May	DISC
--	---	----------	-----------------	------------	--	-----	------

TABLET; ORAL
SERENTIL

	@	NOVARTIS	EQ 25MG BASE	N16774 002		May	DISC
	@		EQ 100MG BASE	N16774 004		May	DISC

METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
FORTAMET

BX		ANDRX	500MG	N21574 001	Apr 27, 2004	Apr	NEWA
----	--	-------	-------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL						
FORTAMET						
	+	ANDRX	1GM			
BX		ANDRX LABS LLC	500MG	N21574 002	Apr 27, 2004	Apr NEWA
	+		1GM	N21574 001	Apr 27, 2004	Sep CAHN
				N21574 002	Apr 27, 2004	Sep CAHN
GLUCOPHAGE XR						
AB		BRISTOL MYERS SQUIBB	500MG	N21202 001	Oct 13, 2000	Jan CFTG
AB	+		750MG	N21202 004	Apr 11, 2003	Oct CFTG
METFORMIN HCL						
AB		ANDRX PHARMS	500MG	N76172 001	Jun 16, 2004	Jun NEWA
>A>	AB	APOTEX	500MG	N76706 001	Dec 14, 2004	Dec NEWA
	AB	BARR	750MG	N76863 001	Oct 14, 2004	Oct NEWA
>A>	AB	COBALT	500MG	N76818 001	Dec 14, 2004	Dec NEWA
>A>	AB	EON	500MG	N76873 001	Dec 14, 2004	Dec NEWA
	AB	IMPAX LABS	500MG	N76249 001	Jul 30, 2004	Jul NEWA
	AB	IVAX PHARMS	500MG	N76545 001	Dec 01, 2003	Jan NEWA
	AB	PUREPAC PHARM	500MG	N76450 001	Oct 01, 2004	Oct NEWA
	AB	RANBAXY	500MG	N76413 001	Jun 18, 2004	Jun NEWA
>A>	AB	SANDOZ	500MG	N76223 001	Dec 14, 2004	Dec NEWA
	AB	TEVA	500MG	N76269 001	Jun 18, 2004	Jun NEWA
TABLET; ORAL						
METFORMIN HCL						
>A>	AB	AUROBINDO	500MG	N77095 001	Jan 14, 2005	Dec NEWA
>A>	AB		850MG	N77095 002	Jan 14, 2005	Dec NEWA
>A>	AB		1GM	N77095 003	Jan 14, 2005	Dec NEWA
<u>METHADONE HYDROCHLORIDE</u>						
TABLET; ORAL						
METHADONE HCL						
		@ EON	5MG			
AA		MALLINCKRODT	5MG	N40241 001	May 29, 1998	Aug DISC
AA			10MG	N40517 001	Apr 27, 2004	Apr NEWA
				N40517 002	Apr 27, 2004	Apr NEWA
<u>METHAMPHETAMINE HYDROCHLORIDE</u>						
TABLET; ORAL						
DESOXYN						
AB	+	OVATION PHARMS	5MG	N05378 002		Feb CFTG
METHAMPHETAMINE HCL						
AB		ABLE	5MG	N40529 001	Feb 25, 2004	Feb NEWA
<u>METHENAMINE HIPPURATE</u>						
TABLET; ORAL						
UREX						
AB		VATRING PHARMS	1GM	N16151 001		Aug CAHN
<u>METHIMAZOLE</u>						
TABLET; ORAL						
TAPAZOLE						
AB		KING PHARMS	5MG	N07517 002		Mar CAHN
AB			10MG	N07517 004		Mar CAHN
<u>METHOCARBAMOL</u>						
TABLET; ORAL						
METHOCARBAMOL						
		@ MUTUAL PHARM	500MG	N84488 001		Aug CAHN
		@	750MG	N84486 001		Aug CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
	METHOTREXATE PRESERVATIVE FREE					
AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METHYL AMINOLEVULINATE

+	PHOTOCURE ASA	16.8%	N21415 001	Jul 27, 2004	Jul	NEWA
---	---------------	-------	------------	--------------	-----	------

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>D>	@ ACCORD HEALTH	125MG	N70070 003	Oct 15, 1985	Dec	CAHN
	@	125MG	N70070 003	Oct 15, 1985	Jun	CAHN
>D>	AB	250MG	N70084 001	Oct 15, 1985	Dec	CAHN
	AB	250MG	N70084 001	Oct 15, 1985	Jun	CAHN
>D>	AB	500MG	N70085 001	Oct 15, 1985	Dec	CAHN
	AB	500MG	N70085 001	Oct 15, 1985	Jun	CAHN
>A>	@ ACCORD HLTH	125MG	N70070 003	Oct 15, 1985	Dec	CAHN
>A>	AB	250MG	N70084 001	Oct 15, 1985	Dec	CAHN
>A>	AB	500MG	N70085 001	Oct 15, 1985	Dec	CAHN
	@ MUTUAL PHARM	125MG	N70073 001	Oct 09, 1986	Aug	CAHN
	@	250MG	N70060 001	Oct 09, 1986	Aug	CAHN
	@	500MG	N70074 001	Oct 09, 1986	Aug	CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987	May	CAHN
AP		50MG/ML	N70699 001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX	CELLTECH PHARMS	10MG	N21259 003	May 27, 2003	May	CTEC
	RITALIN LA					
BX	NOVARTIS	10MG	N21284 004	Apr 10, 2004	May	CTEC
		10MG	N21284 004	Apr 10, 2004	Apr	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001		May	CAHN
AP		EQ 125MG BASE/VIAL	N85855 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85854 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN
AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN
	METHYLPREDNISOLONE SODIUM SUCCINATE					
AP	AM PHARM	EQ 40MG BASE/VIAL	N40583 001	Jul 30, 2004	Jul	NEWA
AP		EQ 125MG BASE/VIAL	N40583 002	Jul 30, 2004	Jul	NEWA

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AM PHARM	EQ 1GM BASE/VIAL	N40612 001	Aug 12, 2004	Aug	NEWA
----	----------	------------------	------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

>D> CONCENTRATE; ORAL

>D> METOCLOPRAMIDE INTENSOL

>D>	ROXANE	EQ 10MG BASE/ML	N72995 001	Jan 30, 1992	Dec	DISC
-----	--------	-----------------	------------	--------------	-----	------

>A>	@	EQ 10MG BASE/ML	N72995 001	Jan 30, 1992	Dec	DISC
-----	---	-----------------	------------	--------------	-----	------

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
----	---------	----------------	------------	--------------	-----	------

	@	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
--	---	----------------	------------	--------------	-----	------

AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
----	--	----------------	------------	--------------	-----	------

AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
----	--	----------------	------------	--------------	-----	------

AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN
----	--	----------------	------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HCL

	@ MUTUAL PHARM	EQ 10MG BASE	N70660 001	Feb 10, 1987	Aug	CAHN
--	----------------	--------------	------------	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	MYLAN	5MG	N76698 002	Oct 19, 2004	Oct	NEWA
----	-------	-----	------------	--------------	-----	------

AB		10MG	N76698 003	Oct 19, 2004	Oct	NEWA
----	--	------	------------	--------------	-----	------

AB	ROXANE	10MG	N76482 002	Apr 29, 2004	Apr	NEWA
----	--------	------	------------	--------------	-----	------

AB	TEVA	2.5MG	N76600 001	Jan 06, 2004	Jan	NEWA
----	------	-------	------------	--------------	-----	------

AB		5MG	N76833 001	Mar 01, 2004	Mar	NEWA
----	--	-----	------------	--------------	-----	------

AB	WATSON LABS	10MG	N76891 001	Jul 21, 2004	Jul	NEWA
----	-------------	------	------------	--------------	-----	------

MYKROX

	@ CELLTECH PHARMS	0.5MG	N19532 001	Oct 30, 1987	Jan	DISC
--	-------------------	-------	------------	--------------	-----	------

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	HOSPIRA	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
----	---------	--------	------------	--------------	-----	------

AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN
----	--	--------	------------	--------------	-----	------

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	100MG	N17963 002		Mar	CRLD
----	----------	-------	------------	--	-----	------

METOPROLOL TARTRATE

	CARACO	25MG	N76670 001	Jan 15, 2004	Jan	NEWA
--	--------	------	------------	--------------	-----	------

AB		25MG	N76670 001	Jan 15, 2004	Mar	CTEC
----	--	------	------------	--------------	-----	------

+	MYLAN	25MG	N76704 001	Jan 16, 2004	Jan	NEWA
---	-------	------	------------	--------------	-----	------

AB		25MG	N76704 001	Jan 16, 2004	Mar	CTEC
----	--	------	------------	--------------	-----	------

AB		50MG	N76704 002	Jan 16, 2004	Jan	NEWA
----	--	------	------------	--------------	-----	------

AB		100MG	N76704 003	Jan 16, 2004	Jan	NEWA
----	--	-------	------------	--------------	-----	------

AB	+	100MG	N76704 003	Jan 16, 2004	Mar	CRLD
----	---	-------	------------	--------------	-----	------

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

AB	KALI LABS	375MG	N76522 001	Jan 29, 2004	Jan	NEWA
----	-----------	-------	------------	--------------	-----	------

CREAM; TOPICAL

METROCREAM

AB	+	GALDERMA LABS LP	0.75%	N20531 001	Sep 20, 1995	May	CFTG
----	---	------------------	-------	------------	--------------	-----	------

CREAM; TOPICAL
METRONIDAZOLE

AB	ALTANA	0.75%	N76408 001	May 28, 2004	May	NEWA
INJECTABLE; INJECTION						
METRONIDAZOLE IN PLASTIC CONTAINER						
AP	+ HOSPIRA	500MG/100ML	N18890 002	Nov 18, 1983	May	CAHN
TABLET; ORAL						
METRONIDAZOLE						
	@ MUTUAL PHARM	250MG	N18818 001	Feb 16, 1983	Aug	CAHN
	@	500MG	N18818 002	Feb 16, 1983	Aug	CAHN

MICONAZOLE

INJECTABLE; INJECTION
MONISTAT
@ JANSSEN PHARMA

10MG/ML

N18040 001 Jul CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL
@ HOSPIRA

EQ 1MG BASE/ML

N75293 001 Jun 20, 2000 May DISC

AP		EQ 1MG BASE/ML	N75409 002	Jun 20, 2000	May	CAHN
AP		EQ 1MG BASE/ML	N75856 001	Jun 13, 2002	May	CAHN
AP	+	EQ 1MG BASE/ML	N75857 001	Jul 22, 2002	May	CAHN
	@	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	May	DISC
AP		EQ 5MG BASE/ML	N75409 001	Jun 20, 2000	May	CAHN
AP		EQ 5MG BASE/ML	N75856 002	Jun 13, 2002	May	CAHN
AP	+	EQ 5MG BASE/ML	N75857 002	Jul 22, 2002	May	CAHN
AP	INTL MEDICATION	EQ 1MG BASE/ML	N76020 001	Jul 16, 2004	Jul	NEWA
AP		EQ 5MG BASE/ML	N76020 002	Jul 16, 2004	Jul	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
MIDODRINE HCL

2.5MG

N76514 001 Sep 11, 2003 Dec CAHN

>D>	AB	EON	2.5MG	N76514 001	Sep 11, 2003	Dec	CAHN
>A>	AB		2.5MG	N76514 001	Sep 11, 2003	Dec	CAHN
>D>	AB		5MG	N76514 002	Sep 11, 2003	Dec	CAHN
>A>	AB		5MG	N76514 002	Sep 11, 2003	Dec	CAHN
>D>	AB		10MG	N76514 003	Jul 02, 2004	Dec	CAHN
>A>	AB		10MG	N76514 003	Jul 02, 2004	Dec	CAHN
	AB		10MG	N76514 003	Jul 02, 2004	Jul	NEWA
	AB	IMPAX PHARMS	2.5MG	N76449 001	May 27, 2004	May	NEWA
	AB		5MG	N76449 002	May 27, 2004	May	NEWA
	AB	UPSHER SMITH	2.5MG	N76725 001	Nov 03, 2004	Nov	NEWA
	AB		5MG	N76725 002	Nov 03, 2004	Nov	NEWA
	AB		10MG	N76725 003	Nov 03, 2004	Nov	NEWA
PROAMATINE							
>A>	AB	SHIRE LABS	2.5MG	N19815 001	Sep 06, 1996	Dec	CAHN
>A>	AB	+	5MG	N19815 002	Sep 06, 1996	Dec	CAHN
>A>	AB		10MG	N19815 003	Mar 20, 2002	Dec	CAHN
>D>	AB	SHIRE PHARM	2.5MG	N19815 001	Sep 06, 1996	Dec	CAHN
>D>	AB	+	5MG	N19815 002	Sep 06, 1996	Dec	CAHN
>D>	AB		10MG	N19815 003	Mar 20, 2002	Dec	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

EQ 1MG BASE/ML

N76427 001 Sep 21, 2004 Sep NEWA

AP	APOTEX	EQ 1MG BASE/ML	N76427 001	Sep 21, 2004	Sep	NEWA
----	--------	----------------	------------	--------------	-----	------

INJECTABLE; INJECTIONMILRINONE LACTATE

AP	HOSPIRA	EQ 1MG BASE/ML	N75884 001	May 28, 2002	May	CAHN
	<u>MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	EQ 20MG BASE/100ML	N76414 001	Aug 18, 2004	Aug	NEWA
AP	HOSPIRA	EQ 20MG BASE/100ML	N75885 001	May 28, 2002	May	CAHN

MINOCYCLINE HYDROCHLORIDETABLET; ORALMINOCYCLINE HCL

AB	MEDICIS	EQ 50MG BASE	N65131 001	Apr 16, 2003	Jan	CFTG
AB		EQ 75MG BASE	N65131 002	Apr 16, 2003	Jan	CFTG
AB	+	EQ 100MG BASE	N65131 003	Apr 16, 2003	Jan	CFTG
AB	RANBAXY	EQ 50MG BASE	N65156 001	Jan 06, 2004	Jan	NEWA
AB		EQ 75MG BASE	N65156 002	Jan 06, 2004	Jan	NEWA
AB		EQ 100MG BASE	N65156 003	Jan 06, 2004	Jan	NEWA

MIRTAZAPINETABLET; ORALMIRTAZAPINE

AB	AUROBINDO	7.5MG	N76921 001	Oct 22, 2004	Oct	NEWA
AB		15MG	N76921 002	Oct 22, 2004	Oct	NEWA
AB		30MG	N76921 003	Oct 22, 2004	Oct	NEWA
AB		45MG	N76921 004	Oct 22, 2004	Oct	NEWA
	CARACO	7.5MG	N76541 004	Apr 22, 2004	Apr	NEWA
AB		15MG	N76541 001	Apr 22, 2004	Apr	NEWA
AB		30MG	N76541 002	Apr 22, 2004	Apr	NEWA
AB		45MG	N76541 003	Apr 22, 2004	Apr	NEWA

MOLINDONE HYDROCHLORIDECONCENTRATE; ORALMOBAN

@ ENDO PHARMS

20MG/ML

N17938 001

May DISC

TABLET; ORALMOBAN

@ ENDO PHARMS

100MG

N17111 008

May DISC

MOMETASONE FUROATEOINTMENT; TOPICALMOMETASONE FUROATE

>A>	AB	TARO	0.1%	N76624 001	Dec 03, 2004	Dec	NEWA
-----	----	------	------	------------	--------------	-----	------

MORPHINE SULFATEINJECTABLE, LIPOSOMAL; EPIDURALDEPODUR

SKYEPHARMA

10MG/ML

N21671 001

May 18, 2004

May

NEWA

15MG/1.5ML (10MG/ML)

N21671 002

May 18, 2004

May

NEWA

+

20MG/2ML (10MG/ML)

N21671 003

May 18, 2004

May

NEWA

INJECTABLE; INJECTION

MORPHINE SULFATE

AP	+	HOSPIRA	0.5MG/ML	N19917 001	Oct 30, 1992	May	CAHN
AP			0.5MG/ML	N71849 001	May 11, 1988	May	CAHN
AP			0.5MG/ML	N73509 001	Sep 30, 1992	May	CAHN
AP	+		1MG/ML	N19916 001	Oct 30, 1992	May	CAHN
AP			1MG/ML	N71850 001	May 11, 1988	May	CAHN
AP			1MG/ML	N73510 001	Sep 30, 1992	May	CAHN

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	KV PHARM	15MG	N76733 001	May 19, 2004	May	NEWA
AB		60MG	N76720 001	May 19, 2004	May	NEWA
	ORAMORPH SR					
BC	+ AAIPHARMA	60MG	N19977 002	Aug 15, 1991	Mar	CRLD

MYCOPHENOLIC ACID

>A>	TABLET, DELAYED RELEASE; ORAL					
>A>	MYFORTIC					
>A>	NOVARTIS	180MG	N50791 001	Feb 27, 2004	Dec	CDFR
>A>	+	360MG	N50791 002	Feb 27, 2004	Dec	CDFR
>D>	TABLET, EXTENDED RELEASE; ORAL					
>D>	MYFORTIC					
>D>	NOVARTIS	180MG	N50791 001	Feb 27, 2004	Dec	CDFR
		180MG	N50791 001	Feb 27, 2004	Feb	NEWA
>D>	+	360MG	N50791 002	Feb 27, 2004	Dec	CDFR
	+	360MG	N50791 002	Feb 27, 2004	Feb	NEWA

NABILONE

CAPSULE; ORAL
CESAMET
@ VALEANT

	1MG	N18677 001	Dec 26, 1985	Jan	CAHN
--	-----	------------	--------------	-----	------

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

	+	SANDOZ	EQ 500MG BASE/VIAL	N62527 001	Aug 02, 1984	Jun	CAHN
AP			EQ 1GM BASE/VIAL	N62527 002	Aug 02, 1984	Jun	CAHN
AP			EQ 2GM BASE/VIAL	N62527 003	Aug 02, 1984	Jun	CAHN
AP			EQ 10GM BASE/VIAL	N62527 004	Aug 02, 1984	Jun	CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

	MERZ PHARMS	1%	N19599 001	Feb 29, 1988	Jul	CAHN
--	-------------	----	------------	--------------	-----	------

GEL; TOPICAL
NAFTIN

	+ MERZ PHARMS	1%	N19356 001	Jun 18, 1990	Jul	CAHN
--	---------------	----	------------	--------------	-----	------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	HOSPIRA	10MG/ML	N70914 001	Feb 03, 1989	May	CAHN
AP		10MG/ML	N70915 001	Feb 03, 1989	May	CAHN
AP		20MG/ML	N70916 001	Feb 03, 1989	May	CAHN
AP		20MG/ML	N70918 001	Feb 03, 1989	May	CAHN
	@ KING PHARMS	10MG/ML	N74471 001	Mar 19, 1998	Mar	DISC

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

	@ MUTUAL PHARM	250MG	N70270 001	Jun 29, 1988	Aug	CAHN
--	----------------	-------	------------	--------------	-----	------

	@	500MG	N70271 001	Jun 29, 1988	Aug	CAHN
--	---	-------	------------	--------------	-----	------

	@	1GM	N70272 001	Jun 29, 1988	Aug	CAHN
--	---	-----	------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE							
	@ BAXTER HLTHCARE	0.4MG/ML		N70298 001	Sep 24, 1986	Aug	CAHN	
	@	0.4MG/ML		N70299 001	Sep 24, 1986	Aug	CAHN	
	NALOXONE HCL							
AP	HOSPIRA	0.02MG/ML		N70171 001	Sep 24, 1986	May	CAHN	
AP		0.02MG/ML		N70252 001	Jan 16, 1987	May	CAHN	
AP		0.02MG/ML		N70253 001	Jan 16, 1987	May	CAHN	
	@	0.4MG/ML		N70172 001	Sep 24, 1986	May	CAHN	
AP		0.4MG/ML		N70254 001	Jan 07, 1987	May	CAHN	
AP		0.4MG/ML		N70255 001	Jan 07, 1987	May	CAHN	
AP		0.4MG/ML		N70256 001	Jan 07, 1987	May	CAHN	
AP		0.4MG/ML		N70257 001	Jan 07, 1987	May	CAHN	

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	REVIA							
AB	+ DURAMED	50MG		N18932 001	Nov 20, 1984	Nov	CAHN	

NAPROXEN

TABLET; ORAL

	NAPROXEN							
	@ BAXTER HLTHCARE	250MG		N74105 001	Dec 21, 1993	Aug	DISC	
	@	375MG		N74105 002	Dec 21, 1993	Aug	DISC	
	@	500MG		N74105 003	Dec 21, 1993	Aug	DISC	
AB	WESTWARD	250MG		N76494 001	Jan 14, 2004	Jan	NEWA	
AB		375MG		N76494 002	Jan 14, 2004	Jan	NEWA	
AB		500MG		N76494 003	Jan 14, 2004	Jan	NEWA	

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN							
AB	+ STAT TRADE	EQ 375MG BASE		N20353 001	Jan 05, 1996	Jun	CAHN	
AB	+ @	EQ 500MG BASE		N20353 002	Jan 05, 1996	Jun	CAHN	
	@	EQ 750MG BASE		N20353 003	Jan 05, 1996	Jun	CAHN	

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

	TILADE							
	+ KING PHARMS	1.75MG/INH		N19660 001	Dec 30, 1992	Jan	CAHN	

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

	NEFAZODONE HCL							
	@ ROXANE	50MG		N76196 001	Sep 16, 2003	Jul	DISC	
	@	100MG		N76196 002	Sep 16, 2003	Jul	DISC	
	@	150MG		N76196 003	Sep 16, 2003	Jul	DISC	
	@	200MG		N76196 004	Sep 16, 2003	Jul	DISC	
	@	250MG		N76196 005	Sep 16, 2003	Jul	DISC	

NIACIN

TABLET; ORAL

	NIACIN							
	@ MK LABS	500MG		N83525 001		Feb	DISC	

TABLET; ORAL

	NIACIN						
	@ TABLICAPS	500MG		N84237 001		Feb	DISC
	NIACOR						
AA	+ UPSHER SMITH	500MG		N40378 001	May 03, 2000	Feb	CRLD

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

	NIFEDIPINE						
AB2	MARTEC	90MG		N75414 003	Mar 23, 2004	Mar	NEWA
	PROCARDIA XL						
AB2	+ PFIZER	90MG		N19684 003	Sep 06, 1989	Mar	CFTG

NITAZOXANIDE

TABLET; ORAL

ALINIA

	+ ROMARK	500MG		N21497 001	Jul 21, 2004	Jul	NEWA
--	----------	-------	--	------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

	@ MYLAN	100MG		N74967 002	Jul 09, 1997	Aug	DISC
AB		100MG		N77025 001	Aug 18, 2004	Aug	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+ PROCTER AND GAMBLE	75MG;25MG		N20064 001	Dec 24, 1991	Mar	CFTG
	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
AB	MYLAN	EQ 75MG BASE;25MG		N76648 001	Mar 22, 2004	Mar	NEWA
AB		75MG;25MG		N76648 001	Mar 22, 2004	Apr	CPOT

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB1	KREMERS URBAN	0.2MG/HR		N75115 001	Aug 10, 2004	Aug	NEWA
AB1		0.4MG/HR		N75115 002	Aug 10, 2004	Aug	NEWA

INJECTABLE; INJECTION

NITROGLYCERIN

AP	+ HOSPIRA	5MG/ML		N18531 001		May	CAHN
	NITROGLYCERIN IN DEXTROSE 5%						
AP	HOSPIRA	0.1MG/ML		N74083 001	Oct 26, 1994	May	CAHN
AP		10MG/100ML		N71846 001	Aug 31, 1990	May	CAHN
AP		20MG/100ML		N71847 001	Aug 31, 1990	May	CAHN
AP		40MG/100ML		N71848 001	Aug 31, 1990	May	CAHN

NIZATIDINE

SOLUTION; ORAL

AXID

	+ RELIANT PHARMS	15MG/ML		N21494 001	May 25, 2004	May	NEWA
--	------------------	---------	--	------------	--------------	-----	------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP	+ HOSPIRA	EQ 1MG BASE/ML		N07513 001		May	CAHN
	NOREPINEPHRINE BITARTRATE						
AP	PHARMAFORCE			N40522 001	Sep 30, 2004	Sep	NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL

@ LILLY

EQ 10MG BASE

N14684 001

Jun DISC

@

EQ 25MG BASE

N14684 002

Jun DISC

NYSTATIN

PASTILLE; ORAL

MYCOSTATIN

@ BRISTOL MYERS SQUIBB 200,000 UNITS

N50619 001 Apr 09, 1987 Jun DISC

POWDER; TOPICAL

NYSTATIN

AT KALI LABS 100,000 UNITS/GM

N65138 001 Jul 23, 2004 Jul NEWA

AT TANON 100,000 UNITS/GM

N65203 001 Jul 15, 2004 Jul NEWA

>A> AT X GEN PHARMS 100,000 UNITS/GM

N65175 001 Dec 17, 2004 Dec NEWA

SUSPENSION; ORAL

MYCOSTATIN

@ APOTHECON 100,000 UNITS/ML

N61533 001 Aug DISC

NILSTAT

AA + GLENMARK PHARMA 100,000 UNITS/ML

N50299 001 Jul CAHN

NYSTATIN

>D> @ BAUSCH AND LOMB 100,000 UNITS/ML

N64042 001 Feb 28, 1994 Dec CMFD

>A> AA 100,000 UNITS/ML

N64042 001 Feb 28, 1994 Dec CMFD

@ 100,000 UNITS/ML

N64042 001 Feb 28, 1994 Aug DISC

AA + MORTON GROVE 100,000 UNITS/ML

N62512 001 Oct 29, 1984 Aug CRLD

AA VISTAPHARM 100,000 UNITS/ML

N64142 001 Jun 25, 1998 Aug CAHN

NYSTEX

@ SAVAGE LABS 100,000 UNITS/ML

N62519 001 Jul 06, 1984 Aug DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

AT + ALLERGAN 0.3%

N19921 001 Jul 30, 1993 May CFTG

OFLOXACIN

AT ALCON 0.3%

N76231 001 May 14, 2004 May NEWA

AT BAUSCH AND LOMB 0.3%

N76622 001 May 14, 2004 May NEWA

AT HI TECH PHARMA 0.3%

N76615 001 May 14, 2004 May NEWA

AT NOVEX 0.3%

N76513 001 May 14, 2004 May NEWA

AT PHARMAFORCE 0.3%

N76830 001 Aug 31, 2004 Nov CDFR

SOLUTION/DROPS; OTIC

FLOXIN OTIC

+ DAIICHI 0.3%

N20799 001 Dec 16, 1997 Jun CTNA

SOLUTION; OPHTHALMIC

OFLOXACIN

AT PHARMAFORCE EQ 0.3% BASE

N76830 001 Aug 31, 2004 Aug NEWA

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

+ LILLY 10MG/VIAL

N21253 001 Mar 29, 2004 Mar NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A> + ALCON 0.2%

N21545 001 Dec 22, 2004 Dec NEWA

OLSALAZINE SODIUM

CAPSULE; ORAL
DIPENTUM

+ CELLTECH PHARMS 250MG N19715 001 Jul 31, 1990 Jun CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
OMACOR

>A> + RELIANT PHARMS INC 1GM N21654 001 Nov 10, 2004 Dec CAHN
>D> + ROSS PRODS 1GM N21654 001 Nov 10, 2004 Dec CAHN
+ 1GM N21654 001 Nov 10, 2004 Nov NEWA

OMEPRAZOLE

FOR SUSPENSION; ORAL
ZEGERID

>A> + SANTARUS 20MG/PACKET N21636 001 Jun 15, 2004 Jun NEWA
+ 40MG/PACKET N21706 001 Dec 21, 2004 Dec NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP + APOTHECON EQ 250MG BASE/VIAL N61490 001 Mar CRLD
>D> AP EQ 1GM BASE/VIAL N62737 001 Dec 23, 1986 Dec CAHN
AP + EQ 2GM BASE/VIAL N61490 004 Mar NEWA
>D> AP EQ 2GM BASE/VIAL N62737 002 Dec 23, 1986 Dec CAHN
AP EQ 2GM BASE/VIAL N62737 002 Dec 23, 1986 Mar CRLD
AP + SANDOZ EQ 250MG BASE/VIAL N61490 001 Jun CAHN
AP + EQ 500MG BASE/VIAL N61490 002 Jun CAHN
AP + EQ 1GM BASE/VIAL N61490 003 Jun CAHN
>A> AP EQ 1GM BASE/VIAL N62737 001 Dec 23, 1986 Dec CAHN
AP + EQ 2GM BASE/VIAL N61490 004 Jun CAHN
>A> AP EQ 2GM BASE/VIAL N62737 002 Dec 23, 1986 Dec CAHN
AP + EQ 10GM BASE/VIAL N61490 006 May 09, 1991 Jun CAHN

OXAMNIQUINE

CAPSULE; ORAL
VANSIL
@ PFIZER

250MG N18069 001 Mar DISC

OXAPROZIN

TABLET; ORAL
OXAPROZIN
APOTEX

AB 600MG N75987 001 Sep 02, 2004 Sep NEWA

OXAPROZIN POTASSIUM

TABLET; ORAL
DAYPRO ALTA
@ GD SEARLE

600MG N20776 001 Oct 17, 2002 Sep DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM
@ MUTUAL PHARM
@
@

10MG N70957 001 Aug 10, 1987 Aug CAHN
15MG N71025 001 Aug 10, 1987 Aug CAHN
30MG N71026 001 Aug 10, 1987 Aug CAHN

CAPSULE; ORAL

	SERAX					
	@ ALPHARMA	15MG		N15539	004	Aug DISC
AB	ALPHARMA US PHARMS	15MG		N15539	004	Nov CMFD

TABLET; ORAL

	OXAZEPAM					
	@ MUTUAL PHARM	15MG		N70683	001	Jan 16, 1987 Aug CAHN
	SERAX					
	@ ALPHARMA US PHARMS	15MG		N15539	008	Nov DISC

OXYBUTYNIN CHLORIDESYRUP; ORAL

	OXYBUTYNIN CHLORIDE					
>A>	AA	VINTAGE PHARMS	5MG/5ML	N76682	001	Dec 28, 2004 Dec NEWA

OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL

	OXYCODONE HCL					
AB	ENDO PHARMS	10MG		N75923	001	Mar 23, 2004 Mar NEWA
AB		20MG		N75923	002	Mar 23, 2004 Mar NEWA
AB		40MG		N75923	003	Mar 23, 2004 Mar NEWA
AB		80MG		N75923	004	Sep 29, 2004 Sep NEWA
AB	IMPAX LABS	80MG		N76318	001	Sep 27, 2004 Sep NEWA
AB	TEVA	80MG		N76168	001	Mar 23, 2004 Mar NEWA

OXYCONTIN

AB	PURDUE PHARMA LP	10MG		N20553	001	Dec 12, 1995 Mar CFTG
AB		20MG		N20553	002	Dec 12, 1995 Mar CFTG
AB	+	40MG		N20553	003	Dec 12, 1995 Mar CFTG
AB	+	80MG		N20553	004	Jan 06, 1997 Mar CFTG
AB		80MG		N20553	004	Jan 06, 1997 Jun CRLD

TABLET; ORAL

	OXYCODONE HCL					
AB	AMIDE PHARM	15MG		N76636	001	Feb 06, 2004 Feb NEWA
AB		30MG		N76636	002	Feb 06, 2004 Feb NEWA
AB	MALLINCKRODT	15MG		N76758	001	Jun 30, 2004 Jun NEWA
AB		30MG		N76758	002	Jun 30, 2004 Jun NEWA
	ROXICODONE					
AB	+	AAIPHARMA	15MG	N21011	001	Aug 31, 2000 Feb CFTG
AB		30MG		N21011	002	Aug 31, 2000 Feb CFTG

OXYTOCININJECTABLE; INJECTION

	OXYTOCIN					
AP	+	AM PHARM PARTNERS	10USP UNITS/ML	N18248	001	Nov CRLD
		SYNTOCINON				
>D>	AP	NOVARTIS	10USP UNITS/ML	N18245	001	Dec DISC
>A>		@	10USP UNITS/ML	N18245	001	Dec DISC

PACLITAXELINJECTABLE; INJECTION

	PACLITAXEL					
AP	SUPERGEN	6MG/ML		N75436	001	Nov 12, 2004 Nov NEWA

PANCURONIUM BROMIDEINJECTABLE; INJECTION

	PANCURONIUM BROMIDE					
AP	HOSPIRA	1MG/ML		N72320	001	Jan 19, 1989 May CAHN

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

AP	HOSPIRA	2MG/ML	N72321 001	Jan 19, 1989	May	CAHN
----	---------	--------	------------	--------------	-----	------

PARICALCITOLINJECTABLE; INJECTION
ZEMPLAR

ABBOTT

0.002MG/ML

N20819 002 Feb 01, 2000 Mar NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75716 001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75716 002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75716 003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75716 004	Mar 08, 2004	Mar	NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75566 002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75566 003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75566 004	Mar 08, 2004	Mar	NEWA

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

SYNTHON PHARMS

EQ 10MG BASE

N21299 001 Jul 03, 2003 Nov CTNA

EQ 20MG BASE

N21299 002 Jul 03, 2003 Nov CTNA

EQ 30MG BASE

N21299 003 Jul 03, 2003 Nov CTNA

+

EQ 40MG BASE

N21299 004 Jul 03, 2003 Nov CTNA

>A> PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ EYTECH PHARMS

EQ 0.3MG ACID/0.09ML

N21756 001 Dec 17, 2004 Dec NEWA

POMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY

EQ 500MG BASE/VIAL

N21462 001 Feb 04, 2004 Feb NEWA

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+ KING PHARMS

300,000 UNITS/ML

N60101 002

Nov CTNA

+

600,000 UNITS/ML

N60101 001

Nov CTNA

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP HOSPIRA

300MG/VIAL

N73479 001 Jun 30, 1992 May CAHN

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N16194 001

May CAHN

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML)

N21749 001 Aug 11, 2004 Aug NEWA

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+ HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML)

N21751 001 Aug 11, 2004 Aug NEWA

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

@ OVATION PHARMS 30MG

@ 100MG

N84095 001

May DISC

N83245 001

May DISC

SODIUM PENTOBARBITAL

+ VALEANT PHARM INTL 100MG

N83264 001

May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ORTHO MCNEIL PHARM 100MG

N20193 001 Sep 26, 1996 Jun CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

SOLVAY PHARMS 2MG

4MG

+ 8MG

N20184 001 Dec 30, 1993 Nov CAHN

N20184 002 Dec 30, 1993 Nov CAHN

N20184 003 Dec 30, 1993 Nov CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA VALEANT 35MG

N85272 001

Aug CAHN

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM 100MG

N88994 001 Dec 04, 1985 Aug CAHN

TABLET; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM 100MG

N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB TARO 125MG/5ML

N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@ HOSPIRA 50MG/ML

@ 50MG/ML

N89521 001 Mar 17, 1987 May CAHN

N89744 001 Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

BP	HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	May	CAHN
BP		10MG/ML	N87955 001	Jul 25, 1983	May	CAHN
	@	10MG/ML	N87956 001	Jul 25, 1983	May	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HCL

AB	COREPHARMA	5MG	N76746 001	Nov 16, 2004	Nov	NEWA
>A> AB	PILOCARPINE HYDROCHLORIDE ROXANE	5MG	N76963 001	Dec 22, 2004	Dec	NEWA
AB	SALAGEN MGI PHARMA INC	5MG	N20237 001	Mar 22, 1994	Nov	CFTG

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	AM PHARM	EQ 40GM BASE/VIAL	N65157 001	Jul 12, 2004	Jul	NEWA
---	----------	-------------------	------------	--------------	-----	------

PIPERAZINE CITRATE

SYRUP; ORAL

MULTIFUGE

@	BLULINE	EQ 500MG BASE/5ML	N09452 001		Jul	DISC
---	---------	-------------------	------------	--	-----	------

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT	+	OCLASSEN	0.5%	N19795 001	Dec 13, 1990	Sep	CAHN
----	---	----------	------	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

AA		SCHWARZ PHARMA	17GM/SCOOPFUL	N76652 001	Jul 02, 2004	Jul	NEWA
AA	+	MIRALAX BRAINTREE	17GM/SCOOPFUL	N20698 001	Feb 18, 1999	Jul	CFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001	Apr 22, 1991	Feb	CFTG
----	---	-----------	--	------------	--------------	-----	------

NULYTELY-FLAVORED

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 002	Nov 18, 1994	Feb	CFTG
----	---	-----------	--	------------	--------------	-----	------

TRILYTE

AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491 001	Feb 05, 2004	Feb	NEWA
----	--	----------------	--	------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

OCL

+	HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001	Apr 30, 1986	May	CAHN
---	---------	---	------------	--------------	-----	------

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

	+	HOSPIRA	2MEQ/ML	N18896 001	Jul 20, 1984	May	CAHN
--	---	---------	---------	------------	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@	HOSPIRA	1MEQ/ML	N80205 003		May	CAHN
	@		1MEQ/ML	N83345 003		May	CAHN
	+		1.5MEQ/ML	N83345 001		May	CAHN
AP	+		2MEQ/ML	N80205 001		May	CAHN
AP			2MEQ/ML	N83345 002		May	CAHN
	@		2.4MEQ/ML	N80205 004		May	CAHN
	@		3.2MEQ/ML	N80205 005		May	CAHN
		POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER					
	@	HOSPIRA	14.9MG/ML	N20161 005	Nov 30, 1992	May	CAHN
	@		745MG/100ML	N20161 001	Nov 30, 1992	May	CAHN
		POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
AP	+	HOSPIRA	29.8MG/ML	N20161 006	Aug 11, 1998	May	CAHN
	@		1.49GM/100ML	N20161 002	Nov 30, 1992	May	CAHN
		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER					
AP	+	HOSPIRA	2.24GM/100ML	N20161 003	Aug 11, 1998	May	CAHN
		POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER					
AP	+	HOSPIRA	2.98GM/100ML	N20161 004	Aug 11, 1998	May	CAHN
		TABLET, EXTENDED RELEASE; ORAL					
		KAON CL-10					
BC		SAVAGE LABS	10MEQ	N17046 002		Nov	CMFD
		POTASSIUM CHLORIDE					
AB		EURAND	20MEQ	N76368 001	Aug 18, 2004	Aug	NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HOSPIRA	149MG/100ML; 900MG/100ML	N19686 001	Oct 17, 1988	May	CAHN
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP		HOSPIRA	298MG/100ML; 900MG/100ML	N19686 002	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

	@	HOSPIRA	370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL	N13025 001		May	CAHN
--	---	---------	------------------------------------	------------	--	-----	------

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	@	EVERYLIFE	2.5MG	N84439 002		May	DISC
	@		5MG	N84439 003		May	DISC
	@	SPERTI	1MG	N80358 001		May	DISC
	@		2.5MG	N80358 002		May	DISC
	@		5MG	N80358 003		May	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDISOLONE SODIUM PHOSPHATE

AA		MORTON GROVE	EQ 15MG BASE/5ML	N76895 001	Oct 04, 2004	Oct	NEWA
----	--	--------------	------------------	------------	--------------	-----	------

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA PADDOCK EQ 5MG BASE/5ML N75988 001 May 25, 2004 May NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

VASOCIDIN

AT + NOVARTIS EQ 0.23% PHOSPHATE;10% N18988 001 Aug 26, 1988 Aug CAHN

PREDNISONE

TABLET; ORAL

DELTASONE

@ PHARMACIA AND UPJOHN 2.5MG

N09986 005 Sep DISC

@ 5MG

N09986 002 Oct DISC

@ 10MG

N09986 006 Sep DISC

@ 20MG

N09986 007 Jul DISC

@ 50MG

N09986 008 Oct DISC

PREDNISONE

@ MUTUAL PHARM 5MG

N80701 001 Aug CAHN

@ 10MG

N86595 001 Aug CAHN

@ 20MG

N84634 001 Aug CAHN

@ 50MG

N86596 001 Aug CAHN

AB + ROXANE 2.5MG N87801 001 Apr 22, 1982 Oct CRLD

AB + 5MG N80352 001 Oct CRLD

AB + 10MG N84122 001 Oct CRLD

AB + 20MG N87342 001 Jul CRLD

AB + 50MG N84283 001 Oct CRLD

@ SANDOZ 20MG N85813 001 Aug DISC

>A> AB VINTAGE PHARMS 1MG N40584 001 Dec 21, 2004 Dec NEWA

>A> AB 2.5MG N40581 001 Dec 21, 2004 Dec NEWA

AB WEST WARD 2.5MG N40538 001 Jan 08, 2004 Jan NEWA

>A> PREGABALIN

>A> CAPSULE; ORAL

>A> LYRICA

>A> PFIZER GLOBAL 25MG N21446 001 Dec 30, 2004 Dec NEWA

>A> 50MG N21446 002 Dec 30, 2004 Dec NEWA

>A> 75MG N21446 003 Dec 30, 2004 Dec NEWA

>A> 100MG N21446 004 Dec 30, 2004 Dec NEWA

>A> 150MG N21446 005 Dec 30, 2004 Dec NEWA

>A> 200MG N21446 006 Dec 30, 2004 Dec NEWA

>A> 225MG N21446 007 Dec 30, 2004 Dec NEWA

>A> + 300MG N21446 008 Dec 30, 2004 Dec NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

AP HOSPIRA 100MG/ML N89069 001 Feb 12, 1986 May CAHN

AP 500MG/ML N89070 001 Feb 12, 1986 May CAHN

AP 500MG/ML N89537 001 Aug 25, 1987 May CAHN

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

AP + HOSPIRA 1% N85362 003 May CAHN

AP + 2% N85362 004 May CAHN

INJECTABLE; INJECTION

NOVOCAIN

	+	HOSPIRA	10%	N86797 001		May	CAHN
		PROCAINE HCL					
AP		HOSPIRA	1%	N80416 001		May	CAHN
AP			2%	N80416 002		May	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP		BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989	Aug	CAHN
AP		BEDFORD	EQ 5MG BASE/ML	N40540 001	May 28, 2004	May	NEWA
AP		HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	May	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP		BEDFORD LABS	25MG/ML	N40524 001	Mar 17, 2004	Mar	NEWA
AP			50MG/ML	N40524 002	Mar 17, 2004	Mar	NEWA
AP		BIONICHE PHARMA	25MG/ML	N40471 001	Nov 21, 2002	Sep	CAHN
AP		HOSPIRA	25MG/ML	N40372 001	Jun 08, 2000	May	CAHN
AP			50MG/ML	N40372 002	Jun 08, 2000	May	CAHN
AP			50MG/ML	N83838 002		May	CAHN

SYRUP; ORAL

PROMETH PLAIN

@ ALPHARMA

6.25MG/5ML

N85953 001

Feb DISC

PROMETHAZINE HCL

AA		HI TECH PHARMA	6.25MG/5ML	N40026 001	Sep 25, 1998	May	CRLD
AA	+		6.25MG/5ML	N40026 001	Sep 25, 1998	Feb	CRLD
		PROMETHAZINE PLAIN					
AA	+	MORTON GROVE	6.25MG/5ML	N87953 001	Nov 15, 1982	May	CRLD

TABLET; ORAL

PHENERGAN

@ WYETH PHARMS INC

12.5MG

N07935 002

Sep DISC

AB			12.5MG	N07935 002		Jul	CFTG
AB			25MG	N07935 003		Jul	CTEC
AB	+		50MG	N07935 004		Jul	CTEC
		PROMETHAZINE HCL					
AB		ABLE	12.5MG	N40558 001	Jul 01, 2004	Jul	NEWA
AB			25MG	N40558 002	Jul 01, 2004	Jul	NEWA
AB			50MG	N40558 003	Jul 01, 2004	Jul	NEWA
		@ MUTUAL PHARM	12.5MG	N84555 001		Aug	CAHN
		@	25MG	N84554 001		Aug	CAHN
		@	50MG	N84557 001		Aug	CAHN

PROPAPENONE HYDROCHLORIDE

TABLET; ORAL

PROPAPENONE HCL

AB		PLIVA	150MG	N76550 001	Apr 23, 2004	Apr	NEWA
AB			225MG	N76550 002	Apr 23, 2004	Apr	NEWA
AB			300MG	N76550 003	Apr 23, 2004	Apr	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@ AAIPHARMA LLC

32MG

N10997 001

Aug DISC

CAPSULE; ORAL

	PROPOXYPHENE HCL					
	@ MUTUAL PHARM	65MG	N83186 001		Aug	CAHN
>A>	AA MYLAN	65MG	N40569 001	Dec 16, 2004	Dec	NEWA

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	PROPRANOLOL					
AP	AM PHARM PARTNERS	1MG/ML	N75826 001	Aug 31, 2001	Jan	NEWA

TABLET; ORAL

PROPRANOLOL HCL

	@ MUTUAL PHARM	10MG	N70319 001	Oct 22, 1985	Aug	CAHN
	@	20MG	N70320 001	Oct 22, 1985	Aug	CAHN
	@	40MG	N70103 001	Oct 22, 1985	Aug	CAHN
	@	60MG	N70321 001	Sep 24, 1986	Aug	CAHN
	@	80MG	N70322 001	Aug 04, 1986	Aug	CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

	@ MUTUAL PHARM	50MG	N83982 001		Aug	CAHN
--	----------------	------	------------	--	-----	------

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	AM PHARM PARTNERS	10MG/ML	N89454 001	Apr 07, 1987	Mar	CRLD
	@ LILLY	10MG/ML	N06460 002		Mar	DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

	@ ODYSSEY PHARMS	5MG	N16012 001		Jun	CAHN
	@	10MG	N16012 002		Jun	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL

>A>	AB RANBAXY	EQ 5MG BASE	N76607 001	Dec 15, 2004	Dec	NEWA
>A>	AB	EQ 10MG BASE	N76607 002	Dec 15, 2004	Dec	NEWA
>A>	AB	EQ 20MG BASE	N76607 003	Dec 15, 2004	Dec	NEWA
>A>	AB	EQ 40MG BASE	N76607 004	Dec 15, 2004	Dec	NEWA

QUINAPRIL HCL

>A>	AB AMIDE PHARM	EQ 5MG BASE	N76459 001	Dec 22, 2004	Dec	NEWA
>A>	AB	EQ 10MG BASE	N76459 002	Dec 22, 2004	Dec	NEWA
>A>	AB	EQ 20MG BASE	N76459 003	Dec 22, 2004	Dec	NEWA
>A>	AB	EQ 40MG BASE	N76459 004	Dec 22, 2004	Dec	NEWA
>A>	AB ANDRX PHARMS	EQ 5MG BASE	N76049 001	Jan 14, 2005	Dec	NEWA
>A>	AB	EQ 10MG BASE	N76049 002	Jan 14, 2005	Dec	NEWA
>A>	AB	EQ 20MG BASE	N76049 003	Jan 14, 2005	Dec	NEWA
>A>	AB	EQ 40MG BASE	N76049 004	Jan 14, 2005	Dec	NEWA
>A>	AB MYLAN	EQ 5MG BASE	N76694 001	Dec 23, 2004	Dec	NEWA
>A>	AB	EQ 10MG BASE	N76694 002	Dec 23, 2004	Dec	NEWA
>A>	AB	EQ 20MG BASE	N76694 003	Dec 23, 2004	Dec	NEWA
>A>	AB	EQ 40MG BASE	N76694 004	Dec 23, 2004	Dec	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION						
RANITIDINE						
AP	BEDFORD	EQ 25MG BASE/ML	N74764 001	Nov 19, 2004	Nov	NEWA
ZANTAC						
AP	+ GLAXOSMITHKLINE	EQ 25MG BASE/ML	N19090 001	Oct 19, 1984	Nov	CFTG
TABLET, EFFERVESCENT; ORAL						
ZANTAC 25						
	GLAXOSMITHKLINE	EQ 25MG BASE	N20251 003	Apr 01, 2004	Apr	NEWA

RIBAVIRIN

CAPSULE; ORAL						
REBETOL						
AB	+ SCHERING PLOUGH RES	200MG	N20903 002	Jul 25, 2001	Apr	CFTG
RIBASPHERE						
AB	THREE RIVERS PHARMS	200MG	N76203 001	Apr 06, 2004	Apr	NEWA
RIBAVIRIN						
AB	SANDOZ	200MG	N76192 001	Apr 06, 2004	Apr	NEWA
AB	TEVA	200MG	N76277 001	Oct 04, 2004	Oct	NEWA

RIFAXIMIN

TABLET; ORAL						
XIFAXAN						
	+ SALIX PHARMS	200MG	N21361 001	May 25, 2004	May	NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR						
RISPERDAL CONSTA						
	JANSSEN PHARMA	25MG/VIAL	N21346 001	Oct 29, 2003	Jul	CAHN
		37.5MG/VIAL	N21346 002	Oct 29, 2003	Jul	CAHN
	+	50MG/VIAL	N21346 003	Oct 29, 2003	Jul	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL						
RISPERDAL						
	JANSSEN PHARMA	0.5MG	N21444 001	Apr 02, 2003	Jun	CAHN
	+	1MG	N21444 002	Apr 02, 2003	Jun	CAHN
		2MG	N21444 003	Apr 02, 2003	Jun	CAHN
>A>		3MG	N21444 004	Dec 23, 2004	Dec	NEWA
>A>		4MG	N21444 005	Dec 23, 2004	Dec	NEWA

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION						
RITODRINE HCL						
	+ HOSPIRA	10MG/ML	N71618 001	Feb 28, 1991	May	CAHN
	+	15MG/ML	N71619 001	Feb 28, 1991	May	CAHN
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+ HOSPIRA	30MG/100ML	N71438 001	Jan 22, 1991	May	CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION						
ZEMURON						
	ORGANON USA INC	10MG/ML	N20214 002	Mar 17, 1994	Jun	CMFD
	@	10MG/ML	N20214 002	Mar 17, 1994	Jul	DISC
ZEMURON (P/F)						
	+ ORGANON USA INC	50MG/5ML (10MG/ML)	N20214 001	Mar 17, 1994	Jul	CPOT
	+	100MG/10ML (10MG/ML)	N20214 003	Mar 17, 1994	Jul	NEWA

ROFECOXIB

SUSPENSION; ORAL

VIOXX

@ MERCK

12.5MG/5ML

N21052 001 May 20, 1999 Sep DISC

@

25MG/5ML

N21052 002 May 20, 1999 Sep DISC

TABLET; ORAL

VIOXX

@ MERCK

12.5MG

N21042 001 May 20, 1999 Sep DISC

@

25MG

N21042 002 May 20, 1999 Sep DISC

@

50MG

N21042 003 Feb 25, 2000 Sep DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

GLAXOSMITHKLINE

EQ 5MG BASE

N20658 005 Sep 19, 1997 May CRLD

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+ HOSPIRA

5%;5% (5GM/100ML)

N18997 001 Aug 27, 1984 May CAHN

LIPOSYN II 20%

+ HOSPIRA

10%;10% (10GM/100ML)

N18991 001 Aug 27, 1984 May CAHN

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+ ROCHE

EQ 500MG BASE

N21785 001 Dec 17, 2004 Dec NEWA

>A>

>A>

>A>

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ CHIRHOCLIN

16UGM/VIAL

N21256 001 Apr 09, 2004 Sep CTNA

HUMAN SECRETIN

+ CHIRHOCLIN

16UGM/VIAL

N21256 001 Apr 09, 2004 Apr NEWA

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREMAX

+ CHIRHOCLIN

16UGM/VIAL

N21136 001 Apr 04, 2002 Jul CAIN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HCL

+ APOTEX

5MG

N74871 001 Jun 06, 1997 Nov CRLD

@ SOMERSET

5MG

N19334 001 Jun 05, 1989 Aug DISC

AB

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

@ GENZYME

403MG

N20926 001 Oct 30, 1998 Jun DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC

2MG

N21110 002 Aug 22, 2002 Feb CRLD

TABLET; ORAL						
RAPAMUNE						
	+ WYETH PHARMS INC	5MG	N21110 003	Feb 23, 2004	Feb	NEWA
<u>SODIUM ACETATE, ANHYDROUS</u>						
INJECTABLE; INJECTION						
SODIUM ACETATE IN PLASTIC CONTAINER						
	+ HOSPIRA	2MEQ/ML	N18893 001	May 04, 1983	May	CAHN
<u>SODIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+ HOSPIRA	9MG/ML	N18800 001	Oct 29, 1982	May	CAHN
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP	HOSPIRA	450MG/100ML	N18090 001		May	CAHN
AP		450MG/100ML	N19759 001	Jun 08, 1988	May	CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	HAEMONETICS	900MG/100ML	N76316 001	Oct 27, 2004	Oct	NEWA
AP	HOSPIRA	9MG/ML	N18803 001	Oct 29, 1982	May	CAHN
AP	+	9MG/ML	N19217 001	Jul 13, 1984	Jul	CRLD
AP		9MG/ML	N19217 001	Jul 13, 1984	May	CAHN
AP		9MG/ML	N19465 002	Jul 15, 1985	May	CAHN
AP		900MG/100ML	N16366 001		May	CAHN
AP		900MG/100ML	N19465 001	Jul 15, 1985	May	CAHN
AP		900MG/100ML	N19480 001	Sep 17, 1985	May	CAHN
SODIUM CHLORIDE IN PLASTIC CONTAINER						
	HOSPIRA	2.5MEQ/ML	N18897 001	Jul 20, 1984	May	CAHN
SOLUTION; IRRIGATION						
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AT	HOSPIRA	450MG/100ML	N17670 001		May	CAHN
	@	450MG/100ML	N18380 001		May	CAHN
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AT	HOSPIRA	900MG/100ML	N17514 001		May	CAHN
AT		900MG/100ML	N18314 001		May	CAHN
<u>SODIUM FERRIC GLUCONATE COMPLEX</u>						
INJECTABLE; INJECTION						
FERRLECIT						
	+ WATSON PHARMS	62.5MG/5ML	N20955 001	Feb 18, 1999	Feb	CAHN
<u>SODIUM IODIDE, I-131</u>						
SOLUTION; ORAL						
SODIUM IODIDE I 131						
	@ CIS	50mCi/ML	N17315 001		Apr	DISC
<u>SODIUM LACTATE</u>						
INJECTABLE; INJECTION						
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER						
AP	HOSPIRA	1.87GM/100ML	N18249 001		May	CAHN
SODIUM LACTATE IN PLASTIC CONTAINER						
	HOSPIRA	5MEQ/ML	N18947 001	Sep 05, 1984	May	CAHN
<u>SODIUM NITROPRUSSIDE</u>						
INJECTABLE; INJECTION						
NITROPRESS						
AP	+ HOSPIRA	25MG/ML	N71961 001	Aug 01, 1988	May	CAHN
	+	50MG/VIAL	N70566 001	Jun 09, 1986	May	CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

HOSPIRA	142MG/ML;276MG/ML	N18892 001	May 10, 1983	May	CAHN
---------	-------------------	------------	--------------	-----	------

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

BIONICHE PHARM USA	20MG/2ML (10MG/ML)	N40541 001	Nov 12, 2004	Nov	NEWA
--------------------	--------------------	------------	--------------	-----	------

+	60MG/2ML (30MG/ML)	N40541 002	Nov 12, 2004	Nov	NEWA
---	--------------------	------------	--------------	-----	------

SOLIFENACIN SUCCINATE

TABLET; ORAL

VESICARE

YAMANOUCHI	5MG	N21518 001	Nov 19, 2004	Nov	NEWA
------------	-----	------------	--------------	-----	------

+	10MG	N21518 002	Nov 19, 2004	Nov	NEWA
---	------	------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN NORDIFLEX

NOVO NORDISK	5MG/1.5ML	N21148 004	Oct 01, 2004	Oct	NEWA
--------------	-----------	------------	--------------	-----	------

	10MG/1.5ML	N21148 005	Oct 01, 2004	Oct	NEWA
--	------------	------------	--------------	-----	------

	15MG/1.5ML	N21148 006	Oct 01, 2004	Oct	NEWA
--	------------	------------	--------------	-----	------

SAIZEN

@ SERONO	6MG/VIAL	N19764 001	Oct 08, 1996	May	DISC
----------	----------	------------	--------------	-----	------

SEROSTIM

BX	SERONO	4MG/VIAL	N20604 003	Jul 25, 1997	Jan	CTEC
----	--------	----------	------------	--------------	-----	------

@	8.8MG/VIAL	N20604 004	Sep 06, 2001	Jan	DISC
---	------------	------------	--------------	-----	------

ZORBTIVE

@ SERONO INC	4MG/VIAL	N21597 001	Dec 01, 2003	May	DISC
--------------	----------	------------	--------------	-----	------

@	5MG/VIAL	N21597 002	Dec 01, 2003	May	DISC
---	----------	------------	--------------	-----	------

@	6MG/VIAL	N21597 003	Dec 01, 2003	May	DISC
---	----------	------------	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HCL

AB2	MUTUAL PHARM	80MG	N76576 001	Apr 08, 2004	Apr	NEWA
-----	--------------	------	------------	--------------	-----	------

AB2		120MG	N76576 002	Apr 08, 2004	Apr	NEWA
-----	--	-------	------------	--------------	-----	------

AB2		160MG	N76576 003	Apr 08, 2004	Apr	NEWA
-----	--	-------	------------	--------------	-----	------

AB2	TEVA	80MG	N76883 001	Jul 26, 2004	Jul	NEWA
-----	------	------	------------	--------------	-----	------

AB2		120MG	N76883 002	Jul 26, 2004	Jul	NEWA
-----	--	-------	------------	--------------	-----	------

AB2		160MG	N76883 003	Jul 26, 2004	Jul	NEWA
-----	--	-------	------------	--------------	-----	------

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

>A>	AP	+	FRESENIUS	10%	N17643 001		Dec	CAHN
-----	----	---	-----------	-----	------------	--	-----	------

>D>	AP	+	FRESENIUS KABI	10%	N17643 001		Dec	CAHN
-----	----	---	----------------	-----	------------	--	-----	------

INTRALIPID 20%

>A>	AP	+	FRESENIUS	20%	N18449 001		Dec	CAHN
-----	----	---	-----------	-----	------------	--	-----	------

>A>	AP	+		20%	N20248 001	Aug 07, 1996	Dec	CAHN
-----	----	---	--	-----	------------	--------------	-----	------

>D>	AP	+	FRESENIUS KABI	20%	N18449 001		Dec	CAHN
-----	----	---	----------------	-----	------------	--	-----	------

>D>	AP	+		20%	N20248 001	Aug 07, 1996	Dec	CAHN
-----	----	---	--	-----	------------	--------------	-----	------

INTRALIPID 30%

>A>	AP	+	FRESENIUS	30%	N19942 001	Dec 30, 1993	Dec	CAHN
-----	----	---	-----------	-----	------------	--------------	-----	------

SULFACETAMIDE SODIUMSOLUTION/DROPS; OPHTHALMIC
SULF-10

AT NOVARTIS 10% N80025 001 Mar CMFD

SULFACYTINETABLET; ORAL
RENOQUID
@ GLENWOOD

250MG

N17569 001 Aug DISC

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE; INJECTION
BACTRIM

AP + MUTUAL PHARM 80MG/ML;16MG/ML N18374 001 Nov CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ BAXTER HLTHCARE 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Sep DISC
AP 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Aug CAHN
AP 80MG/ML;16MG/ML N70628 001 Dec 29, 1987 Aug CAHN
AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN

SUSPENSION; ORAL

BACTRIM
>A> @ MUTUAL PHARM 200MG/5ML;40MG/5ML N17560 001 Dec CAHN
>D> @ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 001 Dec CAHN
BACTRIM PEDIATRIC
>A> @ MUTUAL PHARM 200MG/5ML;40MG/5ML N17560 002 Dec CAHN
>D> @ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 002 Dec CAHN

TABLET; ORAL

BACTRIM
AB MUTUAL PHARM 400MG;80MG N17377 001 Nov CAHN
BACTRIM DS
AB + MUTUAL PHARM 800MG;160MG N17377 002 Nov CAHN
SULFAMETHOPRIM-DS
@ PAR PHARM 800MG;160MG N70032 001 Feb 15, 1985 Sep DISC
SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ MUTUAL PHARM 400MG;80MG N70006 001 Nov 14, 1984 Aug CAHN
@ SANDOZ 400MG;80MG N70889 001 Nov 13, 1986 Sep DISC
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
@ MUTUAL PHARM 800MG;160MG N70007 001 Nov 14, 1984 Aug CAHN

TECHNETIUM TC-99M APCITIDEINJECTABLE; INJECTION
ACUTECT

BERLEX LABS N/A

N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

+ BERLEX LABS N/A

N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP + DRAXIMAGE N/A N18035 001 May CTNA

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE; INJECTION
TECHNISCAN

+ MALLINCKRODT N/A N18321 001 Sep CRLD

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE; INJECTION
CARDIOLITE

+ BRISTOL MYERS SQUIBB N/A N19785 001 Dec 21, 1990 Jul CRLD

MIRALUMA
+ BRISTOL MYERS SQUIBB N/A N19785 003 May 23, 1997 Nov CRLDTELITHROMYCINTABLET; ORAL
KETEK

+ AVENTIS PHARMS 400MG N21144 001 Apr 01, 2004 Apr NEWA

TEMAZEPAMCAPSULE; ORAL
RESTORIL

>A> TYCO HLTHCARE 22.5MG N18163 004 Nov 02, 2004 Dec NEWA

TEMAZEPAM
@ MUTUAL PHARM 15MG N71174 001 Jul 10, 1986 Aug CAHN

@ 30MG N71175 001 Jul 10, 1986 Aug CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

>A> AB TRIGEN EQ 1MG BASE N75317 001 Dec 20, 2004 Dec NEWA

>A> AB EQ 2MG BASE N75317 002 Dec 20, 2004 Dec NEWA

>A> AB EQ 5MG BASE N75317 003 Dec 20, 2004 Dec NEWA

>A> AB EQ 10MG BASE N75317 004 Dec 20, 2004 Dec NEWA

TABLET; ORAL

TERAZOSIN HCL

@ TEVA EQ 1MG BASE N74446 001 May 18, 2000 Nov DISC

@ EQ 2MG BASE N74446 002 May 18, 2000 Nov DISC

@ EQ 5MG BASE N74446 003 May 18, 2000 Nov DISC

@ EQ 10MG BASE N74446 004 May 18, 2000 Nov DISC

TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS 1% N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

AP + AAIPHARMA LLC 1MG/ML N18571 001 Apr CFTG

TERBUTALINE SULFATE

AP AM PHARM 1MG/ML N76887 001 May 26, 2004 May NEWA

AP BEDFORD 1MG/ML N76770 001 Apr 23, 2004 Apr NEWA

AP SICOR PHARMS 1MG/ML N76853 001 Jul 20, 2004 Jul NEWA

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

AB + ORTHO MCNEIL PHARM 0.8% N19964 001 Feb 21, 1991 Apr CFTG

TERAZOL 7

>D> + ORTHO MCNEIL PHARM 0.4% N19579 001 Dec 31, 1987 Dec CFTG

>A> AB + 0.4% N19579 001 Dec 31, 1987 Dec CFTG

TERCONAZOLE

BX + ALTANA 0.8% N21735 001 Oct 01, 2004 Oct NEWA

>A> AB TARO 0.4% N76043 001 Jan 19, 2005 Dec NEWA

AB 0.8% N75953 001 Apr 06, 2004 Apr NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

+ WATSON LABS 5MG/24HR N20489 002 May 02, 1997 Aug CTEC

TESTODERM

@ ALZA 4MG/24HR N19762 001 Oct 12, 1993 Aug DISC

@ 6MG/24HR N19762 002 Oct 12, 1993 Aug DISC

TESTODERM TTS

@ ALZA 5MG/24HR N20791 001 Dec 18, 1997 Aug DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

AB MUTUAL PHARM 250MG N60736 001 Aug CAHN

AB 500MG N60736 002 Aug CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

@ FLEMING PHARMS 65MG N85075 003 Nov 24, 1986 Jun DISC

AEROLATE JR

@ FLEMING PHARMS 130MG N85075 002 Nov 24, 1986 Jun DISC

AEROLATE SR

@ FLEMING PHARMS 260MG N85075 001 Nov 24, 1986 Jun DISC

THEOPHYLLINE

BC INWOOD LABS 100MG N40052 001 Feb 14, 1994 Oct CTEC

BC 125MG N40052 002 Feb 14, 1994 Oct CTEC

BC 200MG N40052 003 Feb 14, 1994 Oct CTEC

BC + 300MG N40052 004 Feb 14, 1994 Oct CTEC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA 4MG/ML N19211 007 Dec 14, 1984 May CAHN

AP + 40MG/100ML N19211 001 Dec 14, 1984 May CAHN

AP + 80MG/100ML N19211 002 Dec 14, 1984 May CAHN

AP + 160MG/100ML N19211 003 Dec 14, 1984 May CAHN

AP + 200MG/100ML N19211 004 Dec 14, 1984 May CAHN

AP + 320MG/100ML N19211 006 Jan 20, 1988 May CAHN

AP + 400MG/100ML N19211 005 Dec 14, 1984 May CAHN

SOLUTION; ORAL

AEROLATE

@ FLEMING PHARMS 150MG/15ML N89141 001 Dec 03, 1986 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

@ 3M 200MG N88369 001 Jul 16, 1987 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

	THEOLAIR-SR								
	@ 3M	250MG		N86363	002	Jul 16, 1987	Jun	DISC	
	@	300MG		N88364	001	Jul 16, 1987	Jun	DISC	
	@	500MG		N89132	001	Jul 16, 1987	Jun	DISC	
	THEOPHYLLINE								
AB	ABLE	300MG		N40548	001	Apr 30, 2004	Apr	NEWA	
AB		400MG		N40543	001	Apr 27, 2004	Apr	NEWA	
AB		450MG		N40546	001	Apr 30, 2004	Apr	NEWA	
AB		600MG		N40539	001	Apr 27, 2004	Apr	NEWA	
	UNIPHYL								
AB	+ PURDUE FREDERICK	400MG		N87571	001	Sep 01, 1982	Apr	CFTG	
AB	+	600MG		N40086	001	Apr 15, 1996	Apr	CFTG	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL								
AP	BAXTER HLTHCARE	100MG/ML		N80575	001		Aug	CAHN	
AP	HOSPIRA	100MG/ML		N40079	001	May 03, 1996	May	CAHN	

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL								
	@ MUTUAL PHARM	10MG		N88375	001	Nov 18, 1983	Aug	CAHN	
	@	15MG		N88461	001	Nov 18, 1983	Aug	CAHN	
	@	25MG		N87264	001	Nov 18, 1983	Aug	CAHN	
AB		50MG		N88370	001	Nov 18, 1983	Aug	CAHN	
	@	100MG		N88379	001	Nov 16, 1983	Aug	CAHN	
	@	150MG		N88737	001	Sep 26, 1984	Aug	CAHN	
	@	200MG		N88738	001	Oct 16, 1984	Aug	CAHN	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLOPIDINE HCL								
>D>	AB WATSON LABS	250MG		N75309	001	Apr 26, 2000	Dec	DISC	
>A>	@	250MG		N75309	001	Apr 26, 2000	Dec	DISC	

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	ISTALOL								
BT	+ ISTA PHARMS	EQ 0.5% BASE		N21516	001	Jun 04, 2004	Sep	CTEC	
	+ SENJU	EQ 0.5% BASE		N21516	001	Jun 04, 2004	Jun	NEWA	
	TIMOLOL MALEATE								
	@ AKORN	EQ 0.25% BASE		N74465	001	Mar 25, 1997	Nov	DISC	
AT	HI TECH PHARMA	EQ 0.5% BASE		N75163	001	Sep 10, 2002	Jun	CDFR	

TINIDAZOLE

TABLET; ORAL

	TINDAMAX								
	PRESUTTI LABS	250MG		N21618	001	May 17, 2004	May	NEWA	
	+	500MG		N21618	002	May 17, 2004	May	NEWA	

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION

	SPIRIVA								
	+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE		N21395	001	Jan 30, 2004	Jan	NEWA	

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ACORDA

EQ 2MG BASE

N21447 001 Aug 29, 2002 Aug CAHN

EQ 4MG BASE

N21447 002 Aug 29, 2002 Aug CAHN

+

EQ 6MG BASE

N21447 003 Aug 29, 2002 Aug CAHN'

TABLET; ORAL

TIZANIDINE HCL

AB IVAX PHARMS

EQ 2MG BASE

N76321 001 Sep 30, 2004 Sep NEWA

AB

EQ 4MG BASE

N76321 002 Sep 30, 2004 Sep NEWA

AB TORPHARM

EQ 2MG BASE

N76533 001 Jan 16, 2004 Jan NEWA

AB

EQ 4MG BASE

N76533 002 Jan 16, 2004 Jan NEWA

ZANAFLEX

AB ACORDA

EQ 2MG BASE

N20397 002 Feb 04, 2000 Aug CAHN

AB +

EQ 4MG BASE

N20397 001 Nov 27, 1996 Aug CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

@ LILLY

EQ 10MG BASE/ML

N50477 005

Jun DISC

@

EQ 10MG BASE/ML

N62008 004

Jun DISC

@

EQ 10MG BASE/ML

N62707 001 Apr 29, 1987 Jun DISC

@

EQ 40MG BASE/ML

N62008 001

Jun DISC

@

EQ 1.2GM BASE/VIAL

N50519 001

Jun DISC

TOBRAMYCIN

AM PHARM

EQ 1.2GM BASE/VIAL

N50789 001

Jul 13, 2004 Jul NEWA

AP + PHARMA TEK

EQ 1.2GM BASE/VIAL

N65013 001

Aug 17, 2001 Jun CRLD

+

EQ 1.2GM BASE/VIAL

N65013 001

Aug 17, 2001 Jul CTEC

TOBRAMYCIN SULFATE

AP HOSPIRA

EQ 10MG BASE/ML

N63080 001

Apr 30, 1991 May CAHN

AP +

EQ 10MG BASE/ML

N63080 001

Apr 30, 1991 Jun CRLD

AP

EQ 10MG BASE/ML

N63112 001

Apr 30, 1991 May CAHN

AP

EQ 40MG BASE/ML

N63111 001

Apr 30, 1991 May CAHN

AP +

EQ 40MG BASE/ML

N63116 001

May 18, 1992 May CAHN

AP

EQ 40MG BASE/ML

N63161 001

May 29, 1991 May CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1.2MG BASE/ML

N63081 003

Jul 31, 1990 May CAHN

+

EQ 1.6MG BASE/ML

N63081 006

Jun 02, 1993 May CAHN

+

EQ 80MG BASE/100ML

N63081 001

Jul 31, 1990 May CAHN

>D> TOCAINIDE HYDROCHLORIDE

>D> TABLET; ORAL

>D> TONOCARD

>D> ASTRAZENECA

400MG

N18257 001

Nov 09, 1984 Dec DISC

>A> @

400MG

N18257 001

Nov 09, 1984 Dec DISC

>D> +

600MG

N18257 002

Nov 09, 1984 Dec DISC

>A> @

600MG

N18257 002

Nov 09, 1984 Dec DISC

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ WATSON LABS

100MG

N70513 001

Jan 09, 1986 Aug DISC

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT	100MG	N20697 001	Jan 29, 1998	Aug	CAHN
+	200MG	N20697 002	Jan 29, 1998	Aug	CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ TEVA	EQ 400MG BASE	N73519 001	May 29, 1992	Sep	DISC
--------	---------------	------------	--------------	-----	------

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

ORTHO MCNEIL PHARM	15MG	N20844 001	Oct 26, 1998	Jul	CAHN
+	25MG	N20844 002	Oct 26, 1998	Jul	CAHN
@	50MG	N20844 003	Oct 26, 1998	Jul	CAHN

TABLET; ORAL

TOPAMAX

ORTHO MCNEIL PHARM	50MG	N20505 005	Dec 24, 1996	Jun	CMFD
--------------------	------	------------	--------------	-----	------

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	PLIVA PHARM IND	100MG	N76346 004	Oct 19, 2004	Oct	NEWA
----	-----------------	-------	------------	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

+	ALCON	0.004%	N21257 001	Mar 16, 2001	May	CAHN
---	-------	--------	------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

>D>	AB	MYLAN	100MG	N71406 001	Feb 27, 1991	Dec	DISC
>A>		@	100MG	N71406 001	Feb 27, 1991	Dec	DISC

TREPROSTINIL SODIUM

INJECTABLE; IV (INFUSION)-SC

REMODULIN

UNITED THERAP	1MG/ML	N21272 001	May 21, 2002	Nov	CDFR
	2.5MG/ML	N21272 002	May 21, 2002	Nov	CDFR
	5MG/ML	N21272 003	May 21, 2002	Nov	CDFR
+	10MG/ML	N21272 004	May 21, 2002	Nov	CDFR

TRETINOIN

CREAM; TOPICAL

AVITA

AB	MYLAN BERTEK	0.025%	N20404 003	Jan 14, 1997	Aug	CAHN
----	--------------	--------	------------	--------------	-----	------

GEL; TOPICAL

AVITA

BT	MYLAN BERTEK	0.025%	N20400 001	Jan 29, 1998	Aug	CAHN
----	--------------	--------	------------	--------------	-----	------

TRIAMCINOLONE

TABLET; ORAL					
ARISTOCORT					
BP	+ FUJISAWA HLTHCARE	4MG	N11161 007		Jun CRLD
KENACORT					
	@ BRISTOL MYERS SQUIBB	8MG	N11283 010		Jun DISC
TRIAMCINOLONE					
	@ WATSON LABS	4MG	N84270 001		Jun DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

	+ KOS	0.1MG/INH	N18117 001	Apr 23, 1982	Apr CAHN
--	-------	-----------	------------	--------------	----------

SPRAY, METERED; NASAL

NASACORT HFA

	+ AVENTIS PHARMS	0.055MG/SPRAY	N20784 001	Apr 07, 2004	Apr NEWA
--	------------------	---------------	------------	--------------	----------

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

	@ SABEX 2002	25MG/ML	N11685 003		Jun DISC
--	--------------	---------	------------	--	----------

	@	40MG/ML	N12802 001		Jun DISC
--	---	---------	------------	--	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL

AP	HOSPIRA	100MG/ML	N88804 001	Apr 03, 1987	May CAHN
----	---------	----------	------------	--------------	----------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

	@ MUTUAL PHARM	100MG	N70494 001	Jan 22, 1986	Aug CAHN
--	----------------	-------	------------	--------------	----------

	@	200MG	N70495 001	Sep 24, 1986	Aug CAHN
--	---	-------	------------	--------------	----------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

	ODYSSEY PHARMS	EQ 25MG BASE	N16792 001		Jun CAHN
--	----------------	--------------	------------	--	----------

		EQ 50MG BASE	N16792 002		Jun CAHN
--	--	--------------	------------	--	----------

	+	EQ 100MG BASE	N16792 003	Sep 15, 1982	Jun CAHN
--	---	---------------	------------	--------------	----------

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

>D>	AA	+ NOVARTIS	50MG	N05914 002		Dec CTEC
-----	----	------------	------	------------	--	----------

>A>		+	50MG	N05914 002		Dec CTEC
-----	--	---	------	------------	--	----------

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

	+ WATSON LABS	11.25MG/VIAL	N21288 001	Jun 29, 2001	Nov CAHN
--	---------------	--------------	------------	--------------	----------

	+ WATSON PHARMS	11.25MG/VIAL	N21288 001	Jun 29, 2001	Sep CAHN
--	-----------------	--------------	------------	--------------	----------

TRELSTAR DEPOT

	+ WATSON LABS	EQ 3.75MG BASE/VIAL	N20715 001	Jun 15, 2000	Nov CAHN
--	---------------	---------------------	------------	--------------	----------

	+ WATSON PHARMS	EQ 3.75MG BASE/VIAL	N20715 001	Jun 15, 2000	Sep CAHN
--	-----------------	---------------------	------------	--------------	----------

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC
 CERUMENEX
 @ PURDUE FREDERICK 10%

N11340 002 May DISC

TROMETHAMINE

INJECTABLE; INJECTION
 THAM
 + HOSPIRA 3.6GM/100ML

N13025 002 May CAHN

TROSPIUM CHLORIDE

TABLET; ORAL
 SANCTURA
 + INDEVUS 20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL
 TROVAN
 @ PFIZER EQ 100MG BASE
 @ EQ 200MG BASE

N20759 001 Dec 18, 1997 Jun DISC

N20759 002 Dec 18, 1997 Jun DISC

>A> TRYPAN BLUE

>A> SOLUTION; OPHTHALMIC
 >A> VISIONBLUE
 >A> + DORC 0.06%

N21670 001 Dec 16, 2004 Dec NEWA

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
 TUBOCURARINE CHLORIDE
 @ BRISTOL MYERS SQUIBB 3MG/ML
 + 3MG/ML
 AP + HOSPIRA 3MG/ML
 @ 3MG/ML

N05657 001 Jul DISC

N05657 001 Jun CTEC

N06095 001 May CAHN

N06095 001 Jun DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
 RESCULA
 + NOVARTIS 0.15%

N21214 001 Aug 03, 2000 Aug CAHN

UREA

INJECTABLE; INJECTION
 STERILE UREA
 @ HOSPIRA 40GM/VIAL
 UREAPHIL
 + HOSPIRA 40GM/VIAL

N17698 001 May CAHN

N12154 001 May CAHN

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
 BRAVELLE
 + FERRING 75 IU/VIAL
 INJECTABLE; SUBCUTANEOUS
 FERTINEX
 @ SERONO 75 IU/AMP

N21289 001 May 06, 2002 Oct CTEC

N19415 005 Aug 23, 1996 Oct DISC

UROKINASE

INJECTABLE; INJECTION

ABBOKINASE

+	ABBOTT	250,000 IU/VIAL	N21846 001	Nov	CMS1
---	--------	-----------------	------------	-----	------

URSODIOL

TABLET; ORAL

URSO 250

	AXCAN SCANDIPHARM	250MG	N20675 001	Dec 10, 1997	Jul CTNA
--	-------------------	-------	------------	--------------	----------

URSO FORTE

+	AXCAN SCANDIPHARM	500MG	N20675 002	Jul 21, 2004	Sep CTNA
---	-------------------	-------	------------	--------------	----------

URSODIOL

+	AXCAN SCANDIPHARM	500MG	N20675 002	Jul 21, 2004	Jul NEWA
---	-------------------	-------	------------	--------------	----------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

+	GLAXOSMITHKLINE	EQ 1GM BASE	N20487 002	Jun 23, 1995	Feb CRLD
---	-----------------	-------------	------------	--------------	----------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOICIN HCL

VIROPHARMA EQ 125MG BASE

N50606 001	Apr 15, 1986	Nov	CAHN
------------	--------------	-----	------

+ EQ 250MG BASE

N50606 002	Apr 15, 1986	Nov	CAHN
------------	--------------	-----	------

FOR SOLUTION; ORAL

VANCOICIN HCL

>D>	@	LILLY	EQ 250MG BASE/5ML	N61667 002	Jul 13, 1983	Dec	CAHN
	@		EQ 250MG BASE/5ML	N61667 002	Jul 13, 1983	Jun	DISC
>D>	@		EQ 500MG BASE/6ML	N61667 001		Dec	CAHN
	@		EQ 500MG BASE/6ML	N61667 001		Jun	DISC
>A>	@	VIROPHARMA	EQ 250MG BASE/5ML	N61667 002	Jul 13, 1983	Dec	CAHN
>A>	@		EQ 500MG BASE/6ML	N61667 001		Dec	CAHN

INJECTABLE; INJECTION

VANCOICIN HCL

>D>	@	LILLY	EQ 500MG BASE/VIAL	N60180 001		Dec	CAHN
	@		EQ 500MG BASE/VIAL	N60180 001		Jun	DISC
>D>	@		EQ 500MG BASE/VIAL	N62476 001	Mar 15, 1984	Dec	CAHN
	@		EQ 500MG BASE/VIAL	N62476 001	Mar 15, 1984	Jun	DISC
>D>	@		EQ 500MG BASE/VIAL	N62716 001	Mar 13, 1987	Dec	CAHN
	@		EQ 500MG BASE/VIAL	N62716 001	Mar 13, 1987	Jun	DISC
>D>	@		EQ 500MG BASE/VIAL	N62812 001	Nov 17, 1987	Dec	CAHN
	@		EQ 500MG BASE/VIAL	N62812 001	Nov 17, 1987	Jun	DISC
>D>	@		EQ 1GM BASE/VIAL	N60180 002	Mar 21, 1986	Dec	CAHN
	@		EQ 1GM BASE/VIAL	N60180 002	Mar 21, 1986	Jun	DISC
>D>	@		EQ 1GM BASE/VIAL	N62476 002	Mar 21, 1986	Dec	CAHN
	@		EQ 1GM BASE/VIAL	N62476 002	Mar 21, 1986	Jun	DISC
>D>	@		EQ 1GM BASE/VIAL	N62716 002	Mar 13, 1987	Dec	CAHN
	@		EQ 1GM BASE/VIAL	N62716 002	Mar 13, 1987	Jun	DISC
>D>	@		EQ 1GM BASE/VIAL	N62812 002	Nov 17, 1987	Dec	CAHN
	@		EQ 1GM BASE/VIAL	N62812 002	Nov 17, 1987	Jun	DISC
>D>	@		EQ 10GM BASE/VIAL	N62812 003	Nov 17, 1987	Dec	CAHN
	@		EQ 10GM BASE/VIAL	N62812 003	Nov 17, 1987	Jun	DISC
>A>	@	VIROPHARMA	EQ 500MG BASE/VIAL	N60180 001		Dec	CAHN
>A>	@		EQ 500MG BASE/VIAL	N62476 001	Mar 15, 1984	Dec	CAHN
>A>	@		EQ 500MG BASE/VIAL	N62716 001	Mar 13, 1987	Dec	CAHN
>A>	@		EQ 500MG BASE/VIAL	N62812 001	Nov 17, 1987	Dec	CAHN

INJECTABLE; INJECTION

VANCOICIN HCL

>A>	@	VIROPHARMA	EQ 1GM BASE/VIAL	N60180 002	Mar 21, 1986	Dec	CAHN
>A>	@		EQ 1GM BASE/VIAL	N62476 002	Mar 21, 1986	Dec	CAHN
>A>	@		EQ 1GM BASE/VIAL	N62716 002	Mar 13, 1987	Dec	CAHN
>A>	@		EQ 1GM BASE/VIAL	N62812 002	Nov 17, 1987	Dec	CAHN
>A>	@		EQ 10GM BASE/VIAL	N62812 003	Nov 17, 1987	Dec	CAHN

VANCOMYCIN HCL

AP		HOSPIRA	EQ 500MG BASE/VIAL	N62911 001	Aug 04, 1988	May	CAHN
AP			EQ 500MG BASE/VIAL	N62931 001	Oct 29, 1992	May	CAHN
AP			EQ 1GM BASE/VIAL	N62912 001	Aug 04, 1988	May	CAHN
AP			EQ 1GM BASE/VIAL	N62933 001	Oct 29, 1992	May	CAHN
AP			EQ 5GM BASE/VIAL	N63076 001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

	+	ABBOTT	4MG/VIAL	N75558 001	Sep 11, 2001	Apr	CAHN
	+	HOSPIRA	4MG/VIAL	N75558 001	Sep 11, 2001	May	CAHN
AP			10MG/VIAL	N75164 001	Oct 21, 1999	May	CAHN
AP			20MG/VIAL	N75164 002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

	+	WYETH PHARMS INC	EQ 50MG BASE	N20151 003	Dec 28, 1993	Oct	CRLD
			EQ 50MG BASE	N20151 003	Dec 28, 1993	May	CRLD
	+		EQ 100MG BASE	N20151 005	Dec 28, 1993	May	CRLD
			EQ 100MG BASE	N20151 005	Dec 28, 1993	Oct	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPTIN

>D>	AP	+	ABBOTT	2.5MG/ML	N18485 001		Dec	CAHN
>A>	AP	+	FSC	2.5MG/ML	N18485 001		Dec	CAHN

VERAPAMIL HCL

AP		HOSPIRA	2.5MG/ML	N70577 001	Feb 02, 1987	May	CAHN
AP			2.5MG/ML	N70737 001	May 06, 1987	May	CAHN
AP			2.5MG/ML	N70738 001	May 06, 1987	May	CAHN
AP			2.5MG/ML	N70739 001	May 06, 1987	May	CAHN
AP			2.5MG/ML	N70740 001	May 06, 1987	May	CAHN
AP			2.5MG/ML	N75136 001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOPTIN SR

>D>	AB	+	ABBOTT	120MG	N19152 003	Mar 06, 1991	Dec	CAHN
>D>	AB	+		180MG	N19152 002	Dec 15, 1989	Dec	CAHN
>D>	AB	+		240MG	N19152 001	Dec 16, 1986	Dec	CAHN
>A>	AB	+	PAR PHARM	120MG	N19152 003	Mar 06, 1991	Dec	CAHN
>A>	AB	+		180MG	N19152 002	Dec 15, 1989	Dec	CAHN
>A>	AB	+		240MG	N19152 001	Dec 16, 1986	Dec	CAHN

VERAPAMIL HCL

AB		BARR	120MG	N75072 001	May 25, 1999	May	CMFD
AB			240MG	N75072 003	May 25, 1999	May	CMFD
AB		KALI LABS	120MG	N75072 001	May 25, 1999	Aug	CAHN
AB			240MG	N75072 003	May 25, 1999	Aug	CAHN

TABLET; ORAL

ISOPTIN

>D>	AB	ABBOTT	40MG	N18593 003	Nov 23, 1987	Dec	CAHN
>D>	AB		80MG	N18593 001	Mar 08, 1982	Dec	CAHN
>D>	AB	+	120MG	N18593 002	Mar 08, 1982	Dec	CAHN
>A>	AB	FSC	40MG	N18593 003	Nov 23, 1987	Dec	CAHN
>A>	AB		80MG	N18593 001	Mar 08, 1982	Dec	CAHN
>A>	AB	+	120MG	N18593 002	Mar 08, 1982	Dec	CAHN
		VERAPAMIL HCL					
		@ MUTUAL PHARM	80MG	N70482 001	Sep 24, 1986	Aug	CAHN
		@	120MG	N70483 001	Sep 24, 1986	Aug	CAHN

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

@ LILLY

1MG/ML

N14103 003 Mar 07, 1984 Mar DISC

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP BAXTER HLTHCARE EQ 10MG BASE/ML

N75992 001 Jun 10, 2003 Aug CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ MAYNE PHARMA USA

EQ 50,000 UNITS BASE/ML

N06823 001 Apr CAHN

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	GENPHARM	1MG	N40415 001	Sep 27, 2004	Sep	NEWA
AB		2MG	N40415 002	Sep 27, 2004	Sep	NEWA
AB		2.5MG	N40415 003	Sep 29, 2004	Sep	NEWA
AB		3MG	N40415 004	Sep 27, 2004	Sep	NEWA
AB		4MG	N40415 005	Sep 27, 2004	Sep	NEWA
AB		5MG	N40415 006	Sep 27, 2004	Sep	NEWA
AB		6MG	N40415 007	Sep 27, 2004	Sep	NEWA
AB		7.5MG	N40415 008	Sep 27, 2004	Sep	NEWA
AB		10MG	N40415 009	Sep 27, 2004	Sep	NEWA

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	100%	N18802 001	Oct 27, 1982	Dec	CRLD
>A>	AP	+	100%	N18802 001	Oct 27, 1982	Dec	CRLD
	AP		100%	N18802 001	Oct 27, 1982	May	CAHN

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

@ B BRAUN

>D>	AP		100%	N19077 001	Mar 02, 1984	May	DISC
			100%	N19633 001	Feb 29, 1988	Dec	CRLD
>A>	AP	+	100%	N19633 001	Feb 29, 1988	Dec	CRLD
>D>	AP	BAXTER HLTHCARE	100%	N18632 001	Jun 30, 1982	Dec	CRLD
>A>	AP	+	100%	N18632 001	Jun 30, 1982	Dec	CRLD
>D>	AP		100%	N18632 002	Apr 19, 1988	Dec	CRLD
>A>	AP	+	100%	N18632 002	Apr 19, 1988	Dec	CRLD
>D>	AP	HOSPIRA	100%	N18233 001		Dec	CRLD
>A>	AP	+	100%	N18233 001		Dec	CRLD

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	HOSPIRA	100%	N18233 001		May	CAHN
>D>	AP	100%	N18801 001	Oct 27, 1982	Dec	CRLD
>A>	AP +	100%	N18801 001	Oct 27, 1982	Dec	CRLD
	AP	100%	N18801 001	Oct 27, 1982	May	CAHN
>D>	AP	100%	N19869 001	Dec 26, 1989	Dec	CRLD
>A>	AP +	100%	N19869 001	Dec 26, 1989	Dec	CRLD
	AP	100%	N19869 001	Dec 26, 1989	May	CAHN

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	HOSPIRA	100%	N17513 001		May	CAHN
AT		100%	N18313 001		May	CAHN

XENON, XE-133

GAS; INHALATION

XENON XE 133

@ GEN ELECTRIC

5-100 CI/CYLINDER

N17550 001 Sep DISC

@

0.25-5 CI/AMP

N17550 003 Sep DISC

>A> ZICONOTIDE

>A> INJECTABLE; INTRATHECAL

>A> PRIALT

>A>	+ ELAN PHARMS	100MG/1ML (100MG/ML)	N21060 002	Dec 28, 2004	Dec	NEWA
>A>	+	200MG/2ML (100MG/ML)	N21060 003	Dec 28, 2004	Dec	NEWA
>A>	+	500MG/20ML (25MG/ML)	N21060 001	Dec 28, 2004	Dec	NEWA
>A>	+	500MG/5ML (100MG/ML)	N21060 004	Dec 28, 2004	Dec	NEWA

ZIDOVDINE

SYRUP; ORAL

RETROVIR

+	GLAXOSMITHKLINE	50MG/5ML	N19910 001	Sep 28, 1989	Jul	CRLD
---	-----------------	----------	------------	--------------	-----	------

ZILEUTON

TABLET; ORAL

ZYFLO

@ CRITICAL

		300MG	N20471 001	Dec 09, 1996	Jul	CAHN
+		600MG	N20471 003	Dec 09, 1996	Jul	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1MG ZINC/ML	N18959 001	Jun 26, 1986	May	CAHN
---	---------	----------------	------------	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

+	PFIZER	20MG	N20825 001	Feb 05, 2001	Sep	CRLD
		80MG	N20825 004	Feb 05, 2001	Sep	CRLD

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO

5MG

N19908 001 Dec 16, 1992 Apr CAHN

TABLET; ORAL
AMBIEN

+ SANOFI SYNTHELABO 10MG

N19908 002 Dec 16, 1992 Apr CAHN

PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2004

2-1

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ NOVARTIS 0.5%;0.05% N18746 002 Jul 11, 1994 Feb CAHN

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

@ BAYER 500MG

N21317 001 Oct 18, 2001 Nov DISC

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ SCHERING PLOUGH 3%;7.5%;3% N20045 001 Dec 07, 1992 Oct CAIN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2% N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

+ REGENT 4% N17768 001 Sep CAHN

HIBISTAT

+ REGENT 0.5% N18300 001 Sep CAHN

SPONGE; TOPICAL

HIBICLENS

+ REGENT 4% N18423 001 Sep CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+ MEDI FLEX HOSP 2%;70% N20832 001 Jul 14, 2000 Jun CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ MEDI FLEX HOSP 2%;70% N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ SANDOZ 12MG

N70797 001 Aug 12, 1988 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

@ SCHERING PLOUGH 8MG

N07638 001 Sep DISC

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+ ALZA 16MG N19746 002 Nov 18, 1994 Mar CRLD

@ 16MG

N19746 002 Nov 18, 1994 Sep DISC

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

>D>	ADAMS LABS	30MG; 600MG	N21620 002	Apr 29, 2004	Dec	CAHN
		30MG; 600MG	N21620 002	Apr 29, 2004	Apr	NEWA
>D>	+	60MG; 1.2GM	N21620 001	Apr 29, 2004	Dec	CAHN
	+	60MG; 1.2GM	N21620 001	Apr 29, 2004	Apr	NEWA
>A>	ADAMS LABS INC	30MG; 600MG	N21620 002	Apr 29, 2004	Dec	CAHN
>A>	+	60MG; 1.2GM	N21620 001	Apr 29, 2004	Dec	CAHN

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK

25MG

N40564 001 Aug 27, 2004 Aug NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

N87907 001 May 23, 1984 Oct CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX

>D>	ADAMS LABS	600MG	N21282 001	Jul 12, 2002	Dec	CAHN
>D>	+	1.2GM	N21282 002	Dec 18, 2002	Dec	CAHN
>A>	ADAMS LABS INC	600MG	N21282 001	Jul 12, 2002	Dec	CAHN
>A>	+	1.2GM	N21282 002	Dec 18, 2002	Dec	CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

ADAMS

600MG; 60MG

N21585 001 Jun 22, 2004 Jun NEWA

+

1.2GM; 120MG

N21585 002 Jun 22, 2004 Jun NEWA

ADAMS LABS INC

600MG; 60MG

N21585 001 Jun 22, 2004 Nov CAHN

+

1.2GM; 120MG

N21585 002 Jun 22, 2004 Nov CAHN

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

TARO

100MG/5ML

N21604 001 Jan 07, 2004 Jan NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN

PERRIGO

50MG

N76359 001 Jan 16, 2004 Jan NEWA

100MG

N76359 002 Jan 16, 2004 Jan NEWA

TABLET; ORAL

IBUPROFEN

LNK

100MG

N76741 001 Jun 17, 2004 Jun NEWA

@ MUTUAL PHARM

200MG

N70493 001 Dec 24, 1985 Aug CAHN

@

200MG

N70908 001 Sep 26, 1986 Aug CAHN

@

200MG

N71462 001 Oct 02, 1986 Aug CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ WYETH CONS 200MG; 30MG

N21374 001 May 30, 2002 Mar CAIN

LORATADINE

SYRUP; ORAL

LORATADINE

APOTEX	1MG/ML	N75565	001	Oct 05, 2004	Oct	NEWA
MORTON GROVE	1MG/ML	N75815	001	Aug 20, 2004	Aug	NEWA
PERRIGO	1MG/ML	N75728	001	Aug 20, 2004	Aug	NEWA
RANBAXY	1MG/ML	N76529	001	Aug 20, 2004	Aug	NEWA
TARO	1MG/ML	N76805	001	Aug 20, 2004	Aug	NEWA

TABLET; ORAL

LORATADINE

PERRIGO	10MG	N21512	001	Jun 24, 2004	Jun	NEWA
	10MG	N76301	001	Jun 25, 2004	Jun	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

@ SCHERING	5MG;120MG	N19670	002	Nov 27, 2002	Aug	DISC
------------	-----------	--------	-----	--------------	-----	------

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ANDRX PHARMS	5MG;120MG	N76208	001	Jan 28, 2004	Jan	NEWA
+ IMPAX LABS	5MG;120MG	N76050	001	Jan 30, 2003	Aug	CRLD
	10MG;240MG	N75989	001	Mar 04, 2004	Mar	NEWA
RANBAXY	10MG;240MG	N76557	001	Sep 22, 2004	Sep	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS	2%,100MG	N76585	001	Mar 26, 2004	Mar	NEWA
--------------	----------	--------	-----	--------------	-----	------

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO	2%,4%	N76357	001	Mar 30, 2004	Mar	NEWA
---------	-------	--------	-----	--------------	-----	------

MONISTAT 3 COMBINATION PACK

PERSONAL PRODS	2%,4%	N21261	003	Jun 17, 2003	Aug	CRLD
----------------	-------	--------	-----	--------------	-----	------

CREAM; VAGINAL

MONISTAT 3

>A>	+ ADV CARE PRODS	4%	N20827	001	Mar 30, 1998	Dec	CAHN
>D>	+ ADVANCED CARE PRODS	4%	N20827	001	Mar 30, 1998	Dec	CAHN

SUPPOSITORY; VAGINAL

MONISTAT 7

>A>	+ ADV CARE PRODS	100MG	N18520	002	Feb 15, 1991	Dec	CAHN
>D>	+ ADVANCED CARE PRODS	100MG	N18520	002	Feb 15, 1991	Dec	CAHN

MINOXIDIL

SOLUTION; TOPICAL

THEROXIDIL

HARMONY LABS	5%	N76239	001	Aug 24, 2004	Aug	NEWA
--------------	----	--------	-----	--------------	-----	------

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

PERRIGO	EQ 200MG BASE;120MG	N76518	001	Mar 17, 2004	Mar	NEWA
---------	---------------------	--------	-----	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO	EQ 2MG BASE	N76775	001	Sep 16, 2004	Sep	NEWA
---------	-------------	--------	-----	--------------	-----	------

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO	EQ 4MG BASE	N76789 001	Sep 16, 2004	Sep	NEWA
WATSON LABS	EQ 2MG BASE	N76568 001	Jul 29, 2004	Jul	NEWA
	EQ 2MG BASE	N76569 001	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76568 002	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76569 002	Jul 29, 2004	Jul	NEWA

NICOTINE POLACRILEX (MINT)

PERRIGO	EQ 2MG BASE	N76777 001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76779 001	Sep 16, 2004	Sep	NEWA

NICOTINE POLACRILEX (ORANGE)

PERRIGO	EQ 2MG BASE	N76776 001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76778 001	Sep 16, 2004	Sep	NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

>A>	FLEMING	65MG/ML	N77218 001	Jan 12, 2005	Dec	NEWA
-----	---------	---------	------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 150

+	PFIZER CONS HLTHCARE	EQ 150MG BASE	N21698 001	Aug 31, 2004	Aug	NEWA
---	----------------------	---------------	------------	--------------	-----	------

ZANTAC 75


	WARNER LAMBERT	EQ 75MG BASE	N20520 001	Dec 19, 1995	Aug	CRLD
--	----------------	--------------	------------	--------------	-----	------

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT

+	NOVARTIS	1%	N21124 002	Mar 17, 2000	Feb	NEWA
---	----------	----	------------	--------------	-----	------



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2004

NO DECEMBER 2004 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
December 2004

Generic Name: Designation:
Treatment for patients with brain stem glioma

Trade Name (if present): Sponsor and Address
A10 & AS2-1 Antineoplaston Burzynski Research Institute, Inc.
9432 Old Katy Road
Houston TX 77055

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name: Designation:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia

Trade Name (if present): Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/10/2004
Marketing Exclusivity Date:

Generic Name: Designation:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride Treatment of acute lymphoblastic leukemia

Trade Name (if present): Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/13/2004
Marketing Exclusivity Date:

Generic Name: Designation:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present): Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Orphan Products Designations and Approvals List December 2004

Generic Name: (3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid
 Designation: For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene.

Trade Name (if present):

Date Designated: 9/1/2004
 Marketing Exclusivity Date:

Sponsor and Address
 PTC Therapeutics
 100 Corporate Court
 South Plainfield NJ 07080

Generic Name: (6R,S)5,10-methylene-tetrahydrofolic acid
 Designation: For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer

Trade Name (if present): CoFactor

Date Designated: 8/13/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Adventrx Pharmaceuticals, Inc.
 6725 Mesa Ridge Road
 Suite 100
 San Diego CA 92121

Generic Name: (9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid
 Designation: Prevention of post-operative complications of aortic aneurysm surgical repair

Trade Name (if present):

Date Designated: 12/8/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Inotek Pharmaceuticals Corporation
 100 Cummings Center
 Beverly MA 01915

Generic Name: 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine
 Designation: Treatment of acute myelogenous leukemia

Trade Name (if present): Cloretazine

Date Designated: 10/21/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Vion Pharmaceuticals, Inc.
 Four Science Park
 New Haven CT 06511

Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)
 Designation: Treatment of multiple myeloma.

Trade Name (if present):

Sponsor and Address
 Kosan Biosciences, Inc

Orphan Products Designations and Approvals List December 2004

Date Designated: 9/9/2004
 Marketing Exclusivity Date:

 Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)
 Designation: For the treatment of chronic myelogenous leukemia

3832 Bay Center Place
 Hayward CA 94545

Trade Name (if present):

Sponsor and Address
 Kosan Biosciences, Inc.
 3832 Bay Center Place
 Hayward CA 94545

Date Designated: 9/3/2004
 Marketing Exclusivity Date:

Generic Name: 1-Deoxygalactonojirimycin
 Designation: Treatment of Fabry Disease

Trade Name (if present):

Sponsor and Address
 Amicus Therapeutics, Inc.
 675 US Route 1
 North Brunswick NJ 08902

Date Designated: 2/25/2004
 Marketing Exclusivity Date:

Generic Name: 20-mer complementary to Akt mRNA
 Designation: Treatment of stomach cancer

Trade Name (if present):

Sponsor and Address
 Rexahn Corporation
 9620 Medical center Drive
 Rockville MD 20850

Date Designated: 12/10/2004
 Marketing Exclusivity Date:

Generic Name: 20-mer oligonucleotide complementary to Akt mRNA
 Designation: Treatment of pancreatic cancer

Trade Name (if present):

Sponsor and Address
 Rexahn Corporation
 9620 Medical Center Drive
 Rockville MD 20850

Date Designated: 12/8/2004
 Marketing Exclusivity Date:

Generic Name: 20-mer oligonucleotide complementary to Akt mRNA
 Designation: Treatment of glioblastoma

Trade Name (if present):

Sponsor and Address
 Rexahn Corporation

Orphan Products Designations and Approvals List December 2004

Date Designated: 12/8/2004
 Marketing Exclusivity Date:

 Generic Name: 20-mer oligonucleotide complementary to Akt mRNA
 Designation: Treatment of renal cell carcinoma

Trade Name (if present):
 Sponsor and Address
 Rexahn Corporation
 9620 Medical Center Drive
 Rockville MD 20850
 Date Designated: 12/1/2004
 Marketing Exclusivity Date:

 Generic Name: 20-mer oligonucleotide complementary to Akt mRNA
 Designation: Treatment of ovarian cancer

Trade Name (if present):
 Sponsor and Address
 Rexahn Corporation
 9620 Medical Center Drive
 Rockville MD 20850
 Date Designated: 12/1/2004
 Marketing Exclusivity Date:

 Generic Name: 3-carboxy-2,3-dihydroxy-propionate 2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-3-methoxy-2H-pyrrolium
 Designation: Treatment of chronic lymphocytic leukemia

Trade Name (if present):
 Sponsor and Address
 Gemin X, Inc.
 5 Great Valley Parkway
 Malvern PA 19355
 Date Designated: 10/8/2004
 Marketing Exclusivity Date:

 Generic Name: 5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)
 Designation: Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
 Pirfenidone
 Sponsor and Address
 InterMune, Inc.
 3280 Bayshore Blvd
 Brisbane CA 94005
 Date Designated: 3/5/2004
 Marketing Exclusivity Date:

 Generic Name: 90Y-hPAMA4
 Designation: Treatment of pancreatic cancer

Trade Name (if present):
 PAN-Cide
 Sponsor and Address
 Immunomedics, Inc.

Orphan Products Designations and Approvals List December 2004

Date Designated: 1/29/2004
Marketing Exclusivity Date:

300 American Road
Morris Plains NJ 07950

Generic Name: Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor
Designation: Treatment of retinitis pigmentosa

Trade Name (if present):

Sponsor and Address
Neurotech USA, Inc.
6 Blackstone Valley Place
Lincoln RI 02865

Date Designated: 9/1/2004
Marketing Exclusivity Date:

Generic Name: Alpha-1-acid glycoprotein
Designation: Treatment of cocaine overdose

Trade Name (if present):

Sponsor and Address
Bio Products Laboratory
Dagger Lane, Elstree
WD6 3BX

Date Designated: 3/5/2004
Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name: Alpha-1-acid glycoprotein
Designation: Treatment of tricyclic antidepressant poisoning

Trade Name (if present):

Sponsor and Address
Bio Products Laboratory
Dagger Lane
Elstree, Hertfordshire

Date Designated: 3/17/2004
Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name: Alpha1-Proteinase Inhibitor (Human) [API] deficiency
Designation: Chronic inhalation therapy of individuals with congenital of alpha1-proteinase inhibitor with demonstrable panacinar emphysema

Trade Name (if present):

Sponsor and Address
Kamada Ltd.
Kiryat Weizmann

Date Designated: 12/22/2004
Marketing Exclusivity Date:

ISRAEL

Generic Name: Alpha1-Proteinase Inhibitor (Human) [API]
Designation: Treatment of cystic fibrosis

Orphan Products Designations and Approvals List December 2004

Trade Name (if present):
ARC-API

Sponsor and Address
Kamada Ltd.
Kiryat Weizmann

Date Designated: 9/1/2004
Marketing Exclusivity Date:

ISRAEL

Generic Name:
Ambrisentan

Designation:
Treatment of pulmonary arterial hypertension

Trade Name (if present):

Sponsor and Address
Myogen, Inc.
7575 West 103rd Avenue
Suite 102
Westminister CO 80021-5426

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name:
Antivenin crotaline (pit-viper) equine immune F(ab)2

Designation:
Treatment of envenomation by Crotaline snakes

Trade Name (if present):
Antivipmyn

Sponsor and Address
Rare Disease Therapeutics, Inc.
1101 Kermit Drive,
Suite 608
Nashville TN 37217

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Generic Name:
Aplidin

Designation:
Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present):

Sponsor and Address
PharmaMar USA, Inc
320 Putnam Avenue
Cambridge MA 02139

Date Designated: 6/18/2004
Marketing Exclusivity Date:

Generic Name:
Autologous incubated macrophage
in

Designation:
Therapy to improve the motor and sensory neurological outcome
acute cases of spinal cord injury

Trade Name (if present):

Sponsor and Address
Proneuron Biotechnologies, Inc.
Weizmann Science Park
P. O. Box 277
Ness-Ziona 74101
ISRAEL

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:

Designation:

Orphan Products Designations and Approvals List December 2004

Bevacizumab Treatment of pancreatic cancer

Trade Name (if present):
Avastin

Sponsor and Address
Genentech, Inc.
1 DNA Way, MS #242
South San Francisco CA 94080-4990

Date Designated: 10/20/2004

Marketing Exclusivity Date:

Generic Name:
Buffered Ursodeoxycholic Acid

Designation:
For the treatment of pruritus in patients with Alagille Syndrome

Trade Name (if present):
Ursocarb

Sponsor and Address
Digestive Care, Inc.
1120 Win Drive
Bethlehem PA 18017

Date Designated: 9/3/2004

Marketing Exclusivity Date:

Generic Name:
C1 esterase inhibitor (human)

Designation:
Treatment of Angioedema

Trade Name (if present):

Sponsor and Address
Lev Pharmaceuticals, Inc.
236 Old Lancaster Road
Merion Station PA 19066

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name:
Chenodeoxycholic acid

Designation:
Treatment of cerebrotendinous xanthomatosis

Trade Name (if present):
Chenofalk

Sponsor and Address
Dr. Falk Pharma GmbH
Leinenweberstrasse 5
9041 Freiburg, GERMANY

Date Designated: 1/29/2004

Marketing Exclusivity Date:

GERMANY

Generic Name:
Coagulation factor VIIa (recombinant)

Designation:
Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 7/21/2004

Marketing Exclusivity Date:

Generic Name:

Designation:

Orphan Products Designations and Approvals List December 2004

Generic Name: Coagulation factor VIIa (recombinant)	Designation: Treatment of bleeding episodes in patients with congenital factor VII deficiency
--	--

Trade Name (if present): NovoSeven	Sponsor and Address Novo Nordisk, Inc. 100 College Road West Princeton NJ 08540
Date Designated: 9/10/2004	
Marketing Exclusivity Date:	

Generic Name: Cyclosporin A	Designation: Treatment of amyotrophic lateral sclerosis and its variants
--------------------------------	---

Trade Name (if present): Cyclosporin	Sponsor and Address Maas BiolAB 1934 Quail Run Loop NE Albuquerque NM 87122
Date Designated: 10/29/2004	
Marketing Exclusivity Date:	

Generic Name: DEAE-rebeccamycin	Designation: Treatment of bile duct tumors
------------------------------------	---

Trade Name (if present):	Sponsor and Address Exelixis, Inc. 170 Harbor Way South San Francisco CA 94083-0511
Date Designated: 3/1/2004	
Marketing Exclusivity Date:	

Generic Name: Deferitron	Designation: Treatment of iron overload
-----------------------------	--

Trade Name (if present):	Sponsor and Address Genzyme Corporation 153 Second Avenue Waltham MA 02451
Date Designated: 4/14/2004	
Marketing Exclusivity Date:	

Generic Name: Depsipeptide	Designation: Treatment of cutaneous T-cell lymphoma
-------------------------------	--

Trade Name (if present):	Sponsor and Address Gloucester Pharmaceuticals, Inc. One Broadway Cambridge MA 02142
Date Designated: 9/30/2004	
Marketing Exclusivity Date:	

Orphan Products Designations and Approvals List December 2004

Generic Name: Desmoglein 3 synthetic peptide (PI-0824)
Designation: Treatment of pemphigus vulgaris

Trade Name (if present):

Sponsor and Address
Peptimmune, Inc.
64 Sidney Street
Cambridge MA 02139-4170

Date Designated: 10/26/2004

Marketing Exclusivity Date:

Generic Name: dexanabinol
Designation: For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury

injury

Trade Name (if present):

Sponsor and Address
Pharmos Corporation
99 Wood Avenue
Suite 311
Iselin NJ 08830

Date Designated: 8/11/2004

Marketing Exclusivity Date:

Generic Name: Dexrazoxane
Designation: Treatment of anthracycline extravasation during chemotherapy

Trade Name (if present):

Sponsor and Address
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen

Date Designated: 3/25/2004

Marketing Exclusivity Date:

DENMARK

Generic Name: diethylenetriaminepentaacetate (DTPA)
Designation: For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.

the

Trade Name (if present):

Sponsor and Address
CIS-US
10 DeAngelo Drive
Bedford MA 01730

Date Designated: 4/14/2004

Marketing Exclusivity Date:

Generic Name: Diethylenetriaminepentaacetic acid (DTPA)
Designation: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
Hameln Pharmaceuticals gmbh
Langes Feld 13
Hameln

Date Designated: 4/28/2004

Orphan Products Designations and Approvals List December 2004

Marketing Exclusivity Date: 8/11/2004
GERMANY

Generic Name: Diethylnorpermine (DENSPM) Designation: Treatment for hepatocellular carcinoma

Trade Name (if present):
Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 5/25/2004

Marketing Exclusivity Date:

Generic Name: Doripenem Designation: Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.

Trade Name (if present):
Sponsor and Address
Peninsula Pharmaceuticals, Inc.
1751 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name: Doxorubicin HCL liposome injection Designation: Treatment of multiple myeloma

Trade Name (if present): Doxil
Sponsor and Address
Johnson & Johnson Pharmaceutical Research & Dev.
920 US Highway 202, P. O. Box 300
Raritan NJ 08869

Date Designated: 12/29/2004

Marketing Exclusivity Date:

Generic Name: Efaproxiral Designation: Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer

Trade Name (if present):
Sponsor and Address
Allos Therapeutics, Inc.
11080 CirclePoint Road
Suite 200
Westminster CO 80020

Date Designated: 7/28/2004

Marketing Exclusivity Date:

Generic Name: Floxuridine, FUDR Designation: Intraperitoneal treatment of gastric cancer.

Trade Name (if present):
Sponsor and Address
Franco Muggia, M.D.
160 East 34th Street
New York NY 10016

Date Designated: 12/22/2004

Orphan Products Designations and Approvals List December 2004

Marketing Exclusivity Date:

Generic Name:
Golimumab

Designation:
Treatment of chronic sarcoidosis

Trade Name (if present):

Sponsor and Address
Centocor, Inc.
200 Great Valley Parkway
Malvern PA 19355-1307

Date Designated: 11/2/2004

Marketing Exclusivity Date:

Generic Name:
heat killed Mycobacterium w immunomodulator

Designation:
Active tuberculosis

Trade Name (if present):

CADI Mw

Sponsor and Address
CPL, Inc.
16020 Swingley Ridge Road
Chesterfield MO 63017

Date Designated: 9/3/2004

Marketing Exclusivity Date:

Generic Name:
Human anti-CD30 monoclonal antibody

Designation:
Treatment of Hodgkin's Disease

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 9/27/2004

Marketing Exclusivity Date:

Generic Name:
human anti-CD4 monoclonal antibody

Designation:
Treatment of mycosis fungoides

Trade Name (if present):

HuMax-CD4

Sponsor and Address
Genmab A/S
Tolbodgade 33
DK-1253 Copenhagen K

Date Designated: 8/13/2004

Marketing Exclusivity Date:

DENMARK

Generic Name:
human anti-integrin receptor avb3/avb5 monoclonal
IV
antibody

Designation:
Treatment of patients with high-risk stage II, stage III, and stage
malignant melanoma

Trade Name (if present):

Sponsor and Address
Centocor, Inc.
200 Great Valley Parkway

Orphan Products Designations and Approvals List December 2004

Date Designated: 12/1/2004 Malvern PA 19355-1307
Marketing Exclusivity Date:

Generic Name: Designation:
human anti-transforming growth factor-B1,2,3 Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
500 Kendall Street
Cambridge MA 02142

Date Designated: 7/9/2004
Marketing Exclusivity Date:

Generic Name: Designation:
Human immunoglobulin (IgG1k)antiCTLA-4 monoclonal antibody Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 6/3/2004
Marketing Exclusivity Date:

Generic Name: Designation:
Human monoclonal antibody against platelet-derived failure To slow the progression of IgA nephropathy and delay kidney growth factor D in patients affected by the disease.

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 11/2/2004
Marketing Exclusivity Date:

Generic Name: Designation:
Hydralazine Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy

Trade Name (if present):

Sponsor and Address
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150

Date Designated: 4/9/2004
Marketing Exclusivity Date:

Edison NJ 08817

Generic Name: Designation:
Icatibant acetate Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Sponsor and Address

Orphan Products Designations and Approvals List December 2004

Date Designated: 5/5/2004
Marketing Exclusivity Date:

Jerini AG
Invalidenstr, 130
10115 Berlin

GERMANY

Generic Name: Idebenone (INN)
Designation: Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Sponsor and Address
Santhera Pharmaceuticals LLC
Hammerstrasse 25
CH-4410 Liestal

Date Designated: 3/25/2004

Marketing Exclusivity Date:

SWITZERLAND

Generic Name: Iloprost inhalation solution
Designation: Treatment of pulmonary arterial hypertension

Trade Name (if present):

Ventavis

Sponsor and Address
CoTherix, Inc.
5000 Shoreline Court
South San Francisco CA 94080

Date Designated: 8/17/2004

Marketing Exclusivity Date:

12/29/2004

Generic Name: Immortalized human liver cells found in the extracorporeal liver assist device
Designation: Treatment of fulminant hepatic failure (acute liver failure)

Trade Name (if present):

ELAD

Sponsor and Address
Vital Therapies, Inc.
15222 Avenue of Science
Suite C

Date Designated: 7/16/2004

Marketing Exclusivity Date:

San Diego CA 92128

Generic Name: Immune Globulin (Human)
Designation: Treatment of chronic inflammatory demyelinating polyneuropathy

Trade Name (if present):

Gamunex

Sponsor and Address
Bayer Corporation
800 Dwight Way
Berkley CA 94701-1986

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Designation: Treatment of the West Nile virus infection

Trade Name (if present):

Orphan Products Designations and Approvals List December 2004

Omr-IgG-am (tm) 5% (WNV)

Sponsor and Address
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621

Date Designated: 3/17/2004

Marketing Exclusivity Date:

ISRAEL

Generic Name:
Immune Globulin Intravenous (human)

Designation:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Sponsor and Address
ZLB Bioplasma AG
Wankdorfstrasse 10
CH-3000 Bern 22

Date Designated: 5/4/2004

Marketing Exclusivity Date:

SWITZERLAND

Generic Name:
Immune Globulin Subcutaneous (Human)

Designation:
Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access

Trade Name (if present):
Vivaglobin P (proposed)

Sponsor and Address
Aventis Behring, L.L.C.
1020 First Avenue
P.O. Box 61501

Date Designated: 9/22/2004

Marketing Exclusivity Date:

King of Prussia PA 19406-0901

Generic Name:
Implitapide

Designation:
Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name:
Implitapide

Designation:
Treatment of patients with Fredrickson type I or V hyperlipoproteinemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/18/2004

Marketing Exclusivity Date:

Generic Name:
Interleukin-1 Trap

Designation:
Treatment of CIAS1-Associated Periodic Syndromes

Orphan Products Designations and Approvals List December 2004

Trade Name (if present):

Sponsor and Address
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591

Date Designated: 12/20/2004

Marketing Exclusivity Date:

Generic Name:
Lenalidomide

Designation:
Treatment of myelodysplastic syndromes

Trade Name (if present):
Revimid

Sponsor and Address
Celgene Corporation
86 Morris Avenue
Summit NJ 07901

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Liarozole

Designation:
The treatment of congenital ichthyosis

Trade Name (if present):

Sponsor and Address
Barrier Therapeutics, Inc
600 College Road East
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:
L-tyrosine-L-serine-L-leucine

Designation:
Treatment of hepatocellular carcinoma.

Trade Name (if present):
CMS-024

Sponsor and Address
PephaRM R&D Limited
Room 1404, 14th Floor
#39 Healthy Street East
North Point
HONG KONG

Date Designated: 9/10/2004

Marketing Exclusivity Date:

Generic Name:
mannopentaose phosphate sulfate

Designation:
Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Progen Industries Limited
P. O. Box 28
Richlands 4077

Date Designated: 4/27/2004

Marketing Exclusivity Date:

AUSTRALIA

Generic Name:
meclorothamine or nitrogen mustard

Designation:
Treatment of mycosis fungoides.

Orphan Products Designations and Approvals List December 2004

Trade Name (if present):

Sponsor and Address
Yaupon Therapeutics, Inc.
259 Radnor Chester Road
Radnor PA 19087

Date Designated: 8/12/2004

Marketing Exclusivity Date:

Generic Name:
Melatonin

Designation:
Treatment of non-24-hour sleep-wake disorder in blind individuals
without light perception

Trade Name (if present):
Circadin

Sponsor and Address
Neurim Pharmaceuticals, Ltd.
8 Hanechoshet St.
Tel-Aviv

Date Designated: 7/9/2004

Marketing Exclusivity Date:

ISRAEL

Generic Name:
mepolizumab
syndrome

Designation:
For first-line treatment in patients with hypereosinophilic

Trade Name (if present):

Sponsor and Address
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Generic Name:
Multi-ligand somatostatin analogue

Designation:
Treatment of patients with functional gastroenteropancreatic (GEP)
neuroendocrine tumors (specifically, carcinoid, insulinoma,
gastrinoma, somatostatinoma, GRFoma, VIPoma and glucagonoma.

Trade Name (if present):

Sponsor and Address
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name:
multi-vitamin infusion without vitamin K
complications

Designation:
Prevention of vitamin deficiency and thromboembolic

in people receiving home parenteral nutrition and warfarin-type

Trade Name (if present):
M.V.I.-12

Sponsor and Address
Mayne Pharma (USA) Inc.
Mack-Cali Centre II
Second Floor

Date Designated: 3/8/2004

Marketing Exclusivity Date:

9/9/2004 Paramus NJ 07652

Orphan Products Designations and Approvals List December 2004

Generic Name: N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide
Designation: Treatment of neuroblastoma

Trade Name (if present):
Sponsor and Address
Abbott Laboratories
Pharmaceuticals Products Division
D-491, AP30-1E
Date Designated: 9/30/2004
Marketing Exclusivity Date: Abbott Park IL 60064-6157

Generic Name: N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
Designation: Treatment of stages IIB-IV melanoma

Trade Name (if present):
Sponsor and Address
3M Pharmaceuticals
3M Center
Building 270-3A-08
Date Designated: 8/13/2004
Marketing Exclusivity Date: St. Paul MN 55144-1000

Generic Name: nelarabine
Designation: Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma

Trade Name (if present):
Sponsor and Address
GlaxoSmithKline
One Franklin Plaza
Phildelphia PA 19101
Date Designated: 8/10/2004
Marketing Exclusivity Date:

Generic Name: Nimotuzumab
Designation: Treatment of glioma

Trade Name (if present):
Sponsor and Address
YM Biosciences Inc.
5045 Orbitor Drive
Mississauga, Ontario L4W 4Y4
Date Designated: 11/17/2004
Marketing Exclusivity Date:

CANADA

Generic Name: Nitric oxide
Designation: To reduce the risk of chronic lung disease in premature neonates

Trade Name (if present): INOmax
Sponsor and Address
INO Therapeutics
6 Route 173
Clinton NJ 08809
Date Designated: 9/27/2004
Marketing Exclusivity Date:

Orphan Products Designations and Approvals List December 2004

Generic Name: Nucleic acid aptamer binding to tumor cell nucleolin
Designation: Treatment of pancreatic cancer

Trade Name (if present):

Sponsor and Address
Aptamera, Inc.
640 S. Fourth Street
Louisville KY 40202

Date Designated: 8/11/2004

Marketing Exclusivity Date:

Generic Name: oral unfractionated heparin
Designation: Treatment of sickle cell disease

Trade Name (if present):

Sponsor and Address
TRF Technologies, Inc.
108 Eagle Trace Drive
Half Moon Bay CA 94019

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name: Paclitaxel (TOCOSOL)
Designation: Treatment of urothelial cancer

Trade Name (if present):

Sponsor and Address
Sonus Pharmaceuticals, Inc.
22026 20th Avenue SE
Bothell WA 98021

Date Designated: 12/22/2004

Marketing Exclusivity Date:

Generic Name: pentetate trisodium
Designation: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.

Trade Name (if present): diethylenetriaminepentaacetate

Sponsor and Address
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co.
Goerzallee 253
Federal of Republic of Germany

Date Designated: 4/12/2004

Marketing Exclusivity Date:

GERMANY

Generic Name: Plitidepsin
Designation: Treatment of multiple myeloma

Trade Name (if present): Aplidin

Sponsor and Address
PharmaMar USA, Inc.
320 Putnam Avenue
Cambridge MA 02139-4616

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List December 2004

Generic Name: Porfimer sodium
Designation: Treatment of cholangiocarcinoma

Trade Name (if present): Photofrin
Sponsor and Address: Axcan Scandipharm Inc.
22 Inverness Parkway
Birmingham AL 35242

Date Designated: 11/18/2004
Marketing Exclusivity Date:

Generic Name: posaconazole
Designation: Treatment of zygomycosis

Trade Name (if present): Posoril
Sponsor and Address: Schering Corporation
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name: Potassium Iodide Oral Solution
Designation: For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine

Trade Name (if present): Famli-GUARD
Sponsor and Address: Fleming & Company, Pharmaceuticals
1733 Gilsinn Lane
Fenton MO 63026

Date Designated: 11/17/2004
Marketing Exclusivity Date:

Generic Name: PR1 Vaccine
Designation: Treatment of myelodysplastic syndromes (MDS) requiring therapy.

Trade Name (if present):
Sponsor and Address: The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name: PR1 Vaccine
Designation: Treatment of acute myelogenous leukemia

Trade Name (if present):
Sponsor and Address: The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Orphan Products Designations and Approvals List December 2004

Generic Name: PRI Vaccine
Designation: Treatment of chronic myelogenous leukemia.

Trade Name (if present):
Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name: Quinine Sulfate
Designation: Treatment of malaria

Trade Name (if present):
Sponsor and Address
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

Date Designated: 6/3/2004
Marketing Exclusivity Date:

Generic Name: recombinant human fibroblast growth factor-20
Designation: Treatment of radiation induced oral mucositis

Trade Name (if present):
Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Generic Name: Recombinant Porcine Factor VIII, B-domain Deleted
Designation: Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII

Trade Name (if present):
Sponsor and Address
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

Date Designated: 3/16/2004
Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name: rh-microplasmin
Designation: Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):
Sponsor and Address
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park

Date Designated: 3/16/2004
Marketing Exclusivity Date:

Dublin 12
IRELAND

Orphan Products Designations and Approvals List December 2004

Generic Name: SGN-40 (anti-CD40 antibody)
Designation: Treatment of multiple myeloma.

Trade Name (if present):
Sponsor and Address
Seattle Genetics, Inc.
21823 30th Drive Southeast
Bothell WA 98021

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name: Sitaxsentan Sodium
Designation: For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure

Trade Name (if present):
Sponsor and Address
Encysive, L.P.
6700 West Loop South
Suite 400

Date Designated: 11/2/2004

Marketing Exclusivity Date:

Generic Name: Sodium thiosulfate
Designation: Prevention of platinum-induced ototoxicity in pediatric patients

Trade Name (if present):
Sponsor and Address
Adherex Technologies, Inc.
600 Peter Morand Crescent
Ottawa, Ontario

Date Designated: 3/17/2004

Marketing Exclusivity Date:

CANADA

Generic Name: Somatropin
Designation: Treatment of patients with HIV-associated adipose redistribution syndrome

Trade Name (if present): Serostim
Sponsor and Address
Serono, Inc.
One Technology Place
Rockland MA 02370

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name: Sorafenib
Designation: Treatment of renal cell carcinoma.

Trade Name (if present):
Sponsor and Address
Bayer Pharmaceutical Corporation
400 Morgan Lane
West Haven CT 06516

Date Designated: 10/8/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List December 2004

<p>Generic Name: Staphylococcus aureus Immune Globulin (Human)</p> <p>Trade Name (if present): Altastaph</p> <p>Date Designated: 1/29/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Prophylaxis against Staphylococcus aureus infections in low birth weight neonates</p> <p>Sponsor and Address Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville MD 20852</p>
---	--

<p>Generic Name: Suberoylanilide hydroxamic acid</p> <p>Trade Name (if present):</p> <p>Date Designated: 3/16/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of T-cell non-Hodgkin's lymphoma</p> <p>Sponsor and Address Merck & Co., Inc. P. O. Box 2000, RY 32-605 Rahway NJ 07065-0900</p>
---	--

<p>Generic Name: Suberoylanilide hydroxamic acid</p> <p>Trade Name (if present):</p> <p>Date Designated: 3/17/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of mesothelioma</p> <p>Sponsor and Address Merck & Co., Inc. P. O. Box 2000, RY 32-605 Rahway NJ 07065-0900</p>
---	---

<p>Generic Name: temocillin sodium</p> <p>Trade Name (if present): Negaban</p> <p>Date Designated: 4/21/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of pulmonary infections caused by Burkholderia cepacia</p> <p>Sponsor and Address Belpharma N.V. 67 Winston Churchill Avenue Brussels</p>
---	---

<p>Generic Name: Temozolomide</p> <p>Trade Name (if present): Temodal</p> <p>Date Designated: 10/18/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of newly diagnosed high grade glioma</p> <p>Sponsor and Address Schering-Plough Research Institute 2000 Galloping Hill Road Kenilworth NJ 07033</p>
---	---

Orphan Products Designations and Approvals List December 2004

<p>Generic Name: Tipifarnib</p> <p>Trade Name (if present): Zarnestra</p> <p>Date Designated: 7/6/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of acute myeloid leukemia</p> <p>Sponsor and Address Johnson & Johnson Pharmaceutical Research & Dev. 920 U.S. Highway 202 Raritan NJ 08869</p>
---	---

<p>Generic Name: trabectedin</p> <p>Trade Name (if present): Yondelis</p> <p>Date Designated: 9/30/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of soft tissue sarcoma.</p> <p>Sponsor and Address Johnson & Johnson Pharmaceutical Research & Dev. 920 US Highway 202 Raritan NJ 08869</p>
--	---

<p>Generic Name: Trisodium zinc Diethylenetriaminepentaacetate</p> <p>Trade Name (if present):</p> <p>Date Designated: 2/27/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.</p> <p>Sponsor and Address CustomCare Pharmacy 5710 Hoover Blvd Tampa FL 33634</p>
---	---

<p>Generic Name: Ubiquinol</p> <p>Trade Name (if present): Ubi-Q-Nol, Li-Q-Nol</p> <p>Date Designated: 4/12/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of Huntington's Disease</p> <p>Sponsor and Address Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590</p>
---	---

<p>Generic Name: Ubiquinol, coenzyme Q10, ubiquinone</p> <p>Trade Name (if present): UBI-Q-NOL</p> <p>Date Designated: 4/12/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Designation: Treatment of pediatric congestive heart failure</p> <p>Sponsor and Address Gel-Tec, Division of TISHCON Corporation 30 New York Avenue P.O. Box 331 Westbury NY 11590</p>
---	---

Orphan Products Designations and Approvals List December 2004

Generic Name: Vaccinia Immune Globulin (Human) Intravenous
Designation: Treatment of complications of vaccinia vaccination

Trade Name (if present):
CNJ-016

Sponsor and Address
Cangene Corporation
104 Chancellor Matheson Road
Winnipeg, Manitoba R3T 5Y3

Date Designated: 6/18/2004
Marketing Exclusivity Date:

CANADA

Generic Name: Vaccinia Immune Globulin (Human) Intravenous
Designation: Treatment of severe complications from the smallpox vaccine

Trade Name (if present):

Sponsor and Address
DynPort Vaccine Company LLC
64 Thomas Johnson Drive
Frederick MD 21702

Date Designated: 6/18/2004
Marketing Exclusivity Date:

Generic Name: Vapreotide
Designation: Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor and Address
H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

Date Designated: 4/6/2004
Marketing Exclusivity Date:

CANADA



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2004 ADDITIONS



PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021652 001	ABACAVIR SULFATE;EPZICOM	5034394	DEC 18, 2011	DS DP		
		5089500	JUN 26, 2009	U257		
		6294540	MAY 14, 2018	DS DP U257		
		5047407	NOV 17, 2009	DS DP U257		
		5905082	MAY 18, 2016	DS DP		
		6417191	MAR 28, 2016	DP U257		
		6180639	JAN 30, 2018	DP U257		
020977 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
020978 001	ABACAVIR SULFATE;ZIAGEN				D-40	AUG 02, 2007
021320 001	ABARELIX;PLENAXIS	5968895	DEC 11, 2016	DP		
		6180608	DEC 11, 2016	DP U549		
		6423686	JUN 07, 2015	DS		
		6455499	JUN 07, 2015	U549		
		5843901	DEC 01, 2015	DS DP		
		6699833	DEC 11, 2016	DP		
021431 001	ACAMPROSATE CALCIUM;CAMPRAL				NCE	JUL 29, 2009
021539 001	ACETYLCYSTEINE;ACETADOTE				ODE	JAN 23, 2011
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	DS DP U470		
		5663159	SEP 02, 2014	DS DP U470		
		6635278	DEC 15, 2018	DS DP		
020899 001	ALBUMIN HUMAN;OPTISON	6723303	APR 20, 2021	DP		
020949 001	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
020949 002	ALBUTEROL SULFATE;ACCUNEB	6702997	DEC 28, 2021	U558		
021457 001	ALBUTEROL SULFATE;ALBUTEROL SULFATE HF				NP	OCT 29, 2007
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6131566	APR 14, 2015	DP U589		
		6532955	APR 14, 2015	DP U590		
020560 005	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
021575 001	ALENDRONATE SODIUM;FOSAMAX				D-87	APR 16, 2007
020886 001	ALITRETINOIN;PANRETIN	5932622	AUG 03, 2016	U562		
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	6710066	JUL 28, 2009	U289		
021727 001	AMLEXANOX;AMLEXANOX				NDF	SEP 29, 2007
021540 001	AMLODIPINE BESYLATE;CADUET	5273995	DEC 28, 2010	DS DP U162	NC	JAN 30, 2007
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		6126971*PED	JUL 19, 2013			
		4681893	SEP 24, 2009	DS DP U161		
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
021540 002	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
021540 003	AMLODIPINE BESYLATE; CADUET	6455574	AUG 11, 2018	U552			
		5969156	JUL 08, 2016	DS			
		5969156*PED	JAN 08, 2017				
		5686104	NOV 11, 2014	DP	U213		
		5686104*PED	MAY 11, 2015				
		6126971	JAN 19, 2013	DP			
		6126971*PED	JUL 19, 2013				
		4681893	SEP 24, 2009	DS	DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010				
		4879303	MAR 25, 2007	DS	DP		
		4879303*PED	SEP 25, 2007				
		4572909	JUL 31, 2006	DS	DP U3		
		4572909*PED	JAN 31, 2007				
		5273995	DEC 28, 2010	DS	DP U162		
		5273995*PED	JUN 28, 2011				
6455574	AUG 11, 2018	U552					
5969156	JUL 08, 2016	DS					
5969156*PED	JAN 08, 2017						
5686104	NOV 11, 2014	DP	U213				
5686104*PED	MAY 11, 2015						
6126971	JAN 19, 2013	DP					
6126971*PED	JUL 19, 2013						
4681893	SEP 24, 2009	DS	DP U161	NC	JAN 30, 2007		
4681893*PED	MAR 24, 2010						
4879303	MAR 25, 2007	DS	DP				
4879303*PED	SEP 25, 2007						
4572909	JUL 31, 2006	DS	DP U3				
4572909*PED	JAN 31, 2007						
5273995	DEC 28, 2010	DS	DP U162				
5273995*PED	JUN 28, 2011						
6455574	AUG 11, 2018	U552					
5969156	JUL 08, 2016	DS					
5969156*PED	JAN 08, 2017						
5686104	NOV 11, 2014	DP	U213				
5686104*PED	MAY 11, 2015						
6126971	JAN 19, 2013	DP					
6126971*PED	JUL 19, 2013						
4681893	SEP 24, 2009	DS	DP U161	NC	JAN 30, 2007		
4681893*PED	MAR 24, 2010						
4879303	MAR 25, 2007	DS	DP				
4879303*PED	SEP 25, 2007						
4572909	JUL 31, 2006	DS	DP U3				
4572909*PED	JAN 31, 2007						
5273995	DEC 28, 2010	DS	DP U162				
5273995*PED	JUN 28, 2011						
6455574	AUG 11, 2018	U552					
5969156	JUL 08, 2016	DS					
5969156*PED	JAN 08, 2017						
5686104	NOV 11, 2014	DP	U213				
5686104*PED	MAY 11, 2015						
6126971	JAN 19, 2013	DP					
6126971*PED	JUL 19, 2013						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021540 006	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		021540 007	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	
4681893*PED	MAR 24, 2010					
4879303	MAR 25, 2007			DS DP		
4879303*PED	SEP 25, 2007					
4572909	JUL 31, 2006			DS DP U3		
4572909*PED	JAN 31, 2007					
5273995	DEC 28, 2010			DS DP U162		
5273995*PED	JUN 28, 2011					
6455574	AUG 11, 2018			U552		
5969156	JUL 08, 2016			DS		
5969156*PED	JAN 08, 2017					
5686104	NOV 11, 2014			DP U213		
5686104*PED	MAY 11, 2015					
6126971	JAN 19, 2013			DP		
021540 008	AMLODIPINE BESYLATE;CADUET			4681893	SEP 24, 2009	DS DP U161
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011			
		6455574	AUG 11, 2018	U552		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017			
		5686104	NOV 11, 2014	DP U213		
		5686104*PED	MAY 11, 2015			
		6126971	JAN 19, 2013	DP		
		021540 009	AMLODIPINE BESYLATE;CADUET	4681893	SEP 24, 2009	DS DP U161
4681893*PED	MAR 24, 2010					
4879303	MAR 25, 2007			DS DP		
4879303*PED	SEP 25, 2007					
4572909	JUL 31, 2006			DS DP U3		
4572909*PED	JAN 31, 2007					
5273995	DEC 28, 2010			DS DP U162		
5273995*PED	JUN 28, 2011					
6455574	AUG 11, 2018			U552		
5969156	JUL 08, 2016			DS		
5969156*PED	JAN 08, 2017					

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES										
021540 010	AMLODIPINE BESYLATE; CADUET	5686104	NOV 11, 2014	DP U213												
		5686104*PED	MAY 11, 2015													
		6126971	JAN 19, 2013	DP												
		6126971*PED	JUL 19, 2013													
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007										
		4681893*PED	MAR 24, 2010													
		4879303	MAR 25, 2007	DS DP												
		4879303*PED	SEP 25, 2007													
		4572909	JUL 31, 2006	DS DP U3												
		4572909*PED	JAN 31, 2007													
		5273995	DEC 28, 2010	DS DP U162												
		5273995*PED	JUN 28, 2011													
		6455574	AUG 11, 2018	U552												
		5969156	JUL 08, 2016	DS												
		5969156*PED	JAN 08, 2017													
021540 011	AMLODIPINE BESYLATE; CADUET	5686104	NOV 11, 2014	DP U213												
		5686104*PED	MAY 11, 2015													
		6126971	JAN 19, 2013	DP												
		6126971*PED	JUL 19, 2013													
		4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007										
		4681893*PED	MAR 24, 2010													
		4879303	MAR 25, 2007	DS DP												
		4879303*PED	SEP 25, 2007													
		4572909	JUL 31, 2006	DS DP U3												
		4572909*PED	JAN 31, 2007													
		5273995	DEC 28, 2010	DS DP U162												
		5273995*PED	JUN 28, 2011													
		6455574	AUG 11, 2018	U552												
		5969156	JUL 08, 2016	DS												
		5969156*PED	JAN 08, 2017													
021303 001	AMPHETAMINE ASPARTATE; ADDERALL XR 10	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004										
		6605300*PED	APR 21, 2019		PED	APR 11, 2005										
		021303 006	AMPHETAMINE ASPARTATE; ADDERALL XR 15	6322819*PED	APR 21, 2019		NPP	AUG 11, 2007								
				6605300*PED	APR 21, 2019		NDF	OCT 11, 2004								
				021303 002	AMPHETAMINE ASPARTATE; ADDERALL XR 20	6322819*PED	APR 21, 2019		PED	APR 11, 2005						
						6605300*PED	APR 21, 2019		NPP	AUG 11, 2007						
						021303 004	AMPHETAMINE ASPARTATE; ADDERALL XR 25	6322819*PED	APR 21, 2019		NDF	OCT 11, 2004				
								6605300*PED	APR 21, 2019		PED	APR 11, 2005				
								021303 003	AMPHETAMINE ASPARTATE; ADDERALL XR 30	6322819*PED	APR 21, 2019		NPP	AUG 11, 2007		
										6605300*PED	APR 21, 2019		NDF	OCT 11, 2004		
										021303 005	AMPHETAMINE ASPARTATE; ADDERALL XR 5	6322819*PED	APR 21, 2019		PED	APR 11, 2005
												6605300*PED	APR 21, 2019		NPP	AUG 11, 2007
															NDF	OCT 11, 2004
															PED	APR 11, 2005
															NPP	AUG 11, 2007
													NDF	OCT 11, 2004		
													PED	APR 11, 2005		
			NPP									AUG 11, 2007				
			NDF									OCT 11, 2004				
			PED	APR 11, 2005												
			NPP	AUG 11, 2007												
			NDF	OCT 11, 2004												
			PED	APR 11, 2005												
			NPP	AUG 11, 2007												

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
050794 001	AZACITIDINE;VIDAZA				ODE	MAY 19, 2011
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2010	U207		
		5164194*PED	MAY 01, 2011			
020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2006			
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN				M-30	MAR 02, 2007
					PED	SEP 02, 2007
021551 001	BISACODYL;HALFLYTELY				NP	MAY 10, 2007
021602 001	BORTEZOMIB;VELCADE	6713446	JAN 25, 2022	DP		
		6747150	OCT 28, 2014	DP		
020746 001	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
020746 002	BUDESONIDE;RHINOCORT	6686346	APR 29, 2017	DP U557		
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5989588*PED	MAR 30, 2016	U349		
020712 001	CARBAMAZEPINE;CARBATROL	6221392	APR 09, 2018	DP		
020712 002	CARBAMAZEPINE;CARBATROL	6221392	APR 09, 2018	DP		
>ADD>	021710 001	CARBAMAZEPINE;EQUETRO			NP	DEC 10, 2007
>ADD>	021710 002	CARBAMAZEPINE;EQUETRO			NP	DEC 10, 2007
>ADD>	021710 003	CARBAMAZEPINE;EQUETRO			NP	DEC 10, 2007
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
		4657927*PED	OCT 14, 2004			
020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020452 004	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	DP U175		
		4657927*PED	OCT 14, 2004			
020637 001	CARMUSTINE;GLIADEL				ODE	FEB 25, 2010
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
		5378804	MAR 16, 2013	DS		
		5514650	MAR 16, 2013	DP U607		
		5792746	MAR 16, 2013	DS DP U607		
		6136783	MAR 28, 2017	U607		
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017	DP	I-438	SEP 29, 2007
		5378804	MAR 16, 2013	DS		
		5514650	MAR 16, 2013	DP U607		
		5792746	MAR 16, 2013	DS DP U607		
		6136783	MAR 28, 2017	U607		
021621 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
		4525358*PED	DEC 25, 2007			
		6455533	JUL 02, 2018	DP		
021621 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007	DS DP U565		
		4525358*PED	DEC 25, 2007			
		6455533	JUL 02, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020989 002	CEVIMELINE HYDROCHLORIDE; EVOXAC	5340821	JUL 07, 2013	U309		
021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL				NP	FEB 24, 2007
021149 002	CHORIOGONADOTROPIN ALFA; OVIDREL	5767251	JUN 16, 2015	DS		
		6706681	MAR 16, 2021	DP		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
021688 002	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016		ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
021688 003	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
		6211244	OCT 23, 2015	DS DP U560	NCE	MAR 08, 2009
		6313146	DEC 14, 2016	DS DP		
		6011068	DEC 14, 2016	DS DP		
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC	5965549	JUN 06, 2015	DP		
075593 002	CIPROFLOXACIN HYDROCHLORIDE; CIPROFLOXACIN				PC	FEB 05, 2005
019847 001	CIPROFLOXACIN; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 001	CIPROFLOXACIN; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
020780 002	CIPROFLOXACIN; CIPRO				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%				I-421	MAR 25, 2007
					PED	SEP 25, 2007
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4670444*PED	JUN 09, 2004			
		4705789*PED	MAY 10, 2005			
		4808583*PED	AUG 28, 2006			
		4957922*PED	MAR 18, 2008			
021473 002	CIPROFLOXACIN; CIPRO XR	4670444	DEC 09, 2003	DS DP U555	NS	AUG 28, 2006
		4670444*PED	JUN 09, 2004		PED	FEB 28, 2007
021644 001	CLOBETASOL PROPIONATE; CLOBEX				NDF	FEB 05, 2007
>ADD>	021673 001	CLOFARABINE; CLOLAR			NCE	DEC 28, 2009
>ADD>					ODE	DEC 28, 2011
>ADD>					PED	JUN 28, 2010
>ADD>					PED	JUN 28, 2012
>ADD>	021513 001	DARIFENACIN HYDROBROMIDE; ENABLEX			NCE	DEC 22, 2009
>ADD>	021513 002	DARIFENACIN HYDROBROMIDE; ENABLEX			NCE	DEC 22, 2009
>ADD>	021165 001	DESLOMATADINE; CLARINEX	4659716	APR 21, 2005	U427	
		4659716*PED	OCT 21, 2005		U427	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021300 001	DES Loratadine; CLARINEX	4659716 6514520	APR 21, 2005 JUN 01, 2018	DP U611 DP	NCE PED	DEC 21, 2006 JUN 21, 2007
021312 001	DES Loratadine; CLARINEX	4659716*PED 4659716*PED	OCT 21, 2005 APR 21, 2005 OCT 21, 2005	U427 U427 U572		
021038 001	DEXMEDETOMIDINE; PRECEDEX	6716867	MAR 31, 2019			
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021620 001	DEXTROMETHORPHAN HYDROBROMIDE; MUCINEX DM	6372252	APR 28, 2020	DP		
021620 002	DEXTROMETHORPHAN HYDROBROMIDE; MUCINEX DM	6372252	APR 28, 2020	DP		
>ADD>	077167 001	DIDANOSINE; DIDANOSINE			PC	JUN 13, 2005
>ADD>	077167 002	DIDANOSINE; DIDANOSINE			PC	JUN 13, 2005
>ADD>	077167 003	DIDANOSINE; DIDANOSINE			PC	JUN 13, 2005
	021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-133	APR 09, 2007
	021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	6528090 6713086 5212326	DEC 18, 2018 DEC 18, 2018 JAN 29, 2008	DP DP U579 DS DP	
	021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	6528091 6528090 6713086 5212326	DEC 18, 2018 DEC 18, 2018 DEC 18, 2018 JAN 29, 2008	U106 DP DP U579 DS DP	
	020449 001	DOCETAXEL; TAXOTERE			I-429 I-436	MAY 19, 2007 AUG 18, 2007
	020931 001	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007		
	020931 002	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007		
	020931 003	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007		
	020869 001	DORZOLAMIDE HYDROCHLORIDE; COSOPT	6316443	APR 17, 2011	DP U561	
	020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413 4619939	APR 28, 2008 OCT 28, 2003	DS DP U103 DP U104	M-38 PED APR 15, 2007 OCT 15, 2007
	020862 001	DOXERCALCIFEROL; HECTOROL				
	020862 002	DOXERCALCIFEROL; HECTOROL	5869473	AUG 02, 2008	U278	
	018651 001	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563	
	018651 002	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563	
	018651 003	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563	
	021098 001	DROSPIRENONE; YASMIN	6787531	AUG 31, 2020	DP	
	021427 001	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269 5508276	JUN 11, 2008 JUL 18, 2014	DS DP U605 DP	NCE AUG 03, 2009
	021427 002	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269 5508276	JUN 11, 2008 JUL 18, 2014	DS DP U605 DP	NCE AUG 03, 2009
	021427 004	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269 5508276	JUN 11, 2008 JUL 18, 2014	DS DP U605 DP	NCE AUG 03, 2009
	021733 001	DULOXETINE HYDROCHLORIDE; CYMBALTA				NCE AUG 03, 2009
	021733 002	DULOXETINE HYDROCHLORIDE; CYMBALTA				NDF SEP 03, 2007
						NCE AUG 03, 2009
						NDF SEP 03, 2007
						NCE AUG 03, 2009
						NDF SEP 03, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021500 001	EMTRICITABINE; EMTRIVA	6703396	MAR 09, 2021	DS DP		
021752 001	EMTRICITABINE; TRUVADA	5935946	JUL 25, 2017	U541		
		5977089	JUL 25, 2017	DS DP U541		
		5922695	JUL 25, 2017	DS U541		
		6043230	JUL 25, 2017	DP U541		
		5814639	SEP 29, 2015	DS DP		
		5914331	SEP 29, 2015	DS DP		
		6642245	NOV 04, 2020	U541		
		6703396	MAR 09, 2021	DS DP		
		5210085	MAY 11, 2010	U541		
021486 001	EPINEPHRINE; LIDOCAINE HCL AND EP				NP	OCT 26, 2007
021504 001	EPINEPHRINE; LIDOSITE TOPICAL SYS	5246418	SEP 30, 2013	DS DP	NP	MAY 04, 2007
		5873850	SEP 30, 2013	DS DP		
		6377847	SEP 30, 2013	DS DP		
		6385488	SEP 30, 2013	DS DP		
		6629968	JUN 30, 2020	DS DP		
		6635045	JUN 29, 2021	DS DP		
>ADD>	021437 001	EPLERENONE; INSPRA	6558707	DEC 08, 2019	DP U537	
			6747020	NOV 05, 2019	U587	
>ADD>	021437 002	EPLERENONE; INSPRA	6558707	DEC 08, 2019	DP U537	
			6747020	NOV 05, 2019	U587	
>ADD>	021437 003	EPLERENONE; INSPRA	6558707	DEC 08, 2019	DP U537	
			6747020	NOV 05, 2019	U587	
021743 001	ERLOTINIB HYDROCHLORIDE; TARCEVA				NCE	NOV 18, 2009
021743 002	ERLOTINIB HYDROCHLORIDE; TARCEVA				NCE	NOV 18, 2009
021743 003	ERLOTINIB HYDROCHLORIDE; TARCEVA				NCE	NOV 18, 2009
021633 001	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007
021633 002	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007
021633 003	ESTRADIOL ACETATE; FEMTRACE				NDF	AUG 20, 2007
021371 001	ESTRADIOL HEMIHYDRATE; ESTRASORB	5629021	JAN 31, 2015	DP	NDF	OCT 09, 2006
021166 001	ESTRADIOL; ESTROGEL				NDF	FEB 09, 2007
021674 001	ESTRADIOL; MENOSTAR	5891868	NOV 21, 2017	DP U594	NP	JUN 08, 2007
		6692763	NOV 21, 2017	DP U594		
		5223261	JUN 29, 2010	DP U594		
		6747019	MAR 20, 2020	U311		
021040 001	ESTRADIOL; PREFEST					
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				D-85	FEB 05, 2007
020992 006	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN				NS	FEB 05, 2007
					D-85	FEB 05, 2007
021443 003	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
021443 004	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
>ADD>	021609 001	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA			NP	DEC 20, 2007
>ADD>	021609 002	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA			NP	DEC 20, 2007
>ADD>	021476 001	ESZOPICLONE; LUNESTA			NCE	DEC 15, 2009
>ADD>	021476 002	ESZOPICLONE; LUNESTA			NCE	DEC 15, 2009
>ADD>	021476 003	ESZOPICLONE; LUNESTA			NCE	DEC 15, 2009
021490 001	ETHINYL ESTRADIOL; OVCON-35	6667050	JUN 12, 2021	DP U1		
021687 001	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 002	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DP U593		
		RE37721	JUN 16, 2015	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021687 003	EZETIMIBE; VYTORIN	4444784 5846966	DEC 23, 2005 SEP 21, 2013	DS DP U592 DP U593	NCE	OCT 25, 2007
021687 004	EZETIMIBE; VYTORIN	RE37721 4444784 5846966	JUN 16, 2015 DEC 23, 2005 SEP 21, 2013	DS DP DS DP U592 DP U593	NCE	OCT 25, 2007
020363 001	FAMCICLOVIR; FAMVIR	RE37721 5840763 5866581	JUN 16, 2015 SEP 01, 2015 OCT 04, 2014	DS DP U96 U96		
020363 002	FAMCICLOVIR; FAMVIR	5916893 6124304 5840763	SEP 01, 2015 OCT 04, 2014 SEP 01, 2015	U96 U96 U96		
020363 003	FAMCICLOVIR; FAMVIR	5866581 5916893 6124304	OCT 04, 2014 SEP 01, 2015 OCT 04, 2014	U96 U96 U96		
075896 001	FELODIPINE; FELODIPINE	5840763 5866581 5916893 6124304	SEP 01, 2015 OCT 04, 2014 SEP 01, 2015 OCT 04, 2014	U96 U96 U96 U96	PC	APR 27, 2005
075896 002	FELODIPINE; FELODIPINE				PC	APR 27, 2005
075896 003	FELODIPINE; FELODIPINE				PC	APR 27, 2005
>ADD>	021695 001	FENOFIBRATE; ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP	
>ADD>	021695 002	FENOFIBRATE; ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP	
>ADD>	021695 003	FENOFIBRATE; ANTARA (MICRONIZED)	4800079	AUG 10, 2007	DP	
>ADD>	021656 001	FENOFIBRATE; TRICOR	6277405	JAN 09, 2018	DS	
>ADD>			6652881	JAN 09, 2018	DS	
>ADD>			5145684	JAN 25, 2011	DP U615	
>ADD>			6375986	SEP 21, 2020	DP U615	
>ADD>	021656 002	FENOFIBRATE; TRICOR	6277405	JAN 09, 2018	DS	
>ADD>			6652881	JAN 09, 2018	DS	
>ADD>			5145684	JAN 25, 2011	DP U615	
>ADD>			6375986	SEP 21, 2020	DP U615	
019922 001	FENOLDOPAM MESYLATE; CORLOPAM				I-422	APR 01, 2007
021704 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA D 24 HOUR	6399632 6613357 5578610 6004582 6187791 6037353 6037353*PED 6187791*PED 6399632*PED 5578610*PED	MAY 11, 2012 DEC 25, 2020 NOV 26, 2013 MAY 29, 2018 MAY 11, 2012 MAR 17, 2017 SEP 14, 2017 NOV 11, 2012 NOV 11, 2012 MAY 26, 2014	U612 DP U612 DS DP U612 DP U612 U612		
020180 001	FINASTERIDE; PROSCAR	4760071 5886184 6046183	JUN 19, 2006 NOV 19, 2012 MAR 20, 2011	DS DP U262 DS DP U577		
019949 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
019949 002	FLUCONAZOLE; DIFLUCAN	4404216*PED	JUL 29, 2004			
019949 003	FLUCONAZOLE; DIFLUCAN	4404216 4404216*PED	JAN 29, 2004 JUL 29, 2004			
		4404216*PED	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019949 004	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020985 001	FLUOROURACIL; CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE; PROZAC WEEKLY	5910319	MAY 29, 2017	U396		
		5985322	MAY 29, 2017	U397		
021077 001	FLUTICASONE PROPIONATE; ADVAIR DISKUS 100/50				M-33	APR 21, 2007
021433 001	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 002	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 003	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021211 001	FOLLITROPIN ALFA/BETA; FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U568		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
021211 002	FOLLITROPIN ALFA/BETA; FOLLISTIM AQ	5929028	JAN 14, 2018	DP U567		
		4589402	JUL 26, 2004	U568		
		5767251	JUN 16, 2015	DS		
		4589402	JUL 26, 2004	U569		
		4589402	JUL 26, 2004	U570		
020378 001	FOLLITROPIN ALFA/BETA; GONAL-F	5767251	JUN 16, 2015	DS		
020378 002	FOLLITROPIN ALFA/BETA; GONAL-F	5767251	JUN 16, 2015	DS		
020378 003	FOLLITROPIN ALFA/BETA; GONAL-F	5767251	JUN 16, 2015	DS		
020378 004	FOLLITROPIN ALFA/BETA; GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
		5767251	JUN 16, 2015	DS		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020378 005	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	ODE	MAY 24, 2007
021765 001	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
021765 002	FOLLITROPIN ALFA/BETA;GONAL-F	5767067	JUN 16, 2015	DS	NP	MAR 25, 2007
021765 003	FOLLITROPIN ALFA/BETA;GONAL-F	5767251	JUN 16, 2015	DS	NP	MAR 25, 2007
021684 001	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
021684 002	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767251	JUN 16, 2015	DS		
021684 003	FOLLITROPIN ALFA/BETA;GONAL-F RFF PEN	5767067	JUN 16, 2015	DS		
021345 001	FONDAPARINUX SODIUM;ARIXTRA	5767251	JUN 16, 2015	DS	I-426	MAY 31, 2007
021345 002	FONDAPARINUX SODIUM;ARIXTRA				I-427	MAY 31, 2007
					I-426	MAY 31, 2007
					NCE	DEC 07, 2006
					I-397	JUN 17, 2006
					NS	MAY 31, 2007
021345 003	FONDAPARINUX SODIUM;ARIXTRA				I-427	MAY 31, 2007
					I-426	MAY 31, 2007
					NCE	DEC 07, 2006
					I-397	JUN 17, 2006
					NS	MAY 31, 2007
021345 004	FONDAPARINUX SODIUM;ARIXTRA				I-427	MAY 31, 2007
					I-426	MAY 31, 2007
					NCE	DEC 07, 2006
					I-397	JUN 17, 2006
					NS	MAY 31, 2007
					I-427	MAY 31, 2007
076608 001	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM AN				PC	JAN 01, 2005
076608 002	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM AN				PC	JAN 01, 2005
021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2005			
		6774122	JAN 09, 2021	U596		
075350 001	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
075350 002	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
075350 003	GABAPENTIN;GABAPENTIN				PC	APR 06, 2005
075694 001	GABAPENTIN;GABAPENTIN				PC	JUN 11, 2005
075694 002	GABAPENTIN;GABAPENTIN				PC	JUN 11, 2005
076017 001	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
076017 002	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
076017 003	GABAPENTIN;GABAPENTIN				PC	FEB 14, 2005
021357 001	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
021357 002	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
021357 003	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
021357 004	GADOBENATE DIMEGLUMINE;MULTIHANCE				NCE	NOV 23, 2009
021358 001	GADOBENATE DIMEGLUMINE;MULTIHANCE MULTIPACK				NCE	NOV 23, 2009
021358 002	GADOBENATE DIMEGLUMINE;MULTIHANCE MULTIPACK				NCE	NOV 23, 2009
021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	DEC 14, 2008	U322		
>ADD< 021615 001	GALANTAMINE HYDROBROMIDE;REMINYL				NCE	FEB 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021615 002	GALANTAMINE HYDROBROMIDE; REMINYL			NCE	FEB 28, 2006
>ADD>	021615 003	GALANTAMINE HYDROBROMIDE; REMINYL			NCE	FEB 28, 2006
	021061 001	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021061 002	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021062 001	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021062 002	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021062 003	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021062 004	GATIFLOXACIN; TEQUIN			I-432	JUN 30, 2007
	021678 001	GATIFLOXACIN; TEQUIN	4980470	DEC 25, 2007	DS	NCE
			5880283	DEC 05, 2015	DS	I-329
			6589955	MAY 09, 2022	DS	U603
	021493 001	GATIFLOXACIN; ZYMAR	4980470	DEC 25, 2007		
			6333045	AUG 20, 2019	DP	
	020509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010	DS	I-428
	020509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010	DS	I-428
	021158 001	GEMIFLOXACIN MESYLATE; FACTIVE	6723734	MAR 20, 2018	DS DP	
			6803376	SEP 21, 2019	DS DP	U608
			6803376	SEP 21, 2019		U609
	021667 001	GLUTAMINE; NUTRESTORE				NCE
						ODE
	021178 001	GLYBURIDE; GLUCOVANCE				M-37
						PED
	021178 002	GLYBURIDE; GLUCOVANCE				M-37
						PED
	021178 003	GLYBURIDE; GLUCOVANCE				M-37
						PED
	076345 001	GLYBURIDE; GLYBURIDE AND METFOR				PC
	076345 002	GLYBURIDE; GLYBURIDE AND METFOR				PC
	076345 003	GLYBURIDE; GLYBURIDE AND METFOR				PC
>ADD>	020239 004	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007		U89
>ADD>			6294548	MAY 04, 2019		
>ADD>			5952340	SEP 14, 2016		U519
	021585 001	GUAIFENESIN; MUCINEX D	6372252	APR 28, 2020	DP	
	021585 002	GUAIFENESIN; MUCINEX D	6372252	APR 28, 2020	DP	
	021732 001	HISTRELIN ACETATE; VANTAS	5292515	MAR 08, 2011	DP	NDF
			5266325	NOV 30, 2010	DP	
	021665 001	HYALURONIDASE; AMPHADASE				NCE
	021640 001	HYALURONIDASE; VITRASE				NCE
	020758 001	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011		
			5994348	JUN 07, 2015		
			5270317*PED	MAR 30, 2012		
			5994348*PED	DEC 07, 2015		
	020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011		
			5994348	JUN 07, 2015		
			5270317*PED	MAR 30, 2012		
			5994348*PED	DEC 07, 2015		
	020758 003	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011		
			5994348	JUN 07, 2015		
			5270317*PED	MAR 30, 2012		
			5994348*PED	DEC 07, 2015		
	021532 002	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 25, 2016	DS DP	U500
	021532 003	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 25, 2016	DS DP	U500

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
021532 005	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 25, 2016	DS DP U500			
076374 001	HYDROCHLOROTHIAZIDE; QUINARETIC				PC	NOV 08, 2004	
076374 002	HYDROCHLOROTHIAZIDE; QUINARETIC				PC	NOV 08, 2004	
076374 003	HYDROCHLOROTHIAZIDE; QUINARETIC				PC	NOV 08, 2004	
076604 001	HYDROCODONE BITARTRATE; HYDROCODONE BITARTRA				PC	OCT 11, 2004	
076642 002	HYDROCODONE BITARTRATE; HYDROCODONE BITARTRA				PC	DEC 05, 2004	
>ADD>	021044 001	HYDROMORPHONE HYDROCHLORIDE; PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 002	HYDROMORPHONE HYDROCHLORIDE; PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 003	HYDROMORPHONE HYDROCHLORIDE; PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021044 004	HYDROMORPHONE HYDROCHLORIDE; PALLADONE	5968551	DEC 24, 2011	DP	NDF	SEP 24, 2007
>ADD>			5958452	NOV 04, 2014	DP		
>ADD>			6743442	NOV 04, 2014	DP		
>ADD>			6294195	DEC 24, 2011	DP		
>ADD>			6335033	NOV 04, 2014	DP U616		
>ADD>			6706281	NOV 04, 2014	DP U616		
>ADD>			5965161	NOV 04, 2014	DP U616		
>ADD>	021604 001	IBUPROFEN; CHILDREN'S ELIXSURE				NP	JAN 07, 2007
>ADD>	021378 001	IBUPROFEN; COMBUNOX	4569937	FEB 11, 2005	DP U55	NC	NOV 26, 2007
>ADD>	076478 001	IBUPROFEN; IBUPROFEN AND PSEUDO				PC	JUL 29, 2004
>ADD>	021321 001	ICODextrin; EXTRANEAL				I-445	DEC 17, 2007
>ADD>						NCE	DEC 20, 2007
>ADD>	021779 001	ILOprost; VENTAVIS				NCE	DEC 29, 2009
>ADD>						ODE	DEC 29, 2011
>ADD>	020723 001	IMIQUIMOD; ALDARA				I-420	MAR 02, 2007
>ADD>						I-433	JUL 14, 2007
>ADD>	020685 001	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554		
>ADD>	020685 003	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554		
>ADD>	020685 005	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554		
>ADD>	020685 006	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554		
>ADD>	021629 001	INSULIN GLULISINE RECOMBINANT; APIDRA	6221633	JUN 18, 2018	DS DP U471	NCE	APR 16, 2009
>ADD>	020563 001	INSULIN LISPRO RECOMBINANT; HUMALOG				D-86	JUN 02, 2007
>ADD>	020563 002	INSULIN LISPRO RECOMBINANT; HUMALOG PEN				D-86	JUN 02, 2007
>ADD>	021425 003	IOPROMIDE; ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	DS DP U113		
>ADD>	021527 001	IPRATROPIUM BROMIDE; ATROVENT HFA	5676930	OCT 14, 2014	DP	NP	NOV 17, 2007
>ADD>			5683677	NOV 04, 2014	DP		
>ADD>			5695743	JUL 06, 2010	DP U610		
>ADD>			5766573	NOV 28, 2009	U610		
>ADD>			6739333	MAY 26, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020757 001	IRBESARTAN; AVAPRO	5270317 6342247	SEP 30, 2011 JUN 07, 2015		I-373 PED	SEP 17, 2005 MAR 17, 2006
020757 002	IRBESARTAN; AVAPRO	5270317*PED 6342247*PED	MAR 30, 2012 DEC 07, 2015		I-373 PED	SEP 17, 2005 MAR 17, 2006
020757 003	IRBESARTAN; AVAPRO	5270317*PED	MAR 30, 2012		I-373 PED	SEP 17, 2005 MAR 17, 2006
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463 6403569	AUG 20, 2007 APR 28, 2020	U449	M-34 PED	JUN 24, 2007 DEC 24, 2007
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463*PED 6403569*PED	FEB 20, 2008 OCT 28, 2020			
020571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	6794370 6794370*PED	MAY 01, 2020 NOV 01, 2020	U606		
021066 001	KETOTIFEN FUMARATE; ZADITOR	6777429 6774137	JAN 13, 2019 JAN 13, 2019	DP U599		
021066 001	KETOTIFEN FUMARATE; ZADITOR	6776982	JAN 13, 2019	DP		
>ADD> 020406 001	LANSOPRAZOLE; PREVACID				NPP	JUN 17, 2007
>ADD> 020406 002	LANSOPRAZOLE; PREVACID				NPP	JUN 17, 2007
021281 001	LANSOPRAZOLE; PREVACID				M-12	AUG 30, 2005
>ADD> 021281 002	LANSOPRAZOLE; PREVACID				NPP	JUN 17, 2007
>ADD> 021281 002	LANSOPRAZOLE; PREVACID				M-12	AUG 30, 2005
>ADD> 021428 001	LANSOPRAZOLE; PREVACID				NPP	JUN 17, 2007
>ADD> 021428 001	LANSOPRAZOLE; PREVACID				M-12	AUG 30, 2005
>ADD> 021428 002	LANSOPRAZOLE; PREVACID				NPP	JUN 17, 2007
>ADD> 021428 002	LANSOPRAZOLE; PREVACID				M-12	AUG 30, 2005
021566 001	LANSOPRAZOLE; PREVACID IV				NPP	JUN 17, 2007
021468 001	LANTHANUM CARBONATE; FOSRENOL	5968976	MAR 19, 2016	DP U613	NDF	MAY 27, 2007
021468 002	LANTHANUM CARBONATE; FOSRENOL	5968976	MAR 19, 2016	DP U613	NCE	OCT 26, 2009
020905 001	LEFLUNOMIDE; ARAVA				NCE	OCT 26, 2009
020905 002	LEFLUNOMIDE; ARAVA				M-32 PED	MAR 05, 2007 SEP 05, 2007
020905 002	LEFLUNOMIDE; ARAVA				M-32 PED	MAR 05, 2007 SEP 05, 2007
020905 003	LEFLUNOMIDE; ARAVA				M-32 PED	MAR 05, 2007 SEP 05, 2007
>ADD> 021731 001	LEUPROLIDE ACETATE; ELIGARD				NP	SEP 05, 2007
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	6083993 6451289	JAN 05, 2010 MAR 21, 2021	U332 DP		DEC 14, 2007
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5362755	NOV 08, 2011	U332		
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5547994	AUG 20, 2013	U332		
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5760090	JAN 05, 2010	U332		
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5844002	JAN 05, 2010	U5		
020182 001	LEVOCARNITINE; CARNITOR	6696493	JAN 18, 2021	U433		
021571 001	LEVOFLOXACIN; IQUIX	5053407	DEC 20, 2010	DS DP U600	NP	MAR 01, 2007
021225 001	LEVONORGESTREL; MIRENA	5785053	DEC 05, 2015	DP		
021451 001	LIDOCAINE; ORAQIX	6031007	APR 01, 2017	DP U553		
021130 001	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021130 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS		
021130 002	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021130 002	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS		
021131 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS	I-431	JUN 23, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021132 001	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021226 001	LOPINAVIR; KALETRA	6559305	JAN 29, 2021	DS		
021251 001	LOPINAVIR; KALETRA	6703403	JUN 26, 2016	U257		
075505 001	LORATADINE; LORATADINE	6703403	JUN 26, 2016	U257		
020386 001	LOSARTAN POTASSIUM; COZAAR				PC	AUG 20, 2004
020386 002	LOSARTAN POTASSIUM; COZAAR				NPP	MAR 11, 2007
020386 003	LOSARTAN POTASSIUM; COZAAR				PED	SEP 11, 2007
020803 001	LOTEPREDNOL ETABONATE; ALREX	5747061	OCT 25, 2013	DP U576		
020583 001	LOTEPREDNOL ETABONATE; LOTEMAX	5747061	OCT 25, 2013	DP U575		
>ADD>	021249 001	LOVASTATIN; ADVICOR	6818229	FEB 15, 2014	DP	
			6676967	SEP 20, 2013	U548	
			6746691	SEP 20, 2013	U586	
>ADD>	021249 002	LOVASTATIN; ADVICOR	6818229	FEB 15, 2014	DP	
			6676967	SEP 20, 2013	U548	
			6746691	SEP 20, 2013	U586	
>ADD>	021249 003	LOVASTATIN; ADVICOR	6818229	FEB 15, 2004	DP	
			6676967	SEP 20, 2013	U548	
			6746691	SEP 20, 2013	U586	
021663 001	MENOTROPINS (FSH; LH); MENOPUR				NP	OCT 29, 2007
021322 001	LUTROPIN ALFA; LUVERIS	5767251	JUN 16, 2015	DS	ODE	OCT 08, 2011
		5650390	JUL 22, 2014	DP		
>ADD>	021583 001	MEDROXYPROGESTERONE ACETATE; DEPO-SUBQ PROVERA 10			NP	DEC 17, 2007
	020938 001	MELOXICAM; MOBIC			I-430	JUL 16, 2007
	020938 002	MELOXICAM; MOBIC			I-430	JUL 16, 2007
	021530 001	MELOXICAM; MOBIC	6184220	MAR 25, 2019	DP	I-430 JUL 16, 2007
					NCE	APR 13, 2005
					NS	NOV 05, 2007
					D-92	NOV 05, 2007
021252 002	MESALAMINE; CANASA					
013217 001	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189		
013217 003	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189		
>ADD>	021410 001	METFORMIN HYDROCHLORIDE; AVANDAMET	5002953	AUG 30, 2008	U493	
>ADD>			5741803	APR 21, 2015	U493	
>ADD>			6288095	FEB 11, 2017	U493	
>ADD>			5965584	JUN 19, 2016	U493	
>ADD>			6166042	JUN 19, 2016	U493	
>ADD>			5002953*PED	MAR 01, 2009		
>ADD>			5741803*PED	OCT 21, 2015		
>ADD>			5965584*PED	DEC 19, 2016		
>ADD>			6166042*PED	DEC 19, 2016		
>ADD>			6288095*PED	AUG 11, 2017		
>ADD>	021410 002	METFORMIN HYDROCHLORIDE; AVANDAMET	5002953	AUG 30, 2008	U493	
>ADD>			5741803	APR 21, 2015	U493	
>ADD>			6288095	FEB 11, 2017	U493	
>ADD>			5965584	JUN 19, 2016	U493	
>ADD>			6166042	JUN 19, 2016	U493	
>ADD>			5002953*PED	MAR 01, 2009		
>ADD>			5741803*PED	OCT 21, 2015		
>ADD>			5965584*PED	DEC 19, 2016		
>ADD>			6166042*PED	DEC 19, 2016		
>ADD>			6288095*PED	AUG 11, 2017		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493	
>ADD>			5741803	APR 21, 2015	U493	
>ADD>			6288095	FEB 11, 2017	U493	
>ADD>			5965584	JUN 19, 2016	U493	
>ADD>			6166042	JUN 19, 2016	U493	
>ADD>			5002953*PED	MAR 01, 2009		
>ADD>			5741803*PED	OCT 21, 2015		
>ADD>			5965584*PED	DEC 19, 2016		
>ADD>			6166042*PED	DEC 19, 2016		
>ADD>			6288095*PED	AUG 11, 2017		
>ADD>	021410 004	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	DS DP U493	
>ADD>			5741803	APR 21, 2015	DS DP U493	
>ADD>			5002953*PED	MAR 01, 2009		
>ADD>			5741803*PED	OCT 21, 2015		
>ADD>	021410 005	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	DS DP U493	
>ADD>			5741803	APR 21, 2015	DS DP U493	
>ADD>			5002953*PED	MAR 01, 2009		
>ADD>			5741803*PED	APR 21, 2015		
	021574 001	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP APR 27, 2007
			6495162	MAR 20, 2018	DP	
			6099859	MAR 20, 2018	DP	
	021574 002	METFORMIN HYDROCHLORIDE;FORTAMET	6790459	MAR 17, 2021	U604	NP APR 27, 2007
			6495162	MAR 20, 2018	DP	
			6099859	MAR 20, 2018	DP	
	076172 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC DEC 14, 2004
	076545 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC MAY 29, 2004
>ADD>	076863 001	METFORMIN HYDROCHLORIDE;METFORMIN HCL				PC APR 16, 2005
	021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE;METHYL AMINOLEVULINA				NE JUL 27, 2007
>ADD>	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>						D-94 OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>						D-94 OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>						D-94 OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>	021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NPP OCT 21, 2007
>ADD>						PED APR 21, 2008
>ADD>						D-94 OCT 21, 2007
>ADD>						PED APR 21, 2008
	021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP	
			6635284	DEC 04, 2015	DP U591	
	021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP	
			6635284	DEC 04, 2015	DP U591	
	021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP	
			6635284	DEC 04, 2015	DP U591	
	021284 004	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	DEC 04, 2015	DP	
			6635284	DEC 04, 2015	DP U591	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021308 001	MICONAZOLE NITRATE; MONISTAT 1 COMBINATI				RTO	JUN 29, 2004
076307 001	MIRTAZAPINE; MIRTAZAPINE				D-90	OCT 01, 2007
076307 002	MIRTAZAPINE; MIRTAZAPINE				PC	JUN 14, 2004
>ADD> 020762 001	MOMETASONE FUROATE MONOHYDRATE; NASONEX	6723713	JAN 27, 2014	U574	PC	JUN 14, 2004
		6723713*PED	JUL 27, 2014		I-443	DEC 15, 2007
021671 001	MORPHINE SULFATE; DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 002	MORPHINE SULFATE; DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021671 003	MORPHINE SULFATE; DEPODUR	5723147	MAR 03, 2015	DP U584		
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	U584		
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP U584		
		6071534	FEB 18, 2008			
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX	6716830	SEP 20, 2019	DP	NCE	DEC 10, 2004
		6716830*PED	MAR 29, 2020		PED	JUN 10, 2005
021009 001	NEDOCROMIL SODIUM; ALOCRI	RE38628	AUG 22, 2012	U304		
>ADD> 020381 001	NIACIN; NIASPAN	6818229	FEB 15, 2014	DP		
		6746691	SEP 20, 2013	U586		
>ADD> 020381 002	NIACIN; NIASPAN	6818229	FEB 15, 2014	DP		
		6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
>ADD> 020381 003	NIACIN; NIASPAN	6818229	FEB 15, 2014	DP		
		6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
>ADD> 020381 004	NIACIN; NIASPAN	6818229	FEB 15, 2014	DP		
		6676967	SEP 20, 2013	U548		
		6746691	SEP 20, 2013	U586		
020381 005	NIACIN; NIASPAN TITRATION ST	6746691	SEP 20, 2013	U586		
021497 001	NITAZOXANIDE; ALINIA				NDF	JUL 21, 2007
					NCE	NOV 22, 2007
					ODE	NOV 22, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021498 001	NITAZOXANIDE; ALINIA				NPP	JUL 21, 2007
076648 001	NITROFURANTOIN; NITROFURANTOIN (MONO				ODE	NOV 22, 2009
021494 001	NIZATIDINE; AXID				PC	SEP 19, 2004
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	NDF	MAY 25, 2007
		5229382	APR 23, 2001	U547	I-417	JAN 14, 2007
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
		5229382	APR 23, 2011	U547		
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U571	NDF	MAR 29, 2007
					NP	MAR 29, 2007
021086 001	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 002	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 003	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021086 004	OLANZAPINE; ZYPREXA ZYDIS				I-417	JAN 14, 2007
					I-400	JUL 10, 2006
021286 001	OLMESARTAN MEDOXOMIL; BENICAR	5616599	APR 25, 2016	DS DP U500		
021286 003	OLMESARTAN MEDOXOMIL; BENICAR	5616599	APR 25, 2016	DS DP U500		
021286 004	OLMESARTAN MEDOXOMIL; BENICAR	5616599	APR 25, 2016	DS DP U500		
>ADD>	021545 001				NP	DEC 22, 2007
>ADD>	021654 001	OMEGA-3-ACID ETHYL ESTERS; OMACOR	5502077	MAR 26, 2013	DS	NOV 10, 2009
>ADD>			5656667	AUG 12, 2014	DS	
>ADD>			5698594	DEC 16, 2009	DS	
	021636 001	OMEPRAZOLE; ZEGERID	5840737	JUL 16, 2016		U588
			6645988	JUL 16, 2016	DS DP	
			6489346	JUL 16, 2016	DS DP	U588
			6699885	JUL 16, 2016		U588
			6780882	JUL 16, 2016	DS DP	
	020007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006		U44
			4695578	JAN 25, 2005		
			5578628	FEB 16, 2005		U44
			4695578*PED	JUL 25, 2005		
			4753789*PED	DEC 24, 2006		
			5578628*PED	AUG 16, 2005		
	020103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006		U44
			4695578	JAN 25, 2005		
			5578628	FEB 16, 2005		U44
			5344658	SEP 06, 2011		
			4695578*PED	JUL 25, 2005		
			4753789*PED	DEC 24, 2006		
			5344658*PED	MAR 06, 2012		
			5578628*PED	AUG 16, 2005		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
020103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		5344658	SEP 06, 2011			
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5344658*PED	MAR 06, 2012			
020103 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628*PED	AUG 16, 2005			
		5344658	SEP 06, 2011			
		5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
020403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658*PED	MAR 06, 2012			
		5578628*PED	AUG 16, 2005			
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
020605 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628*PED	AUG 16, 2005			
		5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005	U183		
		5854270	NOV 20, 2015	DP U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE	5578628*PED	AUG 16, 2005			
		5854270*PED	MAY 20, 2016			
		5578628	FEB 16, 2005	U44		
		4695578	JAN 25, 2005			
		4753789	JUN 24, 2006	U44		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
020781 001	ONDANSETRON; ZOFRAN ODT	5578628*PED	AUG 16, 2005			
		5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
		4695578*PED	JUL 25, 2005			
020781 002	ONDANSETRON; ZOFRAN ODT	4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
		5955488*PED	MAY 14, 2016			
		6063802*PED	MAY 14, 2016			
		5955488	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
		4695578*PED	JUL 25, 2005			
		4753789*PED	DEC 24, 2006			
		5578628*PED	AUG 16, 2005			
		5955488*PED	MAY 14, 2016			
		6063802*PED	MAY 14, 2016			
		6063802	NOV 14, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5763483 5866601 5952375 5763483*PED 5866601*PED 5952375*PED	DEC 27, 2016 FEB 02, 2016 FEB 02, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016		NCE PED	OCT 27, 2004 APR 27, 2005
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5866601 5952375 5763483 5763483*PED 5866601*PED 5952375*PED	FEB 02, 2016 FEB 02, 2016 DEC 27, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016	U376	NCE PED	OCT 27, 2004 APR 27, 2005
021492 001	OXALIPLATIN; ELOXATIN				I-425 I-441	JAN 09, 2007 NOV 04, 2007
021492 002	OXALIPLATIN; ELOXATIN				I-425 I-441	JAN 09, 2007 NOV 04, 2007
013718 001	OXANDROLONE; OXANDRIN	5872147 6670351 6576659 6090799 6828313	DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 DEC 05, 2017	U585 U585 U585 U585 U585		
013718 002	OXANDROLONE; OXANDRIN	5872147 6670351 6576659 6090799 6828313 6743441	DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 DEC 05, 2017 APR 26, 2020	U585 U585 U585 U585 U585 DP U318		
021351 002	OXYBUTYNIN; OXYTROL					
076168 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL				PC	SEP 26, 2004
>ADD> 020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV	6780881	NOV 17, 2021	DP	I-444	DEC 06, 2007
020819 001	PARICALCITOL; ZEMPLAR				M-31 PED	MAR 31, 2007 OCT 01, 2007
020819 002	PARICALCITOL; ZEMPLAR	5246925 5246925*PED 5587497 5587497*PED 6136799 6136799*PED 6361758 6361758*PED	APR 17, 2012 OCT 17, 2012 DEC 24, 2013 JUN 24, 2014 APR 08, 2018 OCT 08, 2019 APR 08, 2018 OCT 08, 2018	U314 DP	M-31 PED	MAR 31, 2007 OCT 01, 2007
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR				D-91	JAN 27, 2007
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR				D-91	JAN 27, 2007
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR				D-91	JAN 27, 2007
>ADD> 021756 001	PEGAPTANIB SODIUM; MACUGEN				NCE	DEC 17, 2009
021462 001	PEMETREXED DISODIUM; ALIMTA	5217974 5344932 5840763 5866581 5916893 6124304	MAR 29, 2011 SEP 06, 2011 SEP 01, 2015 SEP 04, 2014 SEP 01, 2015 SEP 04, 2014	U551 DS DP U501 U501 U501 U501	NCE ODE	FEB 04, 2009 FEB 04, 2011
020629 001	PENCICLOVIR SODIUM; DENAVIR					
021749 001	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TR				NCE ODE	AUG 11, 2009 AUG 11, 2011
021751 001	PENTETATE ZINC TRISODIUM; PENTETATE ZINC TRISO				NCE ODE	AUG 11, 2009 AUG 11, 2011

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021073 001	PIOGLITAZONE HYDROCHLORIDE; ACTOS				M-35	NOV 26, 2006
021073 002	PIOGLITAZONE HYDROCHLORIDE; ACTOS				M-35	NOV 26, 2006
021073 003	PIOGLITAZONE HYDROCHLORIDE; ACTOS				M-35	NOV 26, 2006
>ADD>	021446 001	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 002	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 003	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 004	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 005	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 006	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 007	PREGABALIN; LYRICA			NCE	DEC 30, 2009
>ADD>	021446 008	PREGABALIN; LYRICA			NCE	DEC 30, 2009
020639 001	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 002	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 003	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 004	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020639 005	QUETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
					I-418	JAN 12, 2007
020815 001	RALOXIFENE HYDROCHLORIDE; EVISTA	6797719	MAR 10, 2017	DP		
021698 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150				NP	AUG 31, 2007
020741 001	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 002	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 003	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546		
020903 002	RIBAVIRIN; REBETOL	6177074	NOV 01, 2016	U454		
		6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN; RIBASPHERE				PC	OCT 03, 2004
076192 001	RIBAVIRIN; RIBAVIRIN				PC	OCT 03, 2004
021361 001	RIFAXIMIN; XIFAXAN				NCE	MAY 25, 2009
020835 003	RISEDRONATE SODIUM; ACTONEL	6465443	AUG 14, 2018	DP		
		6432932	JUL 17, 2018	U595		
020659 001	RITONAVIR; NORVIR	6703403	JUN 26, 2016	U564		
020945 001	RITONAVIR; NORVIR	6703403	JUN 26, 2016	U564		
021042 001	ROFECOXIB; VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007
		6239173*PED	DEC 24, 2013			
021042 002	ROFECOXIB; VIOXX	5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES	
021042 003	ROFECOXIB;VIOXX	6239173*PED	DEC 24, 2013				
		6239173	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004	
		5474995	JUN 24, 2013	DS DP U602	I-353	APR 11, 2005	
		5691374	MAY 18, 2015		M-27	AUG 06, 2006	
		6063811	MAY 06, 2017	U602	PED	NOV 20, 2004	
		5474995*PED	DEC 24, 2013		PED	OCT 11, 2005	
		5691374*PED	NOV 18, 2015		PED	FEB 06, 2007	
		6063811*PED	NOV 06, 2017		I-423	MAR 26, 2007	
		6239173*PED	DEC 24, 2013				
		5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004	
021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005	
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006	
		6239173	JUN 24, 2013		PED	NOV 20, 2004	
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007	
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005	
		6063811*PED	NOV 06, 2017				
		6239173*PED	DEC 24, 2013				
		5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004	
		5691374	MAY 18, 2015		I-353	APR 11, 2005	
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006	
021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013		PED	NOV 20, 2004	
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007	
		5691374*PED	NOV 18, 2015		PED	OCT 11, 2005	
		6063811*PED	NOV 06, 2017				
		6239173*PED	DEC 24, 2013				
		5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004	
		5691374	MAY 18, 2015		I-353	APR 11, 2005	
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006	
		6239173	JUN 24, 2013		PED	NOV 20, 2004	
		5474995*PED	DEC 24, 2013		PED	FEB 06, 2007	
>ADD>	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
			6288095	FEB 11, 2017	U420		
			5002953*PED	MAR 01, 2009			
			5741803*PED	OCT 21, 2015			
			6288095*PED	AUG 11, 2017			
			5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
			6288095	FEB 11, 2017	U420		
			5002953*PED	MAR 01, 2009			
>ADD>	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5741803*PED	OCT 21, 2015			
			6288095*PED	AUG 11, 2017			
			5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
			6288095	FEB 11, 2017	U420		
			5002953*PED	MAR 01, 2009			
			5741803*PED	OCT 21, 2015			
			6288095*PED	AUG 11, 2017			
			5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
>ADD>	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U420		
			5002953*PED	MAR 01, 2009			
			5741803*PED	OCT 21, 2015			
			6288095*PED	AUG 11, 2017			
			5002953	AUG 30, 2008	U329	I-384	FEB 27, 2006
			5741803	APR 21, 2015	U329	PED	AUG 27, 2006
			6288095	FEB 11, 2017	U420		
			5002953*PED	MAR 01, 2009			
			5741803*PED	OCT 21, 2015			
			6288095*PED	AUG 11, 2017			
021256 001	SECRETIN SYNTHETIC HUMAN;CHIRHOSTIM				ODE	APR 04, 2009	
					NCE	APR 09, 2009	
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	6727283	OCT 11, 2019	DP U580			
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013				
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	6509013	AUG 11, 2013				
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007				
		4929629	MAY 29, 2007				
		5436272	JUL 25, 2012	U439			
		4746680*PED	DEC 11, 2007				
		4929629*PED	NOV 29, 2007				
		5436272*PED	JAN 25, 2013				

PRESCRIPTION AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
		4929629	MAY 29, 2007			
		5436272	JUL 25, 2012	U439		
		4746680*PED	DEC 11, 2007			
		4929629*PED	NOV 29, 2007			
		5436272*PED	JAN 25, 2013			
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
		4929629	MAY 29, 2007			
		5436272	JUL 25, 2012	U439		
		4746680*PED	DEC 11, 2007			
		4929629*PED	NOV 29, 2007			
		5436272*PED	JAN 25, 2013			
017697 001	SINCALIDE;KINEVAC	6803046	AUG 16, 2022	DP		
021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292	PED	OCT 11, 2006
		5403833	APR 04, 2012	U293	PED	MAR 15, 2005
		5536729	SEP 30, 2013			
		5100899*PED	DEC 06, 2009			
		5212155*PED	NOV 18, 2010			
		5308847*PED	NOV 03, 2011			
		5403833*PED	OCT 04, 2012			
		5536729*PED	MAR 30, 2014			
021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
		5403833	APR 04, 2012	U293	PED	OCT 11, 2006
		5989591	MAR 11, 2018			
		5100899*PED	DEC 06, 2009			
		5212155*PED	NOV 18, 2010			
		5308847*PED	NOV 03, 2011			
		5403833*PED	OCT 04, 2012			
		5989591*PED	SEP 11, 2018			
021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
		5403833	APR 04, 2012	U293	PED	OCT 11, 2006
		5989591	MAR 11, 2018			
		5100899*PED	DEC 06, 2009			
		5212155*PED	NOV 18, 2010			
		5308847*PED	NOV 03, 2011			
		5403833*PED	OCT 04, 2012			
		5989591*PED	SEP 11, 2018			
021110 003	SIROLIMUS;RAPAMUNE				NCE	SEP 15, 2004
					I-386	APR 11, 2006
					PED	MAR 15, 2005
					PED	OCT 11, 2006
					NPP	AUG 13, 2007
					PED	FEB 13, 2008
020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT					
021196 001	SODIUM OXYBATE;XYREM	6780889	DEC 22, 2019	DP		
>ADD> 021518 001	SOLIFENACIN SUCCINATE;VESICARE	6017927	DEC 27, 2015	DS DP	NCE	NOV 19, 2009
>ADD> 021518 002	SOLIFENACIN SUCCINATE;VESICARE	6017927	DEC 27, 2015	DS DP	NCE	NOV 19, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	4968299	JUN 28, 2008	DP		
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN				I-439	NOV 01, 2007
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN				I-439	NOV 01, 2007
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN				I-439	NOV 01, 2007
021148 004	SOMATROPIN RECOMBINANT; NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
021148 005	SOMATROPIN RECOMBINANT; NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
021148 006	SOMATROPIN RECOMBINANT; NORDITROPIN NORDIFLE				I-439	NOV 01, 2007
020168 001	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009	DP		
020168 002	SOMATROPIN RECOMBINANT; NUTROPIN	5096885	MAR 17, 2009	DP		
020522 001	SOMATROPIN RECOMBINANT; NUTROPIN AQ	5763394	JUN 09, 2015	DP		
020522 002	SOMATROPIN RECOMBINANT; NUTROPIN AQ PEN	5763394	JUN 09, 2015	DP		
019764 001	SOMATROPIN RECOMBINANT; SAIZEN				I-440	AUG 26, 2007
019764 002	SOMATROPIN RECOMBINANT; SAIZEN				I-440	AUG 26, 2007
019764 003	SOMATROPIN RECOMBINANT; SAIZEN				I-440	AUG 26, 2007
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020626 002	SUMATRIPTAN; IMITREX	5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
		4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
020626 003	SUMATRIPTAN; IMITREX	5307953*PED	JUN 02, 2013			
		4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
021368 001	TADALAFIL; CIALIS	5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
		5859006	JAN 12, 2016	DS DP		
021368 002	TADALAFIL; CIALIS	6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
		5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
021368 003	TADALAFIL; CIALIS	6821975	NOV 19, 2020	DS DP U614		
		6821975	NOV 19, 2020	U533		
		5859006	JAN 12, 2016	DS DP		
		6140329	JUL 11, 2016	DP U155		
		6821975	NOV 19, 2020	DS DP U614		
021388 001	TALC; TALC				ODE	DEC 24, 2004
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT; CARDIOTEC	6056941	JUL 28, 2019	DP		
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEV	5045302	FEB 09, 2010			
021200 001	TEGASEROD MALEATE; ZELNORM				I-435	AUG 21, 2007
021200 002	TEGASEROD MALEATE; ZELNORM				I-435	AUG 21, 2007
021144 001	TELITHROMYCIN; KETEK	D459798	SEP 24, 2015	DP	NCE	APR 01, 2009
021029 001	TEMOZOLOMIDE; TEMODAR	5635485	APR 21, 2015	DS DP U578		
		5260291	AUG 11, 2013			
021029 002	TEMOZOLOMIDE; TEMODAR	5260291*PED	FEB 11, 2014			
		5260291	AUG 11, 2013			
021029 003	TEMOZOLOMIDE; TEMODAR	5260291*PED	FEB 11, 2014			
		5260291	AUG 11, 2013			
021029 004	TEMOZOLOMIDE; TEMODAR	5260291*PED	FEB 11, 2014			
		5260291	AUG 11, 2013			
021124 002	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	5260291*PED	FEB 11, 2014			
		5681849	OCT 28, 2014			
		4755534	DEC 30, 2006	U73		
		4680291	JUL 14, 2004	U73		
		6121314	MAY 18, 2012	U504		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020846 001	TERBINAFINE; LAMISIL	5681849	OCT 28, 2014	DP		
		6121314	MAY 18, 2012	DP U504		
		6121314	MAY 18, 2012	DP U540		
		6121314	MAY 18, 2012	DP U502		
		6005001	MAY 18, 2012	DP U540		
		6005001	MAY 18, 2012	U502		
		6005001	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	DP U502		
		5856355	MAY 18, 2012	U504		
		5856355	MAY 18, 2012	U540		
021318 001	TERIPARATIDE RECOMBINANT HUMAN; FORTEO	6770623	DEC 08, 2018	DP U597		
020785 001	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
020785 002	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
020785 003	THALIDOMIDE; THALOMID	6755784	SEP 23, 2020	U371		
020898 001	THYROTROPIN ALFA; THYROGEN	6365127	NOV 24, 2015	DS DP U556		
021618 001	TINIDAZOLE; TINDAMAX				NCE	MAY 17, 2009
					ODE	MAY 17, 2011
					ODE	MAY 17, 2011
					NCE	MAY 17, 2009
					ODE	MAY 17, 2011
					ODE	MAY 17, 2011
					ODE	MAY 17, 2011
021618 002	TINIDAZOLE; TINDAMAX				NCE	JAN 30, 2009
021682 001	TINIDAZOLE; TINDAMAX					
021682 002	TINIDAZOLE; TINDAMAX					
021395 001	TIOTROPIUM BROMIDE MONOHYDRATE; SPIRIVA	5610163	MAR 11, 2014	DS DP U566		
		6777423	SEP 24, 2021	DS DP		
020912 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5658929	SEP 27, 2010			
020913 001	TIROFIBAN HYDROCHLORIDE; AGGRASTAT	5658929	SEP 27, 2010			
021228 001	TOLTERODINE TARTRATE; DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020			
021228 002	TOLTERODINE TARTRATE; DETROL LA	6770295	AUG 26, 2019	DP U544		
		6770295*PED	FEB 26, 2020			
020505 001	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 002	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 003	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 004	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 005	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020505 006	TOPIRAMATE; TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
		6503884	OCT 13, 2015	U598		
020844 001	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		6503884	OCT 13, 2015	U598		
		5998380	SEP 13, 2015	U598		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020844 002	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		6503884	OCT 13, 2015	U598		
		5998380	SEP 13, 2015	U598		
020844 003	TOPIRAMATE; TOPAMAX SPRINKLE	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		6503884	OCT 13, 2015	U598		
		5998380	SEP 13, 2015	U598		
021257 001	TRAVOPROST; TRAVATAN	6011062	DEC 22, 2014	DP		
		5849792	DEC 22, 2014	DP U383		
		5889052	DEC 02, 2014	DP U383		
		5510383	AUG 03, 2013	DP U383		
021272 001	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
021272 002	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
021272 003	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
021272 004	TREPROSTINIL SODIUM; REMODULIN	6765117	OCT 24, 2017	DS		
020404 003	TRETINOIN; AVITA				ODE	JUN 04, 2008
021595 001	TROSPIMUM CHLORIDE; SANCTURA				NCE	MAY 28, 2009
>ADD> 021670 001	TRYPAN BLUE; VISIONBLUE				NCE	DEC 16, 2009
>ADD> 020675 002	URSODIOL; URSO FORTE				D-93	JUL 21, 2007
>ADD> 020675 001	URSODIOL; URSO 250	4859660	NOV 19, 2007		D-93	JUL 21, 2007
>ADD> 021266 001	VORICONAZOLE; VFEND				I-442	DEC 21, 2007
>ADD> 021266 002	VORICONAZOLE; VFEND				I-442	DEC 21, 2007
>ADD> 021267 001	VORICONAZOLE; VFEND				I-442	DEC 21, 2007
021630 001	VORICONAZOLE; VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540	I-442	DEC 21, 2007
		5773443	JAN 25, 2011	DS DP U540		
>ADD> 021060 001	ZICONOTIDE; PRIALT				NCE	DEC 28, 2009
>ADD> 021060 002	ZICONOTIDE; PRIALT				NCE	DEC 28, 2009
>ADD> 021060 003	ZICONOTIDE; PRIALT				NCE	DEC 28, 2009
>ADD> 021060 004	ZICONOTIDE; PRIALT				NCE	DEC 28, 2009
020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018	U601		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018	U601		
		5312925	SEP 01, 2012	DS DP		
020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018	U601		
020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031	MAR 02, 2007	DS DP		
		5312925	SEP 01, 2012	DS DP		
		6150366	MAY 27, 2019	DP		
		6245766	DEC 18, 2018	U601		
021450 004	ZOLMITRIPTAN; ZOMIG	6750237	NOV 28, 2020	DP		
		6750237*PED	MAY 28, 2021			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
---------------------	-----------------------------	------------------	----------------------------	-------------------	----------------	-------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 - DS = Drug Substance claim
 - DP = Drug Product claim
 - U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://www.fda.gov/cder/orange/patex.htm).

PATENT & EXCLUSIVITY ABBREVIATIONS

W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
 D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
 D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
 D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
 D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
 D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
 D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
 D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
 D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
 D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)

EXCLUSIVITY INDICATION

I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
 I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
 I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
 I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
 I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
 I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
 I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
 I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
 I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
 I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED

- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION

- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDERS
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 RELIEF OF NAUSEA AND VOMITTING
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF NASAL SYMPTOMS OF SEASONAL ALLERGIC AND PERENNIAL ALLERGIC RHINITIS, IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- U-618 PROPHYLAXIS OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS, IN ADULTS AND ADOLESCENT PATIENTS 12 YEARS AND OLDER
- U-619 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER